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RETROVIRUSES 
Monday, May 24 – Saturday, May 29, 2010 
 
 
Monday 7:30 pm 1  Entry 
   
Tuesday 9:00 am 2  RT and TRIM5 
   
Tuesday 2:00 pm 3  Goin’ Nuclear 
   
Tuesday 7:30 pm Keynote Speaker I 
   
Tuesday 8:30 pm 4  Poster Session I 
   
Wednesday 9:00 am 5  APOBEC 
   
Wednesday 2:00 pm 6  Poster Session II 
   
Wednesday 4:30 pm Wine and Cheese Party* 
   
Wednesday 7:30 pm 7  Integration 
   
Thursday 9:00 am 8  RNA 
   
Thursday 2:00 pm 9  Assembly 
   
Thursday 7:30 pm Keynote Speaker II 
   
Thursday 8:30 pm 10  Poster Session III 
   
Friday 9:00 am 11  Tetherin and XMRV 
   
Friday 2:00 pm 12  Structure, Genome and Defense 
   
Friday 4:00 pm Special Celebration: Keynotes III and IV 
   
Friday 6:00 pm Banquet 
   
Saturday 9:00 am 13  Tetherin and Pathogenesis 
 
Poster sessions are located in Bush Lecture Hall 
* Airslie Lawn, weather permitting 
Mealtimes at Blackford Hall are as follows:   
Breakfast   7:30 am-9:00 am 
Lunch       11:30 am-1:30 pm 
Dinner       5:30 pm-7:00 pm 
Bar is open from 5:00 pm until late 
In Memoriam 
 
With great sadness we report the death of Dr. Daniel Wolf, an 
extraordinary and productive scientist, of an aggressive 
chondrosarcoma. Dan was working in Steve Goff’s lab at the time 
of his death last fall at age 32. Dan was responsible for uncovering 
many aspects of the silencing of retroviral DNAs in embryonic 
stem cells, and presented often at this meeting. His beautiful 
science, enthusiasm, and generosity will be sorely missed. 
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XMRV tropism in hematopoietic cells 
Stig M. Jensen, KyeongEun Lee, Cari Petrow-Sadowski, Ying Huang, 
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Identification of the first cells infected during vaginal 
transmission in the Depo-Provera rhesus macaque model 
Katharina Rothwangl, Ronald S. Veazey, Thomas J. Hope. 
Presenter affiliation: Northwestern University, Chicago, Illinois. 
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William Ince, Gretja Schnell, Ron Swanstrom. 
Presenter affiliation: University of North Carolina, Chapel Hill, Chapel 
Hill, North Carolina. 
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Variable regions of HIV envelope constitute barriers to genetic 
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Meriem S. Hamoudi, Etienne Simon-Loriere, Paola Rossolillo, Andres 
Finzi, Joseph Sodroski, Matteo Negroni. 
Presenter affiliation: Institut de Biologie Moleculaire et Cellulaire, 
Strasbourg, France. 
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Amanda S. Solis, Christopher Aiken. 
Presenter affiliation: Vanderbilt University, Nashville, Tennessee. 
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Linkage between HIV-1 physical properties and entry activity 
Nitzan Kol, Hongbo Pang, Michael S. Kay, Itay Rousso. 
Presenter affiliation: Weizmann Institute of Science, Rehovot, Israel. 
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Mechanism of MLV cell-to-cell transmission 
Jing Jin, Xaver Sewald, Walther Mothes. 
Presenter affiliation: Yale University, New Haven, Connecticut. 
 
 
7 
  
Dynamics of viral proteins during the natural HIV-1 infection—
Insights from a biarsenical-tetracysteine fluorescent labeling 
method 
Candida da Fonseca Pereira, Kate L. Jones, Paula C. Ellenberg, 
Valerie Vivet-Boudou, Roland Marquet, Iain Johnson, Johnson Mak. 
Presenter affiliation: Burnet Institute, Melbourne, Australia; Monash 
University, Clayton, Australia. 
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NC-dependent localization of HIV-1 Gag to uropods in polarized T 
cells facilitates cell-to-cell virus transfer 
Nick Llewellyn, Akira Ono. 
Presenter affiliation: University of Michigan, Ann Arbor, Michigan. 
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Spread of HIV through T cell virological synapses enhances 
multiplicity of infection 
Armando Del Portillo, Joseph Tripodi, Amanda LeBlanc, Vesna Najfeld, 
David N. Levy, Benjamin K. Chen. 
Presenter affiliation: Mount Sinai School of Medicine, New York, New 
York. 
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HIV co-opts trogocytosis to traffic from dendritic cells to T cells 
during Trans-infection 
Hyun Jae Yu, David McDonald. 
Presenter affiliation: Case Western Reserve University School of 
Medicine, Cleveland, Ohio. 
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Gag targeting to glycosphingolipid-enriched microdomains plays 
an important role in dendritic cell-mediated HIV-1 capture and 
transfer 
Hisashi Akiyama, Steven C. Hatch, Hiren V. Patel, Nora P. Ramirez, 
Rahm Gummuluru. 
Presenter affiliation: Boston University, Boston, Massachusetts. 
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TUESDAY, May 25—9:00 AM 
 
 
SESSION 2 RT AND TRIM5 
 
Chairpersons: F. Diaz-Griffero, Albert Einstein College of Medicine,  
  Bronx, New York 
W. Johnson, Harvard Medical School, Boston, 
Massachusetts 
 
  
Evidence for sequence variation in XMRV 
Kathryn S. Jones, Ying K. Huang, Cari Petrow-Sadowski, Max A. Pfost, 
Judy A. Mikovits, Rachel K. Bagni, Dominic Esposito, Francis W. 
Ruscetti. 
Presenter affiliation: SAIC-Frederick, Frederick, Maryland. 
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HIV-1 IN mutants defective for INI1/hSNF5 binding are defective 
for post-entry events of HIV-1 replication 
Sheeba Mathew, Xuhong Wu, Achintya Pal, Ganjam Kalpana. 
Presenter affiliation: Albert Einstein Colllege of Medicine, Bronx, New 
York. 
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A tRNALys3-like element in the HIV-1 genome 5´-UTR assists in 
priming of reverse transcription 
Christopher P. Jones, Jenan Saadatmand, Lawrence Kleiman, Karin 
Musier-Forsyth. 
Presenter affiliation: The Ohio State University, Columbus, Ohio. 
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Duplex structural differences and not 2’-hydroxyls explain the 
more stable binding of HIV-RT to RNA-DNA vs. DNA-DNA 
Jeffrey T. Olimpo, Jeffrey J. DeStefano. 
Presenter affiliation: University of Maryland, College Park, Maryland. 
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Conservation and mechanism of anti-HIV-1 activity of Trim 37 
Lauren Beach, Azah A. Tabah, Anne E. Mayer, Louis M. Mansky. 
Presenter affiliation: University of Minnesota, Minneapolis, Minnesota. 
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Development of an Fv1 binding assay 
Laura Hilditch, Peter Rosenthal, David Goldstone, Ian Taylor, Jonathan 
Stoye. 
Presenter affiliation: NIMR, London, United Kingdom. 
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Contribution of E3 ubiquitin ligase activity to HIV-1 restriction by 
TRIM5α 
Felipe Diaz-Griffero, . 
Presenter affiliation: Albert Einstein College of Medicine, Bronx, New 
York. 
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TRIM5 is bound to the 19S regulatory particle of the 26S 
proteasome 
K Hrecka, S Swanson, T Hope, L Florence, M Washburn, J 
Skowronski. 
Presenter affiliation: CSHL, Cold Spring Harbor, New York; Case 
Western Reserve University, Cleveland, Ohio. 
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p62/Sequestosome1 associates with and sustains the expression 
of the retroviral restriction factor TRIM5α 
Christopher O’Connor, Thomas Pertel, Seth Gray, Seth L. Robia, 
Jeremy Luban, Edward M. Campbell. 
Presenter affiliation: Loyola University Chicago, Maywood, Illinois. 
 
 
 
 
21 
  
Escape from TRIM5α-mediated suppression during cross-species 
transmission and emergence of primate lentiviruses 
Andrea Kirmaier, Ruchi M. Newman, Laura Hall, Jennifer Morgan, 
Mareike Meythaler, Amitinder Kaur, Vanessa Hirsch, Welkin E. 
Johnson. 
Presenter affiliation: New England Primate Research Center, 
Southborough, Massachusetts; Friedrich-Alexander-Universitaet 
Erlangen-Nuernberg, Erlangen, Germany. 
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Conformational diversity enables TRIMCyp to restrict multiple 
viruses 
Amanda J. Price, Matthew Caines, Katsiaryna Bichel, Greg J. Towers, 
Stefan M. Freund, Leo C. James. 
Presenter affiliation: Medical Research Council, Cambridge, United 
Kingdom. 
 
 
 
 
 
23 
  
p21Cip1/WAF1 controls HIV-1 replication in primary human 
macrophages and CD4+ T lymphocytes 
Anna Bergamaschi, Annie David, Françoise Barré-Sinoussi, 
Gianfranco Pancino. 
Presenter affiliation: Institut Pasteur, Paris, France. 
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SESSION 3 GOIN' NUCLEAR 
 
Chairpersons: M. Naghavi, University College Dublin, Ireland 
  E. Bacharach, Tel Aviv University, Israel 
 
  
Cytoskeletal regulatory proteins talin 1 and vinculin downregulate 
retroviral infection 
Craig A. Brown, Scott G. Morham, Mojgan H. Naghavi. 
Presenter affiliation: University College Dublin, Dublin, Republic of 
Ireland. 
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The principal function of the HIV-1 central DNA flap is defense 
against APOBEC3 protein restriction 
Chunling Hu, Dyana T. Saenz, Hind J. Fadel, Mary Peretz, William 
Walker, Eric M. Poeschla. 
Presenter affiliation: Mayo Clinic College of Medicine, Rochester, 
Minnesota. 
 
 
 
 
 
26 
  
HIV-1 interacts with the cytoskeleton via its capsid during its 
transport towards the nuclear compartment 
Sandie Munier, Andreas Becker, Pierre-Olivier Vidalain, Paul Walther, 
Yves Jacob, Pierre Charneau, Nathalie J. Arhel. 
Presenter affiliation: Institut Pasteur, Paris, France. 
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Is transportin-SR2 mediated nuclear import of HIV mediated by 
integrase or capsid? 
Wannes Thys, Stéphanie De Houwer, Jonas Demeulemeester, Oliver 
Taltynov, Jan De Rijck, Rik Gijsbers, Frauke Christ, Zeger Debyser. 
Presenter affiliation: KU Leuven, Belgium. 
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Requirement for cellular Transportin 3 during the early phases of 
lentiviral infection and viral determinants involved 
Xuan Nhi Nguyen, Lise Rivière, Gregory Berger, Stephanie Durand, 
Stephanie Cordeil, Jean-Luc Darlix, Andrea Cimarelli. 
Presenter affiliation: LaboRetro, Lyon, France; INSERM, Lyon, France; 
University of Lyon, Lyon I, IFR128 Biosciences Lyon-Gerland, Lyon, 
France. 
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Distinct motifs within the Transportin 3 cargo binding domain are 
necessary for lentiviral infection 
Eric C. Logue, Kayleigh T. Taylor, Peter H. Goff, Nathaniel R. Landau. 
Presenter affiliation: NYU School of Medicine, New York, New York. 
 
 
 
30 
  
TNPO3 promotes uncoating of HIV-1 in vitro 
Vaibhav B. Shah, Jiong Shi, David R. Hout, Ilker Oztop, Lavanya 
Krishnan, Alan Engelman, Christopher Aiken. 
Presenter affiliation: Vanderbilt University School of Medicine, 
Nashville, Tennessee. 
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Transportin 3 promotes a nuclear uncoating step required for 
efficient HIV-1 integration 
Lihong Zhou, Elena Sokolskaja, Luciano Vozzolo, Ariberto Fassati. 
Presenter affiliation: Wohl Virion Centre, London, United Kingdom. 
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CPSF6 restriction of HIV 
KyeongEun Lee, Alok Mulky, Wendy Yuen, Ilker Oztop, Zandrea 
Ambrose, Thomas D. Martin, Stephen H. Hughes, Derya Unutmaz, 
Alan Engelman, Vineet N. KewalRamani. 
Presenter affiliation: HIV Drug Resistance Program, NCI-Frederick, 
Maryland. 
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HIV-1 couples nuclear entry pathway with integration site 
specificity 
Torsten Schaller, Amanda J. Price, Adam J. Fletcher, Troy Brady, Jane 
Rasaiyaah, Karen Ocwieja, Keshet Ronen, Kyeongeun Lee, Vineet N. 
KewalRamani, Richard G. Jenner, Frederic D. Bushman, Leo C. 
James, Greg J. Towers. 
Presenter affiliation: MRC Centre for Medical Molecular Virology, 
University College London, London, United Kingdom. 
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Nuclear envelope proteomic analysis of HIV-1-infected T-cells 
identifies factors responsible for blocking hnRNP shuttling 
Anne Monette, Andrew J. Mouland. 
Presenter affiliation: Lady Davis Institute for Medical Research, 
Montreal, Canada; McGill University, Montreal, Canada. 
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Discovery of HIV-1 capsid disassembly inhibitors 
Louie Lamorte, Jean-François Mercier, Steve Titolo, Nathalie 
Goudreau, Chris Lemke, Elizabeth Wardrop, Chantal Grand-Maître, 
Eric Malenfant, Olivier Lepage, Anne-Marie Faucher, Stephen Mason. 
Presenter affiliation: Boehringer Ingelheim Canada Limited, Laval, 
Canada. 
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KEYNOTE SPEAKER 
 
Sandra Ruscetti 
National Cancer Institute-Frederick 
 
"Understanding the biological effects of the human retrovirus XMRV— 
Lessons learned from studying murine retroviruses" 
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Inhibition of the budding/release of PERV 
Masumi Abe, Aiko Fukuma, Takayuki Miyazawa, Jiro Yasuda. 
Presenter affiliation: National Research Institute of Police Science, 
Chiba, Japan. 
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M184V mutation increases Rnase H cleavage-mediated 
dissociation of primer-template by HIV-1 reverse transcriptase 
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Antonio J. Acosta, Suzanne E. Matsuura, Walter A. Scott. 
Presenter affiliation: University of Miami Miller School of Medicine, 
Miami, Florida. 
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Presenter affiliation: Vanderbilt University School of Medicine, 
Nashville, Tennessee. 
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UPF1 shuttling function is required for HIV-1 genomic RNA export 
Lara Ajamian, Andrew J. Mouland. 
Presenter affiliation: Lady Davis Institute for Medical Research, 
Montreal, Canada;; McGill University, Montreal, Canada. 
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Failure to detect XMRV in human prostate tumors 
Amanda L. Aloia, Karen S. Sfanos, Angelo M. DeMarzo, Alan Rein. 
Presenter affiliation: National Cancer Institute, Frederick, Maryland. 
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Selective degradation of newly synthesized Bst-2 does not 
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Amy J. Andrew, Eri Miyagi, Klaus Strebel. 
Presenter affiliation: NIAID, National Institutes of Health, Bethesda, 
Maryland. 
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Presenter affiliation: Tel Aviv University, Tel Aviv, Israel. 
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Tamara Bar-Magen, Daniel A. Donahue, Emily I. McDonough, Björn D. 
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Presenter affiliation: McGill University AIDS Centre, Montreal, Canada. 
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derived from different gammaretroviruses 
Hanni Bartels, Massimo Pizzato, Jeremy Luban. 
Presenter affiliation: University of Geneva, Geneva, Switzerland. 
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Mechanisms of Type-I Interferon transcriptional regulation of 
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Mariana G. Bego, Johanne Mercier, Jonathan Richard, Tram N. Pham, 
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Presenter affiliation: Institut de Recherches Cliniques de Montréal 
(IRCM), Montreal, Canada. 
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Cell type specific antiviral effects of APOBEC3A during the early 
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N’guyen, Jean-Luc Darlix, Andrea Cimarelli. 
Presenter affiliation: LaboRetro, Lyon, France; INSERM, Lyon, France; 
University of Lyon, Lyon, France. 
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Presenter affiliation: Institut Cochin, INSERM, U1016, Université Paris 
Descartes, CNRS (UMR 8104), Paris, France. 
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expression reveals a new level of host regulation of retroviral 
gene expression 
Ioana Boeras, John T. West. 
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Iva Pichova, Michaela Rumlova. 
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Excessive splicing of HIV-1 RNA results in defective Gag 
assembly which can be complemented by the expression of 
packagable viral RNA 
Dibyakanti Mandal, Zehua Feng, C M. Stoltzfus. 
Presenter affiliation: University of Iowa, Iowa City, Iowa. 
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Nef both contributes to the establishment of HIV latency and 
enhances the reactivation of latent proviruses 
Hongxia Mao, Jonathan Karn. 
Presenter affiliation: Case Western Reserve University, Cleveland, 
Ohio. 
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 xxxii 
The requirements for NUP153 and NUP358 during lentiviral 
infection map to the capsid protein 
Kenneth A. Matreyek, Alan Engelman. 
Presenter affiliation: Dana-Farber Cancer Institute, Boston, 
Massachusetts. 
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Evidence that Vpr uses the DCAF1 ubiquitin ligase to target two 
host proteins involved in cell growth and viability 
Claire Maudet, Erwann Le Rouzic, Matthieu Bertrand, Diana Ayinde, 
Caroline Goujon, Andrea Cimarelli, Sébastien Nisole, Florence 
Margottin-Goguet, Catherine Transy. 
Presenter affiliation: INSERM U1016, Paris, France; Université Paris 
Descartes, Paris, France. 
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O-glycosylation of proteins on a surface of T cells is critical for 
HTLV-1 cell-to-cell infection 
Dmitriy Mazurov, David Derse, Gisela Heidecker, Alexander Filatov. 
Presenter affiliation: Institute of Immunology, Moscow, Russia. 
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Sprouty2, a PI(4,5)P2-interacting protein, plays a regulatory role in 
events required for release of HIV-1 Gag 
Gisselle N. Medina, Lorna S. Ehrlich, Min-Huei Chen, Carol A. Carter. 
Presenter affiliation: Stony Brook University, Stony Brook, New York. 
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Targeted LEDGF dominant interference proteins demonstrate 
cytoplasmic exposure of HIV-1 integrase 
Anne M. Meehan, Dyana T. Saenz, James H. Morrison, Mary E. 
Peretz, Chunling Hu, Robert Sikkink, Eric M. Poeschla. 
Presenter affiliation: Mayo Clinic, Rochester, Minnesota. 
 
 
 
 
185 
  
Role of HIV-1 Tat in the regulation of viral preintegration 
transcription 
Beatrix W. Meltzer, Yuntao Wu. 
Presenter affiliation: George Mason University, Manassas, Virginia. 
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Effect of the lentiviral accessory protein Nef in HIV-1 protease 
activity in the presence of protease inhibitors 
Luiza M. Mendonça, Thatiane L. Sampaio, Luciana J. Costa. 
Presenter affiliation: Instituto de Microbiologia Prof Paulo de Góes-
UFRJ, Rio de Janeiro, Brazil. 
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Live cell visualization of interactions between HIV-1 Gag and 
cellular RNA-binding protein Staufen1 
Miroslav P. Milev, Chris M. Brown, Andrew J. Mouland. 
Presenter affiliation: Lady Davis Institute for Medical Research, 
Montreal, Canada; McGill University, Montreal, Canada. 
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 xxxiii 
HIV suicide through viral RNase H 
Karin Moelling, Jochen Heinrich. 
Presenter affiliation: University Zürich, Zürich, Switzerland. 
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The efficiency of SEVI-mediated enhancement of virus infection 
correlates inversely with the number of envelope glycoproteins in 
viral particles 
Maral Yolamanova, Kyeong-Ae Kim, Onofrio Zirafi, Uwe Fiebig, Frank 
Kirchhoff, Jan Muench. 
Presenter affiliation: University Hospital Ulm, Ulm, Germany. 
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Evolutionary pathways of raltegravir resistance analyzed by deep 
sequencing 
Rithun Mukherjee, Richard L. Hodinka, Michael D. Miller, Frederic D. 
Bushman. 
Presenter affiliation: University of Pennsylvania, Philadelphia, 
Pennsylvania. 
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Influence of human APOBEC3F on HIV-1 replication in primary 
lymphocytes 
Viviana Simon, Marcel Ooms, Susan Majdak, Jordan Smedresman, 
Caitlin Linscheid, Ariana Harari, Andrea Kunz, Lubbertus C. Mulder. 
Presenter affiliation: Mount Sinai School of Medicine, New York, New 
York. 
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A role for Rac1 and RhoA GTPases in HIV-1 Gag assembly and 
release 
Audrey Thomas, Elise Hamard-Peron, Guillaume Fargier, Jean-Luc 
Darlix, Delphine Muriaux. 
Presenter affiliation: INSERM U758, ENS de Lyon, UCBL1, IFR128, 
Lyon, France. 
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Duplication of the Bst2/Tetherin gene in the sheep genome 
Lita Murphy, Thomas E. Spencer, Sarah Black, Stuart Neil, Frederick 
Arnaud, Massimo Palmarini. 
Presenter affiliation: University of Glasgow, Glasgow, United Kingdom. 
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Role of zinc fingers of HIV-1 GAG in nucleic acid binding and 
chaperone function 
Andrew G. Goodrich, Christopher P. Jones, Ioulia Rouzina, Karin 
Musier-Forsyth. 
Presenter affiliation: The Ohio State University, Columbus, Ohio. 
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 xxxiv 
vRNA and PI(4,5)P2 drive polyhexameric oligomerization of RSV 
Gag 
Shorena Nadaraia-Hoke, Nicole Gudleski, John Flanagan, Leslie 
Parent. 
Presenter affiliation: Penn State College of Medicine, Hershey, 
Pennsylvania. 
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Proteasome-dependent and –independent restriction of HIV-1 by 
TRIM5α 
Hikoichiro Maegawa, Tadashi Miyamoto, Jun-ichi Sakuragi, Tatsuo 
Shioda, Emi E. Nakayama. 
Presenter affiliation: Research Institute for Microbial Diseases, Osaka 
Univertsity, Osaka, Japan. 
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Forced stochastic behavior of viral competition experiments 
provides method to infer effective population size 
Robbie Narang, Igor M. Rouzine, John M. Coffin. 
Presenter affiliation: Tufts University, Boston, Massachusetts. 
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Genomic RNA structures minimize recombination cost through 
gene swapping in HIV 
Etienne Simon-Loriere, Darren P. Martin, Kevin M. Weeks, Matteo 
Negroni. 
Presenter affiliation: Institut de Biologie Moleculaire et Cellulaire, 
Strasbourg, France. 
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Tetherin ubiquitination and degradation are not essential for Vpu-
mediated antagonism of its antiviral activity 
Raphael Vigan, Stuart Neil. 
Presenter affiliation: King's College London, London, United Kingdom. 
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Involvement of the endogenous HERV-F(c)1 retroviral locus on 
the human X chromosome in the etiology of multiple sclerosis 
Bjørn A. Nexø, Kari K. Nissen, Bettina Hansen, Magdalena J. Laska, 
Palle Villesen, Tove Christensen, Annette B. Oturai, Anné M. Larsen, 
Thor Petersen, Finn S. Pedersen. 
Presenter affiliation: University of Aarhus, Aarhus, Denmark. 
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Elevated strand transfer by multiple NRTI resistant HIV-1 RT 
mutant harboring a two amino acid insertion in the fingers 
domain 
Laura A. Nguyen, Sean Rigby, Baek Kim. 
Presenter affiliation: University of Rochester, Rochester, New York. 
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 xxxv 
A novel host factor, ubiquitin-conjugating enzyme E2 variant 1 
(UBE2V1), influences HIV-1 infection in human monocytic cells 
Nidhanapati K. Raghavendra, Heather L. Hoy, Li Wu. 
Presenter affiliation: Ohio State University, Columbus, Ohio. 
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Barriers to intergroup HIV-1 recombination revealed by a new 
dual-marker system 
Olga A. Nikolaitchik, Andrea Galli, Michael D. Moore, Vinay K. Pathak, 
Wei-Shau Hu. 
Presenter affiliation: National Cancer Institute, Frederick, Maryland. 
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Reconstruction of HERV-F(c)1, associated with multiple sclerosis 
Kari K. Nissen, Finn S. Pedersen, Bjørn A. Nexo. 
Presenter affiliation: University of Aarhus, Aarhus C, Denmark. 
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SESSION 7 INTEGRATION 
 
Chairpersons: M. Roth, UMDNJ-Robert Wood Johnson Medical School,  
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Lens epithelium derived growth factor (LEDGF) fusion proteins 
that redirect HIV-1 DNA integration 
Andrea L. Ferris, Xiaolin Wu, Christina M. Hughes, Claudia Stewart, 
Steven J. Smith, Thomas A. Milne, Gang G. Wang, Ming-Chieh Shun, 
C. David Allis, Alan Engelman, Stephen H. Hughes. 
Presenter affiliation: National Cancer Institute-Frederick, Frederick, 
Maryland. 
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Recombinant Ty3 integrase mediates Brf1c-dependent and 
sequence-specific strand transfer in vitro 
Xiaojie Qi, Kim Nguyen, Heather Hatzis, Suzanne Sandmeyer. 
Presenter affiliation: University of California Irvine, Irvine, California. 
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 xxxvi 
MoMLV IN—Structural studies of the N-terminal domain 
William M. Schneider, Paolo Rossi, Rongjin Guan, Rong Xiao, 
Gaetano Montelione, Monica J. Roth. 
Presenter affiliation: UMDNJ-Graduate School of Biomedical Sciences, 
Piscataway, New Jersey. 
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LEDGF/p75 is critical but not essential for multiple round 
replication of HIV-1 in human knockout cells 
Jan De Rijck, Rik Schrijvers, Rik Gijsbers, Keshet Ronen, Frederic D. 
Bushman, Zeger Debyser. 
Presenter affiliation: KULeuven, Leuven, Belgium. 
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Host factors in HIV integration site targeting 
Karen E. Ocwieja, Troy Brady, Keshet Ronen, Nirav Malani, Charles C. 
Berry, Frederic D. Bushman. 
Presenter affiliation: University of Pennsylvania School of Medicine, 
Philadelphia, Pennsylvania. 
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Deciphering the code for retroviral integration target site 
selection 
Federico A. Santoni, Jessica Guerra, Olivert Hartley, Jeremy Luban. 
Presenter affiliation: University of Geneva, Geneva, Switzerland. 
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The HIV-1 intasome and its inhibition—Progress and prospects 
from new structure-based models 
Lavanya Krishnan, Stephen Hare, Peter Cherepanov, Alan Engelman. 
Presenter affiliation: Dana-Farber Cancer Institute, Boston, 
Massachusetts. 
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HIV-1 intasome assembly—From single end complex to stable 
synaptic complex 
Min Li, Svetlana Kotova, Emilios K. Dimitriadis, Robert Craigie. 
Presenter affiliation: NIDDK, National Institutes of Health, Bethesda, 
Maryland. 
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Sequential interactions of viral DNA and LEDGF with HIV-1 
integrase are essential for productive concerted integration 
Jacques J. Kessl, Min Li, Michael Ignatov, Christopher J. McKee, Karin 
Musier-Forsyth, Robert Craigie, Mamuka Kvaratskhelia. 
Presenter affiliation: The Ohio State University, Columbus, Ohio. 
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 xxxvii 
Mechanism of strand transfer inhibitors—Identification of a major 
novel IN-single DNA-inhibitor complex 
Krishan K. Pandey, Sibes Bera, Ajaykumar C. Vora, Duane P. 
Grandgenett. 
Presenter affiliation: Saint Louis University Health Sciences Center, 
Saint Louis, Missouri. 
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Characterization of the dynamic interplay between HIV-1 
integrase and its cellular cofactors during lymphocyte infection 
Annabelle Gérard, Emmanuel Ségéral, Stéphane Emiliani. 
Presenter affiliation: Institut Cochin, Unversité Paris Descartes, Paris, 
France; INSERM U1016, Paris, France. 
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The role of ERV expression as a marker for cellular 
transformation 
Ravi P. Subramanian, Julia H. Wildschutte, John M. Coffin. 
Presenter affiliation: Tufts University, Boston, Massachusetts. 
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Identification of host factors that initiate and maintain retroviral 
epigenetic silencing 
Natalia Shalginskikh, Andrey Poleshko, Anna Marie Skalka, Richard A. 
Katz. 
Presenter affiliation: Fox Chase Cancer Center, Philadelphia, 
Pennsylvania. 
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Cellular transcription factor ZASC1 stimulates HIV-1 TAT activity 
James W. Bruce, John Young, Paul Ahlquist. 
Presenter affiliation: University of Wisconsin-Madison, Madison, 
Wisconsin. 
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Nuclear retention of HIV-1 pre-mRNA through PSF/p54nrb and 
Matrin3 is required for HIV-1 Rev 
Anna Kula, Jessica Guerra, Paolo Maiuri, Danijela Kleva, Anna 
Knezevich, Michael P. Myers, Alessandro Marcello. 
Presenter affiliation: International Centre for Genetic Engineering and 
Biotechnology, Trieste, Italy. 
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 xxxviii 
MMTV Rem protein requires processing by signal peptidase and 
retrotranslocation for nuclear function 
Hyewon Byun, Nimita Halani, Jennifer Mertz, Almas Ali, Mary Lozano, 
Jaquelin Dudley. 
Presenter affiliation: University of Texas at Austin, Austin, Texas. 
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RNA cap hypermethyltransferase and HIV-1 gene expression 
Venkat Yedavalli, Kuan-The Jeang. 
Presenter affiliation: National Institutes of Health, Bethesda, Maryland. 
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RNA helicase A residues necessary for specific recognition and 
translation of avian and human retroviral RNAs 
Amit Sharma, Arnaz Ranji, Cheryl Bolinger, Mamuka Kvaratskhelia, 
Karin Musier-Forsyth, Kathleen Boris-Lawrie. 
Presenter affiliation: Ohio State University, Columbus, Ohio. 
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Specific repression of MoMLV transcription supports the early 
bisection in viral unspliced RNA into mRNA and genome fates 
Eric L. Garcia, Alice Telesnitsky. 
Presenter affiliation: University of Michigan, Ann Arbor, Michigan. 
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Suppression of nonsense-mediated decay by retroviral recoding 
elements 
J. Robert Hogg, Stephen P. Goff. 
Presenter affiliation: Howard Hughes Medical Institute, Columbia 
University, New York, New York. 
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Imaging RSV Gag-viral RNA interactions in the nuclei of living 
cells 
Estelle Chiari-Fort, Eileen Ryan, Leslie Parent. 
Presenter affiliation: Penn State College of Medicine, Hershey, 
Pennsylvania. 
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Dissecting the mechanisms of HIV-2 RNA packaging 
Na Ni, Olga A. Nikolaitchik, Kari Dilley, Jianbo Chen, Wei-Shau Hu. 
Presenter affiliation: National Cancer Institute, Frederick, Maryland. 
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Preferred Gag binding sties are crucial packaging signal elements 
in MLV genomic RNA 
Cristina Gherghe, Tania B. Lombo, Christopher W. Leonard, 
Siddhartha A. Datta, Julian W. Bess, Robert J. Gorelick, Alan Rein, 
Kevin M. Weeks. 
Presenter affiliation: National Cancer Institute, Frederick, Maryland. 
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 xxxix 
Cellular factors that restore HIV-1 assembly in mouse cells 
Nathan M. Sherer, Chad M. Swanson, Michael H. Malim. 
Presenter affiliation: King’s College London School of Medicine, 
London, United Kingdom. 
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Host cell factors in retrovirus assembly and release 
Muthukumar Balasubramaniam, Scott G. Morham, Eric O. Freed. 
Presenter affiliation: Virus-Cell Interaction Section, NCI-Frederick, 
Maryland. 
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Live-cell imaging of SKD1 recruitment and dynamics during HIV-1 
budding 
Viola Baumgaertel, Sergey Ivanchenko, Mikhail Sergeev, Paul W. 
Wiseman, Hans-Georg Kraeusslich, Barbara Mueller, Don C. Lamb. 
Presenter affiliation: Ludwig-Maximilians-University, Munich, Germany. 
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Determinants of HIV-1 capsid assembly 
Eric Barklis, Jacob Eccles, Ben Kukull, Claudia Lopez, Hank McNett, 
Colleen Noviello, Rachel Sloan, Amelia Still, Seyram Tsagli. 
Presenter affiliation: Oregon Health & Science University, Portland, 
Oregon. 
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Assembly and replication of HIV-1 in T cells with low PI(4,5)P2 
levels 
Kazuaki Monde, Vineela Chukkapalli, Akira Ono. 
Presenter affiliation: University of Michigan Medical School, Ann Arbor, 
Michigan. 
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 xl 
The ESCRT-associated Alix protein recruits the ubiquitin ligase 
Nedd4-1 to facilitate HIV-1 release through the LYPxnL late 
domain motif 
Fadila Bouamr, Paola Sette, Joshua A. Jadwin, Vincent Dussupt, Nana 
F. Bello. 
Presenter affiliation: NIAID, National Institutes of Health, Bethesda, 
Maryland. 
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Structure of the HIV-1 CA pentamer 
Owen Pornillos, Barbie K. Ganser-Pornillos, Sankaran Banumathi, 
Yuanzi Hua, Mark Yeager. 
Presenter affiliation: University of Virginia, Charlottesville, Virginia; The 
Scripps Research Institute, La Jolla, California. 
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Serine residues in the p6 protein of HIV-1 are phosphorylated by 
PKC and regulate viral core assembly 
Jörg Votteler, Liane Neumann, Friedrich Hahn, Sabine Hahn, Kerstin 
Schmidt, Nicole Studtrucker, Peter Henklein, David E. Ott, Gudrun 
Holland, Norbert Bannert, Ulrich Schubert. 
Presenter affiliation: Friedrich-Alexander-University, Erlangen, 
Germany. 
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Rescue of HIV-1 budding defects by targeting ubiquitin ligase 
HECT domains to Gag 
Eric R. Weiss, Elena Popova, Hikaru Yamanaka, Jon M. Huibregtse, 
Heinrich Gottlinger. 
Presenter affiliation: UMass Medical School, Worcester, 
Massachusetts. 
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Steps in HIV-1 maturation studied with cryo electron tomography 
Alex de Marco, Baerbel Glass, James D. Riches, Barbara Mueller, 
Hans-Georg Kraeusslich, John A.G. Briggs. 
Presenter affiliation: EMBL, Heidelberg, Germany. 
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A role for clathrin in retrovirus particle morphogenesis 
Fengwen Zhang, Trinity Zang, Marc Johnson, Paul Bieniasz. 
Presenter affiliation: The Rockefeller University, New York, New York. 
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Identification of HIV-1 capsid assembly inhibitors 
Imke Steffen, Clarence R. Hurt, Gudrun Holland, Norbert Bannert, 
Carina Banning, Michael Schindler, Jaisri Lingappa, Vishwanath 
Lingappa, Stefan Pöhlmann. 
Presenter affiliation: Hannover Medical School, Hannover, Germany. 
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 xli 
Rab11a modulates HIV-1 Env incorporation 
MIngli Qi, Jaang-Jiun Wang, Hin Chu, Lingmei Ding, Paul Spearman. 
Presenter affiliation: Children’s Healthcare of Atlanta and Emory 
University School of Medicine, atlanta, Georgia. 
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Lipid depletion modulates TRIM5a -mediated retroviral restriction 
Seiga Ohmine, Ryuta Sakuma, Yasuhiro Ikeda. 
Presenter affiliation: Mayo Clinic, Rochester, Minnesota. 
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The localization of APOBEC3H haplotypes in HIV-1 virions 
determines its antiviral activity 
Marcel Ooms, Susan Majdak, Christopher Seibert, Ariana Harari, 
Viviana Simon. 
Presenter affiliation: Mount Sinai School of Medicine, New York, New 
York. 
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Gag RNA and membrane binding determinants function 
coordinately during HIV-1 Gag particle assembly 
David Ott, Lori Coren, Teresa Shatzer. 
Presenter affiliation: SAIC-Frederick, Inc, NCI-Frederick, Frederick, 
Maryland. 
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Adaptation of HIV-1 to escape rhesus monkey TRIM5-a 
Beatriz Pacheco, Andres Finzi, Joseph Sodroski. 
Presenter affiliation: Dana-Farber Cancer Institute, Boston, 
Massachusetts; Harvard Medical School, Boston, Massachusetts. 
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 xlii 
Mutational analysis of the determinants for cytoplasmic 
localization and anti-retroviral activity of APOBEC3B 
Vladimir Pak, Gisela Heidecker, Shawn Hill, Patricia Lloyd, Vinay 
Pathak, David Derse. 
Presenter affiliation: NCI-Frederick, Frederick, Maryland. 
 
 
 
 
246 
  
MLV diversity in wild mouse species and the role of APOBEC3 
Irvin L. Pan, John M. Coffin. 
Presenter affiliation: Tufts University, Boston, Massachusetts. 
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Mechanism of HIV-1 Nef induced intracellular Lck accumulation 
Xiaoyu Pan, Anja Habermann, Jochen Rudolph, Claudia Haller, 
Jacomine Krijnse-Locker, Hans-Georg Kräusslich, Oliver T. Fackler. 
Presenter affiliation: Heidelberg University, Heidelberg, Germany. 
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Analysis of tetherin antagonism by HIV-1 M and O group Vpu 
proteins 
Sarah J. Petit, Adi Stern, Osnat Penn, Ravi Gupta, Ang Li, Tal Pupko, 
Eran Bacharach, Greg J. Towers. 
Presenter affiliation: UCL, London, United Kingdom. 
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Characterisation and functional implications of the interaction 
between the APOBEC3 and Argonaute protein families 
Prabhjeet Phalora, Chad Swanson, Sarah Gallois-Montbrun, Michael 
Malim. 
Presenter affiliation: Kings College, London, London, United Kingdom. 
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Functional characterization of the Nef-like activity of 
gammaretroviral glycosylated Gag on virion infectivity 
Massimo Pizzato, Hanni Bartels, Jeremy Luban. 
Presenter affiliation: University of Geneva, Geneva, Switzerland. 
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Generation of restriction factor-transgenic domestic cats 
Pim Wongsrikeao, Dyana Saenz, Thomas Rinkoski, Takeshige Otoi, 
Eric Poeschla. 
Presenter affiliation: Mayo Clinic College of Medicine, Rochester, 
Minnesota. 
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Non-productive replication of HIV-1 in renal podocytes—
Implications for HIVAN pathogenesis 
Atanu K. Khatua, Harry E. Taylor, James E. Hildreth, Waldemar Popik. 
Presenter affiliation: Meharry Medical College, Nashville, Tennessee. 
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 xliii 
Evolved conformational adaptations direct Asian macaque 
TRIMCyps to different lentiviral lineages 
Amanda J. Price, Laura M. Ylinen, Jane Rasaiyaah, Stephane Hue, 
Nicola Rose, Flavia Marzetta, Greg J. Towers, Leo C. James. 
Presenter affiliation: MRC, Cambridge, United Kingdom. 
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Immune responses in XMRV-infected rhesus macaques—
Serological markers of XMRV infection 
Xiaoxing Qiu, Priscilla Swanson, Ka-Cheung Luk, Bailin Tu, Jaydip Das 
Gupta, Robert Silverman, Francois Villinger, Sushil Devare, Gerald 
Schochetman, John Hackett Jr.. 
Presenter affiliation: Abbott Diagnostics, Abbott Park, Illinois. 
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Anti-HIV-1 nucleocapsid RNA aptamers reveal a possible 
consensus RNA motif in the packaging signals of diverse 
retroviruses 
Dhivya Ramalingam, Vinayaka R. Prasad. 
Presenter affiliation: Albert Einstein College of Medicine, Bronx, New 
York. 
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The impact of HIV-1 capsid mutants on infection of primary 
human macrophages 
Jane T. Rasaiyaah, Adam Fletcher, Torsten Schaller, Mahdad 
Noursadeghi, Greg J. Towers. 
Presenter affiliation: University College London, London, United 
Kingdom. 
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Role of cellular cofactors in PPXY dependent budding 
Susanne Rauch, Juan Martin-Serrano. 
Presenter affiliation: King's College London, London, United Kingdom. 
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Is SP1 a switch controlling HIV-1 particle assembly? 
Lakew G. Temeselew, Siddhartha A. Datta, Rachael M. Crist, Ferri 
Soheilian, Anne Kamata, Jane Mirro, Demetria Harvin, Kunio 
Nagashima, Raul E. Cachau, Alan Rein. 
Presenter affiliation: National Cancer Institute, Frederick, Maryland. 
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SIVmac Vpx protects HIV-1 from the type I interferon response 
Thomas C. Pertel, Christian Reinhard, Andrea Cimarelli, Jeremy 
Luban. 
Presenter affiliation: University of Geneva, Geneva, Switzerland. 
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 xliv 
Structure-function relationship of feline immunodeficiency virus 
(FIV) RNA packaging determinants 
Tahir A. Rizvi, Julia Kenyon, Jahabar Ali, Suriya J. Aktar, Pretty S. 
Phillip, Akela Ghazawi, Farah Mustafa, Andrew Lever. 
Presenter affiliation: United Arab Emirates (UAE) University, Al Ain, 
United Arab Emirates. 
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The ability of semen to enhance HIV infectivity correlates with 
endogenous levels of SEVI 
Nadia R. Roan, Jan Munch, Frank Kirchhoff, Warner C. Greene. 
Presenter affiliation: Gladstone Institute, San Francisco, California. 
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XMRV Is inhibited by interferon independently of RNase L or 
Tetherin 
Jason J. Rodriguez, Stephen P. Goff. 
Presenter affiliation: Columbia University / HHMI, New York, New York. 
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Defining HIV uncoating kinetics, different assays reveal 
differential outcomes of stability classification 
Christopher J. Rold, Thomas Hope. 
Presenter affiliation: Northwestern University, Chicago, Illinois. 
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Analysis of gamma retrovirus integration by deep sequencing 
Shoshannah L. Roth, Troy Brady, Uta von Schwedler, Ila R. Singh, 
Frederic D. Bushman. 
Presenter affiliation: University of Pennsylvania, Philadelphia, 
Pennsylvania. 
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Effect of HIV-1 NC protein on TAR RNA hairpin opening and 
closing kinetics studied by single-molecule RNA stretching 
Ioulia Rouzina, Micah McCauley, Kelly Hoadley, Karin Musier-Forsyth, 
Mark C. Williams. 
Presenter affiliation: University of Minnesota, Minneapolis, Minnesota. 
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The role of KAP1 in DNA methylation of endogenous retroviruses 
Helen M. Rowe, Daniel Mesnard, Julien Marquis, Nadine Zangger, 
Didier Trono. 
Presenter affiliation: École Polytechnique Fédérale de Lausanne, 
Lausanne, Switzerland. 
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HIV-1 assembly alters dynamics and partitioning of membrane 
components 
Dimitry N. Krementsov, Patrice Rasasm, Emmanuel Margeat, Nathan 
H. Roy, Jürgen Schneider-Schaulies, Pierre-Emmanuel Milhiet, Markus 
Thali. 
Presenter affiliation: University of Vermont, Burlington, Vermont. 
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 xlv 
Domain specific contributions to the biological properties of 
chimeric subtype B and C Vpu proteins 
Autumn Ruiz, M. Sarah Hill, Kimberly Schmitt, Edward B. Stephens. 
Presenter affiliation: University of Kansas Medical Center, Kansas City, 
Kansas. 
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Structural, biochemical and biophysical characterization of the 
interactions between HIV-1 matrix and calmodulin 
Ruba H. Ghanam, Emily L. Fledderman, Tim Fernandez, Lauren K. 
Nolen, Jamil S. Saad. 
Presenter affiliation: University of Alabama at Birmingham, 
Birmingham, Alabama. 
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Involvement of suppressor of cytokine signaling 1 (SOCS1) 
protein in the rhesus macaque TRIM5a mediated late restriction 
Ryuta Sakuma, Sayaka Sukegawa, Seiga Ohmine, Yasuhiro Ikeda, 
Shoji Yamaoka. 
Presenter affiliation: Tokyo Medical and Dental University, Japan; 
Mayo Clinic, Rochester, Minnesota. 
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Analyses of the effect of Nef-deletions on SIVcpzGAB2 provirus 
Thatiane Sampaio, Sandro Poeys, Amilcar Tanuri, Matija Peterlin, 
Luciana Costa. 
Presenter affiliation: Universidade Federal do Rio de Janeiro, Rio de 
Janeiro, Brazil. 
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Evidence for HIV-1 G-to-A hypermutation in vivo by APOBEC3 
proteins 
Kei Sato, Taisuke Izumi, Naoko Misawa, Mamoru Ito, Akifumi Takaori-
Kondo, Yoshio Koyanagi. 
Presenter affiliation: Institute for Virus Research, Kyoto, Japan. 
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Development and evaluation of HDV Rzs targeting HIV RNA 
Robert J. Scarborough, Sébastien Lainé, Dominique Lévesque, Julie 
Motard, Jean-Pierre Perreault, Anne Gatignol. 
Presenter affiliation: Lady Davis Institute, Montreal, Canada; McGill 
University, Montreal, Canada. 
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Characterization of the retroviral silencing machinery in 
embryonic stem cells 
Sharon Schlesinger, Gary Z. Wang, Stephen P. Goff. 
Presenter affiliation: Columbia University P&S, New York, New York. 
 
 
 
275 
  
 xlvi 
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Gammaretroviruses have been studied for more than thirty years, yet until 
recently no strains had been recognized in man. Virus chip screening assays 
revealed the presence of xenotropic murine leukemia virus-related virus 
(XMRV) in human tissue, and subsequent reports have suggested XMRV 
association with both prostate cancer and chronic fatigue syndrome (CFS). 
Antibodies directed against XMRV have been identified in serum from CFS 
patients, and replicating virus has been isolated from both serum and 
activated peripheral blood mononuclear cells (PBMCs). Several studies 
have indicated that the virus is difficult to detect in the PBMCs of infected 
individuals. Following activation of ex vivo cultured PBMCs, expression of 
XMRV is increased due to spread of the virus in the culture, which can be 
blocked by the addition of AZT. Although XMRV has been detected in 
PBMCs, the published studies on tropism of XMRV have not focused on 
hematopoietic cells. As one approach to address this, two different forms of 
soluble XMRV SU proteins were generated and the level of XMRV SU 
binding to various hematopoietic cell lines and primary cells was 
determined. The SU proteins bound at detectable levels to several of the 
hematopoietic cell lines and primary hematopoietic cells, but not to the non-
susceptible murine cell line NIH3T3. The ability of XMRV to infect 
different freshly isolated hematopoietic cells is currently being tested. The 
ability of XMRV to infect cells at a variety of states of activation and 
differentiation conditions are also being assessed. 
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IDENTIFICATION OF THE FIRST CELLS INFECTED DURING 
VAGINAL TRANSMISSION IN THE DEPO-PROVERA RHESUS 
MACAQUE MODEL 
 
Katharina Rothwangl1, Ronald S Veazey2, Thomas J Hope1  
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There is currently a significant effort to develop interventions to prevent the 
transmission of HIV. To facilitate these efforts, a better understanding of 
how the virus can breach mucosal epithelial barriers is required. We have 
previously explored the interaction of HIV with the female genital tract 
using human explants. This analysis revealed that HIV could penetrate both 
the columnar epithelium of the endocervix and the squamous epithelium of 
the vagina and ectocervix. Establishing whether the penetrating virus could 
lead to productive infection however remained to be elucidated. To identify 
the first infected cells, we utilized a SIV based vector system that would 
express the mCherry fluorescent protein. The vector was pseudotyped with 
the R5 tropic HIV envelope JRFL and concentrated by ultracentrifugation. 
Depo-Provera treated female macaques were vaginally exposed to the 
inoculum. Four days later the animals were sacrificed, their genital tracts 
excised, and cryosections of the tissue were analyzed by fluorescent 
microscopy. Analysis revealed large but rare foci of red fluorescent cells. 
The expression of mCherry within these cells was confirmed by emission 
spectrum analysis. These rare foci of transduced cells were found in areas 
protected by both the columnar and squamous epithelium. The target cells 
are primarily CD4+ T cells that have infiltrated into the squamous 
epithelium or reside just below the columnar epithelium. The clustering of 
transduced cells suggests that there are small regions within the female 
genital tract that are susceptible to infection. Understanding the mechanism 
that leads to this increased local susceptibility could lead to novel 
treatments that can reduce the male-to-female acquisition of HIV. 
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EVOLUTION OF ENTRY PHENOTYPE AND HIV PATHOGENESIS 
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The HIV-1 surface Env protein mediates entry into the host cell. Evolution 
of the env gene is a hallmark of infection, and in several ways this evolution 
has been linked to viral pathogenesis within the context of the disease 
course. To the extent this evolution affects protein function, the link to 
pathogenesis may be reflected in the entry phenotype. We have previously 
observed that HIV-1 grown in humanized mice evolves an Env protein that 
assumes a more open conformation, enhancing neutralization by an anti-V3 
antibody by 1000-fold. This open conformation leads to tighter binding to 
CD4 and the ability to use low levels of CD4 to enter cells, a hallmark of 
macrophage tropism. In addition, the open conformation potentiates a low 
level of CXCR4 tropism. In the humanized mouse model this open 
conformation preceded the evolution of an X4 virus. Two major 
determinants of this open conformation are within a length-invariant region 
between the length-variable domains of V1 and V2. We have also isolated 
viral env genes from the CSF of subjects with HIV-associated dementia, 
and in some subjects the encoded Env proteins found in the CSF (but not in 
the blood) are able to mediate entry at low CD4 density, consistent with 
macrophage tropism. Genetic markers for this activity appear to be located, 
at least in part, in this same region between V1 and V2. We propose that 
one type of immunodeficiency may be the loss of anti-V3 antibodies which 
allows the virus to evolve an Env protein with a more open conformation 
allowing tighter CD4 binding, using this V1/V2 spacer region as a 
conformational switch. This potentiates a latent CXCR4 tropism that may 
allow evolution of X4 viruses, and the ability to infect new cell types with 
low levels of CD4, such as macrophages and microglia as one path to HIV-
associated encephalitis. An initial screening of plasma samples has 
identified several examples of infected subjects who do not have enhanced 
neutralization of virus pseudotyped with an Env protein with an open 
conformation, suggesting the absence of anti-V3 antibodies. We predict that 
these subjects are likely to have Env proteins with an open conformation 
and that these subjects may be at risk for more rapid disease progression. 
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VARIABLE REGIONS OF HIV ENVELOPE CONSTITUTE BARRIERS 
TO GENETIC CROSSING 
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Recombination is a frequent source of genetic variability in retroviruses. In 
HIV it has been shown to be a central evolutionary mechanism contributing 
to adaptation to environmental constraints. The remarkable genetic diversity 
of HIV provides a phenomenal tool for defining barriers to genetic crossing 
between viral strains. These barriers can lead to the identification of 
vulnerable aspects of HIV biology and on the identification of potential 
targets for antiviral strategies. 
We recently characterised the steps leading from generation to selection of 
intersubtype recombinant forms generated between primary isolates in the 
envelope gene (Simon-Loriere et al, PLoS Path. 2009). We observed that 
the combined effect of recombination mechanism and of purifying selection 
acting against dysfunctional envelopes explains most of the pattern of 
recombinant forms found for this gene in the database. In particular, a 
region poorly tolerant to recombination could be identified in the C2 region 
of gp120 gene of most isolates studied. 
We now identify the source of this fragility in the rearrangement of the 
variable loops that surround C2. Indeed, the V1/V2 region and, to a lesser 
extent, the V3 loop, constitute important barriers to genetic crossing 
between primary isolates belonging to different subtypes of HIV-1 M 
group. The great variability of these regions is therefore not only limited by 
their implication in essential mechanisms for viral infectivity, as the 
formation of the coreceptor binding site, but also is constrained by a strong 
network of epistatic interactions with other portions of the protein. 
Evolution of these loops seems therefore to be paralleled by coevolution of 
other yet-to-define portions. Their identification will help in defining the 
tridimensional arrangement of the envelope proteins, particularly of gp120, 
also in the context of the functional trimer. This issue, still debated, is 
central for the potential development of new antiviral strategies targeting 
this gene. 
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To become infectious, HIV-1 particles undergo a maturation process 
involving proteolytic cleavage of the Gag polyprotein into its components 
MA, CA, and NC. Mature HIV-1 virions contain a metastable conical core 
composed of CA that is competent for uncoating. By contrast, immature 
particles contain a highly stable spherical Gag lattice. Our laboratory 
previously reported that immature HIV-1 particles retain the Env 
glycoprotein complex gp120/gp41 even after extensive lipid removal by 
treatment with non-ionic detergent (Wyma et al., J. Virol. 74:9381-87, 
2000). This observation suggested that the tight association of the long gp41 
cytoplasmic tail (CT) with the immature viral core might regulate HIV-1 
fusion. Indeed, we and others later showed that immature HIV-1 particles 
are inhibited for fusion with susceptible target cells (Murakami and Freed, 
J. Virol. 78:1026-31, 2004; Wyma et al., J. Virol. 78:3429-3435, 2004). The 
fusion impairment was relieved by truncation of the gp41 CT. The 
molecular mechanism by which HIV-1 fusion is coupled to cleavage of Gag 
is not known. We hypothesized that processing of Gag alters the 
conformation of Env on the viral surface in a gp41 CT-dependent manner. 
To test this, we quantified the binding of specific monoclonal antibodies to 
mature and immature HIV-1 particles by immunofluorescence imaging. The 
results revealed differences in specific epitopes on the surface of mature and 
immature HIV-1 particles. In particular, the membrane proximal external 
region (MPER) epitope of gp41 undergoes a conformational change upon 
maturation resulting in decreased exposure. The differences in epitope 
exposure in mature and immature particles were abolished by truncation of 
the gp41 CT, thus linking the fusion defect with Env conformation. We 
conclude that conformational differences in Env on the surface of mature 
and immature HIV-1 particles may contribute to the repression of immature 
particle fusion. Coupling HIV-1 fusion competence to maturation is likely 
to enhance the overall efficiency of cell-to-cell HIV-1 transmission by 
preventing premature entry, thus promoting HIV-1 dissemination and 
persistence in vivo. Our results also have practical implications for vaccine 
approaches targeting MPER epitopes. 
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LINKAGE BETWEEN HIV-1 PHYSICAL PROPERTIES AND ENTRY 
ACTIVITY. 
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By performing indentation assays on HIV-1 we found that the immature 
state is 14 fold stiffer than the mature state. Truncation of the cytoplasmic 
domain of gp160 (ΔCT-gp160) leads to a dramatic decrease in the stiffness 
of immature viruses, bringing it close to that of mature HIV particles that 
can enter cells with high efficacy. This is in line with the observation that 
truncation of the cytoplasmic domain is known to significantly increase the 
ability of immature HIV to enter cells. Based on this result we proposed that 
the markedly enhanced stiffness of the shell of immature HIV virus 
precludes structural deformations necessary for efficient fusion with the cell 
membrane. Here we show that the stiffness of the immature virion can be 
restored by incorporating gp160 tail fused to a trans-membrane domain and 
GFP (denoted as TM1). Moreover, the particle stiffness gradually increases 
as the amount of TM1 incorporation is elevated. To demonstrate the inverse 
correlation between stiffness and cell entry further, we prepared a series of 
immature HIV samples having a constant amount of ΔCT-gp160 and 
variable amounts of TM1. We find that as TM1 incorporation increases, 
entry activity is significantly reduced. Intriguingly, the stiffness of the 
particles is proportionally inversed with entry activity. To rule out the 
possibility that entry activity is governed by interactions between the intra- 
and extra-cellular segments of gp160, TM1 and ΔCT-gp160 respectively, 
the latter was replaced with VSVg envelope protein. Similar entry activity 
reduction is observed when TM1 is incorporated into immature particles 
having VSVg on their surface. As a control, we show that TM1 
incorporation has little impact on mature entry activity. Based on our 
findings we conclude that the virus physical properties are mechanistically 
linked with entry. 
 
*authors contributed equally 
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The ability of retroviruses to efficiently spread from cell to cell contributes 
to the pathogenesis of virally induced diseases. We have studied the murine 
leukemia virus (MLV) as a model system to understand the mechanism by 
which viruses spread from cell to cell. Co-cultures of MLV infected cells 
with uninfected target cells have revealed that the interaction between the 
viral glycoprotein (Env) expressed on the infected cell and viral receptor, 
expressed on the target cells, establishes cell-cell adhesion. If cell-cell 
adhesion is prolonged, the infected cell can stably anchor target cell 
membranes at the surface of infected cells to form virological synapses. In a 
process that depends on the presence of the cytoplasmic tail of MLV Env, 
the infected cell subsequently redirects de novo virus assembly to sites of 
cell-cell contact. Released viral particles then utilize the underlying F-actin 
flow of the target cell lamellipodium and lamellum to move towards the cell 
body of target cells. Here we present mechanistic insights into the 
establishment of adhesion and polarized assembly. We identify the motifs 
within the cytoplasmic tail of Env that are required to stabilize cell-cell 
contact and redirect assembly to sites of cell-cell contact. Moreover, we 
present the determinants within the viral Gag polyprotein that are required 
for trafficking to sites of cell-cell contact. Our data are consistent with a 
model of adhesion-induced polarity that allows the local nucleation of viral 
assembly at sites of cell-cell contact. 
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Natural HIV-1 infection occurs through receptor-mediated fusion. It has 
recently been suggested that HIV-1 enters target cells via receptor-mediated 
fusion with the endosomal membrane. After the virus enters the target cell it 
will need to reverse transcribe its viral genome. This is a dynamic process that 
involves a myriad of viral and cellular proteins that form the reverse 
transcription complex (RTC), facilitate viral cDNA synthesis and intracellular 
trafficking.  
HIV-1 containing a green fluorescent protein-labeled viral protein R (GFP-Vpr) 
is recognized as the benchmark for the visualization of the RTC. However, 
tracking of Vpr alone is unable to reveal the dynamics of proteins within the 
viral uncoating complex. Furthermore, many HIV tracking studies used VSV-
G-pseudotyped HIV-1 to facilitate entry into target cells through pH-sensitive 
fusion instead of the natural HIV-1 envelope receptor-mediated fusion. In an 
attempt to track HIV infections that rely on HIV envelope-mediated entry, we 
have created dual-labeled viruses where the C-terminus of the matrix protein is 
labeled with tetracysteine-FlAsH, the virion membrane is labeled with S-15-
mCherry and/or the N-terminus of Vpr is labeled with mCherry or GFP. More 
importantly, our labeling of HIV-1 matrix with tetracysteine-FlAsH is highly 
specific without detectable background and does not impair viral reverse 
transcription or infectivity. 
Our dual-tracking system has revealed two novel pieces of information: Firstly, 
approximately 80% of all HIV-1 virions that enter T-lymphocytes still contain 
virion membrane, which supports the notion that HIV enters its natural target 
cells via endocytosis. Secondly, the majority of the detected matrix proteins 
remain associated with the RTC throughout the reverse transcription process.  
In conclusion, we have developed a dual-labeled fluorescent virus system that 
exclusively uses the natural HIV-1 envelope glycoproteins to infect T-
lymphocytes and therefore lays the foundation to delineate the natural uncoating 
process of HIV-1. Furthermore, this system can also be applied to study the 
entry mechanism of other viruses. 
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NC-DEPENDANT LOCALIZATION OF HIV-1 GAG TO UROPODS IN 
POLARIZED T CELLS FACILITATES CELL-TO-CELL VIRUS 
TRANSFER 
 
Nick Llewellyn1, Akira Ono2  
1University of Michigan, Cell and Molecular Biology, Ann Arbor, MI, 
48103, 2University of Michigan, Microbiology and Immunology, Ann 
Arbor, MI, 48103 
 
T cells are highly motile and adopt a polarized morphology in lymph nodes 
where cell-to-cell transmission of HIV-1 is likely frequent. However, little 
is known about the HIV-1 life cycle in polarized T cells. Polarized T cells 
form two ends, the leading edge at the front and a protrusion called a 
uropod at the rear. Using multiple uropod markers, we determined that 
HIV-1 Gag localizes to the uropod in polarized T cells. Infected T cells 
formed contacts with uninfected target T cells preferentially via HIV-1 Gag-
containing uropods compared to leading edges that lack plasma-membrane-
associated Gag. Furthermore, a myosin light chain kinase inhibitor, which 
disrupts uropods, reduced virus particle transfer from infected T cells to 
target T cells. These results suggest that Gag-laden uropods enhance cell-to-
cell transmission of HIV-1. Although cell-to-cell virus transfer required 
Env-CD4 interactions, we determined that Env, which is known to interact 
with Gag, is dispensable for Gag localization to the uropod. Interestingly, 
we observed that Gag copatches with antibody-crosslinked uropod markers 
even in non-polarized cells, suggesting an association of Gag with uropod-
specific microdomains that carry Gag to uropods. Consistent with this 
possibility, lateral movement of Gag-containing patches to uropods was 
observed in live cell imaging of polarizing T cells. Finally, we determined 
that localization of Gag to the uropod depends on higher-order clustering 
driven by its NC domain, which uses RNA as a scaffold. Taken together, 
these results support a model in which NC-dependant Gag accumulation to 
uropods establishes a preformed platform that facilitates HIV-1 cell-to-cell 
transmission upon uropod contact with target cells. 
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HIV can infect cells through a cell-free intermediate or can be directly passed 
from an infected cell to an uninfected recipient cell. Cell-to-cell infection has 
been shown to be a more efficient route of spread in vitro. Our recent studies 
have revealed that large quantities of virus are internalized into recipient cells 
through T cell virological synapses. The amount of virus transferred can be 
thousands of fold greater than that achieved by cell-free virus. Here, we 
examined if cell-cell infection leads to high rates of simultaneous infection by 
multiple proviruses.  
 
To measure the frequency of multiply infected cells following cell-free or cell 
associated infection, we infected with combinations of fluorescent protein-
marked HIV proviruses, where dual or triple color infected cells provide a 
measure of coinfection. In our studies, we titrated cell-free and cell-associated 
infections over the same infection rates. Cell-free virus was harvested from cells 
expressing two different HIV proviruses, and donor cells were generated by 
cotransfection of two or three different HIV proviruses. When cell-free virus 
was titrated onto target cells, the coinfection rate was dependent on the square 
of the overall infection rate, and approached zero at low infection rates. 
However, when donor cells were titrated onto target cells, the coinfection rate 
was high at high infection rates, but remained at a set percentage that did not 
approach zero at low infection rates. To directly measure proviral copy number 
in cells, we performed fluorescence in situ hybridization (FISH) on cells 
infected by cell-free versus cell-associated virus and observed higher numbers 
of proviral DNA per cell following cell-cell infection. 
 
We conclude that cell-free virus can be titrated to levels where coinfection does 
not occur, but cell-associated infection does not readily approach zero. The 
persistance of multiply infected cells at extremely low cell-cell infection rates 
(e.g. <0.05%) may facilitate HIV recombination or favor the maintenance of the 
viral quasispecies observed in vivo. The study suggests that the unit of genetic 
inheritance during cell-cell infection is often greater than one genome and has 
implications for modeling HIV evolution, development of drug resistance, 
immune escape and phenotypic variation.  
This work was supported in part by National Institutes of Health, Institute of Allergy and 
Infectious Diseases (NIAID) grant 5F31AI075570-02 awarded to A.D.P. and NIAID 
grant AI074420-02 awarded to B.C. 
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HIV CO-OPTS TROGOCYTOSIS TO TRAFFIC FROM DENDRITIC 
CELLS TO T CELLS DURING TRANS-INFECTION 
 
Hyun Jae Yu, David McDonald  
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Dendritic cells (DCs) bind and transfer intact HIV to CD4 T cells by 
forming an “infectious synapse,” where the bound virus is recruited to the 
site of cell contact along with CD4 and chemokine receptors on the T cell 
surface, providing an efficient conduit for virus entry. Activation of the DCs 
by bacterial LPS markedly enhances infectious synapse formation and 
trans-infection. We have previously shown that HIV is concentrated within 
a non-endosomal, surface accessible “pocket” within activated DCs and that 
individual virions can traffic from the pocket and rapidly fuse into the T cell 
at the infectious synapse. Here we demonstrate that activated DCs exhibit 
greatly decreased capacity to endocytose and process HIV peptides for 
antigen presentation, suggesting that there is a dynamic balance between 
trans-infection and antigen processing in dendritic cells. Careful 
examination of the synapses revealed that in a subset of conjugates, T cell 
surface markers co-localized with concentrated HIV within the DCs and 
appeared to be connected to the T cells by thin membrane extensions. 
Strikingly, T cell surface antigens were found within the HIV pocket in 30-
40% of DCs even in the absence of interacting T cells. This transfer of 
surface markers between cells, known as “cell nibbling” or trogocytosis, 
occurred with similar efficiency in co-cultures with CD8 T cells and was 
largely blocked by anti-LFA-1 antibodies. Interestingly, the majority of 
CD4 T cells contained 1-2 virions per cell after 30 minutes of co-culture, 
whereas little or no viral transfer into CD8 T cells was observed. Our data 
suggests that LPS activation induces endocytic downregulation and HIV 
sequestration within the pocket-like structure. Contact with T cells results in 
surface invasion into the pocket and LFA-dependent transfer of T cell 
markers into the DC. If CD4 is present on the T cell membrane, HIV can 
exit the pocket and enter the T cell at the infectious synapse. Therefore T 
cells may play an important role in “fishing” HIV out of the pocket during 
trans-infection. 
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GAG TARGETING TO GLYCOSPHINGOLIPID-ENRICHED 
MICRODOMAINS PLAYS AN IMPORTANT ROLE IN DENDRITIC 
CELL-MEDIATED HIV-1 CAPTURE AND TRANSFER. 
 
Hisashi Akiyama, Steven C Hatch, Hiren V Patel, Nora P Ramirez, Rahm 
Gummuluru  
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HIV-1 has exploited dendritic cells (DCs) to promote their transmission to T 
cells. We recently reported that glycosphingolipids (GSLs) on virus particle 
membrane play an important role in DC-mediated virus capture and the 
subsequent virus transmission. HIV-1 is believed to bud from GSL-enriched 
lipid microdomains on the plasma membrane. Thus, we hypothesized that HIV-
1 particles obtain determinants for DC-mediated capture by targeting Gag to 
GSL-enriched microdomains for release. To test this hypothesis, we introduced 
an in frame deletion or point mutations in matrix (MA) domain of HIV-1 Gag to 
potentially alter the site of virus budding, and tested the ability of DCs to 
capture and transfer mutant and wild type (WT) Gag-eGFP virus-like particles 
(VLPs) and infectious virus particles.  
In contrast to WT-Gag-eGFP that was predominantly found at the plasma 
membrane in transfected cells, the Gag-eGFP mutants containing deletion 
(MA) or point mutations (29/31KE) in MA were predominantly distributed at 
an intracellular compartment, indicating that modification of MA altered the 
VLP budding site. Though efficiency of VLP release was unaffected, MA-
VLPs contained significantly less GM3 than WT-VLPs, suggesting the MA 
variant budded from non-GSL-enriched membranes. Interestingly, mature DCs 
could capture less MA- and 29/31KE-VLPs than WT-VLPs (>80% reduction). 
The effect of MA-deletion on infectious virus budding was also confirmed by 
EM and IF and observed to occur mainly from CD63+ Lamp-1+ intracellular 
compartments. Importantly, the ability of mature DCs to capture NL43MA 
virus was dramatically inhibited (~10% of the wild type NL43). Although 
truncating the cytoplasmic tail of gp41 (CT) allowed the MA variant to 
incorporate gp120 into particles similar to levels observed with parental 
NL43CT, and rescued virus infectivity, the NL43MACT remained poor for 
capture by DCs and was severely attenuated for DC-mediated transfer to T 
cells, arguing that Env-independent capture mechanism is crucial for the ability 
of HIV-1 to access the DC-dependent trans infection pathway.  
These results suggest that HIV-1 particles acquire determinants which are 
specifically recognized by DCs when Gag proteins are targeted to the GSL-
enriched microdomains in the plasma membrane for release. Furthermore, these 
findings may explain in part why HIV-1 buds predominantly from the plasma 
membranes rather than from the intracellular membranes even though such 
intracellular virus budding sites might be better protected from antiviral agents 
such as neutralizing antibodies. 
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EVIDENCE FOR SEQUENCE VARIATION IN XMRV  
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Viral genomic sequences of the human gammaretrovirus xenotropic murine 
leukemia virus-related virus (XMRV) have been detected in prostate cancer 
tissue and in the peripheral blood mononuclear cells (PBMCs) of individuals 
with chronic fatigue syndrome, as well as a small percentage of normal blood 
donors. However, several laboratories have been unable to detect XMRV 
sequences in prostate cancer tissue or PBMCs from CFS patients by DNA PCR. 
These differences could be due to a number of factors including geographical 
differences in the distribution of XMRV, differences in the assays used, or the 
presence of variants of XMRV in different populations.  
 
The XMRV sequences published to date suggest that this virus has very little 
sequence diversity. We recently initiated studies to characterize XMRV from a 
large number of infected individuals. Peripheral blood from individuals with 
CFS or prostate cancer were examined, and more than 35 antibody positive 
individuals in each group were identified. Initially, nested PCR and RT-PCR for 
env was performed on DNA and RNA isolated from PBMCs from some of 
these individuals, using previously published primers. Env sequences were 
amplified from several of the samples; the sequences were identical or nearly 
identical to what had been previously reported for XMRV. However, for the 
majority of the samples, we were unable to amplify env sequences, even in 
samples from which virus had been isolated.  
 
In contrast, gag sequences could be amplified from nearly all the samples, 
suggesting that there might be more variability in XMRV that previously 
reported. In addition, preliminary studies suggested that XMRV sequences 
directly amplified from PBMCs in patient samples differed from sequences 
amplified after viral spread following ex vivo culture.  
 
We have now isolated RNA from unactivated PBMCs, and from PBMCs 
activated and cultured ex vivo, from more than 30 XMRV positive individuals 
and have amplified gag sequences using nested RT-PCR. The samples are 
currently being sequencing to determine extent of variability in these samples.  
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HIV-1 IN MUTANTS DEFECTIVE FOR INI1/HSNF5 BINDING ARE 
DEFECTIVE FOR POST-ENTRY EVENTS OF HIV-1 REPLICATION 
 
Sheeba Mathew, Xuhong Wu, Achintya Pal, Ganjam Kalpana  
 
Albert Einstein Colllege of Medicine, Genetics, Bronx, NY, 10461 
 
INI1/hSNF5 (Integrase interactor 1) is incorporated into HIV-1 virions by 
binding to IN. Transdominant mutants of INI1 inhibit HIV-1 replication and 
virions produced in INI1-/- MON cells are defective for infectivity. INI1 
and IN interact with SAP18 and recruit HDAC1 complex into virions, 
which is required for early post-entry events.  
To further understand the role of INI1 and associated SAP18-HDAC1 
complex, we isolated a panel of IN mutants defective for INI1 binding using 
reverse yeast two-hybrid system. INI1 interaction defective mutations of IN 
were mapped on solved crystal structures of IN and mutations of residues 
with high surface accessibility on IN (S147G, Q137R, K71R, H12Y, 
K111E, D202G) were further characterized using virological assays. The 
panel of IN* mutants were incorporated into HIV-1NL4-3 and tested for 
infectivity in CEM-GFP cells. GFP expression and virion-associated p24 
and RT activity were scored in a 16 day infection cycle. ALL mutants 
(including the previously reported K71R) were defective for replication 
compared to wild type in CEM-GFP cells. Two distinct classes of INI1-
interaction defective IN* mutants--those that were highly defective (Q137R, 
H12Y, D202G) or partially defective (K71R, S147G, K111E) for 
replication were noted. The mutants were then incorporated into HIV-Luc 
and tested for their effect on early events. Consistent with the results of 
multiday replication assay, highly defective mutants were 10-100 fold 
defective and partially defective mutants were 2-5 fold defective in the 
HIV-Luc assay. Western blot analysis of mutant virions revealed the stable 
expression of all viral proteins including mutant INs except for highly 
defective H12Y, which showed a processing defect and ~5 fold reduction in 
virion associated IN. Analysis of early post entry stages of replication 
indicated that highly defective mutants were blocked at early and late 
reverse transcription, whereas partially defective mutants were not defective 
in these assays.  
The above analysis indicated a block at or prior to reverse transcription in 
highly defective mutants, similar to a block we noted when HIV-1 virions 
were produced in INI1-/- cells or when defective HDAC1 mutant was 
incorporated into virions. Currently, we are analyzing the ability of these 
mutants to interact with RT, INI1 and/or SAP18 to determine the 
mechanism of block at or prior to reverse transcription. These studies will 
shed light on the role of INI1 and the associated SAP18-HDAC1 complex 
during HIV-1 replication.  
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A wide variety of transposable elements and viruses rely on tRNAs and 
tRNA-like structures during their life cycles. To initiate reverse 
transcription, HIV-1 anneals human tRNALys3 to the complementary primer 
binding site (PBS), and cDNA synthesis begins from the 3´-OH of the 
tRNA. We have previously shown that human lysyl-tRNA synthetase 
(LysRS) is specifically incorporated into HIV-1 by the Gag protein and that 
this interaction is critical for tRNALys3 packaging. Herein, we describe a 
novel conserved tRNALys3-like element (TLE) in the 5´-UTR of the HIV-1 
genome proximal to the PBS. Using electrophoretic mobility shift assays 
and fluorescence anisotropy binding studies, we show that LysRS interacts 
with the TLE, which mimics the anticodon domain of tRNALys3, whereas 
human TrpRS and ProRS do not. The affinity of LysRS for short (23 nt) 
HIV-1 genome-derived RNA hairpins containing the TLE is similar to that 
of in vitro transcribed 76-nt tRNALys3 (Kd ~ 90 nM). Human LysRS 
recognizes tRNALys isoacceptors via a specific interaction with the 
anticodon (UUU in tRNALys3 and CUU in tRNALys1,2). Mutation of the 
corresponding UUU motif in the TLE to AAA or CCC greatly reduces the 
LysRS-TLE interaction (Kd ≥ 2.5 and 8 uM, respectively). Longer 330-nt 
RNAs derived from the 5’-UTR compete even more effectively for LysRS 
binding to a tRNALys3 anticodon stem-loop mimic than tRNALys3, suggest 
that in addition to the U-rich motif in the TLE, other sequence elements in 
the 5´ UTR contribute to preferential binding of LysRS to the HIV-1 
genome. 293T cells transfected with virus containing TLE mutations show 
no change in the level of packaged tRNALys3 but result in a 70% decrease in 
the amount of tRNALys3 placed onto the genome. Taken together, these new 
findings suggest that the HIV-1 genome uses molecular mimicry of 
tRNALys3 to facilitate primer release from LysRS and placement onto the 
PBS. 
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DUPLEX STRUCTURAL DIFFERENCES AND NOT 2’-HYDROXYLS 
EXPLAIN THE MORE STABLE BINDING OF HIV-RT TO RNA-DNA 
VS. DNA-DNA 
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Human immunodeficiency virus reverse transcriptase (HIV-RT) must interact 
with RNA-RNA, RNA-DNA and DNA-DNA duplexes to complete reverse 
transcription. Interestingly, binary complexes between HIV-RT and RNA-DNA 
are much more stable than those with DNA-DNA. The most likely 
explanation(s) for this are: (1) RNA-DNA and DNA-DNA duplexes obtain H-
form (structure between A-form (RNA-RNA duplex structure) and B-form 
(DNA-DNA duplex structure) but closer to the former) and B-form structures, 
respectively, and RT may bind more stably to H-form; (2) Crystal structures of 
RNA-DNA and DNA-DNA with RT have many similarities but a major 
difference is several additional interactions between RT amino acids and 2’-
hydroxyls of the RNA template. This suggests a possible role for these 
interactions in stabilizing binding. Previously we showed that only 5 base pairs 
of RNA-DNA hybrid imbedded in a larger DNA-DNA duplex were required to 
mimic the stable binding of a complete RNA-DNA duplex, provided that the 
RNA-DNA was position in the polymerase active site (Bohlayer and DeStefano, 
2006, Biochemistry 45:7628-38). Here, we present new results indicating that 
only 2 of the 5, the -2 and -4 RNA nucleotides (-1 hybridized to the 3′ recessed 
DNA base), are required to mimic RNA-DNA binding, and even a single RNA 
nucleotide at the -4 position confers significantly greater stability than DNA-
DNA. Replacing 2´- hydroxyls on pivotal RNA bases with 2´-O-methyls did not 
affect stability, indicating that interactions between hydroxyls and RT amino 
acids do not stabilize binding. RT’s Kd (koff/kon) for DNA-DNA and RNA-DNA 
were similar, although koff differed almost 40-fold, suggesting a faster kon for 
DNA-DNA. Avian myeloblastosis and Moloney murine leukemia virus RTs 
also bound more stably to RNA-DNA, but the difference was less pronounced 
than with HIV-RT. We propose that the H- vs. B-form structures of RNA-DNA 
and DNA-DNA, respectively, allow the former to conform more easily to HIV-
RT’s binding cleft, leading to more stable binding. Notably, crystal structures of 
HIV-RT with duplexes show that the 4 base pairs near the polymerase active 
site in the “primer-grip” (the region of RT most associated with substrate 
binding) region of RT obtain an A-form like structure while those in the 
connection and RNase H domains are closer to B-form. The H-form structure of 
RNA-DNA hybrids is also “A-form like” and may simply conform better than 
DNA-DNA for binding in the primer grip region. Biologically, the ability of RT 
to form a more stable complex on RNA-DNA may aid in degradation of RNA 
fragments that remain after DNA synthesis. 
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CONSERVATION AND MECHANISM OF ANTI-HIV-1 ACTIVITY OF 
TRIM 37 
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There is strong experimental evidence that several members of the tripartite 
motif (TRIM) family of proteins possess antiretroviral activity. In 
particular, Trim5alpha, Trim22, Trim19, and Trim32 have all been shown 
to possess anti-HIV-1 activity. We have identified another member, 
Trim37, as having the ability to potently restrict HIV-1 replication. To date, 
our data supports a model in which Trim 37 interacts with HIV-1 reverse 
transcriptase (RT), is incorporated into HIV-1 particles, and interferes with 
reverse transcription. In our current studies, we have investigated whether 
Trim 37 has been under positive selection and whether the antiretroviral 
activity is functionally conserved. Our phylogenetic analyses have 
implicated that Trim 37 has been under positive selection, which supports 
its being associated with intrinsic immunity to retroviral replication. 
Functional analyses of Trim 37 from various mammalian species (i.e., 
various non-human primate species including African green monkey, 
bovine, and feline) have verified conserved antiretroviral activity. These 
studies provide insight into both the antiretroviral determinants of Trim 37 
as well as implicate the ability of Trim 37 to interfere HIV-1 reverse 
transcription by reducing RT processivity. 
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The restriction factor Fv1 confers resistance to Murine leukaemia virus 
(MLV), blocking progression of the viral life cycle after reverse 
transcription has occurred, but before integration into the host chromosome. 
It is known that the specificity of restriction is determined by both the 
restriction factor and the viral capsid (CA), but a direct interaction between 
Fv1 and MLV CA has not yet been demonstrated.  
 
With the development of a novel method for in vitro polymerisation of 
MLV CA, it has now been possible to display a binding interaction between 
Fv1 and MLV CA. C-terminally His-tagged CA molecules were assembled 
on Ni-containing lipid-based nanotubes. Analysis of these tubes by electron 
microscopy showed that at the appropriate concentration of Ni a regular 
lattice is formed. Incubation with of these tubes with lysates from cells 
expressing Fv1 followed by centrifugation enabled binding to be 
demonstrated.  
 
Comparison of binding data with existing restriction data confirms the 
specificity of the interaction. For example, product of the Fv1n allele bound 
CA from B tropic MLV but not N-MLV and was sensitive to mutations 
converting N-MLV to NR-MLV or mutations interfering with proper CA 
assembly. Further, an inactive Fv1 mutation (Int1) previously hypothesized 
to loose restriction activity as a result of mis-localization within the cell was 
shown to bind CA normally whereas a second mutation (in the Fv1 MHR), 
which is likely to interfere with Fv1 folding, did not. We are currently using 
this novel binding assay to further investigate the mechanism by which Fv1 
restricts MLV infection.  
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TRIM5α proteins from rhesus monkeys (TRIM5αrh) block human 
immunodeficiency virus (HIV-1) infection prior to reverse transcription. 
TRIM5αrh protein consists of a RING, B-box 2, coiled-coil and 
B30.2(SPRY) domains. The contribution of each independent TRIM5α 
domain to restriction has been extensively studied with the exception of the 
RING domain. The RING domain of TRIM5α contributes to the potency of 
retroviral restriction and possesses ubiquitylation activity. Substrate 
ubiquitylation starts by the formation of a covalent link between ubiquitin 
and enzyme-1 (E1), which transfers ubiquitin to the active site of E2. The 
ubiquitin conjugated-E2 interacts with an E3 ubiquitin ligase that transfer 
ubiquitin from the E2 to a lysine residue in the ubiquitylation substrate. The 
RING domain of TRIM5α possesses two functional surfaces important for 
E3 ubiquitin ligase activity: 1) the E2 binding surface, and 2) the 
association surface, which in many cases improves the catalytic transfer of 
ubiquitin. Because the contribution of E3 ubiquitin ligase activity to 
restriction is not understood, we tested the hypothesis that the E3 ubiquitin 
ligase activity of the RING domain modulates HIV-1 restriction by 
TRIM5αrh. To test our hypothesis, we correlated the E3 ubiquitin ligase 
activity of a panel of TRIM5αrh RING domain variants to the ability of 
these mutants to restrict HIV-1. These results established a role for E3 
ubiquitin ligase activity in HIV-1 restriction by TRIM5α. 
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TRIM5 proteins restrict retrovirus life cycle at least at two stages: by targeting 
early post-entry event(s) that lead to reverse transcription of the viral genome, 
which requires functional 26S proteasome, and by interfering with transport of 
the viral preintegration complex to the nucleus. To address the underlying 
mechanisms we performed comprehensive proteomic analyses of TRIM5 
associated cellular proteins from cell lines stably expressing rhesus monkey 
TRIM5. Strikingly, we identified 26 out of 31 subunits of 26S proteasome in 
highly purified TRIM5 preparations. This demonstrated that TRIM5 tightly 
associates with 26S complex, but was surprising in that 26S complex normally 
dissociates into its 19S regulatory and 20S catalytic sub-complexes under the 
purification conditions used. This probably reflects TRIM5 degradation since 
such a behavior is expected of stalled 26S proteasome-substrate complexes. 
Next we addressed the roles of TRIM5 poly-ubiquitylation. A systematic scan 
of the TRIM5 molecule with lysine-to-arginine substitutions revealed that at 
most only 4 lysines located in the SPRY domain are required for TRIM5 to 
restrict infection, and these lysines are not the sites of poly-ubiquitylation. We 
also analyzed the ability of a mutant TRIM5 molecule (K74R) that retains only 
6 lysines in its RING domain and is not poly-ubiquitylated to bind 26S 
proteasome. TRIM5 K74R stably and specifically associated with 26S 
proteasome, as it precipitated the complete 26S proteasome complex under 
conditions that stabilize the 26S complex. Strikingly, and in contrast to wild-
type TRIM5, K74R precipitated only the 19S regulatory sub-complex under 
conditions that favor 19S dissociation from 20S, thus indicating that it docks 
specifically to the 19S regulatory sub-complex. The spectrum of 19S subunits 
found associated with K74R suggests that it docks to 19S probably via its base, 
similar to other proteins that modulate proteasome function, and, importantly, 
confirms that K74R binding to 19S is not mediated by TRIM5 poly-
ubiquitylation, because the 19S subunits that serve as polyubiquitin receptors 
were not found. Our findings indicate that TRIM5, besides being degraded by 
the proteasome, also stably associates with the 19S regulatory sub-complex by a 
poly-ubiquitylation-independent mechanism. We hypothesize that via its 
binding to the 19S sub-complex TRIM5 recruits 26S proteasome to the 
restricted viral capsid, and that this physical interaction with 19S sub-complex 
is important for TRIM5’s full ability to restrict retrovirus infection. 
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TRIM5 proteins mediate a potent block to the cross-species transmission of 
retroviruses, the most well known being the TRIM5α protein from rhesus 
macaques, which potently inhibits human immunodeficiency type-1 (HIV-
1) infection. This restriction occurs at an early stage in the replication cycle 
and is mediated by the binding of TRIM5 proteins to determinants present 
in the retroviral capsid. TRIM5, as well as other TRIM family proteins, 
have been shown to be regulated by interferons (IFN). Here we show that 
TRIM5α associates with another IFN-induced gene, Sequestosome-1/p62 
(p62). p62 plays a role in several signal transduction cascades that are 
important for maintaining the anti-viral state of cells. Here we demonstrate 
that p62 localizes to both human and rhesus TRIM5α cytoplasmic bodies, 
and fluorescence resonance energy transfer (FRET) analysis demonstrates 
that these proteins closely associate in these structures. When p62 
expression was knocked down via siRNA, the number of TRIM5α 
cytoplasmic bodies and TRIM5α protein expression was reduced in cell 
lines stably expressing epitope tagged versions of TRIM5α. In accordance 
with this data, p62 knockdown resulted in reduced TRIM5α mediated 
retroviral restriction in cells expressing epitope tagged TRIM5α or 
expressing endogenously expressed human TRIM5α. p62 may therefore 
operate to enhance TRIM5α mediated retroviral restriction, enhancing the 
antiviral state of cells following IFN treatment. 
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TRIM5α blocks retroviral replication when expressed in otherwise 
susceptible target cells. Based on in vitro assays and phylogenetic 
comparisons, it is widely assumed that TRIM5α prevents cross-species 
transmission of retroviruses in nature, and that spread of pathogenic viruses 
in a new host, when it occurs, drives protective alleles of TRIM5 to 
fixation. Simian immunodeficiency viruses of sooty mangabeys (SIVsm) 
are the source of multiple cross-species transmission events, giving rise to 
HIV-2 in humans, SIVmac in rhesus macaques, and SIVstm in stump-tailed 
macaques. We found that SIVsm, SIVstm, HIV-1 and HIV-2 were sensitive 
to multiple alleles of rhesus macaque TRIM5, including TRIM5-CypA, 
while SIVmac was resistant to all alleles tested. We also analyzed 
experimental cross-species transmission of SIVsm into rhesus macaques, 
the most widely used species in preclinical AIDS vaccine research, and 
found a significant correlation between TRIM5 genotype, viral replication, 
and emergence of allele-specific escape mutations in the N-terminal domain 
of capsid. Unexpectedly, transmission occurred even in individuals bearing 
restrictive TRIM5 genotypes, resulting in attenuation of replication rather 
than an outright block to infection. Using phylogenetic analyses and site-
directed mutagenesis experiments, we identified two adaptive changes in 
the SIVmac239 capsid that render it resistant to specific alleles of rhesus 
TRIM5.  
Thus, TRIM5α suppresses viral replication in vivo, exerting selective 
pressure during the initial stages of cross-species transmission. However, 
restriction by TRIM5 alone may be insufficient to prevent cross-species 
transmission of primate lentiviruses, and once a virus has adapted to a host 
population (as is the case with HIV-1 in humans and SIVmac in macaques), 
the role of restriction in limiting spread diminishes relative to genes of 
adaptive immunity. 
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One of the central principles of biochemistry is that the amino acid 
sequence of a protein determines a single three-dimensional structure. This 
fidelity of structure is crucial to maintaining specificity of function in 
proteins such as enzymes. In innate immunity, however, this limits the 
usefulness of antiviral proteins due to the tremendous diversity of viruses 
and their capacity to evolve. We have discovered that the lentiviral 
restriction factor Rhesus TRIMCyp (RhTC) has addressed this problem by 
evolving the ability to isomerise between multiple conformations, each of 
which targets a different virus from a distinct lentiviral lineage. This 
multispecificity has evolved following retrotransposition of a duplicated 
(CypA) domain and fusion with the tripartite domains of TRIM5. We have 
used NMR dynamics to show that subsequent mutation and selection of two 
residues in the CypA domain have released a constrained active-site loop, 
leading to dynamic sampling of conformational space. Determination of 
complexed crystal structures reveal how this modified RhTC CypA domain 
selects a closed loop conformation to bind particular strains of HIV-1 and 
an open loop conformation to bind HIV-2. Although Linus Pauling 
predicted ‘conformational diversity’ over 70 years ago, to our knowledge 
this is the first example of such a mechanism being used to expand protein 
function. Conformational diversity may functionally augment genetic 
diversity and be a general host response to the selective pressure exerted by 
lentiviruses. 
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The cyclin-dependent kinase inhibitor p21Cip1/Waf1 has been involved in the 
resistance of hematopoietic stem cells to HIV-1 infection, by inhibiting viral 
DNA integration. We showed that the induction of p21 expression in monocyte 
derived macrophages (MDM) by immune complex (IC)-aggregation of FcγR or 
by the histone deacetylase inhibitor MS-275 was associated to a strong and 
dose-dependent inhibition of HIV-1 replication. The levels of reverse transcripts 
and integrated proviruses in one-round infections with VSV-G pseudotyped 
HIV-1 (NL4.3VSV-G) were decreased by p21 induction. Gene knockdown of p21 
increased both HIV-1 reverse transcripts and integrated forms in unstimulated 
MDM and rescued the defect of HIV-1 replication in FcγR-activated cells. To 
confirm that p21 is specifically involved in the inhibition of HIV-1 infection, 
we transfected MDM with GST-tagged and HA-tagged p21 expression vectors. 
The overexpression of p21 reduced HIV-1 replication by 96% and 93% 
respectively. These results indicate that p21 inhibits HIV-1 replication blocking 
early post-entry steps of viral life cycle. We next asked whether p21 could play 
an antiviral activity in other cellular targets of HIV-1. We knocked down p21 
expression in primary CD4+ T cells and infected them with NL4.3VSV-G. The 
depletion of p21 produced a significant increase (63%) of HIV-1 replication 
compared to CD4+ T cells transfected with an irrelevant siRNA, indicating that 
p21 exerts an inhibitory activity on HIV-1 infection in these cells.  
However, p21 was previously reported to enhance HIV-1 replication in 
chronically infected MDM. Thus, we asked whether p21 may differently affect 
post-integrative steps of HIV-1 replication. We transfected MDM with an HIV-
1 NL4.3 coding vector and we studied the effect of IC-mediated activation on 
LTR-driven transcription. HIV-1 transcription was increased of 3.2-fold in IC-
activated MDM compared to unstimulated MDM.  
Our data show that p21 acts as an intrinsic barrier to HIV-1 replication in the 
major target cells of HIV-1. In addition, our results also suggest that p21 may 
play a dual role in HIV-1 infection of macrophages, inhibiting the preintegrative 
steps of the incoming virus and enhancing HIV-1 gene transcription after viral 
integration. Pharmacological compounds, such as HDACi, that are currently 
studied as adjuvant to highly active antiretroviral therapy to eradicate HIV-1 
reservoirs, also induce p21 expression and might thus exert a double 
therapeutical role; they may induce HIV-1 expression from latently infected 
cells while limiting HIV-1 reinfection of lymphoid and myeloid target cells.  
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Post-entry transport mechanisms of retroviruses are currently not well 
understood but it is believed that the host cytoskeleton must play an integral 
role and it has been shown that productive human immunodeficiency virus 
type 1 (HIV-1) infection is dependent on functional actin dynamics. Here 
we show that the actin-interacting cytoskeletal regulatory proteins, talin 1 
and vinculin function during retroviral infection. Talin 1 and vinculin 
directly interact with each other and are involved in the linkage of integrins 
to the actin cytoskeleton. To assess the involvement of talin1 and vinculin 
in retroviral infection we have used siRNA to transiently knockdown 
expression of each gene followed by infection with pseudo-typed HIV-1 
virus and measured infection levels. Two independent infection assays have 
confirmed that human cells with either talin 1 or vinculin knocked down 
become more susceptible to pseudo-typed HIV-1 and simian 
immunodeficiency virus (SIV) infection. Additionally, over-expression of 
talin 1 or vinculin decreases susceptibility to HIV-1 infection. Vesicular 
stomatitis virus (VSV-G) and amphotropic- pseudotyped HIV-1 are blocked 
by talin 1 or vinculin indicating that the block to infection is post-entry. 
Viral block assays were performed to examine where in the retroviral life 
cycle talin 1 and vinculin block infection. Our data suggests that both talin 1 
and vinculin down-regulate HIV-1 infection post-entry but before the 
initiation of reverse transcription. 
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HIV-1 and certain other retroviruses initiate plus strand synthesis in the 
center of the genome as well as at the standard retroviral 3’ polypurine tract. 
This peculiarity of reverse transcription results in a central DNA “flap” 
structure that has been of controversial functional significance. We mutated 
both HIV-1 flap-generating elements, the central polypurine tract (cPPT) 
and the central termination sequence (CTS). To avoid an ambiguity of prior 
studies, we did so without changing integrase coding. Single cycle infection 
by 293T cell transfection-produced virus was unaffected in all target cells 
tested. Spreading HIV-1 infection was also normal in most T cell lines and 
in fibroblast cell lines, and flap-mutant viruses replicated equivalently to 
wild type in nondividing cells, including macrophages. However, spreading 
infection of flap-mutant HIV-1 was selectively impaired in Vif non-
permissive cells (HuT78, H9, primary human PBMCs), suggesting 
APOBEC3G (A3G) restriction. Single cycle infections confirmed that vif-
intact flap-mutant HIV-1 is restricted by producer cell A3G. Combining vif 
and cPPT-CTS mutations increased A3G restriction synergistically. 
Moreover, RNAi-mediated knockdown of A3G in HuT78 cells released the 
block to flap-mutant HIV-1 replication. Flap-mutant HIV-1 accrued 
markedly increased A3G-mediated G to A hypermutation compared to 
wild-type HIV-1 (a full log10 in a single cycle in the 0.4 kb downstream of 
the mutant cPPT). We conclude that the triple-stranded DNA structure, the 
flap, is not the main consequential outcome. The salient functional feature is 
central plus strand initiation, which functions as a second line of defense 
against the antiviral effects of A3 proteins that survive producer cell 
degradation by Vif. 
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Although HIV-1 capsid disassembly (defined as uncoating) can occur 
precociously following cell entry, for instance upon TRIM5α restriction, 
evidence suggests that this cannot lead to productive infection. Indeed, 
successful uncoating is thought to occur much later, after reverse 
transcription and immediately prior to nuclear import. Our previous work 
suggests that HIV-1 uses both microtubule and actin networks to reach the 
nuclear membrane and that uncoating occurs at the nuclear pore. We 
therefore hypothesised that the capsid is the viral component that interacts 
with the cytoskeleton during its transport towards the nuclear compartment. 
To identify the cytoplasmic elements that interact with HIV intracellular 
complexes during cytoplasmic transport, we carried out a yeast-two-hybrid 
screen against either whole CA or helices 4-7, which include the interaction 
domain for cyclophilin A. We thus identified six CA-interaction partners, 
four of which are involved in cytoskeletal transport networks and two in 
nuclear transport. We then verified these candidates for interaction with 
native capsid cores, isolated directly from cell-free particles stripped of viral 
envelope. Furthermore we used RNA interference to evaluate which cellular 
interaction partners of viral CA are required or essential for HIV infection. 
This work sheds new light on the functional interplay between HIV-1 
transport towards the nucleus and timely uncoating. 
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Transportin-SR2 (TRN-SR2) is a human karyopherin that imports SR-rich 
proteins from the cytoplasm into the nucleus. We identified TRN-SR2 as a 
binding partner of HIV-1 integrase (IN) and validated TRN-SR2 as an 
important cellular cofactor for the nuclear import of the HIV-1 pre-
integration complex (PIC). In contrast, recent reports have suggested that 
not IN but the viral capsid (CA) protein determines TRN-SR2 dependency 
during viral infection. The HIV-1 N74D CA mutant was shown to be 
insensitive to TRN-SR2 knockdown. These contradictory findings 
prompted us to study in more detail the specific roles of integrase and 
capsid in TRN-SR2 mediated nuclear import of the HIV-1 PIC.  
By infection of HeLaP4 cells depleted for TRN-SR2 and control cells with 
VSV-G pseudotyped single round HIV-1 reporter viruses carrying wild type 
or N74D mutant capsid proteins we confirm that the N74D CA mutation 
abrogates the inhibition of infection by TRN-SR2 knockdown. However, 
when TRN-SR2 knockdown and control cells were infected with viruses 
carrying the HIV-1 envelope, the HIV-1 N74D CA mutant regained 
sensitivity to TRN-SR2 knockdown. Much alike VSV-G, the viral 
envelopes of Ebola and rabies viruses that mediate entry of target cells via 
endocytosis rendered the HIV-1 N74D CA mutant insensitive to TRN-SR2 
knockdown. Together with a lack of evidence for a direct interaction of 
TRN-SR2 with CA, this demonstrates that the TRN-SR2 independent 
phenotype displayed by the VSV-G pseudotyped HIV-1 N74D CA mutant 
is not dependent on TRN-SR2 interacting with CA but rather on the mode 
of viral entry and/or trafficking of the viral particle in the target cell.  
We compared the impact of TRN-SR2 knockdown on transduction 
efficiency by different lentiviral and retroviral vectors and analyzed the 
direct interactions between the viral integrase proteins corresponding to 
these vectors and TRN-SR2. We show that TRN-SR2 binds readily to HIV-
1, HIV-2, EIAV, MLV and RSV integrase in the alphascreen binding assay. 
Using deletion mutants and single amino acid substitutions we were able to 
pinpoint in HIV-1 integrase the TRN-SR2 binding site in in vitro and cell 
culture experiments.  
Together these data support our hypothesis that IN plays a direct role in the 
nuclear import of the viral PIC. By playing a role in uncoating which 
precedes the interaction between IN and TRN-SR2, capsid has an indirect 
effect on the process of nuclear import.  
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The early phases of lentiviral infection are carried out through a complex set 
of interactions established between viral and cellular proteins at basically all 
steps of the viral life cycle, from virus cell entry to vDNA integration. 
Among such cellular factors, a previous genome wide screen identified 
transportin 3 (TNPO3 or TRN-SR2) as a factor modulating the early steps 
of the HIV-1 life cycle, intervening following viral DNA synthesis at or 
immediately after nuclear import. 
TNPO3 has been shown to interact directly with the viral Integrase protein 
(IN) and to be the cellular partner through which the latter mediates nuclear 
import of viral DNA. However, recent data seem to contradict this finding, 
indicating that the Capsid protein (CA), rather than IN mediates viral access 
to the nucleus via TNPO3. 
To identify the viral and cellular determinants required for this rather 
unclear step of the viral life cycle, we have used lentiviral vectors derived 
from HIV-1 deleted or mutated for cis and trans viral elements alone or in 
combination (cPPT-CTS, Vpr, MA, CA and IN). Then, we have examined 
the effect that ablation of the expression of TNPO3 had on these mutants 
with respect to the early phases of infection. Our results indicate that among 
the viral elements examined here only the cPPT-CTS exerted a small, albeit 
measurable effect on the kinetics of viral DNA entry into the nucleus, but 
these effects were independent on TNPO3. When viruses presenting a 
complete deletion of IN were used to infect transportin 3 positive or knock 
down cells similar defects in infectivity were observed, indicating that IN is 
not the viral determinant required for the effect of TNPO3 on viral 
infectivity. 
Next, mutations in CA were coupled to the IN deletion and the requirement 
for TNPO3 studied in cycling, as well as arrested cells in presence or 
absence of cytoskeleton inhibitors that may affect the virus ability to reach 
or cross the nuclear pore. These and other results on the relationship 
between nuclear import, transportin 3, CA and IN will be presented.  
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To infect nondividing cells, the lentivirus preintegration complex (PIC) 
must transit through the nuclear pore into the nucleus. Two independent 
whole genome siRNA screens for host proteins that play a role in HIV-1 
infection and a yeast two-hybrid screen for host proteins that bind to HIV-1 
integrase (IN) identified TNPO3, a protein that transports cellular cargoes 
into the nucleus, as being necessary for HIV-1 nuclear import. These data 
suggest that TNPO3 transports a viral or cellular cargo whose nuclear 
import is directly or indirectly necessary for PIC nuclear import. We 
demonstrated that stable and transient knocked-down of TNPO3 blocked 
single-cycle HIV-1 and SIVmac reporter virus infection. Quantitation of 
reverse transcripts by qPCR showed that TNPO3 knock-down dramatically 
reduced HIV-1 and SIVmac 2-LTR circles, a marker for nuclear import, but 
had no effect on production of the viral cDNA. TNPO3 was also required 
by other lentiviruses, including EIAV and FIV, but not by the γ-retrovirus, 
MLV. Of these lentiviruses, SIVmac and EIAV were the most sensitive to 
TNPO3 knock-down and we are currently using HIV-1/SIVmac hybrid 
viruses to map the viral factors that contribute to these differing sensitivities 
to TNPO3 knock-down. In addition, we mapped functional domains of 
TNPO3 using a complementation assay in which stable TNPO3 knocked-
down cells were transfected with a knock-down resistant TNPO3 construct 
containing silent mutations in the shRNA target site. We used this assay to 
show that the C-terminal cargo-binding domain of TNPO3 was critical for 
the restoration of SIVmac infection. Further mapping studies identified two 
distinct regions within the cargo-binding domain that were necessary for 
complementation. These mutant TNPO3 proteins maintained their nuclear 
localization, suggesting that their inability to restore SIVmac infection was 
the result of an inability to bind an as yet unidentified host or viral cargo. 
Although HIV-1 IN was reported to interact directly with TNPO3, repeated 
attempts to detect this and other interactions with HIV-1 proteins by 
coimmunoprecipitation from human cells were unsuccessful. We are 
currently using a proteomics approach to identify cellular TNPO3 cargo 
proteins that could be critical for lentiviral infection. 
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Uncoating, a poorly understood step in the HIV-1 life cycle, is defined as 
disassembly of the viral capsid following penetration of the core into the 
target cell. Previous results from our group have shown that mutations in 
CA that stabilize or destabilize the capsid are deleterious to infection, 
indicating that the stability of the capsid is optimized for executing the early 
phase of infection and that inefficient uncoating results in a postentry defect 
(Forshey et al., 2002). Furthermore, an HIV-1 CA mutant that undergoes 
inefficient uncoating leads to impaired nuclear entry, suggesting that the 
extent of uncoating is a critical determinant of nuclear import of the HIV-1 
preintegration complex (Dismuke and Aiken, 2006). Though it seems likely 
that host factors regulate the uncoating process, to date no specific HIV-1 
uncoating factor has been identified. Transportin 3/TRN-SR2 (TNPO3) is a 
karyopherin that was recently shown to promote HIV 1 infection (Brass et 
al., 2008). TNPO3 binds to IN and promotes nuclear import of the 
preintegration complex (Christ et al., 2008); however, a recent study 
identified CA as a major viral determinant of TNPO3-dependent retrovirus 
infection (Krishnan et al., 2010). Here we show that TNPO3 promotes 
uncoating of native HIV-1 cores in vitro. We also demonstrate the 
biological relevance of this finding using RNA interference. Depletion of 
TNPO3 resulted in an approximately 90% decrease in cellular 
permissiveness to wild-type HIV-1. By contrast, infection by CA mutants 
with hyperstable capsids was less dependent on TNPO3 expression. 
Collectively, our results suggest that TNPO3 facilitates infection by 
promoting HIV-1 uncoating following reverse transcription, thus facilitating 
translocation of the preintegration complex through the nuclear pore. 
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To replicate, HIV-1 must integrate into host chromosomes however little is 
known on the early events occurring post-nuclear entry but before 
integration. We have found evidence that HIV-1 must undergo a nuclear 
uncoating step to integrate. We have studied the behavior of HIV-1 in cells 
depleted of Transportin 3 (Tnp3) by transient or stable RNAi. HIV-1 
infection efficiency was significantly lower in Tnp3 knock down (KD) cells 
compared to control cells. Viral DNA synthesis proceeded normally in KD 
cells. Production of 2LTR circular viral DNA forms was also unaffected in 
KD cells and fractionation experiments indicated that viral DNA 
accumulated into the nuclei of KD cells as efficiently as in control cells. 
However HIV-1 integration, measured by Alu-PCR, was defective in Tnp3 
KD cells and fully accounted for the reduced infection. Pull-down assays 
showed that Tnp3 bound tRNAs and capsid proteins (CA) present in 
purified viral particles in a RanGTP dependent way. The C-terminus of 
Tnp3 was required for binding to both viral tRNAs and CA, suggesting that 
their binding is cooperative. The dependence on RanGTP strongly 
suggested that Tnp3 was an export factor for viral tRNAs and CA. The 
tRNA export activity of Tnp3 was confirmed in the permeabilized cell 
assay. To test if Tnp3 could also export CA, KD and control cells were 
infected with HIV-1 and the distribution of CA examined by Western blot 
following nuclear and cytoplasmic fractionation. Whereas significant 
amounts of CA were detected in the cytoplasm of control cells, little CA 
was detected in the cytoplasm of KD cells and the ratio of 
nuclear/cytoplasmic CA was greater in KD than control cells. The HIV-1 
mutant bearing a single N74D change in CA was insensitive to Tnp3 KD 
and showed a similar ratio of nuclear/cytoplasmic CA in KD and control 
cells, supporting the link between export of CA and defective HIV-1 
integration. We propose that tRNAs and some CA are retained in the HIV-1 
RTC/PIC to promote its nuclear import, however these elements must be 
removed from the PIC at at stage after nuclear entry to allow efficient 
integration. Our results provide evidence for an unanticipated step in the 
HIV-1 life cycle that connects capsid and tRNA nucleocytoplasmic 
trafficking to HIV-1 integration. 
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HIV replication requires transport of nascent viral DNA and associated 
virion proteins, the retroviral preintegration complex (PIC), into the 
nucleus. Too large for passive diffusion through nuclear pore complexes 
(NPCs), PICs are dependent on cellular nuclear transport mechanisms and 
nucleoporins (NUPs), the NPC components that permit selective nuclear-
cytoplasmic exchange. The mechanism of HIV PIC interaction with the 
NPC has not been defined. We identified a fragment of the cleavage and 
polyadenylation factor 6, CPSF6, as a potent inhibitor of HIV infection. 
When enriched in the cytoplasm, CPSF6 prevents HIV nuclear entry by 
targeting the viral capsid (CA). HIV harboring an N74D mutation in CA 
fails to interact with CPSF6 and evades the nuclear import block. We have 
mapped residues within CPSF6 necessary for HIV restriction. TRIM5, 
lacking viral targeting sequences, when N-terminally fused to 58 residues of 
CPSF6 restricts wild-type but not N74D HIV. Although CPSF6 restricts 
after reverse transcription, TRIM-CPSF6 prevents the initiation reverse 
transcription, providing further evidence for a direct interaction of CPSF6 
with CA. Interestingly, resistance to CPSF6 alters HIV dependence on 
transporters and NUPs. Whereas wild-type HIV requires TNPO3 and 
NUP153, N74D HIV mimics feline immunodeficiency virus nuclear import 
requirements and is more sensitive to NUP155 depletion. Examination of 
primary and transformed cell types reveal different susceptibilities to wild-
type vs. N74D HIV, suggesting transport factors may reciprocally act as 
tropism determinants. These findings reveal a remarkable flexibility in HIV 
nuclear transport and highlight CA as essential in regulating interactions 
with NUPs. 
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Lentiviruses can infect non-dividing cells by trafficking through the nuclear 
pore but the molecular details of this process remain unclear. Mutations of 
the viral capsid protein have been shown to impact on HIV-1 infectivity in 
non-dividing cells suggesting a central role for capsid in this process. Here 
we show that HIV-1 capsid directly interacts with the cyclophilin domain 
(Cyp) of the nuclear pore protein Nup358 with similar affinity and 
thermodynamic characteristics as it binds CypA. Furthermore, mutants that 
do not bind CypA do not bind Nup358. We have also determined the crystal 
structure of an HIV-1 N-terminal capsid domain in complex with the 
Nup358 Cyp domain, revealing how binding is mediated and why the Cyp 
antagonist cyclosporine fails to inhibit Nup358 Cyp-CA interaction. We 
demonstrate that the Nup358 Cyp domain actively catalyses cis-trans prolyl 
isomerisation in a model CypA peptide substrate suggesting that Nup358 
might use this activity to liberate the pre-integration complex from the HIV 
1 core at the nuclear pore. Reducing Nup358 levels using RNAi decreases 
the infectivity of HIV-1. Crucially, capsid mutants that do not interact with 
Nup358 Cyp, as measured by ITC, as well as mutants that are insensitive to 
Nup358 RNAi, are also less dependent on transportin 3 (TNPO3 or TRN-
SR2), suggesting transportin 3 carries the HIV-1 PIC through the Nup358 
nuclear pore. Finally, sequence integration site analysis suggests that entry 
via Nup358 determines integration site specificity. Nup358 RNAi 
insensitive mutants can use alternate pathways for nuclear entry but this 
directly affects site specificity. These observations suggest HIV-1 conserves 
CypA-binding to utilize a Nup358/transportin 3 pathway of nuclear entry 
and ensure integration into preferred sites in the genome that are optimal for 
replication in vivo. 
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HIV-1 utilizes host proteins to its advantage at each step of its replication 
cycle. Consequently, recent investigations have aimed at identifying host 
cellular factors that are modified in expression, or whose functions are 
usurped during HIV-1 infection. In our previous work, we showed that 
HIV-1 induced cytoplasmic relocalization of heterogeneous nuclear 
ribonucleoprotein A1 (hnRNPA1) was dependent on the nuclear export of 
the unspliced viral RNA, and on alterations in the localization and 
abundance of Transportin 1 and nucleoporin p62, respectively. This 
strongly suggested that, like other viruses, HIV-1 causes a block to nuclear 
import as a strategy to enhance its replication. In order to identify key 
compositional changes to the nuclear envelope (NE) by HIV-1, we isolated 
the NEs of T-cells at the peak of HIV-1 infection. We verified the purity of 
NEs by western and imaging analysis at each step of the fractionation 
procedure. Liquid chromatography/tandem mass spectrometry (LC/MS/MS) 
analysis identified 296 proteins, including core NE proteins, nucleoporins, 
transport receptors and shutting proteins. We found that 36% of proteins 
were modified in expression at the peak of viral production. Our 
LC/MS/MS results and western analysis supported our earlier work (i.e., 
hnRNPs, Transportin 1 and p62), and has provided additional insights into 
key proteins that may be responsible for the block in nuclear-cytoplasmic 
shuttling. Additionally, we identified several proteins known to be 
important for HIV-1 replication, as well as others discovered in high 
throughput si/shRNA screens. The block in shuttling imposed by HIV-1, for 
its own expression, provides further evidence of the magnitude of its control 
over host function. 
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To discover inhibitors of the HIV-1 replication cycle, 60,000 compounds 
were screened against replication incompetent HIV-1 pseudotyped with 
VSV-G, the envelope glycoprotein of vesicular stomatitis virus. A novel 
antiviral compound was identified from this screen (compound 1), 
exhibiting an EC50 of 7μM against wild type HIV-1 and a selectivity index 
(SI) greater than 10. The chemical synthesis of additional analogues of 
compound 1 established a structure activity relationship (SAR) for this 
series of antiviral inhibitors. These compounds act following reverse 
transcription and prior to nuclear import of the pre-integration complex 
(PIC), as determined by real-time PCR. Consistent with this observation, 
the activity of this series is maintained against non-nucleoside reverse 
transcriptase inhibitor (NNRTI)-resistant viruses. In vitro assembled capsid 
(CA) core-like structures are stabilized in the presence of these inhibitors, 
as measured by both CA assembly and disassembly assays. In agreement 
with their effect on CA stabilization, compound 1 binds to the N-terminal 
domain (NTD) of CA with a Kd of 16-20μM, as measured by isothermal 
calorimetry and NMR. An X-ray structure of compound 1 with the NTD of 
CA was obtained, demonstrating that Asn57 and Thr107 of the CA NTD 
pocket form three hydrogen bonds with the bicyclic portion of the molecule. 
Importantly, these amino acid residues are conserved in over 99% of HIV-1 
isolate sequences deposited in the Los Alamos HIV sequence database. 
Mutations at either of these residues decrease the susceptibility of the virus 
to this series of compounds. In addition, drug resistant viruses with amino 
acid substitutions in the CA NTD pocket (A105T, G106E, T107A or 
T107N) emerged following the passaging of wild type HIV-1 in the 
presence of compound 2, a more potent analogue of compound 1 (EC50 of 
1.4μM, SI>29). We propose that the inhibition of HIV-1 replication by 
these novel CA disassembly inhibitors involves the stabilization of CA 
cores, thereby blocking the nuclear import of the PIC and preventing further 
steps required for the propagation of the virus. 
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Porcine endogenous retrovirus (PERV) is integrated in the genome of all 
pigs. Use of pigs for human xenotransplantation raises concerns about the 
risks of transfer of this infectious agent from the donor to 
xenotransplantation recipients. PERV consists of three replication-
competent subtypes, PERV-A, PERV-B, and PERV–C. Whereas PERV-A 
and PERV-B are polytropic and can productively infect human cell lines, 
PERV-C is an ecotropic. Recombinant PERV-A/C is able to infect human 
cells and exhibits high titer replication. In this study, to establish the 
strategies to inhibit PERV production from the cells, we investigated the 
mechanism of PERV budding and the anti-PERV activity of Tetherin/BST-
2.  
First, we examined the cellular factors, which are involved in PERV 
budding, using the dominant-negative (DN) mutants of candidate cellular 
factors. The results showed that the DN mutants of Vps4A/B and Tsg101 
markedly reduced PERV-A/C production in human and porcine cell lines. 
This suggests that PERV budding utilizes the cellular multivesicular body 
(MVB) sorting pathway as well as other many retroviruses. Moreover, 
PERV production was also reduced by expression of human and porcine 
Tetherin/BST-2. These data would be useful for development of strategies 
to inhibit PERV production and may reduce the risk for PERV infection in 
xenotransplantation.  
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Replication of HIV-1 is inhibited by azidothymidine (AZT), which leads to 
chain termination and inhibition of DNA synthesis. Resistance to AZT is 
frequently the result of mutations that increase the ability of RT to remove 
the chain-terminating nucleotides after they have been incorporated. It has 
been proposed that RNase H cleavage of the RNA template can occur when 
RT is stalled near the site of chain termination and contributes to the 
inhibition by causing the dissociation of the primer-template before the 
chain terminator can be excised. Mutations in the connection and RNase H 
domains of RT have been shown to increase excision. It has long been 
known that resistance to thymidine analogs is conferred by the mutations 
M41L, D67N, K70R, L210W, T215F/Y and T219Q/E in RT and that this 
resistance is suppressed by the additional presence of the M184V mutation. 
Changes in excision activity on DNA templates have been observed with 
these mutant RTs, but effects on RNase H cleavage resulting in indirect 
effects on excision activity is also possible with RNA templates. We used 
5’-labeled -3’-AZTMP-terminated DNA primer annealed to either DNA or 
RNA template to evaluate primer rescue activities, 5'-labeled RNA template 
to evaluate RNA cleavage activity, and biotin-tagged chain-terminated 
oligodeoxynucleotide to monitor primer-template dissociation.  
Addition of M184V to thymidine analog resistance mutations decreased 
primer rescue to a much greater extent on RNA template than on DNA 
template, and M184V suppression of primer rescue was observed with 
either ATP or PPi as excision substrate. RNase H cleavage at secondary 
cleavage sites (-7, -8) was substantially reduced with M41L-T215Y RT in 
comparison with wild type RT, and primer-template dissociation was 
decreased. In contrast, when M184V was present, RNase H cleavage at the 
secondary cleavage sites and dissociation of the primer-template occurred at 
wild type levels or higher. M184V suppression of primer rescue was not 
observed when the RNase H-negative E478Q mutation was also present. 
These results suggest that RNase H-mediated RNA-DNA template-primer 
dissociation is influenced by mutations associated with thymidine analog 
resistance, and that suppression of resistance to nucleoside RT inhibitors by 
M184V may be partly explained by effects on RNase H cleavage that 
decrease the time available for excision to occur. These results suggest that 
mutations in the polymerase domain of RT can affect excision through an 
RNase H-dependent mechanism. 
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HIV-1 infection is dependent on proper disassembly of the viral capsid, or 
“uncoating,” in target cells. The HIV-1 capsid consists of a conical polymer 
of the CA protein arranged in a hexagonal lattice. Mutations in CA that 
destabilize the viral capsid result in impaired infection owing to defects in 
reverse transcription in target cells. Here we describe the mechanism of 
action of a small-molecule HIV-1 inhibitor, PF-3450074 (PF74), that targets 
the viral capsid protein (CA). PF74 acts at an early stage of HIV-1 infection 
and inhibits reverse transcription in target cells. We show that PF74 binds 
specifically to HIV-1 particles, and substitutions in CA that confer 
resistance to the compound abolish drug association. A single point 
mutation in CA that stabilizes the HIV-1 core also confers strong resistance 
to the virus without inhibiting compound binding. Treatment of HIV-1 
particles with PF74 resulted in destabilization of the viral capsid in vitro. 
PF74 antiviral activity was enhanced on binding of the host protein 
cyclophilin A to the HIV-1 capsid, and PF74 and cyclosporin A exhibited 
mutual antagonism. Finally, mutations in CA conferring resistance to PF74 
stabilized the HIV-1 capsid and rendered the virus resistant to the host 
restriction factors TRIM5α and TRIMCyp. Our data suggest that PF74 
induces premature HIV-1 uncoating in target cells, thereby acting as a small 
molecule mimetic of the restriction factor TRIM5α. The results highlight 
uncoating as a step in the HIV-1 life cycle susceptible to small molecule 
intervention. 
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The upframeshift supressor proteins (UPF1, 2 & 3) are core proteins of the 
major nonsense-mediated decay (NMD) surveillance machinery responsible 
for clearing mRNAs that contain premature termination codons (PTCs). 
UPF1 is also involved in RNA splicing, transport and translation. Previous 
studies from our laboratory identified UPF1 as a host protein involved in 
maintaining HIV-1 genomic RNA (vRNA) stability and translation. We 
also found UPF1 in the Gag ribonucleoprotein complex and in purified 
HIV-1 particles. We investigated the role of UPF1 in vRNA localization 
and the importance of the shuttling function of UPF1 in the fate of the HIV-
1 vRNA. We found that UPF1 expression relocalized HIV-1 vRNA to the 
cytoplasm under Rev- conditions. Shuttling mutants of UPF1 lacking either 
the nuclear export (NES) or the nuclear localization signal (NLS) did not 
effect vRNA export under Rev- conditions. Moreover, UPF1 
overexpression resulted in an increase in expression and the cytoplasmic 
relocalization of TAP/NXF1 with no observed change in CRM1. This 
suggests that this export pathway is favored by UPF1 for proper trafficking 
of the HIV-1 vRNA. Finally, the magnitude of the effect of UPF1 on HIV-1 
vRNA levels and localization as well as those on Gag expression suggest 
that targeting UPF1 function might represent a suitable approach to block 
HIV-1 at the late expression phase. 
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The presence of a gammaretrovirus, termed Xenotropic Murine leukemia 
virus Related Virus (XMRV), in human prostate tumors has been reported 
by several investigators. We have attempted to detect XMRV in prostate 
tumor samples using both real-time PCR on cellular DNA and 
immunohistochemistry (IHC) on tumor sections and tissue microarrays. Our 
PCR methods routinely detect the XMRV in 10 pg of DNA from 22Rv1 
cells (an XMRV-infected prostate cancer cell line) or from cells infected in 
the laboratory. The admixture of 100-1000 ng of uninfected human DNA 
does not interfere with XMRV detection in these experiments. In the same 
PCR wells, a real-time assay for CCR5 DNA is simultaneously performed, 
in order to monitor the integrity of the cellular DNA.  
 
To date, we have tested 146 prostate tumor DNA samples by PCR. Almost 
1/3 of these assays used 100 ng or more of DNA, while 12 used DNA 
prepared from microdissected tumor tissue. Of the 95 samples for which 
less than 100 ng of DNA was used, 47 were tested by nested PCR. 
 
In addition, we have tested tissue microarrays from over 400 prostate 
tumors by IHC, and full tissue sections from an additional 25 prostate 
tumors. Nearly all the tumor samples were from Gleason grade of 7 or 
above; over 50 of them were metastases. Our IHC uses broadly reactive 
anti-MLV CA and anti-MLV SU antisera; cells transfected with a molecular 
clone of XMRV show specific reactivity with both of these antisera. 
 
In every case, the PCR and IHC results were indistinguishable from 
negative controls: thus we have not yet observed the presence of XMRV in 
prostate tumors. Our data raise the possibility that the prevalence of XMRV 
in prostate tumor patients may be much lower than originally reported. 
 
This research was supported in part by the Intramural Research Program of 
the NIH, National Cancer Institute, Center for Cancer Research. 
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Recent work identified BST-2/CD317/tetherin as a host factor whose 
expression results in the inhibition of HIV-1 virus release. It was suggested 
that BST-2 inhibits virus release by tethering viral particles to the cell 
surface and triggering their subsequent endocytosis and degradation. HIV-1 
Vpu counteracts this effect but it is unclear how Vpu accomplishes this task.  
 
Our initial analyses identified significant variation of endogenous BST-2 
expression in HeLa cells, T cell lines, and primary cells that did not directly 
correlate to the degree of inhibition of particle release. While transient 
expression of codon-optimized Vpu led to efficient internalization of cell 
surface BST-2 in HeLa cells we failed to observe similar cell-surface down-
modulation of endogenous BST-2 during acute infection of T cell lines or 
primary cells. We concluded that cell surface downregulation of BST-2 and 
augmentation of virus release from BST-2 expressing cells are separable 
properties of Vpu.  
 
In an extension of this study we performed kinetic studies to determine how 
Vpu affected cell surface downregulation of BST-2. Vpu must either affect 
the turnover of BST-2, internalization rate of BST-2 from the cell surface, 
or the recycling rate of BST-2. We agree with previous reports that Vpu 
does not affect the internalization rate of BST-2 from the cell surface. 
Instead, we found that Vpu increases the turnover of newly synthesized 
BST-2 in transfected 293T cells in a TrCP-dependent manner. Importantly, 
however, Vpu did not increase the turnover of mature BST-2. Results will 
be presented addressing the differences in Vpu sensitivity between 
transiently expressed newly synthesized BST-2 and pre-existing 
endogenous BST-2. The rate of de novo synthesis of endogenous BST-2 is 
very low when compared to transiently expressed protein and we predict 
that depletion of endogenous BST-2 by inhibiting de novo synthesis may be 
too slow to significantly impact virus release. We predict that while Vpu 
might have a slight effect on the turnover of BST-2 this could not result in 
the degree of inhibition observed. Therefore BST-2 recycling is likely to be 
affected by Vpu through a degradation-independent mechanism.  
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The interaction of the human immunodeficiency virus type 1 (HIV-1) with 
the cell is complex. To uncover cellular factors that influence HIV-1 
replication several systematic siRNA screens have recently been preformed; 
each listed hundreds of such factors, with minimal overlap between the 
different lists. Thus, evaluation of the relevance of these specific factors to 
HIV-1 replication is still needed. In these screens, the small GTPases Rab1 
and 2, known to regulate anterograde traffic between the endoplasmic 
reticulum (ER) and the Golgi complex, were identified; Rab1 depletion 
reduced HIV-1 infectivity and this factor was suggested to act in late stages 
of infection. To evaluate Rab1/2-HIV-1 interactions, we over-expressed 
TBC1D20, the recently discovered Rab1/2 GTPase-activating protein 
(GAP), since TBC1D20 overproduction has been shown to block Rab1/2-
mediated ER-to-Golgi transport. We found that over-expression of 
TBC1D20, but not its catalytic-inactive form, together with HIV-1 Gag and 
envelope (Env) proteins, resulted in abnormal gp41 migration in SDS-
PAGE indicating atypical cellular modification of the Env protein, likely 
because of aberrant glycosylation. Moreover, TBC1D20 over-expression 
did not reduce virion like particles (VLPs) production but decreased particle 
infectivity and Env incorporation into HIV-1 VLPs. Immunofluorescence 
analysis revealed ER retention of Env in the TBC1D20-expressing cells. 
Taken together, these results demonstrate that HIV-1 Env is processed and 
migrate towards the virion assembly sites via a TBC1D20/Rab1/2-
dependent secretory pathway. 
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Background: Integrase inhibitors are now a component of highly active 
antiretroviral therapy (HAART) regimens, having now been approved for 
both first-line and salvage therapy. Due to the high inter-subtype genetic 
variability of HIV-1, the potential for subtype-specific patterns of resistance 
to integrase inhibitors exists.  
Methods: This study compares the susceptibility of HIV-1 integrase 
enzymes harbouring previously reported resistance mutations E92Q, 
N155H and E92Q+N155H, from both subtypes B and C to clinically 
relevant integrase inhibitors. This was performed biochemically using a 
microtiter plate system.  
Results: Our results show the existence of subtype-specific differences in 
the susceptibility of integrase enzymes to integrase strand transfer 
inhibitors. Subtype C integrase bearing resistance mutations E92Q+N155H 
derived from the molecular clone pINDIE-C1 was approximately 10-fold 
more susceptible to both Raltegravir and Elvitegravir in vitro, when 
compared to subtype B integrase derived from the molecular clone pNL4-3.  
Conclusions: Polymorphic differences between subtype B and C likely 
cause variations in the contribution of the N155H, alone or in combination 
with E92Q mutation, to integrase inhibitor resistance. This suggests 
different subtypes might favour different mutational pathways, which could 
lead to viral subtypes exhibiting different levels of resistance to integrase 
inhibitors.  
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Glycosylated Gag is a type II MLV transmembrane protein translated from 
an initiation CUG codon upstream and in-frame with the ordinary Gag. We 
have recently reported that glycosylated Gag is an infectivity factor which 
can replace the activity of Nef on HIV-1 infectivity and shares with Nef 
major functional features. A potential ORF encoding glycosylated Gag can 
be found in the genome of many exogenous and endogenous 
gammaretroviruses. However, there is yet no evidence that all these viruses 
are capable of producing the predicted protein. 
We wanted to assess the ability of several retroviruses to encode 
glycosylated Gag and test whether the activity of these molecules on 
retrovirus infectivity is a conserved property. To this end we have analyzed 
retrovirus genomes and selected individual viruses from different 
gammaretrovirus species which contain an ORF encoding a potential 
glycosylated Gag. All protein sequences subjected to in silico analyses were 
predicted to have a type II transmembrane topology. However, an initiation 
codon for glycogag could not be found within the sequences derived from 
gibbon ape leukemia virus. 
We have cloned the 5’ portion of retroviral genomes and the putative 
glycosylated Gag ORF from genomic RNA derived from several 
gammaretroviruses. In contrast to the known genome sequences, a 
conserved glycogag CUG initiation codon is present in genomes of both 
SEATO and X strains of GALV. The predicted ORF encode a protein with 
a cytoplasmic tail highly divergent from that of glycosylated Gag derived 
from MLV. We are currently exploring the activity of all glycogag alleles 
on gammaretrovirus and lentivrus infectivity. This will elucidate the 
aminoacid sequence determinants and the common features functionally 
important for the Nef-like function of glycosylated gag on retrovirus 
infecitivity. 
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Tetherin is an interferon (IFN)-regulated host restriction factor whose expression 
blocks the release of HIV-1 and other enveloped viral particles. While the molecular 
underpinning of Tetherin potent inhibition of HIV-1 release has been well defined, 
the endogenous regulation of this antiviral effector has not been fully elucidated. 
Using flow cytometry, we first established that Tetherin is expressed under basal 
conditions in a number of cell types, including ex-vivo primary human T 
lymphocytes and cells of myeloid linage such as monocytes and macrophages. 
While Tetherin can be mildly induced upon cell culture, its expression is greatly 
stimulated by T cell activation by either PHA or anti-CD3/anti-CD28 stimuli. 
Furthermore, as previously reported, we found that surface expression of Tetherin 
could be further induced following exposure to type-I IFN on all the cell types 
tested.  
 
Using a dual luciferase reporter assay and model cell lines that either constitutively 
express Tetherin (HeLa) or express Tetherin only after IFN induction (HEK293T), 
we identified a minimal promoter region required for Tetherin basal and IFN-
inducible expression. Tetherin minimal promoter consists of a 100base pair region 
containing multiple overlapping transcription factor binding sites, including 
canonical type-I and type-II IFN response elements (ISRE and GAS sites 
respectively), NF-AT, IRF-1 and STAT-3 binding sites; as well as two putative non-
traditional tata boxes. Mutations in a 16bp segment, containing one ISRE and two 
IRF1 binding sites, completely abolished promoter capacity for type-I IFN induction 
without, however, affecting its basal expression. Interestingly, IFN-mediated 
induction could be rescued by reconstituting only one IRF-1 binding site, suggesting 
a potential role of IRF-1, a key product of type-I IFN signaling cascade, in the 
induction of Tetherin expression by IFN. In that regard, we demonstrated that over-
expression of IRF-1 in HEK293T indeed induced the expression of Tetherin. 
Finally, we investigated the role of STAT-1, an early component of type-I IFN 
signaling cascade, in Tetherin expression. We found that induction of Tetherin 
expression by type-I IFN required STAT-1 phosphorylation, whereas Tetherin basal 
expression was independent from STAT-1 protein. Using specific inhibitors and 
shRNA-directed depletion we are currently analyzing further the interplay between 
STAT-1 and IRF-1 on Tetherin transcriptional activation by type-I IFN.  
 
Overall, our results indicate that a complex set of IFN-inducible proteins is involved 
in Tetherin transcriptional regulation. Insights into the molecular pathways 
regulating Tetherin expression may provide key information for the development of 
rational strategies aimed at manipulating levels of endogeneous Tetherin for 
enhancing antiviral immunity.  
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The early steps of HIV-1 replication are characterized by two operationally 
defined nucleoprotein complexes- the reverse transcription complex (RTC) 
and the preintegration complex (PIC). The RTC facilitates reverse 
transcription of the viral RNA into DNA, and the PIC mediates integration 
of the viral DNA into the host chromosome. The architecture and temporal 
regulation of these complexes are unclear, and it remains controversial 
whether these complexes are biochemically distinct. The biochemical study 
of intact complexes has been hampered by both their limited quantity in 
cells and their labile nature. Previous studies have purified RTCs and PICs 
by both density/equilibrium and velocity centrifugation, and size-exclusion 
chromatography. We report in this study that these complexes can be 
biochemically separated using velocity gradient (rate-zonal) centrifugation 
and fractionation. Distinct viral RNA/reverse transcriptase active and viral 
DNA/integration active complexes were separable using short duration 5-
45% sucrose gradients. The sedimentation of the RTC was slower than the 
PIC suggesting it is smaller in size. Both complexes behaved differently 
under varying centrifugal force. The RTC displayed constant sedimentation 
for up to 4 h. In contrast, the PIC rapidly disintegrated- by 4 h there was a 
loss of recoverable integration activity, and a dissociation of the majority of 
vDNA from fractions containing the integration activity. If equilibrium 
gradients were used, both the RTC and PIC factors concentrated to same 
fractions of the gradient. These results demonstrate the biophysical 
properties of RTCs and PICs in sucrose gradients, illustrate the labile nature 
of PICs under high speed centrifugation, and define a protocol to 
biochemically separate RTCs and PICs.  
 
This research is supported by the NIH (RR015635).  
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The early phases of lentiviral infection are generally completed less efficiently 
in cells belonging to the myeloid lineage than in other cell types and this 
behavior is largely influenced by their differentiation status and the exogenous 
stimuli present. The reasons for this more restrictive phenotype are largely 
unknown and have been ascribed either to a general low metabolic state or to 
the cell type specific expression of cellular factors with antiviral activity. To 
date only Vpx, a viral protein coded by members of the HIV-2/SIVSM lineage, 
seems to be able to overcome the restrictive phenotype of myeloid cells and to 
allow their efficient infection by a wide panel of lentiviruses. 
Among known antiviral factors, human APOBEC3A (hA3A) retained our 
attention, as this protein seems expressed almost exclusively in myeloid cells, 
variations in its expression seem to correlate with differences in the cells’ 
susceptibility to infection and a previous study indicated that downregulation of 
this factor in non-stimulated monocytes led to increased replication of HIV-1. 
In contrast, overexpression of hA3A in non-myeloid cells seems to bear no 
consequences on the virus, suggesting a possible cell type specific effect. 
Whether hA3A acts directly on incoming viruses during the early phases of 
infection or else, like other members of the APOBEC family, if it acts during 
assembly to negatively imprint virions remains unknown. 
To gather novel insights into the role that hA3A may exert during viral 
infection, we have first examined the kinetics of its expression during ongoing 
viral replication in primary macrophages and showed that hA3A upregulation 
occurs naturally during infection with both HIV-1 and HIV-2, when expression 
of other members of the APOBEC family is unchanged. Then, we have 
examined the role of hA3A specifically during the early phases of the viral life 
cycle. Knock down experiments indicate that hA3A exerts an antiviral activity 
that targets similarly HIV-1, HIV-2 and SIVMAC. The characterization of this 
antiviral effect, as well as the possible relationship between hA3A and the viral 
HIV-2/SIVSM Vpx protein will be presented here. 
 
Work supported by Sidaction, ANRS and the MENRT 
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The ESCRT machinery, a highly conserved set of four hetero-oligomeric 
protein complexes, is required for multivesicular body formation, sorting 
ubiquitinylated membrane proteins for lysosomal degradation, cytokinesis 
and the final stages of assembly of a number of enveloped viruses, 
including the human immunodeficiency viruses. Here, we show an 
additional role for the ESCRT machinery in HIV-1 release. BST2/tetherin is 
a restriction factor that impedes HIV release by tethering mature virus 
particles to the plasma membrane. We found that HRS, a key component of 
the ESCRT-0 complex, promotes efficient release of HIV-1 and that 
siRNA-mediated HRS depletion induces a BST2/tetherin phenotype. This 
activity is related to the ability of the HIV-1 Vpu protein to down-regulate 
BST2/tetherin. We found that BST2/tetherin undergoes constitutive 
ESCRT-dependent sorting for lysosomal degradation and that this 
degradation is enhanced by Vpu expression. We demonstrate that Vpu-
mediated BST2/tetherin down-modulation and degradation require HRS 
(ESCRT-0) function and that knock down of HRS increases cellular levels 
of BST2 and restricts virus release. Our results provide further insight to the 
mechanism by which Vpu counteracts BST2/tetherin to favour HIV-1 
dissemination and highlight an additional role for the ESCRT machinery in 
virus release. 
This work is funded by ANRS, SIDACTION, ANR-07-JCJC-0102 
programs and is part of the activities of the HIV-ACE research network 
(HEALTH-F3-2008-201095) supported by a grant of the European 
Commission, within the Priority 1 “Health” work programme of the 7th 
Framework Programme of the EU. 
 50 
MUTAGENIC SCREEN-BASED SELECTION OF TRIM5ΑHU 
MUTANTS THAT POTENTLY RESTRICT HIV-1  
 
Quang Toan Pham, Lionel Berthoux  
 
UQTR, GROEM, Trois-Rivières, G9A 5H7, Canada 
 
The restriction factors TRIM5α and the related TRIMCyp are potentially 
excellent gene candidates for AIDS therapeutic strategies involving gene 
transfer. TRIM5α can neutralize incoming HIV-1 very early in its replication 
cycle, before any viral protein is being synthesized de novo. Rhesus macaque 
TRIM5α (TRIM5αrh) strongly restricts HIV-1 while human TRIM5α is inactive 
against this virus but can inhibit other retroviruses. An attractive alternative to 
using potentially immunogenic nonhuman primate versions of TRIM5α is the 
generation of human TRIM5α variants bearing a small number of mutations 
leading to efficient inhibition of HIV-1.  
So far, identifying the determinants of HIV-1 targeting by TRIM5α has been 
done mostly by searching for differences between the PRYSPRY domain 
sequence of TRIM5αhu and those of nonhuman primates. My lab has undergone 
two mutagenic screens to generate novel variants of TRIM5αhu with strong 
HIV-1 restriction activity. One approach involves error-prone PCR of the whole 
PRYSPRY domain while the other one uses a degenerated oligonucleotide and 
is limited to the first variable loop of PRYSPRY. This strategy has allowed us 
to isolate two clones in which resistance was due to expression of TRIM5αhu 
mutated at positions 335 (R335G) or 330 (G330E), both located in the v1 loop. 
Mutations at arginine 332, previously shown by others to be an important 
determinant of HIV-1 restriction, were also found. Individually, each mutation 
resulted in a 10-fold or more decrease in human cells permissiveness to 
transduction by HIV-1 vectors. Mutations found at G330, R332 and R335 all 
affected the charge of the v1 loop, and targeted mutagenesis at positions 330 
and 335 showed that increased acidity was indeed required for HIV-1 restriction 
but was not sufficient. R332G and R335G had partly additive effects while 
mutations at G330 did not enhance HIV-1 restriction by TRIM5αhu mutated at 
positions 332 or 335. The double mutants R332G/R335G and R332G/R335E 
inhibited HIV-1 spreading infection in the T cell line SupT1 as efficiently as 
TRIM5αrh did, confirming their potential as anti-retroviral transgenes.  
We are currently characterizing the mechanism of HIV-1 restriction by these 
mutant TRIM5αhu and monitoring the possible appearance of HIV-1 resistance. 
Our recent data indicate that in human cells, pharmacological inhibition of 
cyclophilin A by cyclosporine A decreases the restriction of HIV-1 by the 
various mutant TRIM5αhu generated in our screens. Therefore, cyclophilin A 
modulation of HIV-1 restriction by Old World monkeys TRIM5α is not a 
peculiarity of these TRIM5α orthologues but seems to be a general 
phenomenon.  
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The newly identified retrovirus – the xenotropic MuLV-related virus 
XMRV – has recently been shown to be strongly associated with familial 
prostate cancer in human (Urisman et al., 2006, PLos Pathog). While that 
study showed evidence of XMRV infection exclusively in the prostatic 
stromal fibroblasts, a recent study found XMRV protein antigens mainly in 
malignant prostate epithelial cells (Schlaberg et al., 2009, PNAS). To help 
understand the mechanisms behind XMRV infection, we show that prostatic 
fibroblast cells express Xpr1, a known receptor of XMRV, but its 
expression is absent in other cells of the prostate (i.e., epithelial and stromal 
smooth muscle cells). We also show for the first time that certain amino 
acid residues located within the predicted extracellular loop (ECL3 and 
ECL4) sequences of Xpr1 are required for efficient XMRV entry. While we 
found strong evidence to support XMRV infection of prostatic fibroblasts 
via Xpr1, we learned that XMRV was indeed capable of infecting cells that 
did not necessarily express Xpr1, such as those of the prostatic epithelial 
and smooth muscle origins. Further studies suggest that the expression of 
Xpr1 and certain genotypes of the RNASEL gene, which could restrict 
XMRV infection, may play important roles in defining XMRV tropisms in 
certain cell types. Collectively, our data reveal important cellular 
determinants required for XMRV infection of human prostate cells in vitro, 
which may provide important insights into the possible role of XMRV as an 
etiologic agent in human prostate cancer.  
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APOBEC3G (A3G) restricts HIV-1 replication by editing and non-editing 
mechanisms. The Viral Infectivity Factor (Vif) protein counteracts 
APOBEC3G action by preventing its incorporation into HIV-1 virus 
particles. Previous studies have shown variation in the anti-A3G activity of 
naturally-occurring subtype B Vif proteins.  
Because of the pronounced sequence diversity between HIV-1 subtypes, we 
hypothesized that Vif proteins of different subtypes vary in their anti-A3G 
activity. We assessed 17 Vif proteins of seven subtypes (A, B, C, D, E, F 
and G) for their ability to degrade A3G as well as to rescue HIV-1 
infectivity in the presence of A3G in single-cycle infections. HIV-1 NL4-3 
viruses were generated by co-transfection of the different Vif proteins with 
the NL4-3ΔVif molecular clone. Expression of tagged and untagged Vifs 
was assessed by western blot.  
All HIV-1 Vifs from the tested panel were active against A3G with the 
exception of a subtype E Vif protein. However the anti-A3G efficacy varied 
significantly, with a 7-fold difference between the most and least active of 
the Vif proteins. Such diversity in activity occurred both within subtypes as 
well as between subtypes. Interestingly, some non-subtype B Vif proteins 
performed better than the Vif proteins from the HIV-1 subtype B reference 
clones NL4-3 and LAI. 
Our work highlights the importance of assessing ‘Vif-A3G’ phenotypes 
since Vif proteins from different HIV-1 subtypes vastly differ in their 
efficiency to counteract A3G. The differences in Vif activity observed in 
single-cycle infection experiments are likely to be amplified in the context 
of a spreading infection. More HIV-1 Vif genotype to phenotype 
determinations are needed since differences in Vif function may impact 
HIV-1 transmission, replication and pathogenesis. 
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The interaction between human immunodeficiency virus (HIV) and 
dendritic cells (DCs) is an important early event in HIV pathogenesis that 
leads to efficient viral dissemination. The majority of virus that is captured 
by DCs remains in an infectious form and is passed to CD4+ T cells through 
a process of trans infection. All of the DC specific attachment factors that 
have been described to date rely upon interactions with the highly variable 
HIV glycoprotein gp160. Our lab has recently demonstrated that DC 
capture and transfer of HIV can be glycoprotein independent, using instead 
a host derived glycosphingolipid (GSL) that is incorporated into the virus as 
it buds from the lipid raft of the producer cell. Using eGFP containing 
virus-like particles (VLPs), we show that this GSL dependent DC binding 
mechanism extends to the paramyxoviruses Hendra and Nipah, which also 
bud from GSL enriched lipid rafts and compete HIV Gag-eGFP VLPs for 
binding to DCs. In all cases, viruses produced in the presence of the GSL 
biosynthesis inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol 
(PDMP) show an approximate eighty percent decrease in DC capture. 
Decreased levels of DC capture translate directly into a decreased efficiency 
in establishing trans infection, suggesting this interaction plays a key role in 
transit of the virion through the DC. Similarly to PDMP inhibition, 
knocking down GSLs in the producer cell using RNAi directed against the 
glucosyltransferase resulted in inhibition of HIV capture by DCs. More 
specifically, the knockdown of ganglioside GM3 synthase enzyme but not 
GM2 synthase or globotriaosylceramide synthase within the producer cell 
also resulted in the inhibition of HIV capture by DCs. Finally, addition of 
GM3 to GSL-depleted virus producer cells to selectively enrich GM3 
within HIV-1 particles resulted in a substantial enhancement of DC capture 
as compared to the capture of GSL deficient virus. This suggests that of the 
larger class of GSLs, the ganglioside GM3 is mediating the interaction 
between HIV and DCs. Since GM3 is a host cell-derived molecule that is 
also enriched within exosomes, this interaction may help the virus to 
successfully navigate past the degradation pathway in DCs. HIV binding via 
GM3 describes an important interaction between the virus and target cell 
that is devoid of the high mutation rate inherent in virally encoded proteins, 
while also suggesting a novel mechanism by which HIV evades degradation 
within the DC and ultimately establishes productive trans infection to the 
CD4+ T cell. 
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Human betaretrovirus (HBRV) is >90% homologous to mouse mammary tumor 
virus (MMTV), and its isolation from patients with primary biliary cirrhosis 
could represent a zoonosis. In experiments to test the possibility that HBRV 
Gag expression could recapitulate the cell surface expression of mitochondrial 
antigens associated with the pathology of PBC, we were unable to achieve 
CMV-driven HBRV Gag protein expression. The endogenous MMTV (MT) 
gag gene derived from an infectious molecular clone also failed to express 
under identical conditions, but MT Gag was readily detectable when expressed 
from an intact provirus. HBRV and MT Gags were equivalently expressed in 
rabbit reticulocyte lysates, leading us to hypothesize that human cells restrict 
MMTV and HBRV Gag expression and that the intact provirus can overcome 
this restriction. Here we describe studies to identify the mechanism of this novel 
restriction/antirestriction nexus. 
An exogenous MMTV gag, (SM), silently mutated in pp21 to support bacterial 
propagation, expresses to high levels in human cells. Chimeras between the 
restricted HBRV or MT and the non-restricted SM gag genes allowed the 
identification of the target of restriction as a 54 nt sequence in the code for the 
pp21 domain.  
To identify the step at which restriction occurs we quantified transcript 
abundance, nuclear to cytoplasmic mRNA transport, and mRNA stability 
among the constructs. Each was found to be equivalent. Proteasome inhibition 
and metabolic labeling demonstrated that lack of detectable HBRV/MT Gag 
protein was not due to protein instability, but rather to a pre-translational block. 
Consistently, we found that HBRV gag blocked expression of a downstream 
IRES GFP cassette in a bicistronic vector, whereas the SM gag did not, 
implying that the restriction acts on the message itself. These results were 
consistent with the concept that restriction was due to a microRNA. However, 
Gag expression remained restricted in cells where Dicer was knocked down 
using siRNAs. In agreement with these findings, when mRNA for either 
restricted or non-restricted gags was introduced into cells no restriction was 
evident. Our results suggest that the HBRV/MT mRNA is negatively regulated 
for translational competence due to exposure to the human nucleus. We are now 
investigating whether nuclear factors prevent the restricted messages from 
interacting with the ribosomes or target them to regions in the cytoplasm where 
they are inaccessible for translation. Our findings reveal a novel layer of 
complexity in the regulation and restriction of retroviral lifecycles in human 
cells. 
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Assembly of immature retroviral particles is a complex process mediated by 
mutual interactions of Gag polyproteins. In all retroviruses, the Gag 
precursor contains matrix (MA), capsid (CA) and nucleocapsid (NC) 
protein and the latter two represent the key interaction domains. Bacterial 
expression/assembly system, in vitro and in vivo assembly assays were used 
to study the effect of N-terminal domain of NC on formation of Mason-
Pfizer monkey virus (M-PMV) particles. Analyzing of truncated and 
mutated constructs of CANC fusion proteins or whole Gag we identified a 
“spacer-like” region consisting of fifteen N-terminal amino acids of the NC 
(NC15). This M-PMV “spacer-like” peptide is indispensable for correct 
assembly and cannot be replaced with dimerizing or trimerizing domains or 
with the HIV-1 spacer peptide sequence. However, this NC15 sequence is 
not sufficient to mediate the assembly when fused to CA. To induce the 
assembly of virus-like particles, the CANC15 must be followed by a short 
sequence that is rich in basic residues. This basic region can be either 
specific, i.e. derived from the downstream NC sequence, or it can be 
substituted by non-specific positively charged peptide. Efficient assembly 
of M-PMV immature-virus-like particles was observed only in the presence 
of both “spacer-like” sequence and basic region. 
 
This work was supported by the Grant Agency of the Czech Republic, grant 
204/09/1388 and by the research project 1M0508 from the Czech Ministry 
of Education of the Czech Republic. 
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Assembly and maturation of HIV-1 Gag precursor constitute a target for the 
design of new molecules able to inhibit virus replication. The polyprotein Gag 
is maturated by the viral protease (PR) to give matrix (MA), capsid (CA), 
nucleocapsid (p7), p6 and two extra spacer peptides (Sp1 and Sp2), separating 
CA/p7 and p7/p6 respectively. The peptide Sp1 plays a crucial role in the 
assembly and in the maturation of HIV-1. Mutations within Sp1 or at the 
CASp1 junction perturb these steps that result in the production of virions with 
aberrant cores. In the same way, the inhibition of the CASp1 cleavage causes 
the production of defective and noninfectious viral particles. Betulinic acid 
derivatives (DSB / PA-457 / Bevirimat) are potent maturation inhibitors against 
HIV-1 replication by interfering with PR at the CASp1 cleavage site. DSB has 
also an effect on the assembly of HIV-1 Gag precursor as shown in vivo, into 
membrane-enveloped virus-like particles (VLP) in baculovirus-infected cells 
(Sf9) expressing Pr55GagHIV. 
 
To attempt to elucidate the role of Sp1 and to determine the mechanism of 
action of the DSB during assembly or maturation of the virion, structural studies 
by NMR and Molecular Modeling have been initiated. The structures of the 
junction CASp1p7 as well as the mutated junction CASp1p7(A1V) have been 
determined by NMR. The main structural motif is a well-defined amphipathic 
_-helix that seems to be bent in the case of the mutated domain. The interaction 
between DSB and the CASp1p7 junctions has been undertaken by NMR to 
propose a structure of the complex and a mechanism for the inhibitor. NMR 
study of both partners was difficult due to the lack of solubility of DSB in water 
as well as in presence of organic solvents. For this reason, new DSB 
derivatives, with higher solubility and containing various C-28 amide 
modifications, were synthesized, characterized by NMR and evaluated for their 
anti-HIV activity by the measure of their IC50. Results show that the activity of 
DSB derivatives could be related to their solubility and that increasing their 
solubility could make possible their structural studies by NMR in association 
with Gag fragments. The structure of such complex should help to elucidate the 
mechanism of inhibition of DSB in assembly and maturation of HIV-1. 
 
This work was supported by the French Agency for AIDS Research (ANRS) and by 
"Ensemble contre le SIDA/SIDACTION" 
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The Nef regulatory protein of HIV-1 is essential in vivo for virus replication 
and AIDS pathogenesis. Despite this critical role in AIDS, Nef is not 
targeted by current antivral strategies. Nef exerts a positive influence on 
virus infectivity and induces profound functional perturbations of host cell 
endocytic and signaling pathways. Here, we describe the generation as well 
as biochemical and virological characterization of a camelid single-domain 
antibody (sdAb) that specifically binds to HIV-1 Nef with a high affinity 
(Kd = 2x10-9 M). When expressed as an intracellular antibody 
(“intrabody”) in Nef-expressing or HIV-1-infected cells, this anti-Nef sdAb 
inhibited the critical biological activities of Nef. First, it interfered with the 
CD4-downregulation activity of Nef through inhibition of the Nef effects on 
CD4 internalization from the cell surface. Second, it was able to interfere 
with the association of Nef with activity of the cellular kinase PAK2 as well 
as with the resulting inhibitory effect of Nef on actin remodeling. Third, 
anti-Nef sdAb counteracted the Nef-dependent enhancement of virion 
infectivity. Since all these Nef functions have been implicated in Nef action 
in vivo, this anti-Nef sdAb represents an efficient tool to elucidate the 
molecular functions of Nef in the virus life cycle and will guide the 
development of new strategies for the suppression of AIDS pathogenesis. 
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Transcription of HIV-1 viral genes is activated by viral protein Tat and also 
uniquely dependent on the interaction of the viral HIV-1 Tat protein with 
host cell factors, including protein kinases CDK9 and CDK2. CDK9/Cyclin 
T1 (P-TEFb) is recruited to HIV-1 transcripts through the interaction with 
Tat protein and the TAR element located in HIV-1 transcripts. Our research 
focuses on the function of CDK2 in the regulation of HIV-1 transcription. 
HIV-1 replication is inhibited in the cells in which CDK2 expression is 
inhibited through stable expression of CDK2-targeting shRNA (293T-59 
cells). Interestingly, inhibition of CDK2 also inhibited CDK9 activity. We 
analyzed whether CDK2 can phosphorylate CDK9 and found that siRNA-
mediated inhibition of CDK2 reduced phosphorylation of CDK9 in vivo. 
Using CDK9-derived synthetic peptides containing potential 
phosphorylation sites for CDK2, we showed that Ser90 is likely the 
phosphorylation site. To further analyze the effect of CDK2 on CDK9 we 
analyzed distribution of CDK9/cyclin T1 between small active and large 
inactive complex in the cells in which CDK2 expression was inhibited by 
CDK2-directed shRNA. In the large complex P-TEFb is bound by 7SK 
RNA and hexamethylene bisacetamide-inducible protein 1 (HEXIM1) and 
Tat recruits P-TEFb from this complex. Using ultracentrifugation in 
glycerol gradients and differential salt extraction, we found less CDK9 and 
cyclin T1 in the large complex of the cells that lack CDK2. Our 
observations suggest that inhibition of HIV-1 in the absence of CDK2 may 
be due to the disappearance of the large CDK9/cyclin T1 complex. Taken 
together, our studies show that CDK2 can potentially phosphorylate CDK9 
and that inhibition of CDK2 inhibited CDK9 activity and also inhibited 
HIV-1 transcription. Our results point to CDK2 as a good candidate for 
HIV-1 drug therapy.  
 
This study was supported by NIH Research Grant 2 R25 HL003679-08 funded by 
the National Heart, Lung, and Blood Institute and The Office of Research on 
Minority Health and by NIH Grant 1SC1GM082325-02 funded by the National 
Institute of General Medical Sciences.  
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After membrane fusion with a target cell, the core of human 
immunodeficiency virus type 1 (HIV-1) enters into the cytoplasm where 
uncoating occurs. The cone-shaped core is composed of a hexameric lattice 
of the viral capsid protein (CA), which disassembles during uncoating. The 
underlying factors and mechanisms governing uncoating are poorly 
understood. Cellular proteins have been implicated in regulating uncoating, 
in both positive and negative manners. TRIM5α is a host restriction factor 
that targets CA and accelerates uncoating. This restriction occurs in a 
species-specific manner, whereby HIV-1 replication is weakly restricted by 
human TRIM5α (TRIM5α-Hu), but potently restricted by rhesus macaque 
TRIM5α (TRIM5α-Rh). The TRIM5α restriction requires CA recognition 
but the underlying mechanism is not completely understood. The weak 
restriction for HIV-1 by TRIM5α-Hu is presumably due to an inability to 
recognize the incoming viral core, based on binding assays with in vitro 
assembled CA-NC complexes, compared to strong affinity with TRIM5α-
Rh. Using isolated cores in binding assays, both TRIM5α-Hu and TRIM5α-
Rh were able to recognize and co-sediment with cores through a sucrose 
cushion, confirming that CA binding is necessary but not sufficient for 
restriction. By using an in vitro uncoating assay, which measures the rate of 
CA disassembly at 37°C over time, CA disassembly was not accelerated, 
but stabilized in the presence of TRIM5α-Hu or TRIM5α-Rh. The results 
show that both TRIM5α-Hu and TRIM5α-Rh are able to recognize HIV-1 
viral cores and lead to the generation of a stable viral core-TRIM5α 
complex, which may represent an intermediate in the TRIM5α restriction 
process. The results indicate that TRIM5α-mediated inhibition of viral 
infection not only requires CA-binding, but is consistent with a model in 
which the restriction mechanism may occur in a step-wise manner and is 
dependent on additional and yet unidentified cellular factors. 
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We describe improved methods for isolating integration site sequences from 
infected cells, and their use in quantitative analysis to track transduced 
clones. Human genetic diseases have been successfully corrected by 
integration of functional copies of the defective genes into the human 
genome, but in some cases integration of therapeutic vectors has activated 
proto-oncogenes and contributed to leukemia. For this reason, extensive 
efforts have focused on analyzing integration site populations from patient 
samples, but previously used methods for recovering newly integrated DNA 
have been labor-intensive and suffered from severe recovery biases. Here 
we show that a new method based on phage Mu transposition in vitro 
allows convenient and consistent recovery of integration site sequences in a 
form that can be analyzed directly using pyrosequencing. Recovery is much 
less biased than methods requiring cleavage of the human genome with 
restriction enzymes, which are strongly influenced by the proximity of 
integration sites to restriction sites. The method also allows simple 
estimation of the relative abundance of gene-modified cells from human 
gene therapy subjects, which has previously been lacking but is crucial for 
detecting expansion of cell clones that may be a prelude to adverse events. 
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It’s becoming increasingly clear that retroviruses take advantage of cellular 
trafficking machineries to assemble and release new HIV particles. Several 
studies have highlighted the crucial role of ESCRT machinery in the late stage 
of HIV assembly, but also the importance of the clathrin adaptor protein 
complexes, the Golgi-localized γ-ear containing Arf-binding and ADP 
ribosylation factor proteins, in HIV release. It was extensively described that 
Rab proteins regulate specific steps of intracellular membrane trafficking, 
including exocytosis and endocytosis in eukaryotic cells, by the recruitment of 
tethering, docking and fusion factors as well as the actin- and microtubule-
based motor proteins to facilitate vesicle traffic. In order to identify new 
intracellular pathway required for HIV morphogenesis, we explored the role of 
8 ubiquitously expressed Rab proteins (Rab1a, Rab4a, Rab5a, Rab6a, Rab7a, 
Rab8a, Rab9a, Rab11a) involved in the main endocytic and exocytic pathways, 
on HIV replication cycle.  
For this purpose, we developed several virological tests based on the specific 
interference RNA targeting Rab proteins (Rab1, Rab4, Rab5, Rab6, Rab7, 
Rab8, Rab9 and Rab11). Here we show that Rab7 plays a major role on HIV-1 
replication. We observed that HIV-1 (NL4-3 strain) fails to propagate in the 
reporter cells HeLa P4R5 (stably expressing CD4 and CCR5) upon siRNA–
induced depletion of Rab7. Analysis of the early step of HIV replication cycle 
showed no major effect of Rab7 silencing on HIV entry. By contrast, study of 
the late steps of the HIV replication cycle using a single cycle infection assay 
showed that Rab7 depletion strongly increases the level of cell-associated 
processed Gag products, CAp24 and MAp17, and reduces the release of CAp24 
from HeLa producer cells. Furthermore, we noted that this diminution of the 
viral release is associated with a modification of Gag processing and with a 
marked decrease of the infectious titer of the produced particles. Interestingly, 
no accumulation of cell-associated processed Gag was detected in Rab7-
depleted HEK 293T cells culture products, whereas the infectious titer of 
produced particles remained lower in this culture compared to the control. 
Altogether, our current results reveal that Rab7 participates to the efficient 
production of full-infectious viral particles by acting at different stages during 
the late steps of HIV replication cycle.  
 
This work is funded by ANRS, ANR-07-JCJC-0102 programs and is part of the 
activities of the HIV-ACE research network (HEALTH-F3-2008-201095) supported 
by a grant of the European Commission, within the Priority 1 “Health” work 
programme of the 7th Framework Programme of the EU. 
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The TRIM5α protein is an intracellular restriction factor known to inhibit 
infection by numerous retroviruses in a species specific manner. The most 
well studied example of this restriction is the TRIM5α protein from rhesus 
macaques (rhTRIM5α), which potently inhibits HIV-1 infection. TRIM5α is 
observed to localize to cytoplasmic accumulations of protein referred to as 
cytoplasmic bodies, though the role that these bodies play in the restriction 
of retroviruses remains unclear. We employed a series of rhTRIM5α 
truncation mutants to identify a discrete region of TRIM5α that is required 
for localization of the protein to cytoplasmic bodies. This region is located 
within the Linker2 (L2) region connecting the coiled coil domain and 
B30.2/PRYSPRY domain. Deletion of this region in the context of full 
length rhTRIM5α abrogates cytoplasmic body localization as well as 
retroviral restriction. Alanine mutagenesis of the residues in this region 
identify two stretches of amino acids that are required for both cytoplasmic 
localization and retroviral restriction. This work suggests that the 
determinants that mediate the localization of TRIM5α to cytoplasmic bodies 
play a requisite role in the process of retroviral restriction. 
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INI1/hSNF5 is an HIV-1 integrase binding protein. Previous studies 
demonstrated that a minimal IN-binding fragment of INI1, termed S6, 
selectively and potently inhibited HIV-1 particle production (Yung et al. 
Nat. Med. 2002 and Yung et al. J. Virol 2004). S6 contains an unmasked 
nuclear export signal (NES), and is cytoplasmic, while full length INI1 is 
nuclear (Craig et al. EMBO J 2002). Here, we have tested to determine if 
cytoplasmic localization of S6 is required for inhibition and have further 
explored the mechanism of inhibition by S6.  
To determine if cytoplasmic localization of S6 is required to inhibit particle 
production, we generated variants of S6 with altered sub-cellular 
localization either by mutating NES and/or by incorporating a strong NLS. 
We found that targeting an NLS-containing S6 variant [NLS-S6(Rpt1)] to 
the nucleoplasm resulted in complete reversal of inhibition of particle 
production. To further explore the mechanism of inhibition, we carried out 
Electron microscopic (EM) and immuno-fluorescence analysis of HIV-1 
producer cells expressing S6 and the non-inhibitory mutant NLS-S6(Rpt1). 
EM analysis indicated that while none or very few electron dense virus 
particles were seen in cells expressing S6, virions were produced to wild 
type levels in cells expressing NLS-S6(Rpt1). Immuno-fluorescence 
analysis revealed that while Gag accumulated along the plasma membrane 
in cells expressing either INI1 or NLS-S6(Rpt1), there was no membrane 
accumulation but a diffuse pattern of Gag localization within the cells 
expressing S6. Furthermore, S6 did not affect the sub-cellular distribution 
of Gag/GagPol when IN was deleted, demonstrating that S6-mediated 
inhibition was dependent on IN. Additionally, in S6-expressing cells, there 
was a decrease in the intracellular Gag levels. These results together 
indicate that ectopic expression of S6, by binding to IN, affects multiple 
stages including Gag synthesis or stability and accumulation of Gag/Gag-
Pol along the plasma membrane, leading to inhibition of assembly at an 
early stage prior to particle formation and budding.  
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An important goal of lentivirus vaccine design is induction of broadly 
neutralizing antibody (bNAb). Ideally, such antibody would target 
conserved epitopes shared among a large number of genetically distinct 
primary isolates. However, broad neutralizing activity could also result 
from an accumulation of antibodies with multiple specificities. Horses 
infected with EIAV develop bNAb, which play an important role in control 
of virus during long-term inapparent infection. Over time, neutralization 
escape variants evolve and lead to recrudescence of clinical disease. A goal 
of our research is to identify the viral targets of bNAb and determine 
mechanisms of neutralization resistance. There are eight variable regions, 
V1-V8, in the surface envelope glycoprotein (SU) of EIAV. Two 
neutralizing epitopes are found in V3, in a region termed the Principal 
Neutralizing Domain (PND). A third neutralization epitope is found in a 
conserved region of V5. To investigate the role of variable regions V5, V6, 
and V7 in neutralization of EIAV, we used the cell culture-adapted EIAV-
19 and the virulent wild-type EIAV-Wyo to generate a series of chimeric 
reporter viruses that differed in the PND and/or variable regions V5, V6 and 
V7. These viruses were tested in neutralization assays against a panel of 
serum collected from horses experimentally infected with EIAV-19 or 
EIAV-Wyo. Most sera were able to neutralize all chimeric viruses, 
regardless of the PND or V5-V7 genotype, indicating the presence of 
bNAb. In general, highest neutralizing titers were against chimeric viruses 
that were homologous in V5-V7; in only one horse was the homologous 
PND region observed to be immunodominant. Sera from two horses 
neutralized viruses containing either homologous or heterologous PND, but 
introduction of heterologous V5-V7 resulted in a loss of neutralizing 
activity. For these samples, the neutralization phenotype depended on the 
identity of the V6 region, suggesting the presence of a novel neutralization 
epitope in this region. Neutralizing antibody titers against chimeric viruses 
heterologous in both the PND and V6 were markedly reduced as compared 
to titers against homologous virus. Thus, there appears to be at least two 
distinct immunodominant neutralizing epitopes in EIAV SU, and a portion 
of the broadly neutralizing activity in EIAV-infected horses results from 
accumulation of antibodies with different specificities. 
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Activated CD4+ T cells and macrophages express APOBEC3G (A3G) and 
APOBEC3F (A3F), which are potent inhibitors of retroviral replication. HIV-1 
Vif binds to A3G and A3F, targeting them for proteasomal degradation, thereby 
allowing HIV-1 replication in these cells. Distinct regions of Vif interact with 
A3G and A3F; Y40RHHY44 is important for binding to A3G, whereas 
D14RMR17 is critical for binding to A3F. In single-cycle infectivity assays, a vif 
mutant in which 5 alanines replaced Y40RHHY44 (YRHHY>A5) failed to block 
A3G but not A3F antiviral activity; in contrast, a vif mutant in which D14RMR17 
was replaced with 4 alanines (DRMR>A4) failed to block A3F but not A3G 
antiviral activity (Russell et al. J. Virol. 81:8201,2007). Here, we used 
replication-competent HIV-1 YRHHY>A5 and DRMR>A4 mutants to 
determine the relative antiviral activity of A3G and A3F in activated CD4+ T 
cells and macrophages by comparing their replication kinetics and the nature 
and extent of G-to-A hypermutation.  
In the first round of infections, both YRHHY>A5 and DRMR>A4 mutants 
replicated in activated CD4+ T cells and macrophages; only the YRHHY>A5 
mutant showed a 2 - 4 day delay in replication compared to WT. In the second 
round of infections, initiated with virus derived from the first round, a longer 8-
10 day delay in replication was observed for the YRHHY>A5 mutant, and a 2-6 
day delay was observed for the DRMR>A4 mutant compared to the WT. These 
observations indicated that A3G is a more potent inhibitor of HIV-1 replication 
than A3F. The YRHHY>A5 mutant- and DRMR>A4 mutant-derived proviruses 
displayed G-to-A hypermutations primarily in a GG and GA dinucleotide 
contexts, suggesting hypermutation by A3G and A3F, respectively. Inclusion of 
additional mutations (E76A and/or W79A) to DRMR>A4, previously shown to 
diminish Vif’s ability to block A3F, did not further delay the replication kinetics 
of the DRMR>A4 mutant.  
A3G expression was higher in CD4+ T cells than in macrophages. Treatment 
with interferon alpha (IFNα) substantially increased A3G expression in 
macrophages and completely abrogated virus replication; in contrast, IFNα 
treatment did not appreciably increase A3G expression in activated CD4+ T 
cells, but did increase the delay in replication kinetics and hypermutation of 
both mutants.  
In summary, we conclude that A3G and A3F both exhibit antiviral activity in 
macrophages and CD4+ T cells and A3G is a more potent inhibitor of HIV-1 
replication than A3F.  
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The viral structural protein Gag interacts with the plasma membrane (PM) 
through an N-terminal membrane binding domain (MBD). In HIV-1, the 
MBD is composed of a myristate moiety, which can be sequestered or 
exposed, a phosphatidylinositol (PI) 4,5-bisphosphate [PI(4,5)P2)] binding 
pocket [1], and a highly basic region (HBR). Previous studies suggest that 
HIV-1 Gag binds to PI(4,5)P2, which causes a conformational change in the 
MBD that exposes the myristate moiety. This mechanism allows for 
specific targeting of Gag to the PM and enhances the membrane binding 
affinity of Gag. Reduction of PI(4,5)P2 levels at the PM compromises virus 
release and results in a re-localization of HIV-1 Gag to late endosomes [2]. 
A recent study suggests that RNA interactions with the HBR can also 
regulate membrane binding of HIV-1 Gag [3].  
 
RSV Gag interacts with membranes through a highly basic patch [4, 5] 
similar to that of HIV-1 Gag, but RSV Gag is not myristoylated. We show 
by fluorescence microscopy that RSV Gag appears to bind to the PM by a 
PI(4,5)P2-independent mechanism. These results suggest that RSV Gag 
interacts with membranes only electrostatically, as shown previously for 
purified MA [5]. Preliminary results from liposome flotation assays of full 
length RSV Gag are consistent with this conclusion. We are currently 
assessing the effects of RNA on RSV Gag membrane binding. 
 
[1] Saad et al (2006 ) PNAS 103:11364; [2]Chukkapalli et al (2008) J Virol 
82:2405; [3] Chukkapalli et al (2010) PNAS 107:1600; [4] Callahan & Wills (2000) 
J Virol 74:11222; [5] Dalton et al (2005) J Virol 79:6227. 
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It has been reported that HIV-1, HIV-2, and SIV Nef downmodulate several 
chemokine receptors including CCR1, CCR4, CCR2, CCR3 CXCR4, 
CCR5, CXCR1, CXCR2, and CXCR4. We show here that HIV-1 Nef 
downmodulates a tested set of chemokine receptors to a variable extent 
based on the cell type, receptor, and primary cell donors. Of all the 
chemokine receptors examined, CXCR4 in different primary cells and 
tumor cell lines and CXCR1 and CXCR2 in certain cell lines were 
downregulated better by different HIV and SIV Nef alleles in the context 
DNA transfection, single-cycle HIV infection or Nef protein transduction, 
although the downregulation was quite modest compared to that of CD4. 
Previous studies have mapped the domains of CXCR4 and Nef required for 
the down regulation of this receptor. However the understanding of the 
mechanisms involved is limited. In general the Agonist bound receptors 
undergo phosphorylation recruiting E3 ligase, which ubiquitinates (Ubq) 
CXCR4. The Ubq residues serve as endolysosomal sorting signals through 
the ESCRT pathway. We hypothesized that the HIV-Nef serves as an 
intracellular agonist surrogate for CXCR4 and other chemokine receptors, 
recruiting AIP4/NEDD4 E-3 ligases to ubiquitylate CXCR4 followed by a 
dynamin dependent endocytosis into MVBs for proteolyis. This mechanism 
was confirmed by interaction between Nef, AIP4 and CXCR4 and by 
reversal of Nef effect through siRNA knockdown of AIP4 or by a small 
molecular weight inhibitor of dynamin. We also show that both naturally 
truncated mutants of CXCR4 as in WHIMS or engineered truncated 
variants of CXCR2 and CXCR4 (which lack the classical motifs for 
endocytosis and ubiquitylation) are downregulated more profoundly than wt 
receptors, probably through direct recruitment of AP2 adapter. Thus, we 
demonstrate here that the mechanism of Nef induced CXCR4 
internalization follows the general paradigm of agonist occupied chemokine 
receptors. 
 68 
AUTOPROCESSING OF HUMAN IMMUNODEFICIENCY VIRUS 
TYPE 1 PROTEASE MINIPRECURSORS FUSED TO GLUTATHIONE 
TRANSFERASE IN MAMMALIAN CELLS 
 
Liangqun Huang, Chaoping Chen  
 
Colorado State University, Biochemistry and Molecular Biology, Fort 
Collins, CO, 80523-1870 
 
HIV protease (PR) is a virus-encoded aspartic protease that is essential for 
viral replication. The fully active and mature dimeric protease is produced 
from the Gag-Pol polyprotein as a result of autoprocessing. We here 
describe a cell based assay examining HIV protease autoprocessing in 
transfected mammalian cells. A well characterized miniprecursor consisting 
of the mature protease along with its upstream transframe region (TFR) was 
in-frame fused to the C-terminus of GST and the resulting chimeric 
precursors were able to autoprocess releasing mature protease in E. coli and 
HEK 293T cells. Protease inhibitors Indinavir and Duranavir suppressed 
autoprocessing when transfected cells were incubated with the inhibitors. 
To further evaluate the mammalian expressed GST fusion miniprecursors 
for their utility, we constructed mutants that were previously characterized 
with other model systems and examine their protease autoprocessing in 
transfected 293T cells. These mutants displayed previously reported 
phenotypes including: 1) H69E mutation in a pseudo wild type protease 
backbone reduced autoprocessing; 2) the H69E inhibitory effect was 
partially rescued by A95C mutation; 3) H69D suppressed autoprocessing 
more than H69E in NL4-3 protease sequence. With this system, we also 
demonstrated that N-terminal truncations of TFR, up to 46 out of a total of 
54 residues, do not affect protease autoprocessing. Consistent with this, 
replacing the TFR with an unrelated peptide (55 amino acid long derived 
from the N-terminus of Hect1 protein) while keeping the cleavage site 
between TFR and PR had no impact on protease autoprocessing. Taken 
together, we suggest that the mammalian expressed GST fusion 
miniprecursor is a simple and useful model to study protease 
autoprocessing, and it can be further developed for cell-based screening of 
new drugs that interfer with protease autoprocessing. 
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HIV-1 envelope protein (Env) is a trimer of heterodimers (gp120/gp41) that 
is responsible for a virus attachment and fusion. Individual virions contain a 
low number of Env trimers with some studies indicating the requirement of 
a concerted action of several Env trimers for entry. Despite the detailed 
knowledge about HIV-1 Env structure and its fusion mechanism, not much 
is known about the actual distribution of Env on individual particles and 
their rearrangements on the virus surface during the early stages of 
attachment and entry. Stimulated Emission Depletion microscopy (STED) 
is a subdiffraction fluorescence microscopy technique that can resolve 
biomolecules at a resolution of up to 20 nm thus offering a unique 
possibility to study subviral structures by a fluorescence microscopy. Here, 
we have used STED microscopy to observe HIV-1 Env distribution on 
wild-type (wt) and mutant virions and to detect Env rearrangements upon 
CD4 receptor engagement. Mature wt HIV-1 particles predominantly 
displayed a clustering of Env molecules, with the majority of virions 
showing only a single Env cluster. This was different for immature HIV-1 
particles which revealed a broader, multi-clustered distribution. A similar 
phenotype was observed when the immature Gag lattice was stabilized by a 
mutation of cleavage sites or when the C-terminal tail of Env was truncated. 
These results indicate that a virion maturation affects the outer surface of 
the particle and also alters Env lateral motility dependent on the Env C-
terminal tail. These findings were correlated with a parallel cryo-electron 
tomography analysis of Env distribution. We have also analyzed 
rearrangements of Env molecules upon the receptor engagement by 
determining Env colocalization with CD4 patches on the cell membrane for 
wt and mutant HIV-1. These experiments indicate a maturation-dependent 
differences in Env distribution on the virion surface and its redistribution 
during the receptor interaction which may play a role in HIV-1 entry. 
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Human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper factor 
(HBZ) is transcribed from the antisense genomic DNA strand and functions 
differently in its RNA and protein forms. To distinguish between the roles 
of hbz mRNA and HBZ protein, we generated mutants in a proviral clone 
that specifically disrupt the hbz gene product. A proviral clone with a splice 
acceptor mutation that disrupts expression of the predominant hbz mRNA 
resulted in lower levels of tax mRNA, as well as lower levels of Gag 
proteins. Heterologous hbz expression restored Tax activity to cells 
expressing this mutant clone. In contrast, proviral mutants that disrupt HBZ 
protein but not hbz mRNA did not affect levels of tax mRNA. Since hbz is a 
natural antisense RNA to genes expressed from the (+) genomic DNA 
strand, we hypothesized that hbz mRNA represses an inhibitor of tax. p30II, 
an accessory viral protein, has been shown to down-regulate tax expression, 
and since the majority of the hbz transcript is complementary to the p30II 
transcript, we suggest that hbz promotes expression of tax by down-
regulating p30II expression. Mutation of p30II overcame the effects of the 
splice acceptor mutation of hbz, and restored tax expression. Additionally, 
levels of p30II mRNA were reduced in the presence of HBZ. Thus, there is a 
complex interplay of viral regulatory proteins controlling levels of HTLV-1 
gene expression. 
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When expressed in mating populations of S. cerevisiae, the retrotransposon 
Ty3 utilizes mRNA for both the template for translation and the packaging 
of genomes into virus-like particles (VLPs). As there is no separate pool of 
Ty3 genomic (g)RNA used solely for packaging into VLPs, translation and 
selection for packaging are likely to be inherently linked. However, the 
point at which commitment to packaging occurs for Ty3 is not known. Ty3 
RNA and proteins co-localize with cellular proteins involved in RNA 
processing, degradation, and translation regulation. Additionally, while 5’ 
untranslated regions (UTRs) of Ty3 are predicted to contain stable 
secondary structure motifs important for identifying transcripts for 
packaging – as is the case for retroviruses – the presence of these structures 
could restrict translation initiation and ribosome scanning. Regions of Ty3 
RNA were investigated to determine the features required for gRNA 
dimerization and packaging. Our results show that UTRs are not required 
for localization of GAG3-POL3 RNA with P-body proteins but do 
contribute significantly to packaging. Preliminary analysis of native GAG3 
RNAs suggests that other features apart from UTRs may contribute to the 
formation of GAG3 RNA dimers in vivo. Ty3 RNA that has been packaged 
into VLPs maintains a 5’ cap structure, indicating that RNA decapping is 
not a requirement for Ty3 gRNA packaging. We also investigated the role 
of host cell proteins in committing a Ty3 RNA for translation or packaging. 
In a genome-wide screen of host factors required for transposition, the P-
body protein and DEAD-box helicase Dhh1p and DEAD-box helicase 
Dbp3p were identified. As DEAD-box family proteins have been shown to 
be global regulators of translation and RNA processing, and can also be 
constituents of P bodies, the roles of these proteins in Ty3 replication were 
investigated. Deletion of DHH1 resulted in a dramatic decrease in Ty3 
RNA and protein during alpha factor- and galactose-induced Ty3 
expression. Over-expression of Dhh1p also decreased Ty3 protein levels. 
Deletion of DBP3 resulted in a lesser effect on Ty3 RNA and protein levels, 
and WT levels of cDNA production, but produced an equally dramatic 
decrease in transposition as that of the DHH1 deletion. Thus, Dhh1p 
appears to act on the Ty3 lifecycle at the translational level, potentially by 
modulating the switch between RNA degradation/packaging and 
translation. Contrastingly, the absence of Dpb3p results in a phenotype 
consistent with a post- translational, pre-integration defect. 
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HIV-1 assembles and buds at the plasma membrane of T cells and most 
epithelial cell-lines, whereas in macrophages, HIV-1 particles are 
predominantly found in intracellular compartments. Some recent reports 
suggest that these intracellular compartments are in fact modified plasma 
membrane compartments that are continuous with the cell surface. In this 
study, we present several lines of evidence that show that these 
compartments are endocytic in nature and describe a potential role of 
tetherin in the formation of these compartments. With immunofluorescence 
and electron microscopic methods, we demonstrated that the majority of the 
virus-containing compartments (VCCs) in HIV-1 infected macrophages 
were not accessible from the plasma membrane. We further found that the 
VCCs were intensely enriched in tetherin, which is a HIV-1 restriction 
factor that normally recycles through the cellular endocytic network. Next, 
we examined the endocytosis of tetherin by pulse-labeling cell surface 
tetherin. We found that tetherin was rapidly endocytosed into the VCCs 
from the plasma membrane and at where it was retained together with the 
HIV-1 particles. Altogether, our data suggest that the viral compartments in 
infected macrophages are part of the endocytic pathway, and are highly 
enriched in tetherin. The rapid endocytosis of tetherin, together with its 
known ability to retain HIV-1 particles, and its co-enrichment in the 
intracellular endosomes with HIV-1 further suggests that it plays a role in 
sequestering the virus in these intracellular sites. 
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HIV-1 assembly is mediated by the polyprotein precursor Gag that contains 
four major structural domains: matrix (MA), capsid (CA), nucleocapsid 
(NC) and p6. One of the most crucial steps in HIV-1 assembly is membrane 
binding of Gag. This step is facilitated by bipartite signals of MA: N-
terminal myristoylation and the highly basic region (HBR) between amino 
acids 17 and 31. The N-terminal myristate is normally sequestered into the 
MA globular domain, and a structural change exposes myristate and 
enhances membrane binding. The HBR, on the other hand, facilitates 
membrane binding by interacting with an acidic lipid, phosphatidylinositol-
(4,5)-bisphosphate [PI(4,5)P2]. Additionally, analyses of liposome binding 
of Gag synthesized in vitro using rabbit reticulocyte lysates suggest that the 
HBR can also suppress PI(4,5)P2-independent membrane binding by 
keeping the myristate sequestered.  
Membrane binding of Gag is also enhanced by Gag multimerization. In 
addition to CA dimerization, RNA bound to NC can act as a scaffold and 
bring Gag molecules together. To understand the role of RNA in Gag-
membrane binding, we treated Gag synthesized in vitro with RNase before 
mixing with liposomes. To our surprise, RNase-treated Gag binds 
liposomes much more efficiently compared to non-treated Gag suggesting 
that RNA inhibits membrane binding. Mutational study suggests that the 
RNA bound directly to MA HBR but not NC is involved in this regulation 
of membrane binding. Further analysis indicates that RNA inhibits 
electrostatic interaction between HBR and acidic lipids. In addition, 
enhanced binding of RNase-treated Gag to neutrally-charged liposomes 
suggest that RNA can also modestly inhibit myristate exposure. Preliminary 
results show that MA HBR interacts with RNA not only in the in vitro 
system but also in cells. Currently, we are investigating which RNA is 
bound to the MA HBR and whether it inhibits membrane binding in cells. 
In summary, RNA bound to the MA HBR inhibits membrane binding by 
blocking both electrostatic interaction with acidic lipids and myristate 
exposure and may represent a novel regulator of Gag-membrane binding. 
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In addition to K65R, the other mutation that is observed at RT codon 65 is K65N. 
This mutation is rarely observed during clinical trials. The <I>in vitro</I> selection 
of this mutation along with K70R has been shown to occur during the passaging of 
HIV-1 LAI with the combinations of emtricitabine (FTC) and tenofovir (TDF).  
Also, in vivo selection of this mutation in patients with M184V or non nucleoside 
reverse transcriptase mutation has been demonstrated with abacavir-lamivudine-
TDF or FTC-ddI-efavirenz treatments. The development of K65N with other 
mutations was attributed to the variable drug concentrations. We hypothesized that 
viruses containing K65N mutation will be attenuated in comparison to viruses with 
K65R change. 
 
In order to assess the relative impact of K→N with respect to K→R change, we 
performed site-directed mutagenesis to insert K65R and K65N in proviral clone 
pNL4-3. Viruses were generated upon transfection of 293T cells and replication 
kinetics assays were performed in PHA-stimulated PBM cells and MT-2 cells  in the 
absence of drug. We found K65N has a significant loss in replication capacity in 
comparison to K65R (p = <0.011). In order to understand the biochemical 
mechanisms involved in viral attenuation, in vitro RT processivity was performed 
using virion-associated RT with homopolymer poly (rA) and oligo (dT) primer in 
the presence of radio-labelled dNTP (α-<SUP>32</SUP>P TTP) and trap poly (rC)-
oligo (dG). A significant decrease both in the length of cDNA (p = 0.001) and the 
density of cDNA (p = 0.0001) synthesis was observed with K65N RT in comparison 
to K65R RT. Since our previous studies have shown that K65R+L74V mutant is 
highly crippled and the initiation of replication of this virus leads to R→K reversion, 
we performed amino acid polymorphism analysis of RT codon 65 and created 
various mutants singly or in the background of L74V mutation: K65A, K65E, 
K65Q, K65I, K65T K65N+L74V, K65A+L74V, K65E+L74V, K65Q+L74V, 
K65I+L74V, K65T+L74V. Replication kinetics assays showed absence of any 
measurable RT activity in PBM cells. A low level of replication was observed in 
MT-2 cells but the viruses from MT-2 cells failed to initiate any replication in PBM 
cells. Comparison of RT processivity between doubly mutants K65R+L74V and 
K65N+L74V showed a significant decrease in single cycle RT activity (p = 0.001) 
and processivity (p = 0.05) of latter RT. 
 
Our observations suggest that due to slower growth kinetics of K65N viruses in 
comparison to K65R, the selection of the K65R mutation may be favored in clinical 
use of antiretroviral drugs compared to K65N. The deleterious effect on viral 
replication by various changes at RT codon 65 could not be compensated by the 
addition of L74V on the same viral genome. An anti-retroviral therapy regimen 
enforcing the selection of K65N and L74V on the same viral genome may be a 
useful strategy for the management of HIV disease. 
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The interferon-induced protein kinase RNA-activated (PKR) is activated 
after virus infection. This activation is only transient during human 
immunodeficiency virus (HIV) infection of lymphocytes and the protein is 
not activated at the peak of infection. We observed that the interferon-
induced Adenosine deaminase acting on RNA (ADAR)1-p150 and 
ADAR1-p110 expression increases while the virus replicates actively. 
Furthermore, both forms of ADAR1 and the PKR activator (PACT) show 
enhanced interactions with PKR at the peak of HIV infection suggesting a 
role of these proteins in the regulation of PKR activation. We observed that 
ADAR1p150 reverses PKR inhibition of HIV virus expression and 
production in HEK 293T cells. This activity requires the Z-DNA binding 
motif and the three double-stranded RNA binding domains, but not the 
catalytic domain. Surprisingly, PACT also reverses PKR inhibition of HIV 
virus expression and production in HEK 293T cells suggesting a role of 
PACT as a PKR inhibitor. These results indicate that two interferon-induced 
proteins, ADAR1 and PKR can have antagonistic functions. They also 
suggest that PACT switches from a PKR activator to a PKR inhibitor in the 
context of active HIV replication. 
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Encapsidation of viral RNA into a HIV-1 particle requires interactions between 
cis elements localized primarily in the 5’ UTR of the viral RNA and trans 
factors encoded by the virus, & host cell genome. The HIV-1 Rev protein was 
recently shown to influence encapsidation of HIV-1 RNA in the presence of the 
major cis packaging elements. Conceivably, the encapsidation functions 
attributed to cis elements in the 5’ UTR and the Rev/RRE system are separable. 
We investigated whether a gain of encapsidation function could be achieved 
through transfer of HIV cis elements to a heterologous RNA. The HIV-1 RRE 
and major cis packaging determinants (HIV-1 R, U5, PBS, & canonical 
packaging signal) were systematically incorporated into a murine leukemia 
virus (MLV) vector RNA to assess encapsidation into HIV-1 viral particles. 
Chimeric HIV-1 particles harboring MLV RNA can transduce cells, thereby 
supporting a rapid method for assessing encapsidated RNA into viral particles 
by titering for a GFP reporter. In an MLV vector, devoid of all conventional 
HIV-1 cis packaging elements, the Rev/RRE enhanced encapsidation of the 
MLV vector RNA 5-10 fold into a HIV-1 viral particle. Encapsidation was 
augmented nearly an additional 100-fold by incorporating all HIV-1 major cis 
packaging determinants into the middle of the MLV vector. Cis elements 
consisting of both the R-U5-PBS, and conventional packaging signal, are 
necessary to achieve a synergistic encapsidation effect in the presence of the 
Rev/RRE. Rev/RRE-mediated nuclear export of RNAs through the CRM-1 
pathway may impact the capacity to enhance encapsidation. Employing a 
previously characterized RevM10-Tap fusion protein to redirect RRE-
containing vector RNAs from the CRM-1 to the Tap-dependent nuclear export 
pathway we demonstrate that encapsidation with the RevM10-Tap system was 
comparable to that obtained with conventional Rev. We provide evidence 
showing that i) Rev can enhance encapsidation of heterologous RNA 
independent of a conventional HIV-1 packaging signal; ii) the R, U5, PBS, & 
canonical packaging signal dramatically enhance encapsidation upon transfer to 
a heterologous RNA; iii) cis elements in the entire 5’ UTR and the Rev/RRE 
system function synergistically to support RNA encapsidation specifically into 
HIV-1 particles; and, iv) Rev/RRE dependent encapsidation can be 
accomplished through CRM-1, or Tap dependent nuclear export. 
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Dendritic cells (DCs) have close interactions with CD4+ T cells, the main 
targets of HIV replication. DC subsets have been investigated for their role 
in transmission of captured HIV from the site of infection to the main T cell 
pool. Immature DCs (iDCs) and mature DCs (mDCs) transmit HIV-1 to 
cocultured CD4+ T cells with different efficiencies. Various stimuli 
including lipopolysaccharide (LPS) and interferons (IFN) have been used to 
induce DC activation. DC-mediated HIV-1 transmission can be regulated 
by host factors. Tetherin (CD317 or BST-2) is a type-1-IFN-induced 
cellular protein that restricts HIV-1 particle release. Tetherin acts as an 
important component of the innate defense against several other enveloped 
viruses. The potential role of tetherin in DC-mediated HIV-1 transmission 
remains unknown. To explore the potential role of tetherin in DC-mediated 
cell-to-cell transmission and replication of HIV-1, monocyte-derived iDCs, 
mDCs induced by LPS (mDC-LPS) and IFN alpha (mDC-IFN-α) were 
compared for tetherin expression and HIV-1 replication and transmission 
efficiency. DC surface and total expression of tetherin was assessed by flow 
cytometry and immunoblotting, respectively. iDCs were negative for 
tetherin, while mDCs-LPS were highly positive in both measures; and 
mDC-IFN-α were partially positive by flow cytometry and highly positive 
by immunoblotting, indicating efficient up-regulation of intracellular, but 
not surface tetherin expression by IFN-α. Interestingly, mDC-IFN-α 
displayed significantly reduced capacity of HIV-1 uptake and transmission 
compared to mDC-LPS, and reduced HIV-1 replication compared to iDCs. 
Furthermore, mDC-IFN-α showed unique chain-like localization of HIV-1 
particles on the cell surface, suggesting altered viral trafficking by IFN-α 
activation. The potential role of tetherin in mDC-LPS-mediated HIV 
transmission is being examined by silencing tetherin expression using 
specific siRNA. The mechanisms of mDC-IFN-α restrictions of HIV 
infection and transmission are under investigation. These studies will help 
to further understand the mechanisms of cell-to-cell transmission of HIV-1. 
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RNA interference (RNAi) regulates gene expression in eukaryotes. The 
assembly of a ribonucleoprotein complex, the RNA-Induced Silencing 
Complex (RISC), is crucial for RNAi activity. In addition, many organisms 
use RNAi as an antiviral defence mechanism. Although it is still unclear 
whether or not this is the case in humans, several viruses have been shown 
to suppress RNAi activity.  
One key protein of the human RISC is the TAR-RNA Binding Protein 
(TRBP). TRBP was characterized for its ability to bind to the Human 
Immunodeficiency Virus (HIV) TAR RNA, and is required for productive 
viral replication. This work explores the relationship of TRBP to RNAi and 
HIV replication to determine whether elements of HIV are able to inhibit 
RNAi activity in the cell. 
HIV has been suggested to inhibit RNAi by sequestering TRBP from the 
RISC through the TAR RNA element. We tested the ability of this and 
other HIV-encoded elements to inhibit RNAi activity. Our results indicate 
that certain HIV elements interact with TRBP and restrict RNAi. 
RNAi has emerged as a critical regulator of cellular functions. The ability of 
HIV components to disrupt RNAi activity may have important implications 
in both pathogenesis and treatment options at a time when RNAi-based 
gene therapy is becoming an attractive new tool for the control of infectious 
diseases. 
 
This work is supported by the Canadian Institute of Health Research. 
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Understanding HIV-1 population dynamics is essential to better predict 
viral disease progression to AIDS, durable antiretroviral drug regimens, and 
for the development of an effective vaccine. HIV-1 populations are best 
described as a quasispecies. In this study, we investigated a fundamental 
feature of HIV-1 quasispecies formation by exploring the relationship 
between viral fitness and mutation rate. We propose a model in which 
optimal viral fitness corresponded to the defined optimal viral mutation rate, 
and reductions in viral fitness would coincide to either increases or 
decreases in viral mutation rate. In order to experimentally test our model, 
we have created a set of HIV-1 mutants, most of which contain single 
amino acid mutations that confer drug-resistance to nucleoside reverse 
transcriptase analogs. These mutants were used in parallel assays to assess 
viral fitness, mutation rate and rate of viral DNA synthesis. Our findings 
support our model of the relationship of viral fitness and mutation rate and 
this study represents the first comprehensive analysis of such mutants. A 
prediction made from our model and our studies is that purposeful increases 
or decreases in viral mutation rate can result in reductions in viral fitness – 
an outcome that would have therapeutic applications. 
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Xenotropic murine leukemia virus-related virus (XMRV) is a new human 
retrovirus first identified in prostate cancer tissues from men with a subtle 
deficiency in an innate immunity gene. Currently, in different studies, 0 to 
27% of prostate cancer cases and 0 to 67% of chronic fatigue syndrome 
(CFS) patients showed evidence of XMRV infections. While the 
explanation for these different results is unknown, differences in genetics, 
geographical distribution, sequence diversity in viral strains, or 
methodological variations are suspected. Here we will describe our methods 
for detecting low copies of XMRV nucleic acids and the challenges we 
have encountered. Various clinical samples were obtained from prostate 
cancer patients just prior to and following radical prostatectomy. Prior to 
surgery, prostate massage was performed and urine samples were collected 
containing prostatic secretions. Flash frozen prostate tissues from the 
peripheral zones were obtained after radical prostatectomy. In addition, 
expressed prostatic secretions (EPS) were obtained by manually milking the 
prostate after surgery. RNA (or DNA) were extracted from the samples and 
real-time RT-PCR (or PCR) were used to measure low copies (as few as 10) 
of XMRV RNA or DNA. Confirmation of the presence or absence of 
XMRV nucleic acids was obtained by nested RT-PCR (or PCR). These 
methods specifically amplify env sequences corresponding to variable 
regions A & C of the gp70 envelope protein. The identity of the amplicon 
was confirmed by DNA sequencing. Results show less than 100 copies of 
XMRV DNA was present per microgram of total DNA from prostate tissue. 
Similarly, RNA isolated from patient samples contained 500 or fewer 
copies of XMRV RNA per microgram of total RNA. These low levels of 
XMRV nucleic acids in patient samples highlight the challenges of 
performing PCR methods as an indicator of XMRV infections. However, 
once fully developed, PCR methods may lead to large-scale high throughput 
assays for monitoring XMRV in prostate cancer patients, in other diseases, 
and in the general population.  
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HIV-1 infects non-dividing cells. This implies that the virus traverses the 
nuclear pore before it integrates into chromosomal DNA. Recent studies 
characterizing HIV-MLV chimeras and HIV-1 Capsid (CA) mutants 
suggest that CA plays a critical role in nuclear entry of the viral 
preintegration complex (PIC). To shed light on the mechanism by which 
CA contributes to this essential step in HIV-1 infection we have engineered 
a panel of single-cycle HIV-1 vectors bearing CA mutations that have been 
partially characterized in previous studies. These mutants will be 
extensively characterized using standard methods for virion assembly, 
capsid stability, virion infectivity, synthesis of viral cDNA, 2-LTR circles, 
and proviral DNA. Infectivity of the mutants will be analyzed under 
conditions of cell cycle arrest, and knock-down of CA interacting proteins. 
At the same time we are attempting to develop new methods for visualizing 
PICs in fixed and living cells; these methods will be used to better 
characterize the replication defects of the above-mentioned CA mutants. 
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Vpr is a 96 residue basic protein that impacts on the cell physiology during 
HIV replication 1. The protein is detected in the blood serum of infected 
patients and enters non-infected cells causing G2/M cell cycle arrest and 
apoptosis 2. Rhodamine and fluorescein derivative of the Vpr C-terminus 
were used to describe the mechanism of Vpr(52-96) cellular uptake. The 
clathrin-coated pits or the caveolae pathways were followed by transferrin 
and methyl-β-cyclodextrin suggesting an energy dependent uptake of 
Vpr(52-96) but a fraction of peptide could translocate at 4°C. Vpr C 
terminus forms large aggregates that interact with the PM even though the 
inhibition of macropinocytosis by N,N-dimethylamylorid did not limit the 
uptake. In the cell, Vpr(52-96) diffuses in the cytoplasm and in the nucleus 
while aggregates stain in late endosomes/lysosomes and are highly stable as 
monitored by FRET based images 3. Moreover, we show a direct interaction 
with lipids that destabilize the bilayer rather than inducing channel 
segments.  
 
1 R. Y. Zhao et al., Advances in pharmacology (San Diego, Calif 55, 233 (2007). 
2 C. Arunagiri et al., Apoptosis 2 (1), 69 (1997); P. Henklein et al., J Biol Chem 275 
(41), 32016 (2000); E. N. Sabbah et al., J Neurovirol 11 (6), 489 (2005). 
3 J. V. Fritz et al., Retrovirology 5, 87 (2008); J. V. Fritz et al., J Virol 84 (3), 1585 
(2010). 
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Background: In 2003 we identified the cellular protein, LEDGF/p75, as a 
strong binding partner of HIV-1 integrase (IN) in eukaryotic cells. We have 
since established a thorough validation procedure for novel HIV co-factors. 
Implementation of our validation scheme corroborated LEDGF/p75 as an 
important co-factor of HIV integration and validated the virus-host 
interaction as a potential drug target for antiviral therapy.  
Methods: The resolved X-ray structure of IN-core complexed with the IBD 
of LEDGF/p75 revealed a well defined interphase suggesting that small 
molecule protein-protein interaction inhibitors (SMPPII) might be capable 
of disrupting the interaction. We have now applied rational drug design to 
identify small molecules potentially binding to the interaction site. For in 
vitro hit identification we developed a high throughput Alphascreen assay 
monitoring the LEDGF/p75 HIV-1 Integrase interaction. Antiviral activity 
and cytotoxicity of initial hits from in vitro screening were evaluated in cell 
culture in the MT4/MTT HIV replication system.  
Results: We have rationally designed a series of 2-(quinolin-3-yl)acetic 
acid derivatives that act as potent inhibitors of the LEDGF/p75-integrase 
interaction and HIV-1 replication at submicromolar concentration by 
blocking the integration step. A 1.84 Å resolution co-crystal structure 
corroborates the binding of the inhibitor in the LEDGF/p75 binding pocket 
of integrase. This structure and the lack of cross-resistance with two clinical 
integrase inhibitors (Raltegravir and Elvitegravir) defines the 2-(quinolin-3-
yl)acetic acid derivatives as the first genuine allosteric HIV-1 integrase 
inhibitors.  
Conclusion: Our work demonstrates the feasibility of rational design of 
small molecules inhibiting the protein-protein interaction between a viral 
protein and a cellular host factor.  
The discovery of the 2-(quinolin-3-yl)acetic acid derivatives as the first 
inhibitors of LEDGF/p75-IN interaction (LEDGINs) and HIV replication 
provides the ultimate proof for the crucial role of the cofactor in HIV 
replication. The antiviral profiling as well as their ADMEDTox profile 
demonstrate their potential for antiviral therapy.  
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The active nuclear import of HIV-1 through the nuclear pore accounts for 
its ability to replicate in non-dividing cells. Despite many papers published 
on the topic, it remains entirely unknown how the HIV-1 DNA genome 
achieves translocation through the nuclear pore. It is assumed that it is 
compacted, protected and rendered karyophilic by viral and possibly 
cellular proteins that associate with it. Indeed, viral nuclear import factors 
have been proposed, such as integrase (IN) and the central DNA Flap, 
however their cellular interaction partners remain unknown. Transportin-
SR2 (TNPO3) is a karyophilic shuttle protein shown to be involved in HIV-
1 replication and nuclear import. Although TNPO3 was originally identified 
as binding partner for IN, the identity of the physiological viral interaction 
partner for TNPO3 is currently under debate. We therefore sought to 
determine the mechanistic implication of TNPO3 in HIV-1 nuclear import. 
We were intrigued to note that the Saccharomyces cerevisiae orthologue of 
TNPO3, MTR 10, shuttles tRNAs from the cytoplasm back into the 
nucleus, and hypothesised that TNPO3 might act as an interaction partner 
for the single stranded DNA Flap that is present at the centre of the HIV-1 
genome following reverse transcription. To test this hypothesis, we infected 
knock-down Hela cells for TNPO3 with HIV-luc-VSV-G viruses with wild 
type or 225T Flap mutant. As previously published, we observed a ~10-fold 
reduction in infectivity in the absence of TNPO3, and a ~10-fold reduction 
in infectivity in the absence of the central DNA Flap. However, the 
enhancement of infectivity brought by the presence of DNA Flap was not 
lost upon TNPO3 knock-down, indicating that the central DNA Flap still 
confers an infection advantage in the absence of TNPO3. Therefore, we 
conclude that TNPO3 does not interact with the central DNA Flap to 
promote nuclear import. Interestingly, CA point mutations have been 
reported that render HIV-1 insensitive to TNPO3 knock-down, and work is 
undergoing to investigate whether TNPO3 might interact functionally or 
physically with HIV-1 CA. 
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TRIMCyp is a fusion protein related to the prototype restriction factor 
TRIM5α, which restricts retroviral replication at a post-entry step. 
TRIMCyp evolved independently in Old World and New World monkeys, 
representing a striking example of convergent evolution. Old World 
TRIMCyp has been reported in three species of Asian macaques, Macaca 
nemestrina, M. mulatta, and M. fascicularis. Because M. nemestrina 
belongs to the earliest diverging branch of Asian macaques, TRIMCyp must 
have evolved before the radiation of Asian macaques. However, the only 
other Old World primate species tested for TRIMCyp is the sooty 
mangabey, an African monkey, which was found to lack TRIMCyp. To 
further define the evolutionary origin of Old World TRIMCyp, we 
examined two species of baboons and three additional macaque species. M. 
sylvanus is the only macaque species found outside Asia, and represents the 
earliest diverging branch of the macaque lineage. Baboons and sooty 
mangabeys belong to a sister clade to macaques. Old World TRIMCyp 
expression requires the presence of a cyclophilin A (CypA) pseudogene 
retrotransposed into the 3’ untranslated region of the TRIM5 gene, and of a 
single nucleotide polymorphism (SNP) that allows alternative splicing to 
the CypA transcipt. Neither TRIMCyp expression, nor the CypA 
pseudogene, nor the SNP was found in baboons or M. sylvanus. We 
conclude that TRIMCyp evolved in macaques approximately 5-6 million 
years ago, after the divergence of Asian macaques from M. sylvanus but 
before the radiation of Asian macaques. This likely occurred as a result of 
retroviral threat(s) to the ancestors of Asian macaques. We also tested 
single individuals from two additional Asian macaque species, M. nigra and 
M. thibetana. Both animals were homozygous for the absence of the CypA 
insertion and of the SNP associated with the TRIMCyp allele. This 
indicates that at least some individuals of both of these species lack the 
capacity for TRIMCyp expression. Because TRIMCyp is fixed in M. 
nemestrina, which is closely related to M. nigra, this fixation must have 
occurred after these species diverged, approximately 2 million years ago. 
The macaque lineage is unique among primates studied so far due to the 
presence and diversity of TRIM5 and TRIMCyp restriction factors. Studies 
of these antiviral proteins may provide valuable information about natural 
antiviral mechanisms, and give further insight into the factors that shaped 
the evolution of macaque species. 
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A number of studies have demonstrated that Nedd4 (neuronal precursor 
cell-expressed developmentally down-regulated-4) family ubiquitin ligases 
(ULs) are involved in virus release via interacting with the late domains of 
retroviral Gag proteins. Nedd4 family E3 ULs contain nine members in 
humans including Nedd4, Nedd4L, NEDL1 (BUL1), NEDL2 (BUL2), 
WWP1, WWP2, ITCH, SMURF-1 and SMURF-2. HTLV-1 Gag has two 
late domain motifs, PPPY and PTAP. Previous studies by us and by the 
other groups have shown that the PPPY motif is more important for HTLV-
1 release than the PTAP motif and that the PPPY motif interacts with WW 
domains of E3 ULs. Mutations of the PPPY late domain motif of HTLV-1 
arrest release of virus particles from cells at an early stage of budding. We 
found that one particular Nedd4-like E3 UL, called ITCH could overcome 
the block in virus release of HTLV-1 mutants where the PPPY motif was 
changed to APPY or PPPF. Electron microscopic analyses showed that 
these PPPY-mutant viruses budded with normal morphology in the presence 
of ITCH and infectivity studies demonstrated that the specific infectivity of 
these virus like particles was close that of wt particles. In contrast, PPPY 
mutants PPPG and PPPD could not be rescued. Surprisingly, we also found 
that another UL, SMURF-1, restored virus budding to APPY mutants but 
that the resulting particles were not infectious. Furthermore, SMURF-1 
completely inhibited the infectivity of HTLV-1 WT and PTAP mutant, but 
had no effect on virus release. Catalytically inactive mutants of ITCH and 
SMURF-1 showed no effects on the infectivity and release of HTLV-1. 
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The human T-cell leukemia virus type 2 (HTLV-2) expresses a p28 accessory 
protein that negatively regulates viral replication. p28 in encoded by open 
reading frame (ORF) II from a singly spliced mRNA and is localized to the 
nucleus. p28 has been found to act post-transcriptionally by binding tax/rex 
mRNA and retaining it in the nucleus thereby reducing the amount of Tax. The 
negative regulation of Tax, although leading to reduced protein expression and 
reduced virion production, was found to be essential for viral persistence in the 
in-vivo rabbit model of HTLV-2 infection. HTLV-1 encodes a related p30, 
which acts similarly to p28 in a post-transcriptional manner to repress viral 
replication. However, p30 also acts in a transcriptional manner to modulate viral 
replication, an activity not apparent in p28.  
In the present study we aim to elucidate the mechanism of p28 repressive 
activity by understanding the role of the functional domains of p28, the effect of 
post-translational modifications on p28 function and biochemical properties, 
and the potential contributions of the host proteins on p28 function. We 
generated a panel of p28 deletion mutants and tested their ability to repress Tax 
function in a reporter assay. Our preliminary data shows that the last 60 amino 
acids of p28 are not required to repress Tax function, and the region 100-216 
might be exercising an inhibitory role on p28 function. Interestingly amino 
acids 1-50, which share homology to the c-terminus of p30/p13 of HTLV-1, can 
still cause repression of Tax in our reporter assay. In addition, we evaluated 
post-translational modifications on p28 and identified 6 serines and 1 tyrosine 
that are phosphorylated in 293T cells. The functional role of these residues will 
be discussed. Finally, we identified several cellular binding partners to p28 
using proteomics analysis. We are in the process of validating the interactions 
and the overall contribution of these interactions to p28 function and results will 
be presented. This study will provide further insight into the mechanism of 
action of the HTLV-2 p28 accessory gene product and will allow us to better 
understand its role in viral infectivity, regulation of viral gene expression, and 
persistence.  
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Mouse mammary tumor virus (MMTV) encodes a regulatory protein 
(Rem). Rem expression, similar to other Rev-like retroviral proteins, 
increases nuclear export of genome-length viral RNA. Rem also has a post-
export function that requires the presence of the Rem-responsive element 
(RmRE), which spans the junction of the envelope gene and the 3’ LTR. 
Our previous data have shown that Rem has a 98-amino-acid long signal 
peptide (SP). Rem contains all of the Rev-like domains, including a 
nuclear/nucleolar localization sequence, an RNA-binding motif, and a 
nuclear export sequence. Recent results suggest that Rem is cleaved by 
signal peptidase to yield SP and a C-terminal glycosylated product. SP 
activity can be detected using a luciferase reporter vector based on the 3’ 
end of the MMTV genome, including the RmRE. Furthermore, expression 
of SP alone is functional in the reporter assay, whereas expression of the 
Rem C-terminus alone has no detectable activity. Rem expression vectors 
carrying a proline at position 71 show poor cleavage to SP as well as 
reduced activity in the reporter assay. GFP-tagging of Rem at the N-
terminus allows cleavage to GFP-SP, which is active in the reporter assay. 
However, addition of the GFP tag to the Rem C-terminus shows poor 
cleavage to SP and little reporter activity. GFP-tagging at the N-terminus 
also appears to increase stability of SP, but not its specific activity in 
functional assays. The amount of transfected rem expression vector 
influences cleavage to SP. Transfection of large amounts of expression 
vector leads to an accumulation of uncleaved Rem and no further increases 
in reporter activity. Analysis of C-terminal truncation mutants of Rem 
suggests that removal of the C-terminal 50 amino acids has little effect on 
SP activity. Removal of 100 or 150 amino acids from the Rem C-terminus 
dramatically affects stability of the truncated protein and activity in reporter 
assays. These data suggest that the Rem C-terminus interacts with multiple 
cellular proteins that influence Rem cleavage and trafficking to the nucleus 
for binding to MMTV RNA. 
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HIV-1 release is mediated through the PTAP and LYPXnL motifs, termed 
Late or L domains, located in the p6 region of Gag. These two motifs 
recruit the cellular proteins Tsg101 and Alix, respectively, and link Gag to 
the host ESCRT budding machinery via two different routes. We recently 
reported a new role for the nucleocapsid region (NC) of Gag in assisting p6 
during viral budding although the exact mechanism remains unclear. Here 
we show that mutations of basic residues in NC caused a pronounced 
decrease in particle release from 293T cells, even though the NC mutant 
viruses trafficked normally to cell membranes and retained the ability to 
bind cellular RNAs. Electron microscopy (EM) analysis of these NC 
mutants showed a clear accumulation of arrested budding particles at the 
plasma membrane. We analyzed the NC mutant viruses in physiologically 
relevant T-cell lines such as CEM and Jurkat and found that they displayed 
severe budding defects as observed by both biochemical and EM analyses. 
NC mutants’ release defects were strikingly similar quantitatively and 
qualitatively to those seen with Late-domain mutant viruses. Moreover, 
release defects caused by mutations in NC were fully alleviated by co-
expression of the E3 ubiquitin ligase Nedd4-2s that is known to rescue the 
release of L-domain mutants. This result suggests that mutations of basic 
residues in NC interfere with the recruitment of cellular factors that 
facilitate HIV-1 budding. Taken together our data support a new role for the 
NC domain of Gag in cooperating with L domain functions essential for 
HIV-1 budding. 
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We are using the computational software ICM Pro (MolSoft, LaJolla, CA) 
to assess the hydrogen bond interactions of inhibitors of human 
immunodeficiency virus type 1 (HIV-1) integrase with the active site of the 
enzyme (Protein Data Bank entry 1BIS). Many of these inhibitors have 
drug-like properties that follow Lipinski’s rule of five, that were introduced 
for predicting oral bioavailability. These rules include: molecular mass less 
than 500 g/mole, log P (the partition coefficient, defined as the ratio of the 
concentration of a drug in octanol to its concentration in water) less than 5, 
and no more than 5 hydrogen bond donors and 10 hydrogen bond acceptors 
(reviewed in J.B. Ealy and V. Kvarta, J. Chem. Ed. 83:1779, 2006). 
However, some integrase inhibitors do not follow these rules. Thus, we are 
addressing two questions: (1) Is there a difference in the number of 
hydrogen bond interactions of drugs that follow Lipinski’s rule of five and 
those that do not?; and (2) Is there is a difference in the amino acid contacts 
for the two groups of inhibitors? Additionally, this work demonstrates how 
in silico approaches can introduce undergraduate students at non-research-
intensive campuses to research on the acquired immunodeficiency 
syndrome (AIDS). 
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RNAi is a sequence-specific gene silencing mechanism induced by double-
stranded RNA and a promising tool for the development of a durable gene 
therapy against HIV-1. Such RNAi attack usually focuses on target 
sequences within the HIV-1 RNA genome. Despite potent inhibition, we 
previously observed the rapid selection of RNAi-resistant HIV-1 variants 
with a point mutation in the target, even for highly conserved viral target 
sequences. Viral escape can be blocked by a combinatorial RNAi attack on 
multiple viral target sequences. Alternatively, RNAi-mediated suppression 
of the level of cellular proteins that are critically involved in HIV-1 
replication may also prevent the evolution of RNAi-escape variants, 
although this concept has not been tested experimentally.  
Many cellular co-factors have been described in literature, e.g. based on 
large RNAi-screens. We set out to probe the importance of 30 cellular co-
factors by producing stable knockdowns in a T cell line and testing for the 
impact on virus replication. Several co-factors appear to be important for 
cell physiology, as their knockdown resulted in a loss of cell proliferation. 
Knockdown of 15 co-factors significantly inhibited virus replication 
without any apparent cytotoxicity. We focused on three top candidate co-
factors for which knockdown results in prolonged inhibition of HIV-1 
replication; ALIX, TARBP and ATG16. We specifically tested whether 
HIV-1 can escape from the restrictions imposed by co-factor knockdown 
and - despite many attempts - were not able to document any viral escape.  
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The precursor polyprotein, Gag, of HIV-1 is necessary and sufficient for 
assembly and release of virus-like particles (VLPs). Previous studies have 
shown that addition of Ca2+ to HIV-infected or Gag-expressing cells 
increased viral particle release. However, no specific cellular factor has 
been implicated as mediator of physiologic Ca2+ provision. Here, we show 
that efficient release of assembled HIV-1 Gag requires the inositol 1,4,5-
triphosphate receptor (IP3R). IP3R is a transmembrane channel through 
which Ca2+ is released from intracellular stores. Depletion of IP3R by 
siRNA inhibited release of VLPs and infectious virus. Confocal microscopy 
of IP3R-depleted cells showed significant reduction of plasma membrane-
associated Gag. Immuno-electron microscopy showed that Gag was mostly 
sequestered inside vacuolar structures. Interference with production of and 
IP3R binding of the IP3 ligand inhibited VLP release, implying the need for 
IP3R gating activity. These findings identify IP3R as a novel cellular co-
factor in viral particle release. Whether calcium provision arose from IP3R-
mediated release of store Ca2+ or the subsequent Ca2+ influx that is coupled 
to store emptying was determined from the effect of thapsigargin (TG)-
induced store Ca2+ release on Gag while the cells were in calcium-free 
media which effectively nullified Ca2+ influx. Both the plasma membrane 
accumulation of Gag and VLP release were enhanced, indicating that store 
Ca2+ facilitated both events. To identify the determinant in Gag that confers 
the ability to utilize store Ca2+, the p6 region was tested, since Gag release 
efficiency maps to Late Domains in p6. Using the pharmacological agent 2-
aminoethoxydiphenyl borate (2-APB) to block Ca2+ influx, the effect on 
VLP release of WT Gag and a Gag mutant missing the entire p6 region 
(Δp6-Gag) was determined. 2-APB had no detectable effect on release of 
WT Gag VLPs but inhibited release of Δp6-Gag. Disruptive mutations in 
Late Domain motifs in p6 mapped 2-APB resistance to the PTAP motif. By 
inference, this finding links utilization of store Ca2+ to Gag recruitment of 
Tsg101, which binds the PTAP motif. It is unlikely that IP3R is an effector 
of Tsg101 since IP3R depletion did not result in defective Gag processing 
or loss of viral infectivity, events that characterize Tsg101 depletion. 
Rather, the results suggest that Tsg101 and IP3R play distinct roles in 
facilitating Gag release.  
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HIV-1 replication requires integration of the viral cDNA made by reverse 
transcription into the host chromosome for effective infection and 
maintaining the infected state in the host. The integration step is catalyzed 
by the retroviral enzyme integrase (IN). In vivo this process is regulated by 
multiple viral and cellular cofactors. Among these, lens epithelium derived 
growth factor (LEDGF/p75) has been identified as the principal cellular 
cofactor critical for effective HIV-1 integration. LEDGF/p75 has been 
shown to tether the viral IN protein to chromosomal DNA using a C-
terminal integrase binding domain (IBD) and an N-terminal domain 
ensemble that interacts with chromatin. The N-terminal region of 
LEDGF/p75 contains a PWWP domain, nuclear localization signal, and 
dual copies of the AT-hook DNA binding element. While the N-terminal 
region of LEDGF/p75 is essential for interactions with the chromatin, the 
molecular mechanism of these interactions is not well understood. We have 
utilized our mass spectrometry-based protein footprinting approach to 
examine LEDGF interactions with naked DNA and chromatinized 
templates (MN). This approach allows comparison of the surface topologies 
of free protein versus protein-DNA complex using amino acid-specific 
modifiers and MALDI-ToF MS analysis. LEDGF/p75 surface residues 
readily modified in the free protein but protected from modification in both 
LEDGF/p75-DNA and LEDGF/p75-MN complexes are interpreted as direct 
contacts with DNA. Additional protections detected only in the 
LEDGF/p75-MN complex will reveal potential protein-protein contacts 
established between LEDGF/p75 and the chromatinized template. Our 
results have revealed several Lys residues that are surface exposed in free 
LEDGF/p75 and are protected from modifications by the bound DNA. 
Interacting amino acids have been mapped to the N-terminal region of the 
full-length protein, specifically in the PWWP domain, AT-Hook motifs and 
CR2. Interestingly, these protections are seen only in the context of the full 
length protein, while the isolated PWWP domain of LEDGF/p75 failed to 
interact with DNA. We are currently extending the application of the MS-
based footprinting approach to probe LEDGF interactions with the 
chromatinized templates. The results will define the nature of LEDGF/p75 
interactions with chromatin and provide important structural details for 
LEDGF mediated targeting of HIV integration into the active genes.  
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A number of cell lines derived from certain Carnivoran species, e.g., 
domestic dog and cat, do not discernibly restrict HIV-1 between entry and 
integration. Consistent with this, TRIM5a has ablated restriction function 
due to a truncated B30.2 domain in felidae and the gene is disrupted in the 
dog. It may be that Carnivorans in general harbor relatively fewer cellular 
blocks to replication of primate lentiviruses than do other orders of non-
primate placental mammals. However, felids encode APOBEC3 proteins 
that effectively restrict HIV-1 and generalizing about intrinsic cellular 
restrictions across the Carnivora in either the Caniformia or Feliformia 
suborders is not warranted. Lion cells, for example, strongly restrict 
lentiviruses post-entry by unknown mechanisms.  
 
Species in the large Mustelidae (weasel) family (Caniformia) have received 
comparatively little analysis but a few fibroblast cell lines  apparently lack 
post-entry restricting activity toward N-MLV and HIV-1.   
Dependency/restriction factors have not been cloned or characterized. Some 
of these species are accessible small lab animals used for the study of other 
viruses, e.g., ortho- and paramyxoviruses.  
 
We are characterizing Mustelidae cells (mink, ferret) for ability to support 
defined phases of retroviral life cycles. Infection of ferret and mink cell 
lines with pseudotyped HIV-1 reporter viruses showed that these cells 
support early life cycle steps comparably to human cells. FIV and EIAV 
vectors were similarly non-restricted and N- and B-tropic MLV were 
equivalently infectious. Late, Rev-dependent HIV-1 gene expression and 
virion production were also comparable between human and Mustelidae cell 
lines. Infectivities of output HIV-1 virions are being compared now. We 
have stably expressed human CD4 and CXCR4 in the cell lines using 
various lentiviral vectors and verified efficient gp120-mediated entry. 
Preliminary evidence suggests that at least one of the lines supports 
spreading HIV-1 infection. The studies are also being extended to other cell 
lines, primary PBMCs, splenocytes, and primary solid organ fibroblasts.  
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A recent cDNA screen identified a truncated isoform of the nuclear factor 
CPSF6 that limited the nuclear import of HIV-1 and SIVmac when over-
expressed in vitro. A block to nuclear import was implied by a reduction in 
2-LTR circle formation. Here we show that over-expression of a related 
mutant, ∆CPSF6, truncated at a similar position, restricts HIV-1, HIV-2 and 
SIVmac, but not distantly related lentiviruses FIV and EIAV. Whilst the 
putative CPSF6 nuclear localisation signal has been lost in these 
truncations, immunofluoresence staining suggests that the ∆CPSF6 
truncation is capable of entering the nucleus. Over-expression in both 
human and non-primate cells has the same effect on lentiviral infection 
suggesting that the restriction is virus and not host specific. We use 
isothermal calorimetry (ITC) to show that a CPSF6 derived peptide binds 
HIV-1 capsid (CA) and CypA-binding site mutant G89V but not ∆CPSF6 
escape mutant N74D. Furthermore, restriction by ∆CPSF6 can be saturated 
by co-expression of full length HIV-1 CA. Interestingly, mutation of the 
residue corresponding to N74 in SIVmac and HIV-2 (N73D) also allows 
their escape from ∆CPSF6. We propose that ∆CPSF6 blocks infection by 
binding to CA and preventing interaction with the nuclear import 
machinery. 
 96 
BIOPHYSICAL ANALYSIS OF HTLV-1 GAG TRAFFICKING AND 
PARTICLE RELEASE 
 
Keir Fogarty1,2, Jolene Johnson-Armstrong1, Iwen Grigsby2, Wei Zhang2, 
Xiao Wang1, Yan Chen1,2, Jonathan Rawson2, Joachim Mueller1,2, Louis M 
Mansky2  
 
1University of Minnesota, Department of Physics, Minneapolis, MN, 55455, 
2University of Minnesota, Institute for Molecular Virology, Minneapolis, 
MN, 55455 
 
The Gag protein is required for virus particle assembly and release. 
Nonetheless, crucial mechanistic details remain poorly understood, 
particularly for the deltaretroviruses – the prototype being human T-cell 
leukemia virus type 1 (HTLV-1). In this study, we investigated Gag 
stoichiometry in virus particles and as well as Gag-Gag interactions in 
living cells. We used the novel biophysical technology of fluorescence 
fluctuation spectroscopy (FFS) in conjunction with cryo-electron 
microscopy (cryo-EM), to study (1) Gag behavior (FFS) at the single 
molecule level in living cells, (2) Gag stoichiometry (FFS), and (3) virus-
like particle (VLP) size (FFS & Cryo-EM) and morphology (Cryo-EM). 
FFS determines the brightness, mobility, and concentration of fluorescent 
particles from the intensity bursts generated by individual particles passing 
through a small observation volume, which yields information about protein 
stoichiometry, interactions and transport. Experiments focused in two areas: 
(1) the self-associative behavior of HTLV-1 and HIV-1 Gag-YFP and 
various Gag-YFP mutants in the cytoplasm, which can provide insight into 
the earliest events initiating viral assembly, (2) the stoichiometry and size of 
HTLV-1 and HIV-1 Gag-YFP complexes present in VLPs, which can 
provide insight on the possible relation of Gag stoichiometry to virion size. 
Cytoplasmic studies using FFS revealed that HTLV-1 and HIV-1 Gag 
exhibit distinct differences in cytoplasmic behavior – such as mobility and 
oligomerization – that appeared to be dependent on the myristoyl moiety. 
FFS VLP studies revealed distinct differences in Gag stoichiometry and 
particle size between HTLV-1 and HIV-1 VLPs. Cryo-EM of HTLV-1 
VLPs confirmed the differences in VLP size compared to HIV-1, as well as 
allowing comparison of HTLV-1 and HIV-1 VLP morphology. In 
summary, FFS and cryo-EM are complimentary and versatile techniques 
that can be used to investigate the full range of retroviral Gag behavior, 
from the initial stages of virus assembly, to the Gag complexes present in 
VLPs.  
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RD114 virus is a feline endogenous retrovirus and appears to be produced 
as infectious viruses in some feline cell lines. Recently, we have reported 
that the isolation of an infectious RD114 virus in a proportion of live 
attenuated vaccines for pets. It is very difficult to completely exclude the 
proviral DNA of RD114 from cells, since endogenous retroviruses (ERVs) 
are usually integrated in the multi-locus of host chromosome. However, it 
may be possible to reduce the risk by regulating the release of infectious 
RD114 from cells. For this purpose, in this study, we analyzed the 
molecular mechanism of RD114 virus budding and examined the antiviral 
activity of Tetherin/BST2 for RD114. The analysis for L-domain mutants of 
RD114 showed that the PPPY sequence play a critical role in RD114 
release as viral L-domain. Furthermore, we investigated the cellular factors 
required for RD114 budding. We demonstrated that RD114 virus release 
was inhibited by overexpression of dominant negative mutants of Vps4A, 
Vps4B, and BUL1, but not Nedd4.1, Tsg101, and Alix. These results 
strongly suggest that RD114 budding utilizes the cellular multivesicular 
body (MVB) sorting pathway as well as other many retroviruses. In 
addition, we observed that human Tetherin/BST2 significantly inhibited the 
production of RD114 from cells. We are also investigating the anti-RD114 
activity of feline Tetherin/BST2. These data would be useful for 
development of strategies to inhibit RD114 production in feline cells. 
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HIV-1 reverse transcriptase (RT) is responsible for replicating the HIV genome, 
and the errors during this replication result in the genetic variation from which 
drug- and immune escape variant viruses emerge. In order for a point mutation 
to occur, a nucleotide must be misinserted, and the mismatched primer terminus 
thus formed must be extended further. HIV-1 RT is relatively efficient at both 
misinsertion and mismatched primer extension. While the influence of K65 and 
other residues in RT on misinsertion fidelity has been previously examined, 
factors influencing mispair extension are poorly understood. We have examined 
the role of K65 and K66, in the fingers subdomain of RT in these two aspects of 
polymerase fidelity. While K65 is conserved among nearly all retroviruses, K66 
is conserved among lentiviruses and betaretrovirus RTs. 
We previously hypothesized that K65 enhances misinsertions via interactions 
with the γ-phosphate of incoming dNTP. Here, we present pre-steady state 
kinetic analysis of the wild type HIV-1 RT and two substitution mutants, K65A 
and K65R, which supports our hypothesis. Next, we examined extension by all 
three RTs on matched and mismatched primer termini. All enzymes 
discriminated against the mismatched primer at the catalytic step (kpol). Both 
K65A and K65R mutants displayed a further decrease in mismatch extension 
efficiency, primarily at the level of dNTP binding. Our results show the 
influence of the stabilizing interactions of Lys65 with the incoming dNTP in 
affecting two different aspects of polymerase fidelity. 
The K66 residue is positioned close to the penultimate base-pair of the primer 
strand; we hypothesized that this residue could also influence the efficiency of 
extension from mismatched primer termini. We tested this hypothesis using 
wild-type HIV-1 RT and four substitution mutants: K66R/A/N/T. All K66 
substitution mutants were inefficient at mispair extension, showing up to a 10-
fold difference compared to wild-type, suggesting that Lys66 is a determinant 
of mispair extension. 
Using site-specific hydroxy radical footprinting, we demonstrated that the wild 
type HIV-1 RT occupies a non-productive position (-2 with respect to the 
templating base) on the mismatched primer, compared to position +1 on 
matched template-primer. The lysine substitutions at either the K65 or K66 did 
not alter this change in position when presented with the mismatched primer-
template, but rather reduced nucleotide utilization in the context of the 
mismatched terminus. Our results suggest that HIIV RT has evolved 
mechanisms to decrease overall fidelity, and that the mechanisms for 
misinsertion and mismatch primer extension act in concert. 
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The replication cycle of retroviruses requires the integration of the viral 
genome into the genomic DNA of the infected cells. The aim of our work is 
to identify cell signalling pathways that might be specifically activated or 
repressed during Human Immunodeficiency Virus (HIV) integration to 
maintain genome integrity. We infected human fibroblast cells with an 
HIV-based lentiviral vector devoid of a reporter gene. As a control, we used 
the same vector that was defective for integration but that still remained 
able to perform the early steps of integration (i.e. entry, reverse 
transcription, PIC transport…). By nested quantitative PCR assays, (i) we 
determined the kinetic of integration of the first vector at different 
multiplicity of infection (ii) we checked that the second vector was unable 
to integrate. Then, at a time post-infection corresponding to the beginning 
of the exponential curve of integration, we took RNAs and proteins of cells 
infected with one or the other vectors. RNAs were studied using human 
microarrays (U133 Plus Whole Human Genome, Affymetrix). Proteins 
were analyzed on 2D denaturing gels. By comparing RNAs and proteins 
from each cell population, we were able to detect and discriminate signals 
specifically due to integration (Ingenuity Pathways Analysis Software, 
Ingenuity systems). These analyses led us to identify several major cellular 
processes in which RNA and proteins are up- or down- regulated. These 
processes include DNA repair, innate immunity, chromatin remodelling. 
We selected 20 factors for their biological relevance. We are currently 
analysing their expression, in cells infected with one or the other vectors, by 
RT-qPCR or Western Blot. As the integration of additional DNA not only 
concerns viral processes but also cellular processes (transposition of mobile 
elements, chromosomal reorganizations during cancers induction..), data 
obtained in this study may allow: (i) the development of defensive strategies 
against integrative viruses (such as HIV (ii) the evaluation of cellular 
perturbations caused by the integration of a therapeutic vector into the cell 
genomes during gene therapy or gene transfer experiments 
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HIV-1 Viral protein R (Vpr) induces a cell cycle arrest at the G2/M phase 
by activating the ATR DNA damage/stress checkpoint. Recently, we and 
several other groups showed that Vpr performs this activity by recruiting 
the DDB1-CUL4A (VPRBP) E3 ubiquitin ligase. While recruitment of this 
E3 ubiquitin ligase complex has been shown to be required for G2 arrest, 
the subcellular compartment where this complex forms and functionally 
acts is unknown.  
Using immunofluorescence and confocal microscopy, we show that Vpr 
forms nuclear foci in several cell types including HeLa cells and primary 
CD4+ T-lymphocytes. These nuclear foci were found to co-localize with 
VPRBP and the DNA repair factors 53BP1 and RPA32. While treatment 
with the non-specific ATR inhibitor caffeine or depletion of VPRBP by 
siRNA did not inhibit formation of these foci, mutations in the C-terminal 
domain of Vpr and cytoplasmic sequestration of Vpr by overexpression of 
Gag-Pol resulted in impaired formation of these nuclear foci. Consistently, 
we observed that G2 arrest-competent sooty mangabey Vpr could form 
these foci but not its G2 arrest-defective paralog Vpx, suggesting that 
formation of these foci represents a critical early event in the induction of 
G2 arrest. The inability of Vpr C-terminal mutants to form foci did not 
result from inefficient dimerization, as measured by bioluminescence 
resonance energy transfer (BRET), but rather correlated with defective 
chromatin association. Indeed, nuclease treatment of cellular extracts 
showed that Vpr could associate to chromatin via its C-terminal domain and 
that it could form a complex with VPRBP on chromatin.  
Overall, our results suggest that Vpr would target a chromatin-bound 
cellular substrate for ubiquitination in order to induce DNA 
damage/replication stress, ultimately leading to ATR activation and G2 cell 
cycle arrest. 
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Proviral integration of HIV and HIV-derived lentiviral vectors favors 
transcriptionally active regions. LEDGF/p75, a transcriptional co-activator, 
is the dominant cellular co-factor of HIV-1 integrase (IN) that tethers the 
PIC to chromatin. IN interacts with the IN binding domain (IBD, aa 347-
429) in the C-terminus of LEDGF/p75. Stable overexpression of the 
LEDGF/p75 C-terminal end (LEDGF325-530) results in a severe inhibition of 
HIV replication. LEDGF/p75 coordinates the nuclear accumulation and 
chromosomal localization of HIV IN via an N-terminal domain containing 
an ensemble of chromatin binding elements, containing a PWWP-domain 
(aa 1-93) and two AT-hook-like domains; however, the exact orchestration 
of this process remains unknown.  
In order to study the role of the LEDGF PWWP domain, we generated a 
series of PWWP-truncation mutants (ΔN18, ΔN26, ΔN30, ΔN50, ΔN85, 
ΔN93) and chimeric proteins, replacing the PWWP-domain of LEDGF/p75 
with that of HDGF and HRP-2. Together with LEDGF/p75, HDGF and 
HRP-2 are members of the HRP-family sharing a conserved PWWP 
domain. Next to LEDGF/p75, HRP-2 is the only other protein that contains 
an IBD-like domain in addition to a PWWP-domain. All constructs were 
stably expressed in LEDGF/p75-deficient cells. All mutant proteins 
migrated at the expected size in Western analysis and located to the nucleus. 
All cell lines were tested for lentiviral vector transduction and HIV-1 
infection (HIV ΔNefΔEnv-fLuc or HIV NL4.3).  
In our hands, PWWP-truncations do not rescue viral vector transduction or 
HIV infection in LEDGF deficient cells. Swapping the PWWP-domain of 
LEDGF with that of either HDGF or HRP-2 rescued LV transduction and 
HIV replication to nearly wild-type levels. Also, introduction of HRP-2 in 
LEDGF-depleted cells rescued HIV replication. Analysis of proviral 
integration sites revealed an integration site pattern for HRP-2 that is not 
different from LEDGF-depleted cells, whereas the integration site profile 
for the PWWP-swaps is similar to that of WT LEDGF.  
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Avian leukosis viruses (ALVs) are the type members of the Alpharetrovirus 
genus, and are classified into ten subgroups (A-J) distinguished by receptor 
usage, host range, and superinfection resistance patterns. Subgroups A-F 
display remarkable receptor usage variation despite having very similar env 
sequence(approximately 80% identity). The receptor-binding specificity of 
ALV has been mapped to two regions within SU, hr1, and hr2, by our 
laboratory. We have studied the evolution of receptor usage in avian 
retroviruses based on the hypothesis that all 10 subgroups evolved from a 
common ancestor through accumulation of point mutations within these 
regions. Previously, we have described two independent mutations in hr1 of 
subgroup B ALV that allow infection of receptor-negative cells. We found 
that introduction of these mutations into subgroup C, but not A virus, 
conferred a similar host range extension (HRE) phenotype. We extended the 
analysis to show that many, but not all, additional mutations tested at these 
sites, produced a similar HRE phenotype in subgroups B and C. Here we 
show that subgroup C HRE mutant L154S is able to infect cells in a 
receptor independent manner. In support of this conclusion, we found that 
the ALVC L154S virus was less sensitive to superinfection resistance 
compared to the wild-type (WT) ALVC virus and that binding assays 
showed that the L154S mutation does not result in the binding of an SU 
immunoadhesin to a new receptor on receptor negative cells. Additionally, 
the ALVC L154S virus was inactivated by pre-incubation with low pH 
buffer, while the ALVC WT virus was not, suggesting the loss of the 
requirement for receptor-induced conformational change for low pH 
mediated entry of WT virus. Peptide R99, which inhibits the formation of 
the six helix bundle (6HB) of ALV, inhibited the infection of receptor 
positive cells by ALVC WT and L154S. We are currently extending this 
analysis to the additional mutants we have previously described for 
subgroups B and C to determine if all use a similar mechanism. Taken 
together, our data support a model in which these mutants represent 
evolutionary intermediates that allow the virus to respond to selective 
pressure resulting from the absence of functional receptor in the host and 
subsequently to adapt to use new receptors for entry. 
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Lentiviruses of the HIV-2/SIVmac/SIVsm lineage encode the non-structural 
protein, Vpx. Vpx facilitates the infection of macrophages and dendritic 
cells where it has been proposed to neutralize the antiviral activity of an 
unidentified restriction factor. In monocyte derived macrophages (MDM) 
infected with Δvpx SIVmac, the production of early, late and 2-LTR circular 
viral cDNA was markedly reduced, suggesting that replication was blocked 
prior to nuclear import and possibly during uncoating. The defect could be 
restored by pre-incubation of MDM with virus-like particles (VLP) loaded 
with Vpx. Vpx-containing VLP also potently increased the infectivity of 
HIV-1 on MDM, although this virus does not encode for Vpx. To test 
whether the effect of Vpx is specific to SIV and HIV or whether other 
retroviruses are affected by this block, we infected MDM with FIV, EIAV, 
N-, B-, and NB-tropic MLV GFP reporter virions in the presence or absence 
of Vpx-containing VLP. By analyzing single-cycle infections using flow 
cytometry, we found that Vpx-VLP enhance infection of FIV and EIAV, 
but do not promote MLV infection of MDM. MDM from some donors 
showed low level of infection for B- and NB-tropic MLV but no significant 
impact of Vpx on infectivity could be observed. Infection of MDM by N-
tropic MLV with or without Vpx was low, probably due to the additional 
restriction by human TRIM5alpha. We measured the accumulation of NB-
tropic MLV cDNA at different time points post-infection by qPCR. We 
found that Vpx enhanced the formation of early and late reverse transcripts 
indicating that Vpx overcomes a block early in MLV infection, similar to its 
effect on HIV and SIV. However, Vpx failed to enhance infection beyond 
that step, probably due to impaired nuclear import of MLV in non-dividing 
MDM. Taken together, our results show that Vpx counteracts a cellular 
restriction that affects not only SIV and HIV, but a variety of retroviruses 
including FIV, EIAV and MLV at the level of reverse transcription. 
However, preincubation of MDM with Vpx-containing VLP was not 
sufficient to lift the block to MLV infection in MDM. 
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Xenotropic murine leukaemia virus-related virus (XMRV) has recently 
been associated with prostate cancer and more controversially with chronic 
fatigue syndrome in humans. It has also been claimed that XMRV is present 
in a low percentage of apparently healthy individuals. Phylogenetic analysis 
reveals that XMRV is a gammaretrovirus closely related (92% similarity) to 
endogenous xenotropic murine gamma retroviruses that are often found as 
contaminants in laboratory cell lines. Here we have screened 411 human 
tumour cell lines by Taqman QPCR and found that 9 (2.2%) are infected 
with xenotropic murine leukaemia viruses. Further, neither XMRV, nor 
related sequences, were detected in blood samples from 543 HIV-1 infected 
individuals. XMRV has been described as having a unique deletion of 24 
nucleotides in the gag leader sequence allowing its specific detection by 
PCR. We applied phylogenetic methods to determine the origin of XMRV 
amongst endogenous gamma retroviruses found in inbred mice, but failed to 
identify an unambiguous ancestor. However, we have found evidence for 
sequences described as XMRV-specific in at least one inbred mouse strain. 
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The production of retroviral Pol enzymes in the gammaretroviruses is 
controlled by translational readthrough of the stop codon at the end of the 
gag ORF by secondary mRNA structures – pseudoknots -- in the pol coding 
sequence. Pol gene products are made only as a fusion product with the 
upstream Gag proteins; translation of pol genes depends on suppression of 
the normal termination event. This occurs via incorporation of an amino 
acid at a UAG stop codon and continued translation. Gag-pol products are 
produced in approximately 5% of ribosomal elongation cycles, and close 
adherence to the normal gag:gag-pol ratio is necessary for efficient viral 
replication. We have previously shown that large ribosomal protein L4 
(RPL4) increases readthrough at the MoMLV/XMRV gag:gag-pol junction 
(containing a well-defined pseudoknot structure) in a dose-dependent 
manner in a dual-luciferase reporter context. We are now investigating the 
effects of aminoglycoside antibiotics and small molecules thought to 
suppress premature stop codons on the retroviral readthrough event. 
Preliminary results show that these molecules increase readthrough at the 
MoMLV/XMRV pseudoknot in our reporter assays. We are also analyzing 
the effect of RPL4 and readthrough promoting drugs on viral replication: 
specifically, we are asking whether increasing readthrough diminishes the 
ability of these viruses to replicate. Effectiveness of particular molecules 
with well-characterized modes of function may elucidate how the 
MoMLV/XMRV pseudoknot interacts with the translation machinery to 
promote readthrough. 
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The incorporation of functional Env glycoproteins is a necessary aspect of 
assembling an infectious virion. As well as incorporating native Env, 
retroviruses are also able to incorporate some foreign glycoproteins, a 
process known as pseudotyping. Though it is known to be an active process, 
the mechanism for incorporation still remains largely a mystery. Several 
studies have provided evidence for direct and indirect interactions between 
HIV-1 matrix (MA) and HIV Env. It is likely that such interactions are 
responsible for native Env incorporation for all retroviruses. For 
pseudotyping, the recruitment of foreign glycoproteins, MA to Env 
interactions are still possible, though less likely. To help elucidate the 
mechanisms of recruitment for both native and foreign Env proteins, we 
made HIV-1 and MLV constructs with the MA domain replaced by either 
non-viral membrane binding domains or the MA domain of a foreign 
retrovirus. These constructs were assayed for the ability to recruit and form 
infectious particles with various viral glycoproteins. Our findings suggest 
that HIV MA is both necessary and sufficient for HIV-1 Env recruitment 
and infectivity. Replacing HIV MA with any other domain significantly 
reduced infectivity. Conversely, although MLV is poorly infectious when 
pseudotyped with HIV-1 Env, replacement of MLV MA with HIV MA 
greatly enhances this infectivity. Unlike HIV Env, MLV Env is a 
promiscuous glycoprotein that can efficiently form infectious particles with 
HIV-1 or MLV. However, if MLV and HIV are introduced into the same 
cells and forced to compete for limiting Env, MLV Env strongly favors the 
formation of infectious MLV particles. Replacement of MLV MA with HIV 
MA reduces, but does not eliminate this selectivity. The selectivity shown 
by MLV is MLV Env specific and requires only Gag, though Pol also 
appears to contribute. 
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Tetherin is a cellular restriction factor that inhibits the release of enveloped 
viruses from host cells. Recent evidence suggests that this restriction occurs via 
physical tethering of host and viral membranes, followed by endocytosis of 
tethered virions. Tetherin has been shown to co-localize with HIV-1 Gag 
protein by immunofluorescence microscopy and with plasma-membrane-
tethered virions by immuno-TEM. The specific mechanism of this co-
localization is currently unknown. Given tetherin's ability to restrict diverse 
enveloped viruses, it is unlikely that tetherin is recruited to assembling virions 
by binding to specific viral proteins. We hypothesized that this recruitment may 
instead be facilitated by a common feature of many enveloped viruses such as 
plasma-membrane microdomains. 
 
Tetherin contains two membrane-interacting domains: its transmembrane 
domain and C-terminal GPI anchor. These two domains, along with its 
dimerization capability, are thought to facilitate simultaneous incorporation of 
tetherin into cell and viral membranes. Tetherin, like other GPI-anchored 
proteins, is thought to reside in cholesterol-enriched microdomains known as 
lipid rafts, based on the presence of tetherin in detergent-resistant membrane 
fractions. We and others have shown the likely involvement of lipid rafts in 
HIV-1 assembly, providing a possible mechanism for the recruitment of tetherin 
to assembling virions. In addition, it has been reported that tetraspanin-enriched 
microdomains (TEMs) also associate with sites of virus assembly. 
 
To determine whether tetherin associates with lipid rafts or TEMs, copatching 
of tetherin with antibody-crosslinked specific microdomain markers was 
examined by fluorescence microscopy. Preliminary data show that endogenous 
tetherin in HeLa cells does co-localize with a lipid raft marker, CD59, but not 
with tetraspanins CD9, CD63, and CD81 in the absence of Gag. 
 
To further examine the relationship between tetherin and assembling virions, we 
utilized HIV-1 Gag mutants with different membrane binding properties. In 
these studies WT Gag is compared to a mutant with the triple-acylation signal 
of Fyn kinase in place of the N-terminal myristate, which is capable of 
cholesterol-independent assembly. Surprisingly, our data suggest that both 
forms of Gag are susceptible to tetherin restriction in both untreated and 
cholesterol-depleted cells. These results suggest that microdomain association 
of tetherin alone fails to completely account for its specific recruitment to 
assembling virus particles. 
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Previously we have demonstrated that HIV-1 gp120-CXCR4 interaction 
triggers signal transduction critical for the latent infection of human resting 
CD4 T cells. This study served to identify amino acid residues of the gp120 
glycoprotein responsible for mediating signal transduction in human resting 
CD4 T cells. The env gene of HIV-1NL4-3 was cloned into a vector and 
subjected to alanine scanning mutagenesis. A subset of 22 amino acid 
residues occurring in the V1/V2 loop, V3 loop, β19 sheet, C1 and C2 
domains were selectively mutated and used to produce viral particles 
expressing mutant gp120 glycoproteins. Resting CD4 T cells were infected 
with the viral mutants and analyzed for the activation of signaling 
molecules such as cofilin. Cytoskeletal actin rearrangement mediated by the 
gp120 mutants were also measured with F-actin staining and flow 
cytometry. In addition, the impacts of the gp120 mutations on the ability of 
HIV-1 to establish latent infection of resting CD4 T cells were further 
evaluated. 
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High throughput sequencing such as Roche 454 and Illumina are powerful tools 
for investigating the integration patterns of transposons and retroviruses. They 
usually provide tens of thousands of integration positions in one sequencing 
reaction. When blasting the sequences of integration sites we often find many 
sequence reads are duplicated, suggesting multiple integration events occurred 
at the same chromosome coordinate and in the same strand. There could be 
three origins for duplicate reads. They could result from independent 
integrations, the growth of cells with integration, or, PCR amplification. Since it 
is hard to know what fraction of the duplicate reads represent independent 
events, researchers avoid analyzing the duplicate sequences. We find studying 
the duplicate sequence reads does help us in understanding the integration 
profile of target sites. 
In a previous study, we used 454 sequencing to study the integration of 
retrotransposon Tf1 in Schizosaccharomyces pombe. We sequenced 
approximately 20,000 insertions in each of four independent experiments and 
obtained a saturated collection of target sites. Here we report the insertions have 
a distinct preference for specific nucleotides that extends 50 base pairs on either 
side of its insertion sites. We find the nucleotide preferences are enhanced 
substantially if the duplicate sequence reads are included. We also find that Tf1 
integrates where nucleosome occupancy is relatively low. Interestingly, Tf1 
integration sites with higher numbers of duplicate reads tend to have lower 
nucleosome occupancy. These observations indicate that at least some of the 
duplicate reads are from independent insertion events. Therefore, the duplicate 
reads can reveal important information about the targeting frequency of 
integration sites. When we deleted the chromodomain from the integrase of Tf1, 
the positions targeted by the transposon correlated well with those targeted by 
wild type Tf1. However, when the duplicate reads are considered, we find the 
mutant transposon has a substantial change in the integration frequency of the 
target sites. This indicates that if the duplicate reads are discarded, low 
frequency target sites can not be distinguished from the highly active sites. In 
order to distinguish independent insertion events from the results of cell 
duplication and PCR amplification, we have designed a version of Tf1 with a 
“serial number” tag system. Thus, we will be able to measure the targeting 
frequency of individual nucleotide positions. 
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A single novel HIV-1 strain RBF168, related to simian immunodeficiency 
virus from gorillas (SIVgor), has been designated group P. It was isolated 
from a woman of Cameroonian origin with no history of exposure to 
bushmeat. Here we have conducted a phylogenetic and in vitro study into 
RBF168 in order understand its evolutionary history. After extensive 
analyses we found no evidence to support a recombinant origin for this 
virus. We also dated the HIV-1 group P and SIVgor most recent common 
ancestor (tMRCA) using a Bayesian framework, as an estimate of the time 
at which the two lineages diverged from each other. We found good 
agreement in the RBF168/SIVgor tMRCA estimates obtained on the basis 
of the gag (1899 [95% Higher Probability Density: 1855-1938]) and env 
genes (1845 [1766-1912]). RBF168 also showed a lack of adaptation to 
humans in lineage specific positive selection analyses on the gag, pol, env, 
vpu and nef genes. However, there was evidence for adaptation in the vpu 
gene in branches leading to HIV-1 group M and N as well as in the branch 
leading to the SIVgor/HIV-1 group P/HIV-1 group O clade (corresponding 
to SIV zoonotic events). Of note, no evidence for adaptation was found in 
the nef phylogeny for any branches. Like group O, neither HIV-1 group P 
Vpu or Nef proteins were able to antagonise restriction by human tetherin. 
Furthermore, although SIVgor Nef was able to counteract gorilla tetherin, 
RBF168 Nef could not. This suggests that RBF168 is not adapted to 
replicate/transmit well in humans or gorillas. Overall our data suggest that 
despite diverging from SIVgor about 150 years ago, group P represents a 
rare zoonotic virus that has failed to adapt well to its new human host 
leading to low transmission rates and low incidence.  
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Recent studies have reported the first gammaretrovirus that infects humans, 
named xenotropic murine leukemia virus-related virus (XMRV). XMRV was 
isolated from human prostate cancer tissue and from activated CD4+ T cells and 
B cells of patients with chronic fatigue syndrome, suggesting an association 
between XMRV infection and these two disease states.  
Since APOBEC3G (A3G) and APOBEC3F (A3F), which are potent inhibitors 
of the murine leukemia virus and Vif-deficient human immunodeficiency virus 
type 1 (HIV-1), are expressed in human CD4+ T cells and B cells, we sought to 
determine whether and how XMRV evades suppression of replication by 
APOBEC proteins. Surprisingly, we found that XMRV infectivity is potently 
inhibited by A3G and A3F, and to a lesser extent, by murine APOBEC3 
expressed in viral producer cells. All three APOBEC3 proteins were packaged 
in XMRV virions and induced G-to-A hypermutation of the proviral DNA.  
Analysis of A3G and A3F mRNA levels in different cell lines using quantitative 
real-time RT PCR indicated that human T-cell lines CEM and H9 exhibited 
higher A3F mRNA levels than prostate cell lines 22Rv1, LNCaP, and DU145. 
In contrast to high levels of A3G mRNA in CEM and H9 cells, A3G mRNA 
was not detectable in 22Rv1 and LNCaP cells and very low in DU145 cells. We 
found few XMRV proviral genomes with G-to-A hypermutation in 22Rv1, 
LNCaP and DU145 cells, primarily in the GA dinucleotide context, indicating 
A3F activity. In A3G/A3F-positive T cell lines (CEM and H9) XMRV proviral 
genomes were extensively G-to-A hypermutated, but not in CEM-SS cells with 
low A3G/A3F expression. These hypermutations occurred mostly in a GG 
dinucleotide context known to be targeted by A3G and caused stop codons in 
nearly all analyzed proviruses.  
We also analyzed the sensitivity of XMRV to several antiretroviral drugs and 
compared the 50% inhibitory concentration values (IC50) to those for HIV-1 
inhibition. XMRV was found to be susceptible to the nucleoside reverse 
transcriptase inhibitors AZT and tenofovir and the integrase inhibitor raltegravir 
at similar concentrations to those that inhibit HIV-1.  
Overall, these results show that XMRV is targeted and inhibited by the tested 
APOBEC3 proteins. Therefore, cells that express low levels of A3G/A3F, such 
as prostate cells, may provide a suitable target for XMRV replication and 
spread. Furthermore, anti-HIV-1 drugs AZT, tenofovir, and raltegravir may be 
useful for treatment of XMRV infection. 
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The major function of primate lentiviral protein Vif is to neutralize the 
antiretroviral activity of host cytidine deaminases APOBEC3G (A3G) and 
APOBEC3F (A3F). Vif serves as an adaptor protein that bridges A3G/A3F 
to a Cullin5 (Cul5) E3 ligase. This interaction then triggers the 
polyubiquitylation of A3G/A3F on lysine residues, resulting in A3G/A3F 
degradation by proteasomes. However, Vif itself not only has multiple 
lysines, but also is polyubiquitylated by the same Cul5 E3 ligase. Currently, 
it is still unclear which polyubiquitylation, either in A3G or Vif, is more 
critical for A3G proteasomal degradation. Here, we present evidence that 
Vif polyubiquitylation is required for A3G degradation. 
 
Vif from NL4-3 has 192 amino acids, including sixteen lysines (K22, K26, 
K34, K36, K50, K63, K91, K92, K141, K155, K157, K160, K168, K176, 
K179, and K181). Previously, when we mutated all these lysines to 
arginines (Vif 16K/R), Vif failed to neutralize A3G, although it still bound 
to Cul5. Because residues K22 and K26 belong to a functional motif 
21WxSLVK26, which critically regulates A3G neutralizing activity, we 
first repaired these two lysines in the Vif 16K/R mutant, and determined its 
A3G neutralizing activity. However, this new mutant was still completely 
inactive in A3G neutralization. Since the other lysines are not involved in 
Vif interactions with A3G, Cul5, and elongin C, this result indicated that 
additional lysines on Vif are required for A3G neutralization; and most 
likely, these lysines are involved in Vif polyubiquitylation. Indeed, we were 
able to map these additional lysines and found that either the N-terminal 
four lysines (K34, K36, K50, K63) or C-terminal four lysines (K168, K176, 
K179, K181) could restore a full activity of Vif. Thus, these results not only 
demonstrate that multiple lysines are required, but also suggest that Vif may 
have two polyubiquitylation signals, which critically regulate its A3G 
neutralizing activity.  
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Several viruses such as HIV-1, PFV, and SIV are potently restricted by 
members of the APOBEC3 family of DNA cytidine deaminases. The 
restriction induced by APOBEC3 proteins is of such consequence to these 
parasitic elements that they have evolved extensive counter-defense 
mechanisms. The interaction between the human APOBEC3G protein and 
HIV-1 Vif is the prototypic example. 
 
APOBEC3A is an understudied member of the APOBEC3 family, possibly 
because it is such a potent DNA deaminase (frequently toxic to E. coli). In 
contrast to APOBEC3G, over-expressed APOBEC3A is not efficiently 
encapsidated in HIV-1 virions. APOBEC3A does not diminish HIV-1 
infectivity when it is expressed in producer or target cells. HIV-1 Vif also 
fails to trigger the degradation of APOBEC3A. These observations strongly 
suggest that APOBEC3A poses little threat to HIV-1. 
 
However, we recently found that, unlike APOBEC3G, APOBEC3A does 
have potent activity against foreign DNA substrates such as plasmids and 
bacterial chromosomal DNA (1). This deaminase-dependent restriction 
activity results in the hypermutation and degradation of plasmid DNA, 
greatly limiting procedures such as transient or stable gene transfections. 
APOBEC3A appears to be expressed exclusively in myeloid lineage cells 
and its expression is massively upregulated by treating cells with IFNalpha 
or immunostimulatory DNA. We conclude that APOBEC3A primarily 
functions as an inducible foreign DNA restriction system analogous to 
bacterial restriction-modification systems. 
 
Selected Reference: 
1. Stenglein, M. D., M. B. Burns, M. Li, J. Lengyel, and R. S. Harris (2010) 
APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat 
Struct Mol Biol 17: 222 - 229 
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The seven distinct APOBEC3 cytidine deaminases (A3A-A3H) are part of 
the human intrinsic immunity against retroviruses. A3B, contrary to 
A3G/A3F, resists HIV-1 Vif mediated proteosomal degradation. Genome-
wide copy number variation studies have shown that the A3 locus is 
polymorphic among different human populations with one specific copy 
number variant deleting the complete coding region of A3B. Recently, a 
large epidemiological study showed a significant association between 
homozygous A3B copy number loss and increased risk of HIV-1 
acquisition and disease progression. We hypothesized, therefore, that 
human A3B has a profound impact on replication of HIV-1 variants with 
functional Vif alleles.  
In this study, we used lymphoblastoid B cell-lines (LCLs) from HapMap 
participants because of their physiological A3 expression levels and because 
of the availability of extensive information on their genomic profiles. LCLs 
homozygous for the A3B deletion and their matched controls with two A3B 
copies were used for infection experiments using wild-type and VSV-G 
pseudotyped HIV-1 (n=18). Endogenous A3B mRNA expression was 
measured using qRT-PCR. We could not detect any A3B mRNA in the 
LCLs homozygous for the A3B deletion whereas the expression varied 
considerably (>20 fold) between the LCLs with two A3B copies. We found 
that LCLs homozygous for the A3B deletion were significantly more 
susceptible to HIV-1 infection than wild-type controls (Mann-Whitney U 
test: p<0.05). The restriction exerted by A3B was independent of viral 
entry. Transduction of LCLs harboring two A3B copies with shRNA 
directed against A3B decreased A3B mRNA by 80% and strongly increased 
HIV-1 replication (100-fold, replication competent full-length, Vif wild-
type NL4-3, MOI: 0.005).  
Our results demonstrate that the Vif-resistant A3B is expressed in LCLs and 
efficiently inhibits HIV-1 replication. Conversely, knocking down A3B 
expression increases HIV-1 replication. Taken together, A3B might play a 
critical role in the host intrinsic defense against HIV-1, in a cell type 
specific manner. Consequently, individuals that have a homozygous loss of 
this gene may have an increased susceptibility to HIV-1 infection. This 
observation has important public health consequences considering the high 
frequency (>10%) of the A3B deletion among Asian populations. 
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Cytidine deaminases of the APOBEC3 family are editing enzymes endowed 
with restriction activity against a variety of mobile genetic elements. 
Human APOBEC3A can block efficiently the parvovirus adeno-associated 
virus type 2 (AAV-2) or the retrotransposon LINE-1 but cannot inhibit 
human-immunodeficiency virus-1 (HIV-1) replication, while APOBEC3G 
can block HIV-1 but not AAV-2 or LINE-1. The molecular determinants 
underlying the susceptibility of each element to one or the other APOBEC3 
proteins have remained largely undefined or controversial. Here, we 
performed a comprehensive functional analysis of evolutionarily conserved 
residues in human APOBEC3A and APOBEC3G required for inhibition of 
two viruses, HIV-1 and AAV-2, and two retrotransposons, LINE-1 and Alu. 
Despite different intrinsic activities of the two proteins, structural modeling 
revealed that functionally important residues mapped on homologous loops 
close to the active site. Phylogenetic analysis showed that the nature of the 
loops largely differed between APOBEC3A and APOBEC3G primate 
paralogues including at amino-acids of functional importance, in stark 
contrast with secondary structure elements. The residues important for 
restriction activity mediated intersubunit contacts between APOBEC3G 
monomers and the predicted dimer interface shaped a groove that can 
accomodate single-stranded nucleic-acids, in agreement with experimental 
data. For APOBEC3A however, it is on the monomer that residues critical 
for restriction and editing activities formed a groove with single-stranded 
DNA binding potential. In summary, this study unveils critical determinants 
of restriction activity that mapped on homologous loops between 
APOBEC3A and APOBEC3G, and suggests that target selectivity by 
APOBEC3 proteins may stem from structural variations in this region. 
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Here we demonstrate that Mov10, a protein associated with P-bodies that 
has a putative RNA-helicase domain, can inhibit the production of 
infectious retroviruses when ectopically expressed. Although Mov10 co-
purifies with cytoplasmic APOBEC3G, the inhibition appears to be 
APOBEC3G-independent as Vif-positive HIV is Mov10-sensitive, and 
Mov10 impairs HIV production from APOBEC3G-negative cells. At 
intermediate levels of Mov10 overexpression, the specific infectivity of 
HIV is impaired, whereas increased levels of Mov10 potently inhibit both 
the specific infectivity and production of HIV. HIV expressed in the 
presence of high levels Mov10 exhibits diminished amounts of processed 
Gag products, and virions that are released display maturation defects. 
Mov10 directly interacts with HIV. It associates with HIV RNA during 
virus production and is subsequently incorporated into viral particles. 
Interestingly, reducing endogenous Mov10 levels in virus-producing cells 
through siRNA treatment also modestly suppresses HIV infectivity 
suggesting a positive role in infection. The actions of Mov10 are not limited 
to HIV, as ectopic expression of Mov10 restricts the production of other 
lentiviruses as well as the gammaretrovirus, murine leukemia virus. We 
mutated domains of Mov10 to better understand its inhibition of HIV when 
overexpressed. While specific mutation of the Mov10 RNA helicase 
domain hindered virion incorporation, it did not eliminate antiviral activity. 
Similarly, the N-terminal domain of Mov10, which is not incorporated into 
virion particles, was also sufficient to impair both the production and 
specific infectivity of HIV. Together these results indicate that manipulation 
of Mov10 levels may provide a potent antiviral strategy. These data also 
suggest a link between cytoplasmic RNA machinery and infectious 
retrovirus production. 
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The MOV10 gene locus was first discovered in M-MuLV-infected mice 
when the provirus was inactivated after integration into this site. It encodes 
a 110 kDa GTP-binding protein, and was classified as a SF-1 RNA helicase. 
The function of MOV10 remained unknown until its orthologs SDE3 in 
Arabidopsis and Armitage in Drosophila were found to play a critical role 
in the RNAi pathway. SDE3 was isolated as the first non-RNA-dependent 
RNA polymerase (RdRP) factor in plants that amplifies RNAi by increasing 
the production of dsRNA, whereas Armitage was found to be required for 
RISC assembly. The role of MOV10 in RNAi was further highlighted in 
human. It was found that MOV10 not only interacts with Ago2, but 
MOV10 also is associated with a multiprotein complex containing TRBP 
and eIF6, which are another two important components of RISC. A 
depletion of MOV10 from cells seriously compromised the activity of the 
RNAi pathway. In addition, MOV10 has been found to co-localize with 
Ago1 and Ago2 in P bodies and stress granules. Interestingly, MOV10 also 
interacts with APOBEC3G and APOBEC3F in these cellular compartments.  
 
Here, we report that MOV10 inhibits retrovirus replication. When it was 
over-expressed in viral producer cells, MOV10 was able to reduce the 
infectivity of HIV, SIV, and MuLV. Conversely, when MOV 10 expression 
was reduced by siRNAs, HIV-1 infectivity was increased. Consistently, 
silencing of MOV10 expression in human T cell line enhanced HIV-1 
replication. Furthermore, we found that MOV10 interacts with HIV-1 NC 
and is packaged into virions. It blocks HIV-1 replication at a post-entry 
step. In addition, we also found that HIV-1 could suppress MOV10 protein 
expression to counteract this cellular resistance. All these results indicate 
that MOV10 has a broad antiretroviral activity that can target a wide range 
of retroviruses, and it could be actively involved in host defense to 
retroviral infection.  
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The HIV-1 viral infectivity factor (Vif) allows productive infection of non-
permissive cells (including most natural HIV-1 targets) by counteracting the 
cellular restriction factor APOBEC3G (hA3G). The Vif-induced 
degradation of hA3G by the proteasome has been extensively studied, but 
little is known about the translational repression of hA3G by Vif, which has 
also been proposed to participate in Vif function. 
 
To address the role of Vif in the translational regulation of hA3G, we 
characterized Vif binding to the full-length hA3G mRNA and to fragments 
corresponding to its coding or unstranslated regions (UTR). Filter binding 
assays and fluorescence titration curves revealed that Vif tightly binds to 
hA3G mRNA. Vif binding affinity was higher for the 3’-UTR than for the 
5’-UTR, even though this region contained at least one high affinity Vif 
binding site. Several Vif binding sites were mapped in these regions by 
enzymatic footprinting. Finally, we analyzed the effect of Vif on hA3G 
translation in an in vitro transcription/translation assay and evidenced that 
Vif inhibits translation of hA3G mRNA when the 5’-UTR is present. 
Successive truncations in the 5’ UTR revealed a structural motif containing 
at least one Vif binding site that was required for the regulation of hA3G 
translation by Vif, suggesting that the molecular mechanism of translational 
control is more complicated than a simple physical blockage of scanning 
ribosomes. Finally, analysis in transfected cells +/– proteasome inhibitors 
only slightly increased the hA3G levels, irrespective of the mRNA used to 
translate. Thus, our experiments strongly suggest that Vif also inhibits 
hA3G in transfected cells and that under our conditions this mechanism is 
more potent than the Vif-induced hA3G degradation. 
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Computational analysis pointed out a new member of the APOBEC-protein 
superfamily in 2005, APOBEC4 (1). APOBEC4 is present in mammals, 
birds and amphibia, while it could not be found in fishes so far. The tissue 
expression profile of the murine orthologue suggests that the protein might 
be highly expressed in mammalian testes (Novartis Gene Expression Atlas) 
and thereby be active in spermatogenesis. As numerous APOBEC3-proteins 
show antiviral activity against various retroviruses, human APOBEC4 was 
tested here for its potential antiviral activity against HIV-1. The reduction 
of infectivity reported for APOBEC3 proteins was not observed. In contrast, 
in a titration experiment using HIV-1wt, we found an APOBEC4-dependant 
increase of the virus titer. The same dependency was observed by 
measuring intracellular p24 concentration. The increase in nef ORF 
expression suggests that early viral products are affected in the same 
manner. A4 did not raise the LTR-driven expression and thus 
increases/stabilizes the HIV-protein production by a novel unknown way. 
Additionally, we were able to prove mRNA expression of endogenous A4 
in 293T and in HeLa cells by PCR and sequencing. siRNA mediated down 
regulation of APOBEC4 resulted in reduced virus production. As editing 
activity of APOBEC proteins have already been described in detail, we also 
tested APOBEC4 for its potential editing properties. APOBEC-like editing 
of HIV or editing activity in the E. coli mutation assay was not detectable.  
Taken together, A4 seems to be recruited as a cellular co-factor for HIV 
replication. 
 
 
(1) Rogozin, Bazu, Jordan, Pavlov, Koonin. 2005. APOBEC4, a New Member of 
the AID/APOBEC Family of Polynucleotide (Deoxy)cytidine Deaminases Predicted 
by Computational Analysis. Cell Cycle 4:9, 1281-1285. 
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Non-primate animal models of HIV-1 infection are prevented by missing 
cellular cofactors and by antiviral actions of host defense factors. These 
blocks are profound in rodents but may be less abundant in certain 
Carnivora. Here we enabled productive, spreading replication and passage 
of HIV-1 in feline cells. We demonstrate that feline APOBEC3 (fA3) 
proteins are the principal non-receptor block to this virus. Feline fibroblasts, 
T cell lines and primary peripheral blood mononuclear cells supported early 
and late HIV-1 life cycle phases equivalently to human cells with the 
exception that produced virions had low infectivity. Stable expression of 
FIV Vif-GFP in HIV-1 entry receptor-complemented feline (CrFK) cells 
enabled robust spreading wild-type HIV-1 replication. FIV Vif interacted 
with all three fA3s, targeted them for degradation and prevented G to A 
hyper-mutation of the HIV-1 cDNA by fA3CH and fA3H. In contrast, HIV-
1 Vif interacted with fA3s but did not cause their degradation and even 
paradoxically augmented restriction. SIVmac Vif prevented hypermutation 
by fA3CH and fA3H effectively but was less active than FIV Vif in fA3H 
restriction and degradation assays. HIV-1 clones that encode FIV Vif or 
SIVmac Vif (HIV-1VF and HIV-1VS) were then constructed. HIV-1VF and 
HIV-1VS replicated productively in HIV-1 receptor-complemented feline 
cells and could be passaged serially to uninfected cells. Thus, except for 
entry receptors, feline cells can supply all necessary dependency factors 
needed by HIV-1, and the main restriction can be countered by vif 
chimerism. 
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The Apobec3 locus in humans encodes a family of cytidine deaminases 
(Apobec3A, B, C, DE, F, G and H) that inhibit the replication of retroelements 
during reverse transcription. The Apobec3 family members have a broad 
spectrum of strengths and targets, suggesting their adaptation to particular 
retroelements. Moreover, the adaptive evolution of these family members 
suggests that their sequence divergence between primates has been driven by 
genetic conflict with ancient pathogens. We previously characterized the rapid 
evolution of Apobec3G and 3H. However, the Apobec3 gene with the highest 
human-chimp divergence is Apobec3DE, a gene for which a clear role for in 
antiviral host defense has not yet been identified.  
 
Using phylogenetic analysis by maximum likelihood, we found that much of the 
sequence divergence between human and chimp Apobec3DE is due to extensive 
positive selection in the chimpanzee lineage before divergence with bonobos, 
suggesting that the strength of the selective pressure was much greater in 
chimps than in humans. The amino acids that show the greatest evidence of 
positive selection cluster in the C-terminal domain of chimp Apobec3DE, near a 
putative packaging signal and Vif interaction domain, and near the N-terminus 
in human Apobec3DE, suggesting that the nature of the selective pressure on 
Apobec3DE was also very different between the two species. From this data, 
we hypothesize that a nucleocapsid-like factor or a Vif-like factor may have 
driven the adaptive evolution in chimp Apobec3DE. 
 
While both human and chimp Apobec3DE are able to significantly restrict Alu 
and MusD, two distantly-related retrotransposons, the chimp ortholog is very 
active against lentiviruses, including HIV-1 and SIVagm (while human 
Apobec3DE has poor activity against both). These results further suggest that 
Apobec3DE has evolved to restrict a different pathogen, specifically an 
extracellular retroelement, in chimpanzees than in humans. We mapped the 
residues of Apobec3DE that are responsible for the differential human vs. 
chimp anti-viral activity to a region within the C-terminal domain. We are 
testing whether these amino acids alter packaging efficiency in human and 
chimp Apobec3DE. Additionally, we are comparing the sensitivity of human 
and chimp Apobec3DE to multiple lentiviral Vif proteins. These results point to 
a paleovirus infection in the ancient chimpanzee lineage approximately 2-5 
million years ago that drove selection of chimp Apobec3DE, while having more 
minor effects on the human lineage. 
 122 
CHARACTERIZATION OF THE BARRIER CONFERRED BY TYPE I 
INTERFERON ON THE EARLY STEPS OF HIV-1 INFECTION IN 
PRIMARY CELLS 
 
Caroline Goujon, Fransje A Koning, Michael H Malim  
 
King's College London, Infectious Diseases Department, London, SE1 9RT, 
United Kingdom 
 
Type I interferon (IFN) induces blocks to infection by many viruses at various 
steps of their life cycles. It has been known for a long time that treatment of 
certain cell types with IFN confers a potent block to both the early and late steps 
of HIV-1 replication. However, the early block has remained poorly 
characterized and the identity of the anti-viral factor(s) that mediate this effect is 
unknown. 
We have investigated in detail the effect of type I IFN on HIV-1 infection in 
cell types relevant to natural infection, including primary CD4+ T cells, 
monocyte-derived macrophages, as well as several monocytic and T cell lines. 
We have found that IFN treatment of macrophages, THP-1 cells, and to a lesser 
extent CD4+ T cells, has a profound effect on the outcome of HIV-1 infection, 
whereas the effect is much less pronounced in U937 cells and minimal in CEM, 
CEM-SS, HUT78, Jurkat or SupT1 T cell lines. Using a BlaM-Vpr entry assay, 
we have observed that viral entry is not affected by IFN treatment. More 
specifically, the block directly correlates with a strong decrease in the 
accumulation of viral cDNA. Interestingly, proteasome inhibitors rescue viral 
cDNA accumulation, reminiscent of what is seen with non-human isoforms of 
TRIM5α. We have also shown that IFN exerts potent anti-viral effects against a 
broad range of retroviruses, including diverse HIV-1 strains (IIIB, BK132, 
NL4-3, YU-2, Ba-L), HIV-1 derived lentiviral vectors (LVs), SIVmac and FIV 
LVs, as well as B-MLV. 
Taken together, our results indicate that one or several effectors of the type I 
IFN response are able to block viral DNA accumulation of distant retroviruses. 
Interestingly, the restriction factors currently known to affect retroviral DNA 
accumulation, namely TRIM5α and APOBEC3G/F, are part of the IFN 
response. Considering the range of retroviruses that are restricted, we consider it 
unlikely that TRIM5α mediates this restriction, though we are currently 
investigating the potential role of different APOBEC3 family members. 
Interestingly, all the cells we have examined efficiently induce numerous 
interferon stimulated genes (ISGs) such as ISG15, OAS1 and PKR, indicating 
that a general loss of IFN-responsiveness does not underlie the lack of an IFN 
phenotype in T cell lines. Rather, we hypothesize that these cell lines are unable 
to induce expression of the critical anti-retroviral effector(s), contrary to 
macrophages, THP-1 or CD4+ T cells. Consequently, comparative 
transcriptomic analysis will be a tool of choice to help identify the ISG(s) 
responsible for the early block to retroviral infection.  
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Interferon constitutes a major host defense mechanism against virus 
infection. Replication of human immunodeficiency virus type 1 (HIV-1) is 
substantially suppressed by interferonalpha in certain T cell lines such as 
SupT1. We have employed a shRNA-based knockdown approach to 
identify anti-HIV-1 ISGs (interferon stimulated genes) in interferonalpha-
treated SupT1 cells. Among several ISG candidates thus identified is 
IFITM1 (interferon induced transmembrane protein 1). To assess the anti-
HIV-1 activity of IFITM1 and its two homologues IFITM2 and IFITM3, we 
utilized the Tet-ON retroviral expression vector system to crease SupT1 cell 
lines that express these proteins in the presence of doxycycline. The results 
showed that expression of IFITM proteins profoundly inhibited HIV-1 
replication in tissue culture. This inhibition was further shown to take place 
at the early steps of HIV-1 infection in the one-round infection experiment. 
Using the Vpr-BlaM-based HIV-1 virion fusion assay, we demonstrated 
that HIV-1 entry was impaired. Our data suggest that IFITM proteins act as 
a new group of cellular restriction factors that inhibit HIV-1 infection by 
targeting virus entry.  
 
Jennifer Lu and Qinghua Pan contributed equally to this work. 
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HIV-1 carrying the “Q151M complex” (Q151Mc, A62V/V75I/F77L/ 
F116Y/Q151M in reverse transcriptase [RT]) shows multi-drug resistance 
(MDR) to FDA-approved nucleoside RT inhibitors (NRTIs) but has been 
considered susceptible to tenofovir disoproxil fumarate (TNV-DF).  
We have isolated a Q151Mc-containing clinical isolate with phenotypic 
resistance to TNV-DF under TNV-DF-treatment. Genotypic and phenotypic 
analyses over the course of this patient’s therapy suggested that resistance to 
TNV-DF emerges upon appearance of the previously unreported K70Q 
mutation in the Q151Mc background. Virological analysis revealed that the 
K70Q mutation by itself did not significantly affect resistance to TNV-DF and 
resulted in marginal resistance to didanosine (ddI) and lamivudine (3TC). 
However, addition of the K70Q mutation to the Q151Mc background enhanced 
resistance to all FDA-approved NRTIs, including TNV-DF (10-fold). 
Biochemical analysis showed that K70Q/Q151Mc RT does not become more 
efficient in ATP-based excision of chain-terminated primers. Pre-steady state 
kinetic analysis of the recombinant enzymes demonstrated that the K70Q 
mutation significantly affects incorporation of TNV-diphosphate (TNV-DP) 
into the nascent chain due to decreased TNV-DP binding affinity. Molecular 
modeling analysis suggested that the K70Q mutation may indirectly influence 
binding of the TNV-DP through interactions with residue K65.  
Mutations at position 70 of RT have been known to confer NRTI resistance 
either a) by enhancing excision (through K70R), or b) by decreasing the 
incorporation rate of the inhibitor (kpol-dependent, through K70E). In this 
study, we present a third possible mechanism: c) by decreasing the binding 
affinity of the inhibitor (Kd-dependent, through K70Q). These findings 
highlight the remarkable ability of RT to use different mutations at this position 
to acquire NRTI resistance through three different mechanisms. The discovery 
of the novel mutational pattern (K70Q/Q151Mc) that causes high-level 
resistance to TNV as well as other NRTIs may have clinical implications in 
therapeutic strategies for NRTI-experienced patients with MDR mutations.  
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Our previous work has shown that the neuronal specific factor FEZ1 
(fasciculation and elongation protein zeta-1) blocks retroviral infection early 
in the viral life cycle, after reverse transcription but before nuclear entry. 
We also recently demonstrated that neurons unlike astrocytes and microglia 
naturally express high levels of FEZ1 and are correspondingly less 
susceptible to HIV-1 infection. FEZ1 overexpression was recently shown to 
be the cause of multi-lobulation of the nucleus, a phenotype frequently seen 
in leukemia cells. The same research group also demonstrated that FEZ1 
binds and forms a functional complex with NIMA-related kinase 1 (NEK1) 
and CLIP-associated protein 2 (CLASP2) in a perinuclear region in 
mammalian cells. NEK1 and CLASP2 participate in cell cycle and cell 
division processes and localise to the centrosome. Here we examined FEZ1 
overexpressing microglia CHME3 cells by fluorescence microscopy and 
confirmed that FEZ1 overexpression is the cause of multi-lobulation of the 
nucleus in these cells. Our preliminary data suggests that knockdown of 
endogenous NEK1 significantly increases the susceptibility of a neuronal 
cell line to pseudotyped human immunodeficiency virus type 1 (HIV-1) 
infection. Moreover, overexpression of NEK1 in HeLa cells showed an 
increased resistance of these cells to HIV-1 infection. As such, NEK1 and 
FEZ1 act as negative regulators of retroviral infection. We have generated 
truncation mutants of FEZ1 with the aim of identifying domains required 
for the inhibition of HIV-1 infection and binding to NEK1, which may 
actually be the same domain required for the formation of a larger 
FEZ1/NEK1 complex that affects nuclear architecture and HIV-1 entry. 
 126 
XMRV IS NOT DETECTED IN QUEBEC PATIENTS WITH CHRONIC 
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It was recently reported that 67% of US patients with chronic fatigue 
syndrome (CFS) show the presence of xenotropic murine leukaemia virus-
related virus (XMRV) in peripheral blood mononuclear cells (PBMC). 
However, similar results could not be reproduced with CFS patients from 
other countries, the UK or the Netherlands.  
We studied a Quebec cohort of sixty-two (62) CFS patients to determine 
whether XMRV is also associated with CSF in this part of the world. We 
used a PCR method to amplify gag- and env- specific XMRV sequences 
with PBMC DNA from CFS patients. None of these DNA samples tested 
gave a positive and/or reproducible signal. In addition, PHA + IL-2 
activated PBMC from each patient were co-cultured with susceptible 
LNCaPs cells for 1.5-2 months. Virus particles were then assessed by an 
rA.dT assay. None of the 62 cultures gave a positive read-out with this 
assay. In addition, we could not detect viral footprints in activated PBMC 
by immunofluorescence with anti-p30 antibodies.  
Therefore, it appears that XMRV footprints cannot be easily detected in 
Quebec CFS patients by the methods used. Possible explanations for these 
contrasting results could be: (a) the virus titers may be too low in PBMC to 
be easily detectable; (b) the virus may be divergent enough in our cohort to 
be undetectable with the approaches used; (c) or XMRV may not be 
associated with the development of XMRV in Quebec patients.  
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All lentiviruses except EIAV use the small accessory protein Vif to 
counteract the restriction activity of the relevant APOBEC3 (A3) proteins 
of their host species. Prior studies have indicated that the Vif-A3 interaction 
is species-specific. Here, using APOBEC3H (Z3)-type proteins from five 
distinct mammals, we report that this is generally not the case: some 
lentiviral Vif proteins are capable of triggering the degradation of both the 
A3 proteins of their normal host species and those of several of the other 
mammals. For instance, SIVmac Vif can mediate the degradation of the 
human and rhesus macaque A3H proteins and the cow A3Z3 protein, but 
not degradation of sheep, cat, or mouse A3Z3 type proteins. MVV Vif is 
also very promiscuous, degrading not only sheep A3Z3 but also the Z3-type 
proteins of humans, rhesus macaques, cows and cats. In contrast, the 
interactions between HIV Vif, BIV Vif, and FIV Vif appear specific to their 
host A3Z3 proteins. Taken together with the fact that all of these 
experiments were done with an HIV-based vector in human cells to 
minimize non-Vif/A3 experimental variables and that only 25 Vif/A3 
combinations were surveyed, it is likely that all lentiviral Vif proteins will 
show significant degrees of cross-species A3 neutralization. Our studies 
also suggest that the Vif/A3Z3 interaction is relevant to lentivirus 
pathogenesis and that the flexibility of this interaction may facilitate 
zoonotic infections. 
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The host RNA silencing machinery downregulates HIV-1 expression, 
presumably by specific miRNAs. Cell culture experiments have 
demonstrated host miRNAs that are detrimental to HIV-1, that Dicer 
downregulation increases HIV-1 virion production, and that HIV-1 Tat 
possesses RNA silencing suppressor (RSS) activity that counteracts 
translational repression of HIV-1. Comparison of Tat RSS with plant and 
animal virus RSS has demonstrated that Tat RSS activity is conserved 
across kingdoms, and Tat RSS is active at a step downstream of miRNA 
maturation. Herein trends in miRNA expression profiles observed in a 2008 
study of 36 HIV-1 infected individuals were compared to miRNA 
expression profiles observed in CEMx174 lymphocytes infected with HIV-
1NL4-3 or the K51A derivative strain deficient in Tat RSS activity. 
Unexpectedly, results identified similar profiles between the cell culture 
system and a cohort of 36 HIV-1 patients previously characterized, 
supporting the validity of a cell culture model to evaluate HIV-1 miRNA 
biology prior to targeted experiments in patient samples. Removal of Tat 
RNA silencing suppressor activity (K51A) affected the magnitude of a 
subset of miRNAs. Discussion will include the possible impact of Tat RSS 
activity on host miRNA activity, relation to steady-state miRNA level, and 
interplay of feedback on alternative target genes. 
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The Apobec3 (A3) loci vary significantly between different mammalian 
orders, showing both evidence of expansion and contraction in the number 
of paralogous genes as well as rearrangements, which reflect the selective 
histories of different genes. Old world monkeys share a common 
arrangement of seven genes within the locus in the order A3A through 
A3H. These are made up of monomeric or dimeric combinations of three 
paralogous sequences (Z1, Z2 and Z3) encoding zinc-coordinating proteins 
with deaminase activity. In contrast, the mouse has a single gene with a Z2-
Z3 configuration. In addition to the seven genes in the A3 locus, all old and 
new world monkeys share a processed syntenic A3G pseudogene; in the 
human genome this sequence is located on chromosome 12 q23.3. The 
presence of this pseudogene in both old and new world monkeys indicates 
that the A3G locus was already present in the common ancestor around 35 
million years ago. Attempts to detect the pseudogene by Southern blot 
analysis or PCR amplification in the DNA of the more distantly related 
lemur have so far been unsuccessful. Interestingly, the genomes of new 
world monkeys carry additional processed pseudogene copies of A3G. 
Some of these amplifications seem quite recent based on sequence 
similarity to the active A3G genes. There is no evidence of processed 
pseudogenes for any of the other monkey A3 genes based on the genomes 
of primates in the database.  
We compared the common pseudogene of new and old world monkeys 
using sequences found in data bases as well as established by direct 
sequence analysis, and found that they all show overt inactivating mutations 
which interrupt the reading frame. We derived a consensus sequence with 
an open reading frame based on sequences from new and old world 
primates and generated an expression construct termed PsuA3G. The 
protein encoded by the initial construct was highly instable due to poly-
ubiquitination and was consequently inactive in retroviral restriction. Using 
human/Psu A3G hybrids we identified the carboxy-terminal domain as the 
major determinant of the instability. A change of one residue (S267P) in the 
C-terminal domain of the PsuA3G protein resulted in its stabilization and 
reactivation. PsuA3G-S267P shows 2-fold less activity in restriction of 
HIVΔvif compared to human A3G. We are currently analyzing other point 
mutations in an attempt to further increase the activity of PsuA3G. 
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We have previously shown that representative members of the 
Betaretrovirus genus— Jaagsiekte sheep retrovirus (JSRV) and mouse 
mammary tumor virus (MMTV)—share with lentiviruses the phenotype of 
non-covalently associated envelope (Env) subunits. Furthermore, subunit 
association can be predicted by the pattern of cysteine residues in the 
flexible region of the transmembrane (TM) domain, with a two-cysteine 
motif indicating non-covalent association and a three-cysteine subunit, 
covalent bonding between the TM and the surface subunit (SU) of Env. A 
look at the TM sequences of the human endogenous retroviruses (HERV), 
for instance, reveals that the HERV-K group contains the motif associated 
with non-covalent subunit association, and this prediction was supported by 
our demonstration that HERV-K108—a member of the HERV-K(HML-2) 
group, whose env reading frame is open and functional—indeed has non-
covalently associated subunits. This finding indicates that the non-covalent 
phenotype first infected the ancestor of humans at least 55 million years 
ago, in the form of HERV-K(HML5). 
 
We are currently analyzing the species distribution of elements with the 
non-covalent motif, and comparing phylogenies of these viruses with those 
of their hosts to gain insight into how this structure evolved in relation to its 
hosts over time. Preliminary results suggest that, while the non-covalent 
phenotype has been quite successful in infecting the germ-lines of 
mammals, the covalent phenotype has a broader species distribution. 
Information gained from this analysis should also be useful for fine-tuning 
the taxonomy of the Class II retroviruses in general and the Betaretrovirus 
genus in particular, which currently include viruses with both phenotypes. 
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Late stages in the replication cycle of HIV-1 are highly organized processes 
involving the interaction of viral components with complex cellular 
machineries which are currently only partly understood. Although recent 
high-throughput siRNA screens identified many putative host cell factors 
involved in HIV-1 replication, still only a limited number of essential 
cofactors for viral egress are known. To specifically address this question, 
we set up a simple assay suitable for random screening approaches, 
allowing both the identification of chemical compounds interfering with 
assembly or release of HIV-1 particles, and of important host cell factors by 
screening of siRNA libraries. 
The protocol comprises transfection of 293T cells with a fluorescently 
labeled HIV-1 derivative, which carries an eYFP domain within the main 
viral structural protein Gag. This allows direct quantification of released 
particles by measurement of the YFP intensity in the cell culture 
supernatant. To control for potential differences in transfection efficiencies 
and cytotoxic effects, YFP intensities in the cell lysates were quantitated in 
parallel, and YFP intensity in the culture medium was normalized to the 
total fluorescence in the supernatant and cell lysate.  
A primary screen was performed for a subgenomic siRNA library targeting 
740 human kinases. After statistical analysis, candidates scoring positively 
were tested in a validation screen. Bioinformatics analyses of validated host 
factors are currently performed in order to identify potentially relevant 
protein pathways and networks. Thorough characterization of the functional 
role of such potential host factors may contribute to a better understanding 
of HIV-1 morphogenesis in the future.  
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The assembly of retroviruses is a highly ordered process that is driven by 
the multi-functional polyprotein Gag. In the immature stage Gag is 
responsible for packaging of cellular factors, self-targeting to the site of 
assembly, virus assembly and release of the virus particles from the infected 
cell. After the ordered assembly and release from the cell Gag is processed, 
which allows the individual domains of Gag to take on new roles as the 
structural domains that are responsible for creating a fully infectious 
particle. Even though a large amount of structural data is available on the 
mature domains of Gag, the mechanism that orchestrates the metamorphosis 
of Gag is still largely unknown.  
 
Here we describe the conformation of the full-length HIV-1 Gag 
polyprotein and its cleavage products in solution and show that HIV-1 GAG 
changes conformation during maturation. We show that the immature full-
length HIV-1 Gag polyprotein adopts a compact structure, which is 
mediated through the C-terminus of Gag. Comparison of the monomeric 
solution structure of the Gag precursor protein, processing intermediates 
and mature products revealed that a conformational epitope within the HIV 
matrix domain is not accessible in the precursor form but is exposed in the 
context of the processing intermediate and mature product. This same 
conformational epitope is not detected in immature HIV, but is readily 
recognized in mature infectious HIV.  
 
To summarize, our results show that HIV Gag undergoes dramatic tertiary 
structure changes during maturation and we hypothesize that these 
conformational changes are likely to be important for the production of 
infectious HIV.  
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Lipid rafts are ordered domains within the cell membrane, enriched in 
cholesterol and sphingolipids, and known to be critical for entry and egress 
of many viruses from the cell. HIV-1 is known to bud from lipid rafts and 
several HIV-1 proteins localize to these domains, including Env, Gag, and 
Nef. The HIV-1 Vpu protein has two major functions, downregulation of 
CD4 from the cell surface and enhanced virion release/relief of BST-2 
restriction. As BST-2 is a GPI-anchored, lipid raft protein, we examined 
whether HIV-1 Vpu is a lipid raft protein. We found that approximately 
10% of Vpu is consistently localized to detergent resistant membranes 
(DRMs) when exogenously expressed in the absence of other viral proteins, 
with or without a C-terminal EGFP tag, and also from virus-infected cells. 
A Vpu protein from a clinical isolate of HIV-1 subtype C was isolated from 
resistant fractions in similar ratios. Cholesterol depletion of cells with 
lovastatin and methyl-β-cyclodextrin removed Vpu from DRMs indicating 
the specificity of Vpu partitioning into DRMs. A Vpu protein with a 
scrambled transmembrane domain previously described was no longer 
found in detergent resistant fractions. A series of alanine mutations in the 
transmembrane and proximal cytoplasmic domain were analyzed to 
determine if a specific portion of these domains was involved in raft 
targeting. The ability of mutant Vpus to partition into DRMs was correlated 
with the ability of Vpu to enhance virion release from HeLa cells in a single 
round replication assay. This work supported by NIHAI51981. 
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The APOBEC3 family of cytidin deaminases protects vertebrates from viral 
pathogens. Although the APOBEC3 protein family is very homologues 
sharing a characteristic motif for zinc-coordination, the specificity of each 
APOBEC3 differs from the others. Several APOBEC3 proteins (e.g. A3F 
and A3G) restrict Human immunodeficiency virus (HIV) replication in the 
absence of the viral infectivity factor (Vif) protein. Another member, 
APOBEC3C(A3C) so far is only known to be active against Simian 
immunodeficiency virus (SIV) and LINE-1 retrotransposons, but not against 
HIV. 
Our study confirmed that A3C has no antiviral effect against HIV-1 Δvif 
although it is incorporated into viral particles. Aguiar et al. (JBC 2008) 
showed that fusion of VPR (HIV-1) to the N-Terminus of A3A resulted in 
antiviral activity against HIV-1 due to a change in sub-viral localization of 
the fusion-protein. We tested this idea also for A3C, and observed a strong 
antiviral activity against Δvif HIV-1. Interestingly, also wt HIV-1 was 
inhibited by VPR-A3C indicating a block of A3C interaction with Vif. This 
dose-dependent effect was shown for VPR fused to either the N- or the C-
Terminus of A3C. We speculated that the interaction of VPR with the 
nucleocapsid (NC) protein of HIV-1 could alter sub-viral localization and 
target A3C directly to the viral core or RNP, respectively. But, 
unexpectedly, we could not see any difference in sub-viral localization of 
the fusion-protein compared to wtA3C and wtA3G. In pull-down assays of 
NC (HIV-1) with A3C and A3G we observed equal binding properties for 
both proteins. In ongoing experiments, we characterized the relevance of 
small A3C-interacting RNAs like 5.8S or 7SK RNA for the different 
activities of the A3 constructs. Our findings implicate, that enhancing the 
antiviral activity of the broadly expressed A3C would likely repress HIV-1 
replication in patients and thus should be considered as a novel approach for 
treatment. 
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The nature of biological membranes is fundamental to the study of assembly 
and egress of enveloped viruses. The current consensus is that the plasma 
membrane (PM) is heterogeneous, consisting of diverse microdomains. This 
partitioning of membrane components is regulated by lipid-lipid, protein-
protein, and protein-lipid interactions to compartmentalize cellular processes. 
Previously, we and others have reported that HIV-1 Gag co-fractionates with 
detergent resistant membranes, and is sensitive to cholesterol depletion. More 
recently, two types of microdomains, lipid rafts and tetraspanin-enriched 
microdomains (TEMs), have been proposed to be platforms of HIV-1 assembly. 
 
Lipid rafts are dynamic, sub-microscopic domains enriched in sterols, 
sphingolipids, GPI-anchored proteins. TEMs are membrane microdomains 
organized by oligomerization of tetraspanin proteins, such as CD81, CD9, and 
CD63. Importantly, despite some similarities, lipid rafts and TEMs can be 
distinguished by a variety of assays, and are therefore thought to be distinct 
classes of microdomains. Yet, it has been reported that Gag associates with both 
lipid rafts and TEMs, suggesting that Gag may induce the coalescence of these 
otherwise distinct microdomains during HIV-1 assembly. 
 
In this study, using an antibody-mediated co-patching assay, we observed the 
cell-surface distribution of canonical lipid raft markers, such as GPI-anchored 
proteins and influenza HA, and tetraspanin proteins, in the presence or absence 
of Gag derivatives. We confirm previous observations that lipid raft and TEM 
markers segregate upon patching, and therefore appear to constitute distinct 
microdomains in the absence of Gag. However, we demonstrate that Gag does 
induce the coalescence of lipid rafts and TEMs. Using a panel of Gag mutants 
designed to alter Gag acylation, PI(4,5)P2 affinity, multimerization, and ability 
to induce membrane curvature, we investigate the molecular determinants of 
this coalescence. Preliminary data indicate that Gag membrane binding is 
necessary, but a variety of alternate membrane binding domains are sufficient to 
allow Gag-mediated microdomain coalescence. 
 
The ability of Gag to reorganize membrane microdomains may have important 
implications for viral fitness. If Gag-mediated reorganization of microdomains 
increases the affinity of Gag for these microdomains, this could confer 
cooperativity on Gag membrane and microdomain association, possibly 
favoring multimerization and assembly. Additionally, Gag-induced 
microdomains may facilitate the incorporation of important viral or cellular 
factors, such as viral glycoproteins or restriction factors (e.g. tetherin). 
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U937 is a promonocytic cell line that can be differentiated into 
monocyte/macrophages with PMA treatment. U1/HIV-1, a subline of U937, 
has integrated HIV-1 proviral DNAs and initiates HIV-1 production upon 
PMA treatment. Here we employed U937 and U1/HIV-1 models to 
investigate the cellular metabolic alterations during viral production. First, 
we found that 100 nM PMA treatment for 24h worked well leading to better 
adherence of the U937 cells as compared to U1/HIV-1 cells. Next we 
examined p24 level at the cellular level by FACS analysis and found over 
50% of the U1/HIV-1 cells expressed p24 by 48h. We found an increase 
p24 level by ELISA in the supernatants between 24h and 72h after PMA 
treatment. Cell death was examined by Trypan blue exclusion and was 
found to be very low at 24h, but steadily increased to 96h, the end point of 
these studies. U937 appears more susceptible to death after PMA as 
compared to U1/HIV-1 cells. With this finding, we examined the steady 
state profiles of various cellular metabolic intermediates using LC/tandem-
MS at 24h and 48h post PMA treatment, in order to monitor metabolic 
alterations during viral production. Moreover, we will monitor HIV-1 
induced metabolic changes by using a flux measurement with C13-labeled 
glucose. This system will be used to examine alterations in metabolism for 
glucose consumption and energy generation induced by HIV-1 production. 
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HIV-1 replication begins with fusion of the viral particle with the target cell 
membrane, resulting in the release of the viral core into the cell. Once in the 
cytoplasm, the p24 capsid protein (p24CA) disassembles from the core by a 
process called uncoating. Uncoating is required for viral replication, yet little is 
known about the kinetics and factors involved with the process. Previous 
studies have shown that mutations in p24CA can affect reverse transcription. 
Reverse transcripts have been detected in viral particles that contain p24CA 
using microscopy. Collectively, these data suggest that the processes of 
uncoating and reverse transcription may be functionally linked. Here, we have 
examined the timing and role of reverse transcription in HIV-1 uncoating.  
 
We developed an uncoating assay which uses fluorescent microscopy to 
examine the association of p24CA with viral cores in the cytoplasm of infected 
cells. The membrane label S15-mCherry was incorporated into HIV-1 virions 
containing GFP-Vpr. HeLa cells were spinoculated with dual labeled virions at 
17°C, temperature shifted to 37°C to allow infection, and then fixed and stained 
with an antibody to p24CA. A subsequent loss of mCherry signal correlates with 
productive viral fusion, and the percentage of fused virions that retain p24CA 
was determined. We found that p24CA remained associated with the viral core 
after fusion and was gradually lost over time. This assay was validated using a 
set of p24CA mutants that previously have been shown to alter capsid stability 
and reduce infectivity. A correlation between the results of the uncoating assay 
and previous biochemical uncoating data was observed. Interestingly, four 
hours post-infection wildtype and p24CA mutants uncoated to a similar extent. 
These results indicate that an uncoated viral core is not solely sufficient for viral 
replication and that alterations in the rate of uncoating soon after fusion can 
impact viral replication. Finally, the effect of reverse transcription on uncoating 
was examined by treating cells with the reverse transcriptase inhibitors AZT 
and nevirapine. In treated cells we observed an increase in the percentage of 
virions associated with p24CA over time compared to no treatment. We 
complemented these experiments using TRIM abrogation and washout assays. 
These assays are based on the ability of the restriction factor TRIMCyp to 
inhibit HIV-1 replication through binding to an intact viral capsid. Treatment 
with nevirapine enhanced the ability of HIV-1 to saturate TRIMCyp restriction. 
These data correlate with observations from the uncoating assay in which 
uncoating was prolonged when reverse transcription was inhibited. Therefore, 
these results further support the idea that the processes of uncoating and reverse 
transcription are linked and suggest that steps in reverse transcription may be 
required for uncoating. 
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Xenotransplantation using pig organs and tissues is considered as the possible 
answer to overcome the increasing needs for human transplantation donors. 
However porcine endogenous retrovirus (PERV) received much attention due to 
its unique nature of being endogenously present in every porcine tissue and due 
to its ability to integrate into human genome. There has been no evidence that 
PERV infection is associated with human diseases. It is necessary to analyze the 
construct and sequences of PERV genomes for the assessment of the capability 
of the self replication in cells after transmission.  
It was calculated from the standard curve with real time PCR that 860 copies of 
gag and 55 copies of pol were present in a peripheral blood mononuclear cell 
(PBMC) of SNU miniature pig, which means that many defective PERVs are 
present in pig cells in genomic level. PCR amplification of PERV genes 
spanning of mid-5’ LTR and 3’ end of env in the chromosomal DNA of PBMC 
of SNU miniature pig revealed products with the approximate molecular weight 
of 7.5, 4.0 and 3.5 kDa. Gene products were cloned into Topo XL cloning 
vector, and their sequences were analyzed. The cloned PERV genes were 
classified into 6 groups according to the deleted or inserted genome patterns and 
the sizes of constructs. Group I was comprised of clones with full-length genes, 
group II to V clones with the variably and partially defective genes in pol, env, 
or gag-pol junction, and group VI clone with the inserted chromosomal 
sequences in gag portion. The sequence alignment suggested that most of the 
defective region in clones of group II to V was formed by the mechanism of 
splicing. The sequence analysis revealed that the cloned PERV genes in all the 
groups contained the presumed packaging signal sequences, from mid-5’ LTR 
to 5’ portion of gag, as compared with those from other retroviruses. It was 
detected mainly defective sizes of PERV genes when RT-PCR was performed 
in the cellular mRNA and virion RNA from PHA- and PMA-stimulated PBMC 
of SNU miniature pig with the primer set for the full-length PERV genes. It 
seemed a long time ago that PERV virion assembled with the defective genes 
could be produced and transmitted to germ line cells where the defective PERV 
genes were integrated into chromosomal DNA and handed over to offspring 
forever.  
In conclusion, it would be very difficult for PERV from SNU miniature pig to 
replicate by itself in a cell after transmission if it is not complemented with 
other retroviral components in the PERV-transmitted cell.  
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The ability of mammalian cytidine deaminases encoded by the APOBEC3 
(A3) genes to restrict a broad number of endogenous retroelements and 
exogenous retroviruses, including Murine Leukemia Virus (MLV) and 
human immunodeficiency virus (HIV)-1, is now well established. The RNA 
editing family member apolipoprotein B (apo B)-editing catalytic subunit 1 
(APOBEC1; A1) from a variety of mammalian species, a protein involved 
in lipid transport and which mediates C-to-U deamination of mRNA for apo 
B, has also been shown to modify a range of exogenous retroviruses, but it’s 
activity against endogenous retroelements remains unclear. Here we show 
in cell culture based retrotransposition assays that A1 family proteins can 
also reduce the mobility and infectivity potential of LINE-1 (long 
interspersed nucleotide sequence-1, L1) and long-terminal-repeats (LTR) 
retrotransposons (or endogenous retroviruses) such as murine intracisternal 
A-particle (IAP) and MusD sequences. The anti-L1 activity of A1 was 
mainly mediated by a deamination-independent mechanism, and was not 
affected by subcellular localization of the proteins. In contrast, the 
inhibition of LTR-retrotransposons appeared to require the deaminase 
activity of A1 proteins. Thus, the AID/APOBEC family proteins including 
A1s employ multiple mechanisms to regulate the mobility of autonomous 
retrotransposons in a wide range of mammalian species. 
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Xenotropic murine leukemia virus (MLV)-related virus (XMRV) is a novel 
human retrovirus recently identified in patients with prostate cancer. 
Although XMRV infects human cells by targeting XPR1 cell surface 
receptor, it cannot infect cells from laboratory mice. Recently, Dr. Kozac’s 
group has demonstrated that cells from certain wild mouse strains are 
permissive to xenotropic mouse gammaretroviruses. Here, we examined 
whether a wild mouse strain, Mus pahari, can serve as a small animal model 
for XMRV infection. First, we examined the susceptibility of primary Mus 
pahari fibroblast cells to XMRV. When the cells were infected with XMRV, 
they became XMRV Gag-positive and produced 2 x 105 IU/ml of cell-free 
virions. Mus pahari cell-derived virus showed no notable mutation. These 
observations indicate that Mus pahari-derived cells support early and late 
phases of XMRV replication. Next, we examined susceptibility of Mus 
pahari to XMRV in vivo. Single injection of XMRV induced high levels of 
XMRV neutralizing antibodies (>320) in 9 out of 10 injected mice as early 
as 2 weeks after injection. XMRV Env-specific antibodies were detected in 
the plasma samples obtained at 2 weeks post injection, while strong Env- 
and Gag-specific antibodies were detected at 2 to 3 months after injection. 
When the biodistribution of XMRV was examined, spleen (5 out of 9), 
blood (4 out of 9) and brain (4 out of 9) were found to have high copies of 
viral DNA. Sequencing analysis confirmed the amplified fragments from 
blood and spleen as XMRV. By co-culturing mouse blood cells with 293T 
cells, we were able to isolate XMRV from four XMRV-infected mice. 
These data suggest the lymphotropic nature of XMRV in this mouse strain. 
Unexpectedly, DNA extracted from a brain sample of an uninfected mouse 
was shown to be positive for XMRV by the realtime PCR assay. 
Subsequent studies, however, identified another MLV, which is closely 
related to a previously reported wild mouse isolate CasE#1, suggesting 
circulation of an exogenous CasE#1-like MLV strain in Mus pahari. In 
summary, our data demonstrate the possible use of this wild mouse strain to 
study XMRV infection in vivo, although we may need to pre-screen 
animals for CasE#1-related virus infection. 
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The recently discovered tetherin enlarges a group of cellular proteins with 
antiviral activity. Acting non-specifically, tetherin is capable to prevent 
release of at least four virus families. In response to this challenge, viruses 
developed different approaches to overcome tetherin activity: Vpu in HIV, 
K protein of KSHV, HIV2 and SIV envelopes, envelope glycoprotein in 
Ebola virus, and SIV Nef.  
It is understood that tetherin keeps HTLV1 attached to the cell surface, but 
it is unknown by what mechanism HTLV1 escapes tetherin retention. To 
answer the question of possible anti-tetherin activity of HTLV1 we 
compared the level of tetherin expression in non-infected and HTLV1-
chronically infected T-cell lines. The level of tetherin expression in 
HTLV1-chronically infected cell lines was higher than in non-infected, 
suggesting that HTLV1 does not have a mechanism to downregulate 
tetherin. The finding that GPI-truncated tetherin is incorporated into VLPs 
indicates that HTLV1 does not remove tetherin from the sites of viral 
release. While tetherin expression severely affects infectivity in cell-free 
assays, its effect on cell-cell transmission (more typical for HTLV1) is 
much less profound. Fluorescent staining reveals colocalization of tetherin 
and HTLV1 Gag in cell-cell contact areas established between Jurkat and 
HTLV1-chronically infected MS9 cells. We did not observe polarization of 
tetherin in Jurkat cells expressing only HTLV1 Gag or only Tax. Tax causes 
polarization of a cell and directs Gag toward the cell-cell contact area. The 
accumulation of tetherin in the cell-cell contact area is a result of the 
polarized release of viral particles. It is probable that tetherin, in tight cell-
cell contact area, does not prevent transmission of HTLV1 to the target cell.  
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The Gag polyprotein is necessary and sufficient for retroviral assembly. 
HIV-1 assembles predominantly on the plasma membrane (PM). The basic 
cluster of amino acids in matrix (MA) domain of HIV-1 Gag interacts with 
phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2], a phospholipid that is 
enriched on the PM. This interaction is essential for PM-specific HIV-1 
assembly in HeLa cells. As many retroviral Gag also use basic amino acids 
in MA for membrane binding, PI(4,5)P2 or other acidic lipids may be the 
common cellular factors involved in Gag targeting among retroviruses. 
Unlike HIV-1 Gag, Human T-lymphotropic virus type-1 (HTLV-1) Gag 
localizes to the intracellular compartments in HeLa cells. To study the role 
of HTLV-1 MA in Gag localization and virus assembly, we constructed a 
Gag chimera, by replacing the MA of HIV-1 Gag with that of HTLV-1 
(HTMA). This Gag derivative, along with HIV-1 and HTLV-1 Gag, were 
expressed by CMV-promoter-driven plasmids. We compared the 
localization and VLP release efficiency of each Gag construct in HeLa cells. 
HIV-1 Gag localized mostly to the PM, but in the presence of 5ptaseIV, 
which depletes cellular PI(4,5)P2, it displayed hazy cytosolic signal. 
Consistent with the lack of PM localization, VLP release was reduced 5 fold 
when compared to cells expressing inactive 5ptaseIV, 5ptaseIVΔ1, that 
lacks the catalytic domain. In contrast, both HTLV-1 and HTMA Gag 
localized to intracellular compartments in the presence or absence of 
5ptaseIV, and the VLP release was only modestly reduced upon 5ptaseIV 
expression. To examine the contribution of PI(4,5)P2 in membrane binding 
of HTLV-1 and HTMA Gag, we carried out an in vitro liposome binding 
assay. Consistent with previous data, HIV-1 Gag bound to liposomes in the 
absence of PI(4,5)P2 poorly, whereas it bound 9-fold more efficiently to 
PI(4,5)P2-containing liposomes. On the other hand, both HTLV-1 and 
HTMA Gag were able to bind efficiently to non-PI(4,5)P2-containing 
liposomes, and the binding efficiency increased only 2 fold when PI(4,5)P2 
was present in the liposomes.  
Altogether, these results indicate that MA of HTLV-1 determines the site of 
assembly. In addition, our data suggest that PI(4,5)P2 plays a less important 
role in the assembly of HTLV-1 and HTMA compared to that of HIV-1. We 
seek to identify the key factors that determine the localization of HTLV-1 
Gag. 
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APOBEC3G (A3G) is a host cytidine deaminase that serves as a cellular 
defense protein and a potent inhibitor of HIV-1 replication. Abrogation of 
A3G function involves the HIV-1 Vif protein, a specific substrate receptor 
for ubiquitination that binds A3G. More specifically, Vif facilitates 
ubiquitination of A3G by forming an E3 complex consisting of Cullin5-
ElonginB/C-Rbx2-E2, which targets A3G for rapid proteasomal 
degradation. Yet, despite our knowledge that these proteins interact with 
each other in the complex, the details of how the complex dictates A3G 
ubiquitination and subsequent degradation have remained unclear. 
 
Here, extensive mutagenesis, guided by a structural model of full-length 
human A3G, has allowed us for the first time to identify four Lys residues 
(Lys297, 301, 303, and 334) that are required for HIV-1 Vif-dependent 
ubiquitination and degradation. Remarkably, substitution of Arg for Lys at 
these residues (the mutant is termed super A3G [S-A3G]) confers Vif 
resistance and restores A3G’s antiviral activity even in the presence of Vif. 
In addition, we found that the interaction between WT A3G and S-A3G 
with Vif is very similar and that S-A3G is incorporated into WT and vif-
deficient viral particles to the same extent. Interestingly, the Vif sensitivity 
of S-A3G was changed by addition of the C-terminal tags, indicating that 
Lys residues in the C-terminal tag can serve as ubiquitination sites. In our 
A3G structure model, the critical four residues cluster at the C-terminus, 
which is opposite to the known N-terminal A3G-Vif interaction region 
containing the 128DPD130 motif. Moreover, HIV-2 and SIVmac Vif proteins 
target the same Lys residues in A3G as HIV-1 Vif. Collectively, these 
findings suggest that spatial constraints imposed by the E3 complex and 
especially the rigid scaffold Cullin5 protein may be an important 
determinant for Vif-dependent A3G ubiquitination/degradation. 
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Background: Host restriction factor A3G blocks HIV-1 replication by 
inducing G to A hypermutation. HIV-1 Vif counteracts A3G by promoting 
its degradation via the ubiquitin-proteasome pathway. Previous studies have 
revealed that the Arg24 residue is important for its dimerization and virion 
incorporation which is mediated through interaction with viral or non-viral 
RNAs. Recently, we have also demonstrated that PKA binds and 
specifically phosphorylates A3G at Thr32 which interacts with Arg24 and 
that its phophorylation would stabilize this interaction, blocking its binding 
to Vif. We tested the possibility that the Arg24 residue of A3G is involved 
in the binding to Vif. 
Method: We examined the protein binding between A3G and Vif with co-
immunoprecipitation assays. We used VSV-G pseudotyped luciferase 
leporter viruses to assess the anti-HIV-1 activity of A3G and its mutants.  
Results: We made several mutants at the position 24 of A3G, in which a 
residue was replaced by negatively charged or neutral amino acids and 
analyzed the binding of these mutants to Vif. R24A-A3G was still able to 
bind Vif, whereas R24E-A3G not, suggesting that the charged residue at the 
position 24 is important for interaction between A3G and Vif. In additon, 
the R24A mutant associated with hY or 7SLRNA less efficiently than the 
wild type and this was further impaired by the R24E substitution. The R24A 
and R24E mutants oligomerized less efficiently than the wild type. We 
conducted computer-assisted structural modeling of the A3G N-terminal 
domain including the wild-type, R24A, and R24E. Thermodynamically 
optimized three dimensional structures showed that the N-terminal region of 
A3G formed the pocket surrounded by Y22, R24, and R122 residues. 
Conclusions: These data suggested that the pocket in the N-terminal region 
of A3G is constructed with Y22, R24, and R122 residues and the interaction 
between these residues is important for association of RNA, leading to 
oligmeriation and Vif binding.  
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The hinge or linker region between the N- and C-terminal domains of HIV-
1 CA consists of residues S146, P147, T148, S149, and I150 and is flanked 
by residues Y145 and L151. To investigate the role of these residues in 
maintaining CA structure and function, we mutated each residue to Ala, 
with the exception of P147, which was changed to Leu. The mutants all 
produced particles, but only S146A and T148A had substantial infectivity. 
Thin-section EM revealed that three of the five non-infectious mutants, 
Y145A, I150A, and L151A had eccentric or centric cores and no conical 
cores. Surprisingly, two other mutants in this group, P147L and S149A, had 
a mixed population of conical cores (~50% of the WT value) as well as 
aberrant cores. The distinctive nature of these two mutants was also 
apparent in other assays. When viral DNA products were assayed in 
infected cells by qPCR, both mutants synthesized about 10-fold less DNA 
than WT. In strong contrast, I150A made ~104-fold less DNA than WT. We 
isolated virus cores and determined the amount of RT and CA retained in 
core fractions of sucrose gradients. RT values were on average ~35% of the 
WT level for P147L and S149A, whereas for the other non-infectious 
mutants the values were no more than 12% of WT. Retention of CA was 
more limited: for P147L and S149A, ~20% of the WT value was measured; 
and baseline levels were observed for Y145A, I150A, and L151A. Taken 
together, our results clearly demonstrate that perturbation of the CA protein 
in the hinge region leads to core instability and distortion of core 
architecture, with downstream effects on reverse transcription and 
infectivity. Attenuation of these effects in P147L and S149A is intriguing 
and is currently under investigation. This work was funded in part with 
federal funds from NCI, NIH, under contract HHSN261200800001E. 
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The nucleocapsid (NC) domain of the Moloney murine leukemia virus 
(MLV) Gag polyprotein is the determinant of genomic RNA (gRNA) 
packaging specificity. Of the ~2000 copies of Gag in an MLV virion, only a 
about a dozen appear required for specific gRNA recruitment (1). This 
suggests that the ~2000 NC domains are partitioned into at least two 
functional classes: those that engage in high-affinity interactions with 
gRNA, and those that do not. Testing phenotypically mixed virions 
generated by co-expressing WT and W35G NC Zn finger mutant MLVs 
confirmed that virions can package WT levels of gRNA when amounts of 
packaging-competent NC are reduced 4 to 10 fold, with packaging cut 
roughly in half for virions with only 5% WT NC. We next explored whether 
the Gag-Pol polyprotein, which is produced via termination suppression at a 
rate of about one Gag-Pol per twenty Gags, can function as well as Gag as 
the source of packaging-competent NC. This question was answered using 
two separate plasmids, pGagonly and pGag-Polonly, that each expressed only a 
single polyprotein. It has previously been established that MLV virus-like 
particles can form when Gag is expressed alone, but not when only Gag-Pol 
is expressed. When cells were co-transfected with 20:1 ratios of WT 
pGagonly and WT pGag-Polonly, complementation was observed, and served 
as a baseline for subsequent studies. Co-transfecting 20:1 ratios of WT 
pGagonly and W35G pGag-Polonly yielded virions as infectious as those 
where both pGagonly and pGag-Polonly were WT. 20:1 ratios of W35G 
pGagonly and WT pGag-Polonly also complemented, albeit to a significantly 
reduced level. To more accurately assess the effects of NC polyprotein 
context on packaging, phenotypically mixed virions generated by 
transfecting 19:1:1 ratios of W35G pGagonly, WT pGagonly and W35G pGag-
Polonly, respectively, were compared to virions produced by 20:1 ratios of 
W35G pGagonly and WT pGag-Polonly. Under these conditions, where the 
amount of WT NC was the same but its polyprotein context differed, titers 
were indistinguishable. Taken together, our results suggest that Gag and 
Gag-Pol can serve equally well to package MLV gRNA. 
 
(1) Miyazaki et al. (2010) J Mol Biol 396:141-152. 
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We have recently observed that endogenous TRIM22 is responsible for 
impairing HIV-1 long terminal repeat (LTR)-driven gene expression in a 
subset of promonocytic U937 cells non permissive for viral replication (A. 
Kajaste-Rudnitski et al., submitted). HIV transcription is regulated by a 
variety of cis-acting DNA sequence elements within the proviral LTR, 
responsive to specific host transcription factors. With the aim of identifying 
which of these factors could be involved in the TRIM22-mediated 
inhibition of HIV-1 transcription, an HIV-1 LTR Luciferase (Luc) reporter 
construct was transfected in 293T cells along with increasing amounts of 
TRIM22-expressing plasmid, followed by stimulation with Tumor Necrosis 
Factor-α (TNF-α), phorbol myristate acetate (PMA), either alone or in 
combination with ionomycin (I). Increasing amounts of TRIM22 expressing 
plasmid did not affect the HIV LTR basal transcription, however, PMA+I-
induced HIV-1 LTR activation was inhibited down to basal level 
transcription. Since NF-κB, NFAT-1 and AP1 are among the most potent 
activators of HIV-1 LTR driven transcription, individual Luc reporter 
constructs were transfected in 293T cells along with increasing amounts of 
TRIM22-expressing plasmid, followed by stimulation with TNF-α, PMA, I 
or PMA+I combination. TRIM22 did not affect either NF-κB or AP-1-
driven basal or stimulated Luc expression. In contrast, PMA+I stimulation 
of NFAT-1-driven Luc expression was inhibited by TRIM22 down to basal 
level transcription (from 6791±923 RLU upon PMA+I stimulation to 
1890±207 RLU for PMA+I stimulation in presence of TRIM22 vs. 
1832±149 RLU for basal activity). Stimulation with PMA alone did not 
induce NFAT-1-driven Luc expression, while Ionomycin did, although to a 
lesser extent than what observed in the presence of PMA+I. Interestingly, 
TRIM22 was able to inhibit also this activation. Overall, our results strongly 
indicate that TRIM22-mediated inhibition of HIV-1 transcription occurs 
through impairment of NFAT1-dependent activation of the proviral LTR. 
We are currently investigating whether a direct interaction between 
TRIM22 and NFAT-1 occurs and whether other molecular partners are 
involved. 
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INI1/hSNF5 is a host protein that directly binds to HIV-1 integrase (IN) and 
is selectively incorporated into HIV-1 virions. The minimal IN-binding 
fragment of INI1, S6, potently inhibits HIV-1 late events (Yung et al. Nat. 
Med. 2003). INI1 and IN directly bind to SAP18 (Sin3a associated protein 
18kD), a component of the HDAC1 complex, and selectively recruits a 
Sin3a-HDAC1 complex into HIV-1 (but not SIV) virions in an HIV-1 IN-
dependent manner (Sorin/Cano et al PLoS pathogens 2009). 
 
To determine the significance of the INI1-SAP18 association, we isolated a 
panel of SAP18 interaction defective mutants of INI1 (SID-INI1*) using a 
reverse yeast two-hybrid system. Two mutants [INI1(G66A,V333E) and 
INI1(N149S,R239I)] that were stably expressed in both yeast and 
mammalian cells and selectively defective for binding to SAP18, but not for 
interaction with IN or c-MYC, were used for further study. Similar to our 
earlier report of transdominant negative effect of S6, co-transfection of SID-
INI1* mutants along with HIV-1 viral vectors resulted in potent inhibition 
of HIV-1 particle production, 100-1000 fold, compared to either the wild 
type or the empty vector control. Expression of SID-INI1* resulted in 4-6 
fold reduction in intra-cellular viral mRNA but ~100-fold reduction in viral 
protein levels. Determining the ratio of intracellular p24 to virion associated 
p24 indicated a further block in particle release. Analysis of LTR 
transcription indicated that while INI1 repressed basal as well as Tat-
mediated LTR transcription, SID-INI1* mutants did not repress 
transcription, consistent with the recruitment of HDAC1 complex (and thus 
repression) by wild type INI1 but not by the SID-INI1*. Lastly, expression 
of SID-INI1* mutants did not affect nuclear export of viral RNA. These 
results together indicate that SID-INI1* mutants do not block viral 
transcription or RNA transport but block multiple steps of late events 
including viral RNA stability and viral protein translation and/or stability, 
assembly and particle release. These studies, for the first time, indicate that 
INI1-SAP18 interaction is required for late events of HIV-1 replication and 
that mimicking the effect of SID-INI1* mutants can be a new strategy to 
potently inhibit HIV-1 replication. 
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Human T lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) are capable 
of transforming and immortalizing T lymphocytes. HTLV-1 is highly 
pathogenic and causes ATL and HAM/TSP. HTLV-2 is rarely pathogenic and 
sporadically associated with neuropathies. Both in vitro and in vivo studies 
indicate that HTLV-1 has a preferential tropism for CD4+ T cells while HTLV-
2 for CD8+ T cells, yet the precise mechanisms for this differential tropism is 
poorly understood. We have already shown that the transformation tropism 
maps to the viral envelope. The viral envelope has two glycoproteins – surface 
(SU), which binds to cell receptor and transmembrane (TM), which triggers the 
fusion of the viral and cellular membranes, facilitating virus entry. Therefore, 
we aimed to further map the molecular determinant of the viral envelope, SU 
and TM components, of HTLV-1, in the context of the entire provirus for their 
contribution to the transformation tropism. HTLV-1 proviral recombinants with 
the HTLV-2 env sequences (SU2 or TM2) were generated. Both HTLV-1/SU2 
and HTLV-1/TM2 recombinants showed Tax activity in transiently transfected 
cells, and produced p19 Gag levels that were proportional to wt virus in both 
transiently and stably transfected cells. Both HTLV-1/SU2 and HTLV-1/TM2 
recombinant viruses were replication competent and transformed T cells in 
vitro. T cell phenotyping of these transformed T cells revealed that both HTLV-
1/SU2 and HTLV-1/TM2 recombinant viruses shifted the cellular tropism of 
wtHTLV-1 from CD4+ T cell predominance to CD8+ T cell predominance, 
which was comparable to wtHTLV-2. Thus, our data indicates that although 
only SU binds to the cellular receptor, both SU and TM contribute to the 
transformation tropism. Our results in the context of the provirus reiterates the 
in vitro binding studies indicating that the HTLV-1 SU component is 
responsible for the preferential binding to CD4+ T cells. This implicates that the 
transformation tropism of HTLV-1 is indeed dictated at the receptor binding 
stage. Our data also suggests that TM component plays a significant role in 
conferring this tropism. Whether TM complements SU at the receptor binding 
stage to confer tropism or, there are additional determinants at the post-entry 
level conferring this tropism irrespective of the role of SU is yet to be explored. 
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In addition to activities needed to catalyze integration, retroviral integrases 
have a nonspecific endonuclease activity (J Virol 70:2598, 1996) that is 
enhanced by certain small compounds (J Biol Chem 276:114, 2001). These 
facts suggest a novel antiviral strategy in which integrase is stimulated to 
damage viral DNA before integration occurs (with any damage to cellular 
DNA being limited to cells that had just been entered by the virus and thus 
also blocking infection). In fact, we have found that noncytotoxic 
concentrations of some integrase stimulator (IS) compounds inhibit the 
replication of Rous sarcoma virus and human immunodeficiency virus. To 
identify additional IS compounds that induce integrase to nick DNA 
nonspecifically, we obtained support from the NIH Microbicide Innovation 
Program (R21AI075929) and developed a nonradioactive assay that is 
suitable for high-throughput chemical screening (Anal Biochem 396:223, 
2010). The assay uses a 49-mer oligonucleotide that is 5'-labeled with a 
fluorophore, 3'-tagged with a quencher, and designed to form a hairpin that 
mimics the radioactive double-stranded substrates in gel-based nicking 
assays. Reactions are conducted in 384-well plates, then analyzed on a real-
time PCR machine after a single heat denaturation and subsequent cooling 
to a point between the melting temperatures of unnicked substrate and 
nicked products (no cycling is required). Under these conditions, unnicked 
DNA reforms the hairpin and quenches fluorescence, whereas completely 
nicked DNA yields a large signal. The assay was linear with time, 
stimulator concentration, and amount of integrase, and 20% concentrations 
of dimethylsulfoxide (the solvent for many chemical libraries) did not 
interfere with the results; it also had an excellent Z'-factor and reliably 
detected known IS compounds. We are currently using this assay to screen a 
library of 50,000 drug-like chemicals to identify additional IS compounds 
for the novel antiviral strategy of stimulating integrase to destroy retroviral 
DNA. 
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Background: APOBEC3 proteins are cytidine deaminases that can provide 
intrinsic immunity against a broad range viruses and retrotransposons. The 
best-characterized member of this enzyme family is human APOBEC3G, 
which can restrict the infectivity of Vif-deficient HIV and introduce harmful 
hypermutations in the single-stranded DNA replication intermediates of the 
virus. Endogenous mouse APOBEC3 has been shown to restrict murine 
retroviruses such as Friend MLV and the mouse mammary tumour virus, 
but in absence of detectable levels of deamination. AKV is an endogenous 
leukemogenic retrovirus of the AKR mouse strain. In this study, we 
investigate whether sensitivity of AKR mice to AKV could in part be 
explained by a failure of the APOBEC3 allele expressed in these mice to 
restrict AKV. 
 
Materials and methods: In vitro assays were performed by infecting NIH 
3T3 cells with viruses produced in 293T cells transiently expressing 
APOBEC3 proteins. Ex vivo infection assays were performed by infecting 
lymphocytes isolated from the spleens of various mouse strains or from 
those of APOBEC3-deficent mice. FACS analysis was used to measure the 
infectivity of eGFP-expressing indicator viruses in NIH 3T3 target cells.  
 
Results: Here we show that endogenous APOBEC3 can inhibit the 
infectivity of the AKV murine leukemia virus, and that this restriction is 
associated with hypermutations in the retroviral genome that are attributable 
to the deaminase activity of APOBEC3. This restriction, however, is highly 
dependent on the level of APOBEC3 mRNA expression which appears to 
be particularly low in AKR mice and polymorphic amongst various mouse 
strains. 
 
Conclusions: Our findings demonstrate that APOBEC3 confers an effective 
protection to mouse lymphocytes against retroviral pathogens when 
expressed at sufficient levels, and also provide good support to the proposal 
that APOBEC3-mediated hypermutation may have contributed to murine 
retroviral genome evolution. 
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HIV-1 reverse transcription is an essential step in the HIV-1 viral lifecycle, 
and both its efficiency and fidelity are directly dependent upon the cellular 
2’-deoxy ribonucleotide triphosphate (dNTP) concentration. Reverse 
Transcriptase (RT) exhibits high dNTP binding affinity which facilitates 
replication in macrophages with low dNTP pools, and are thought to be a 
potential reservoir in the host. Moreover HIV-RT is an error prone 
polymerase relative to those responsible for both bacterial and eukaryotic 
genome replication, and is thought to be a prominent driver of viral 
mutagenesis resulting in the viral diversity required for drug resistance and 
immune evasion. 
Here, we hypothesize that the HIV-1 replication is more error-prone in 
macrophage than activated CD4 T cells due to: i) extremely low dNTP 
concentration in macrophage, which induces RT pausing known to generate 
mutational hot spots, ii) imbalanced dNTP pools, and iii) higher 
incorporation of ribonucleotide triphosphates (rNTPs) as a consequence of 
rNTP/dNTP ratio in macrophage relative to known RT kinetic properties. 
First, we have measured the dNTP and rNTP pools with LC/MSMS in both 
cell types, which facilitates direct simulation of biologically relevant 
substrate conditions in all biochemical experiments. Second, using the 
estimated cellular nucleotide concentrations, we found that HIV-1 RT 
synthesizes more mutations in macrophage dNTP pools than in the 
activated CD4 T cell dNTP pools with a M13 lacZα forward mutation 
assay. Interestingly, the macrophage dNTP pools generate fourfold more 
point mutations than frame-shift mutations, while the T cell dNTP pool 
produces a similar ratio between point mutations and frame shift mutations. 
Third, we observed that HIV-1 displays an equal incorporation efficiency of 
both dNTP and rNTP at their concentrations found in macrophages. We are 
currently investigating the impact of rNTP incorporation on DNA 
polymerization kinetics and mutation synthesis both biochemically with 
appropriate cellular substrate pools and in biologically relevant primary 
human cells. Study of mutation rate in HIV-1 target cells will provide 
valuable insight into viral diversity generation, replication, and persistence 
in the host.  
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An immunocompetent, permissive small-animal model would be valuable 
for the study of HIV-1 pathogenesis and for the testing of drug and vaccine 
candidates. However, the development of such a model has been hampered 
by the inability of primary rodent cells to efficiently support several steps of 
the HIV-1 replication cycle. Although transgenesis of the HIV receptor 
complex and human Cyclin T1 have been beneficial, additional late-phase 
blocks prevent robust replication of HIV-1 in rodents and limit the range of 
in vivo applications. In this study, we explored the HIV-1 susceptibility of 
primary T-cells and macrophages derived from New Zealand white rabbits.  
Envelope-specific and co-receptor-dependent entry of HIV-1 was achieved 
by expressing human CD4 and CCR5. A block at HIV-1 DNA synthesis, 
likely mediated by rabbit TRIM5, was overcome by limited changes to the 
HIV-1 gag gene. Unexpectedly and in stark contrast to mice and rats, 
primary cells from rabbits fully supported the functions of the regulatory 
viral proteins Tat and Rev, Gag processing, and the release of HIV-1 
particles at levels comparable to human cells. While HIV-1 produced by 
rabbit T-cells was highly infectious, a macrophage-specific infectivity 
defect was identified that became manifest by a novel pattern of 
hypermutations. These results reveal an extraordinary natural HIV-1 
permissivity of the rabbit species. Receptor complex transgenesis combined 
with modifications in gag and possibly vif to evade species-specific 
restriction factors might render lagomorphs fully permissive to infection by 
this pathogenic human lentivirus.  
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Previous studies indicate that the HIV-1 structural protein Gag drives virus 
assembly, and its expression alone is sufficient to form virus like particles. 
However, current understanding of the mechanism(s) by which Gag 
localizes to the site of virus assembly is limited. In primary T-cells, T-cell 
lines, as well as epithelial cell lines that support viral replication, virus 
assembly is thought to occur at the plasma membrane. Alternatively, in 
primary human macrophages, virus assembly has been reported to occur on 
late endosomes as well as at the plasma membrane. Additional studies 
indicate that Gag co-localizes with late endosomes in a variety of cell types, 
regardless of the intracellular site of virus assembly, which suggests a 
functional role for late endosomes in the viral replication cycle.  
 
Adaptor protein (AP) complexes 1 and 3 have been reported to mediate Gag 
trafficking to late endosomes through a direct interaction of their subunits μ 
and δ, respectively, with the matrix region of Gag. Disruption of the AP-
1μ/Gag or AP-3δ/Gag interactions has been shown to reduce Gag co-
localization with late endosomes and lead to a block in particle production. 
Taken together, these results strongly suggest that AP-1 and AP-3 play key 
roles in the late stage of viral replication. However, the role of AP-1 or AP-
3 in HIV-1 replication has not been demonstrated in natural host cells or in 
cells that support virus assembly on late endosomes. In this study, we ablate 
endogenous AP-1μ or AP-3δ function using RNA interference, and analyze 
HIV-1 replication and the intracellular localization of Gag in primary 
human macrophages. 
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Upon entry into the host cell, retrovirus undergoes uncoating of the viral 
casid and completes generation of reverse-transcripts to form the pre-
integration complex (PIC), which delivers retroviral reverse transcipts into 
the host genome. The host cellular factor, TRIM5α, was discovered to block 
retroviral infection in species-specific manner. How TRIM5α blocks the 
infection is a still unsolved question.  
As a member of the tripartite motif (TRIM) family of proteins, TRIM5α 
contains RING, B-box, coiled coil, and B30.2 domain. Each of these 
domains has its own function(s) contributing to the ability of TRIM5α to 
block retrovirus infection. B30.2 domain has been suggested to recognize 
the incoming sensitive viral capsid. The coiled coil domain is responsible 
for multimerization to form trimer. B-box also has been reported to be 
essential for retroviral restriction. The N-terminal RING domain has E3 
Ubiquitin ligase activity. However the precise role of the RING domain that 
plays in retroviral restriction has not been addressed. Recently, effect of 
proteasome inhibitor on HIV-1 infection was reported, suggestting that 
ubiquitin-related pathways might be involved in retroviral restriction. In an 
effort to address what functions TRIM5α RING domain has and how these 
functions are connected to viral restriction, we found that one amino acid 
change within RING domain switched on and off the restriction ability of 
some TRIM5α against HIV-1/SIV without affecting functions mediated by 
other domains. By using series of mutants within the RING domain, 
chimera proteins, and other biochemical assays, we investigated the 
relationship between HIV-1/SIV restriction and in vitro E3 ligase activity 
mediated by RING domain. Several evidences not only confirm some of 
effects of proteasome inhibitors on viral restriction, but also extend further 
our understandings on how TRIM5a blocks retroviral infection. 
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Bst-2, also known as tetherin, is an interferon-inducible antiviral host factor 
that blocks the release of HIV and other retroviruses. HIV-1 Vpu 
antagonizes Bst-2 via inducing its β-TrCP-dependent degradation and/or 
sequestration. Vpu antagonizes only against human Bst-2 (huBst-2), but not 
Bst-2 proteins derived from other species such as African green monkey 
Bst-2 (agmBst-2). It was previously reported that the transmembrane 
domain (TM) of Bst-2 defines this species-specific antagonism. However, it 
remains unclear how Vpu recognizes the TM domain of huBst-2. In this 
study, we performed a series of mutagenesis analysis to determine the 
region in Bst-2 which is responsible for its species-specific interaction to 
Vpu. We developed a novel technique based on bi-molecular fluorescence 
complementation (BiFC). The amino- and carboxy- terminal fragments of 
Kusabira-Green fluorescent protein (KGN and KGC) were individually 
fused to Bst-2 and codon optimized Vpu proteins. Bst-2 and Vpu interaction 
facilitated association of the KG fragments to produce a stable fluorophore. 
Using KGN-Vpu-stably expressing HEK 293 cells, we were able to 
quantify the amount of Bst-2 and Vpu complex in live cells. A series of 
KGC-tagged plasmids encoding mouse Bst-2-based chimeras with 
substitutions involving corresponding domains from reciprocal huBst-2 
were transfected into the KGN-Vpu-expressing cells. As expected, mouse 
Bst-2-based chimeras only replaced with the reciprocal TM of huBst-2 
significantly provided a KG fluorophore signal. We further performed 
alanine-scanning mutagenesis within the huBst-2 TM. The results led to the 
identification of several a.a. residues as interaction motif to Vpu. 
Interestingly, this motif was highly conserved among primate Bst-2, 
although the ability of agmBst-2 to interact Vpu was clearly lower than that 
of huBst-2. We hypothesized that this difference of Vpu interaction 
efficiency is due to the interface change within α-helix structure of TM 
domain by the two a.a. insertion. We generated the a.a.-inserted agmBst-2 
mutant (agmBst-2 LL) and analyzed the Vpu interaction to detect the effects 
of the insertion. The ability of agmBst-2 LL to interact Vpu was 
significantly augmented compared to that of agmBst-2, suggesting that the 
presence of two amino acids is critical for both specific interaction and as a 
space holder. These data implicates that Vpu is specifically adapted to 
interact huBst-2 by recognizing its TM sequences and contributes to the 
efficient replication of HIV-1 in human cells. 
 157 
STRUCTURAL INSIGHTS INTO CO-EVOLUTION OF THE P1-P6 
CLEAVAGE SITE AND NELFINAVIR-RESISTANT HIV-1 PROTEASE. 
 
Madhavi Kolli, Celia A Schiffer  
 
University of Massachusetts Medical School, Biochemistry and Molecular 
Pharmacology, Worcester, MA, 01605 
 
Background. The evolution of resistance against anti-retroviral therapy is a 
major obstacle in the treatment of HIV-1 infection. HIV-1 protease is an 
important therapeutic target as its function is essential for viral maturation. 
However, the selective pressure of protease inhibitor therapy results in a 
wide spectrum of mutations that confer resistance to nearly all drugs in this 
class. Furthermore, the virus also evolves mutations within the Gag 
polyprotein, which sometimes correlate with known sites of resistance in 
the protease. Previously we showed that Gag L449F and S451N mutations 
within p1-p6 cleavage site of Gag co-evolve with the nelfinavir-resistant 
D30N/N88D protease variant. We present here structural changes resulting 
from this co-evolution. 
Methods. In this study, X-ray crystallography was used to investigate in 
detail the structural changes resulting from co-evolution of p1-p6 cleavage 
site. Structures of WT and nelfinavir-resistant protease in complex with p1-
p6 peptide variants were determined and compared to WT protease in 
complex with the WT p1-p6 peptide.  
Results. In the WT protease, Asp30 interacts with Arg 452 within the p1-p6 
cleavage site. The D30N mutation disrupts this interaction and causes 
arginine to adopt new orientation. However, this loss of interaction is 
compensated by the co-evolving L449F and S451N mutations in the p1p6 
cleavage site, which significantly increase available surface area for 
interaction with the protease. Increased interactions were also observed 
between Asp 29 and Ile 50 of the protease and the p1-p6 peptide. 
Conclusions. These results suggest that the reduced interactions with p1-p6 
peptide resulting from D30N/N88D protease mutations are partly 
compensated by additional changes within this cleavage site. These findings 
highlight the interdependency of interactions between HIV-1 protease and 
the p1-p6 substrate. In conclusion, this study provides a rationale for 
substrate co-evolution and the impact this has on resistance to anti-retroviral 
therapy. 
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An infectious HIV-1 virion incorporating a fluorescent marker allows us to 
visualize the viral entry in living cells. To generate a high titer infectious 
virus containing more than a thousand GFP molecules per virion, we 
genetically engineered amino-terminus of HIV-1 Gag.  
 
In a previous study, we showed that substitution of the HIV-1 Gag 
myristoylation signal with the phospholipase C (PLC)-delta 1 pleckstrin 
homology (PH) domain or attachment of heterologous myristoylation 
signals on the amino-terminus of Gag increased the production of the HIV-
1-based lentiviral vector (Urano et al, J Gen Virol 2008; Aoki et al, in 
submission). The infectivity of these pseudovirions was comparable to that 
of the wild type. These data suggest that the addition of foreign proteins at 
the amino-terminus of Gag do not damage the viral infectivity. We 
therefore tested whether the attachment of GFP at the amino-terminus of 
Gag is able to produce infectious pseudovirion. 
 
We constructed two mammalian gag-pol expression plasmids, myr-GFP-
gag-pol and GFP-PH-gag-pol. The former has lyn myristoylation signal 
attached to the amino-terminus of GFP-gag. The latter has GFP fused to the 
PH-gag-pol construct (Urano et al, J Gen Virol 2008). The gag-pol is 
human codon-optimized, and the original start codon of Gag is destroyed. 
Expressed in 293T cells, the majority of the mutant Gag/Gag-pol proteins 
were distributed to the plasma membrane similar to Gag-GFP as judged by 
the GFP fluorescence. The VLP production by the mutant gag-pol was 
verified by Western blotting, and visualized under the confocal microscopy. 
The efficiency of VLP prduction by the mutants was reduced by 2-fold 
compared with the WT. The pseudovirions produced by these mutants were 
infectious. The infectivity of mutant viruses relative to the WT is under 
evaluation. The proviral construction bearing similar genetic modifications 
is underway. The high titer "bright" virions containing approximately 3,000 
GFP molecules per virion should be useful in single virus tracking studies. 
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Many mutations in the highly conserved membrane-spanning domain 
(MSD) of the HIV-1 gp41 negatively affect the efficiency of membrane 
fusion. However, the exact mechanism is not well understood. In this study, 
we applied a novel cell-based fusion assay to analyze mutants of gp41 
MSD. The new assay allows us to perform a real-time kinetic assay of 
membrane fusion in a simple manner. This system relies on the recovery of 
the functions of a pair of split proteins composed of split Renilla luciferase 
(Rluc) and split green florescent protein (GFP). These reporters recover 
both RL and GFP functions upon reassociation and hence named dual split 
proteins (DSPs). One of DSPs was expressed in 293FT cells together with 
HIV-1 Env, and the other was expressed in 293CD4 cells. These cells were 
cocultured to induce membrane fusion and the process was monitored 
continuously. Several gp41 mutants were analyzed: some of which have the 
entire MSD replaced with heterologous MSDs and others carry point 
mutations of the conserved arginine residue in the middle of the MSD. All 
these mutants showed slower kinetics of membrane fusion as compared 
with the wild type. This tendency was more prominent in the mutants 
carrying heterologous MSDs. The preliminary data suggest that these 
mutants have the defect in conformational changes during membrane 
fusion. Thus, the mutations within the MSD seem to cause an allosteric 
negative effect on the extracellular portion of HIV-1 Env. 
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The HIV-1 accessory protein Vpu antagonizes the restriction of retroviral 
particle release by Tetherin (CD317/BST2) and mediates its cell surface 
removal and degradation. Vpu localizes to multiple membrane 
compartments, including the Trans-Golgi Network (TGN). Recent evidence 
suggests that TGN localization of Vpu is important for tetherin antagonism, 
but the subcellular trafficking of Vpu is undefined. Addition of an 
endoplasmic reticulum (ER) retention signal (KKDQ) to the C-terminus of 
Vpu blocked its ability to antagonize tetherin-mediated restriction, implying 
that post-ER trafficking of Vpu is essential for its function. We found that 
Vpu localizes to compartments that contain the cation-independent 
mannose-6-phosphate receptor (CI-MPR), suggesting a dynamic trafficking 
of Vpu between TGN and endosomal compartments. Consistent with this, 
we have identified a conserved variant of an acidic/di-leucine sorting signal, 
ExxxLV, in the second alpha-helix of the Vpu cytoplasmic tail. Targeted 
disruption of this sequence in the HIV-1 NL4.3 Vpu protein led to its 
accumulation in endosomal compartments. Furthermore, mutation of the 
ExxxLV motif impaired the ability of Vpu both to rescue HIV-1 particle 
release in the presence of tetherin, and also to downregulate cell-surface 
tetherin levels. Interestingly, in the presence of wildtype Vpu, tetherin itself 
localizes predominantly to the TGN. Since D/ExxxL(L/I/V) sorting motifs 
are known to interact with multiple clathrin adaptors to mediate trafficking 
of membrane proteins between the endosome and TGN, these data indicate 
that the ability of Vpu to traffic between these compartments is required for 
its anti-tetherin activity, potentially to block tetherin recycling to the plasma 
membrane. The roles of cellular factors known to be required for these 
processes are currently being investigated. 
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The HIV-1 Gag polyprotein precursor is responsible for directing virus 
assembly and release, and contains domains that mediate specific steps in 
the pathway of virus production. The p6 domain of HIV-1 Gag is required 
for virus budding. Small peptide motifs in p6, known as “late” or “L” 
domains, promote the release of virions from infected cells by interacting 
directly with host cell factors. Specifically, a Pro-Thr-Ala-Pro (PTAP) motif 
binds the ESCRT-I component Tsg101 and a Tyr-Pro-Xn-Leu (YPXnL, 
where X is a variable residue and n is 1–3) motif binds Alix, a protein that 
interacts with both ESCRT-I and ESCRT-III. The primary Alix binding 
sequence is located near the C-terminus of p6, where p6-Y36, L41, and L44 
are particularly critical for Gag–Alix binding. Previous work from our lab 
has demonstrated a functional role of p6–Alix binding in HIV-1 particle 
production and replication. Specifically, mutations were introduced at 
residues Y36, L41 and L44 in p6 to characterize the effects on 1) binding to 
the Alix-V domain, 2) HIV-1 Gag processing and virus release, 3) 
replication kinetics in a variety of relevant cell types, 4) virion 
morphogenesis and 5) single-cycle infectivity. One of the most striking 
results was the severe delay in virus replication in Jurkat T cells induced by 
these mutations. Viruses collected at the delayed replication peaks 
demonstrated enhanced replication kinetics upon re-passaging to fresh 
Jurkat T cells relative to the original mutants. Sequencing of the putative 
revertant isolates revealed several mutations mapping to gp120, gp41 and 
Vpu. We have confirmed that the Env and Vpu mutations do indeed 
compensate for the effects of the p6 mutations on virus replication, and 
have characterized the effects of the Env and Vpu mutations on HIV-1 Gag 
processing and virus release in HeLa cells. We have also examined the 
effect of these compensatory mutations in single-cycle infectivity, cell-free 
infection and cell-to-cell infection of relevant cell types. We propose that 
defects in cell-to-cell transmission induced by mutations in the p6 Alix 
binding site are rescued by the substitutions in Env and Vpu. 
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EARLY EVENTS IN HIV-1 ASSEMBLY AND RNA PACKAGING 
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HIV-1 Gag polyprotein is the only viral protein that is required for particle 
assembly and drives a number of different events during this process. 
Although we have a reasonable understanding of the molecular details of 
events that take place at the late stages of HIV assembly, the early assembly 
processes mediated by Gag are still not well defined. In this regard, an 
important question is where in the cell Gag initially interacts with the viral 
RNA. A second key question is whether Gag-RNA interaction requires or 
induces higher order Gag multimerization in cells. To address the first 
question, we developed an assay in which RNA-immunoprecipitation was 
coupled with membrane flotation analysis in transfected or infected cells. 
We found that Gag-RNA interaction takes place in the cytoplasm, is 
independent of the ability of Gag to localize to the plasma membrane, but 
was influenced by the C-terminal domain (CTD) of capsid (CA), which 
mediates multimerization of Gag in virions. Specifically, the absence of the 
CA CTD does not lead to a defect in recruitment of viral RNA to the plasma 
membrane. However, the formation of a stable immunoprecipitable 
complex containing Gag and viral RNA at the plasma membrane required 
intact CA.  
 
In an attempt to address the second question, we employed a cross-linking 
based Gag multimerization assay, coupled to membrane flotation analyses. 
These assays indicated that Gag is present as monomers and low order 
multimers in the cytoplasm, but does not form higher-order multimers in the 
cytoplasm. Rather, higher order multimers formed only in the plasma 
membrane fractions, and when Gag was able to bind to membrane. Taken 
together, our results suggest that the initial site of Gag-RNA interaction is 
the cytoplasm, involves Gag monomers or low order multimers and that 
these interactions per se do not induce or require higher order Gag 
multimerization in the cytoplasm. Instead, membrane interactions appear to 
be required to induce higher order Gag multimerization in cells. 
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ANALYSIS OF THE INTERACTION OF WILD-TYPE AND MUTANT 
HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 PROTEASE WITH HIV-
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Human T cell leukemia virus type 1 (HTLV-1) has infected >30 million 
individuals worldwide, of which up to 3-5% will develop an aggressive and 
terminal adult T-cell leukemia for which there is currently no effective 
treatment. The HTLV-1 protease has been reported to be resistant to all 
commercial HIV-1 protease inhibitors. And while HTLV-1 infections can 
be treated with HIV-1 reverse transcriptase inhibitors, resistance has 
developed. The X-ray crystal structure of HTLV-1 protease with a bound 
peptidomimetic inhibitor was solved. Using this structure, the interaction of 
the HTLV-1 protease with commercial HIV-1 protease inhibitors was 
analyzed using computational chemistry software. The interaction energy 
scores between the wild type and mutant HTLV-1 proteases and 
commercial HIV-1 protease inhibitors were calculated and revealed that 
both proteases bound with a similar strength to the inhibitors, using 
structurally equivalent residues/atoms. The HTLV-1 PR was then mutated 
to test whether binding to HIV-1 PR inhibitors could be increased. An in 
vitro fluorescent assay was then used to quantitate the wild-type and mutant 
HTLV-1 PRs binding to HIV-1 inhibitors. This work is directed at 
understanding how HTLV-1 protease interacts with native substrates and 
HIV-1 protease inhibitors, so that effective therapies can be developed to 
target the HTLV-1 PR and control HTLV-1 infections. 
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IDENTIFICATION OF AN APOBEC3 RESIDUE THAT SEPARATES 
CELLULAR LOCALIZATION FROM HIV-1 RESTRICTION 
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APOBEC3B and APOBEC3G are both double domain cytidine deaminases, 
sharing 68% amino acid similarity. APOBEC3G is a cytoplasmic protein 
with potent HIV-1 restrictive ability, while APOBEC3B predominantly 
resides in the nucleus and is a comparatively weak restrictor of HIV-1. 
Current models suggest that cytoplasmic APOBEC3G is packaged into 
assembling HIV-1 particles en route to infection of an unsuspecting target 
cell where retrovirus restriction by cytidine deamination occurs during 
reverse transcription. Thus, it is tempting to hypothesize that cellular 
localization is a property that determines which APOBEC3 can restrict 
HIV-1. Here, we identify a residue in APOBEC3B that when mutated to 
match its counterpart in APOBEC3G, allows APOBEC3B to become a 
potent HIV-1 restrictor. Surprisingly, this APOBEC3B variant retains 
nuclear localization. These data suggest that an as yet unidentified 
mechanism exists to target the APOBEC3 proteins to their retroviral 
substrates. These results have implications for endeavors to boost the 
activity and/or expression of these potent deaminators for anti-viral 
therapeutic purposes. 
 
Selected reference: 
M.D. Stenglein, H. Matsuo and R.S.Harris. 2008. Two regions within the 
amino-terminal half of APOBEC3G cooperate to determine cytoplasmic 
localization. J.Vir. 82: 9591-9599. 
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The human Trim5 alpha protein possesses a capsid-specific restriction 
activity against a broad range of retroviruses, including a small effect on 
HIV-1. TRIM5 mRNA is up-regulated upon Type I IFN stimulation. This 
fact, along with other observations, stimulated a search for other links 
between TRIM5 and innate immune signal transduction. TRIM5 
knockdown was found to decrease the antiviral effect of LPS and other 
pathogen recognition receptor (PRR) agonists. Then the effect of TRIM5 on 
the activity of luciferase reporters for transcription factors involved in 
innate immunity was tested. TRIM5 overexpression had a modest 
stimulatory effect on NFkB (<5-fold) but a very strong induction of AP-1 
reporter (50 to 150-fold). The activity of different TRIM5 orthologues and a 
panel of TRIM5 mutants on AP1 reporter induction was tested next. The 
ability to induce the NfKB and AP1 reporters was conserved in TRIM5 
orthologues from macaques (Macaca mulatta), two species of african green 
monkey (Cercopithecus), and even the TRIM5-cyclophilin A fusion 
proteins of owl monkey (genus, Aotus) and macaque. In fact, the owl 
monkey fusion protein was ~5 times more potent than human Trim5 alpha. 
In future experiments we will map domains critical for these activities. 
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HDAC1 complex deacetylates histones to mediate transcriptional 
repression. However, HDAC1 complex also activates transcription of 
certain genes (e.g. interferon signal induced genes, ISGs) by deacetylating 
non-histone transcription factors (Jana et al Blood 2007; Nusinzon et al 
Science 2005). INI1/hSNF5, an HIV-1 IN binding protein, directly interacts 
with SAP18 (Sin3a associated protein 18kD), a component of the Sin3a-
HDAC1 complex and selectively recruits it to HIV-1 virions (Sorin/Cano et 
al PLoS pathogens 2009). INI1 transcriptionally activates ISGs including 
IFIT1, IFITM1, IFITM3, ISG15, PML and OAS etc. in INI1-/- cells 
(Morozov/Lee et al Clin. Can. Res. 2007). 
To determine the significance of INI1-associated SAP18-HDAC1 complex 
to interferon signaling, we isolated a panel SAP18 interaction defective 
mutants of INI1 (SID-INI1*), and tested them for ability to stimulate ISGs. 
We found that unlike wild type INI1, SID-INI1* were defective for 
activation of ISGs. In addition, we found that: (i) TSA (histone deacetylase 
inhibitor); (ii) siRNA to HDAC1; and (iii) expression of a dominant 
negative mutant of HDAC1 (HDAC1H141A) all inhibited INI1-medaited 
activation of ISGs. Furthermore, the addition of HDAC1 stimulated the 
INI1-mediated activation of ISGs. Chromatin-immunoprecipitation assay 
indicated that INI1 and SAP18 directly bind to IFITM1 promoter. SID-
INI1* mutants, while being able to bind to IFITM1 promoter, were unable 
to recruit SAP18 and HDAC1, indicating that interaction of INI1 with 
SAP18 is required for recruitment of HDAC1 complex to ISG promoter. 
These results, together, indicate that SAP18-HDAC1 complex is necessary 
for INI1-mediated induction of ISGs and provide direct evidence for co-
activator function of SAP18-HDAC1 complex. 
We have previously established that binding of IN to INI1 leads to 
encapsidation of INI1 associated SAP18-HDAC1 complex into HIV-1 
virions. We propose that depletion (and/or inactivation) of this complex in 
the producer cells, by IN, may inhibit interferon signaling. However, the 
knock-down of INI1 in target cells may lead to down-modulation of 
interferon signaling, and thus increased HIV-1 replication. 
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EFFECTS OF Β -ESTRADIOL ON THE SAFETY OF ANTI-HIV DRUGS 
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Background: Female hormones are known to play an important role in 
predisposition for many infectious diseases. Epidemiological study suggests 
there are gender effects in serum HIV-1 load.  
 
Objectives: To determine whether β-estradiol affects the replication of 
HIV-1 or the efficacy of a common anti-retroviral drug, Stavudine (D4T). 
To determine the effect of β -estradiol on metabolic conversion of D4T into 
active drug D4T-TP and critical enzymes involved in D4T metabolism.  
 
Methods: Human PBL from different donors or various T cell lines were 
infected with HIV-1 in the presence or absence of combinations of β-
estradiol and the anti-retroviral drug, D4T. After four and seven days in 
culture, supernatants were assayed for HIV-1 p24 protein. H9 cells were 
treated with radiolabeled (3H) D4T or radiolabeled (3H) thymidine in the 
presence and absence of β -estradiol and extracted at various time points to 
follow the metabolic conversion of D4T into the active metabolite and 
thymidine kinase activity.  
 
Results:. β-estradiol resulted in a modest inhibition of HIV-1 replication in 
male- and older-female-derived PBLs, but β-estradiol did not affect the 
HIV-1 P24 level in PBLs from female donors, suggesting that β-estradiol 
attenuates the anti-HIV-1 efficacy of D4T in primary PBLs in a gender- and 
age-specific manner.  
β-estradiol also inhibited HIV-1 replication and attenuated the anti-HIV-1 
efficacy of D4T in H9 cell lines, facilitating studies of mechanism. Results 
will be presented on the effects of β -estradiol on the level of the active drug 
metabolite D4T-TP and on the activity of thymidine kinase, which 
phosphorylates D4T to D4T-P.  
 
Conclusion: β -estradiol impairs the antiretroviral efficacy of D4T through 
affecting drug metabolism. To optimize antiretroviral drug therapy, it may 
be necessary to monitor patient hormonal status.  
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POLYMORPHISMS IN HUMAN APOBEC3H DETERMINE ITS 
SENSITIVITY TO VIF AND SUBCELLULAR LOCALIZATION: 
IMPLICATIONS FOR HIV-1 EVOLUTION 
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The APOBEC3 family of cytidine deaminases (APOBEC3A-H) restricts 
various retroviruses and retroelements by causing G-to-A hypermutation in 
the viral genome and other mechanisms. In order to replicate efficiently in 
vivo, retroviruses have evolved strategies to evade or counteract APOBEC3 
antiviral activities. HIV-1 encodes the viral Vif protein that binds and 
targets APOBEC3 for degradation. However, it is not completely clear how 
Vif counteracts multiple APOBEC3 proteins at once.  
Previous work in the lab has shown that APOBEC3H is polymorphic in 
humans, with four major population-dependent haplotypes that encode 
proteins with different levels of antiviral activity. Haplotype II, present 
most frequently in African populations, encodes the most stable protein and 
is most active against HIV-1. We recently showed that this APOBEC3H 
protein is mostly resistant to HIV-1 LAI Vif. In order to find Vif variants 
that can better counteract APOBEC3H, we characterized the evolution of 
vif alleles within individuals carrying haplotype II over the course of 
infection and found at least one individual where APOBEC3H is a driving 
force of Vif evolution. We mapped the Vif determinant important for 
functional interaction with APOBEC3H that is independent of Vif 
counteraction of APOBEC3G and 3F. Using recently developed 
monoclonal antibodies against endogenous APOBEC3H, we are 
investigating the tissue expression profile of APOBEC3H in individuals 
who are likely to encode the stable protein.  
Surprisingly, one of the polymorphisms in APOBEC3H that determines the 
stability of the protein is also responsible for the differential subcellular 
localization of the various human APOBEC3H proteins. We found that 
haplotype II encodes a cytoplasmic protein whereas the less active protein 
encoded by haplotype I is localized to both the cytoplasm and nucleus 
which could be potentially more mutagenic to host genome. The relevance 
of APOBEC3H localization to function is currently being explored.  
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Integrase, the HIV-1 enzyme that catalyzes integration, has been implicated 
to play other roles in the viral lifecycle. Integrase directly interacts with 
reverse transcriptase and can affect the activity of recombinant polymerase 
in vitro. Integrase mutant viruses that are defective for HIV-1 replication at 
steps other than integration are typed as class II, and reductions in the level 
of viral DNA synthesis is the most common class II mutant viral phenotype. 
Integrase has also been shown to interact with various elements of the 
cellular nuclear import machinery and some integrase mutant viruses show 
marginal defects at viral cDNA nuclear transport. A third phenotype 
commonly associated with class II mutant integrase viruses is defective 
virus assembly and/or release from cells. 
 
Integrase functions during integration as an obligate tetramer. Due to the 
relatively wide range of class II mutant phenotypes, we have investigated 
correlations between integrase multimerization, integrase activities, and the 
class II mutant phenotype. Eighteen integrase proteins derived from class II 
mutant viruses were purified following their expression in Escherichia coli. 
The purified proteins were assayed for integrase 3’ processing and DNA 
strand transfer activities using relatively short oligonucleotide donor DNAs 
and denaturing polyacrylamide gel electrophoresis that does not distinguish 
single viral DNA end integration from concerted integration of two donor 
DNA ends. The mutants were also tested for concerted integration activity 
using longer restriction fragment donor DNA or short oligonucleotide donor 
DNA in the presence of the LEDGFp75 integrase-binding cofactor. 
Integrase multimerization was detected following protein cross-linking. The 
results of these experiments will be discussed. 
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APOBEC3G (A3G) is a DNA cytidine deaminase that potently restricts 
HIV-1 and a variety of other retroelements. To identify small molecule 
inhibitors of A3G activity, we have developed, optimized and miniaturized 
a fluorescence-based single-strand DNA deaminase assay (1, 2). We used 
this assay to screen several small chemical libraries in collaboration with 
the Institute for Therapeutics Discovery and Development at the University 
of Minnesota. Thus far, we have evaluated approximately 6,000 compounds 
and we have identified 64 that appear to specifically inhibit A3G DNA 
deaminase activity. Kinetic, specificity, and NMR binding data indicate that 
low micromolar concentrations of these chemicals block activity by several 
distinct mechanisms. We will discuss these data and the results of cell-
based studies currently in progress. We anticipate that these compounds will 
become useful chemical probes in the ongoing efforts to elucidate the A3G-
dependent HIV-1 restriction mechanism. 
 
 
Selected References 
1. Thielen BK, Klein KC, Walker LW, Rieck M, Buckner JH, Tomblingson 
GW, Lingappa JR. 2007. T cells contain an RNase-insensitive inhibitor of 
APOBEC3G deaminase activity. PLoS Pathog. 3:1320-34. 
 
2. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. 2010. APOBEC3 
proteins mediate the clearance of foreign DNA from human cells. Nat 
Struct Mol Biol. 17:222-9. 
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Foamy viruses (FV) are complex retroviruses that display numerous unique 
features distinguishing them from all other retroviruses. FV Pol is expressed 
independently of Gag, and both Gag and Pol undergo only single cleavage 
events. Therefore, the mature FV Gag protein does not consist of the matrix, 
capsid, and nucleocapsid (NC) proteins as in orthoretroviruses. Furthermore 
the putative NC domain of FV Gag lacks the hallmark Cys-His motifs that 
are otherwise essential at different steps of the viral replication cycle, like 
reverse transcription, infectivity, RNA packaging, integration and viral 
assembly. However, FV Gag contains three glycine-arginine-rich boxes 
(GR boxes) instead that might resemble a functional equivalent to the Cys-
His motifs. We used a transcriptional independent 4-Plasmid prototype FV 
(PFV) vector system to analyze deletion and substitution mutants of each 
GR box for particle release, particle protein composition, nucleic acid 
content, infectivity and intracellular localization. While viral particle release 
and particle protein composition are not affected by the mutations; DNA 
content and infectivity are severely reduced for deletion mutants and not 
detectable for full-length substitution mutants. Substitutions with shorter 
fragments then the original GR box show an intermediate phenotype. In 
addition GR box II mutants lack nuclear localization potential. Furthermore 
we show that the deficiency phenotypes are at least partially rescued by 
substitution of one GR box with another. Thus it appears that just like the 
Cys-His motifs in orthoretroviruses the PFV Gag GR boxes have numerous 
functions at different steps of the viral life cycle. 
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Jaagsiekte sheep retovirus (JSRV) and enzootic nasal tumor virus (ENTV) 
are two closely related betaretroviruses that cause contagious lung and nasal 
tumors in sheep and goats, respectively. One unusual feature of these two 
acutely transforming retroviruses is that, in addition to mediating viral entry 
their envelope proteins also act as potent oncogenes eliciting oncogenic 
transformation in vitro and in vivo. We and others previously reported that 
the cytoplasmic tails (CTs) of JSRV and ENTV Env proteins are critical for 
cell transformation in vitro, but whether or not these domains are sufficient 
for oncogenesis remains elusive. Here we have generated a series of 
chimeric Envs between JSRV/ENTV and an endogenous sheep retrovirus 
that is not oncogenic, and determined their oncogenic potentials in vitro and 
in vivo. We found that, despite their relative low surface expressions in the 
transfected cells, chimeras harbouring the CTs of JSRV/ENTV Envs were 
able to induce substantial transformation in dog MDCK epithelial cells and 
rat 208F fibroblasts. Importantly, subcutaneous injection of the transformed 
MDCK cells into nude mice readily induced tumor formations. In addition, 
we found that the signalling pathways activated in the chimeras-transformed 
cells paralleled those of cells transformed by the wildtypes, further arguing 
that CTs of JSRV and ENTV Envs alone are sufficient for oncogenic 
transformation. While prior results from our lab and others showed that the 
YXXM motif in the CTs of JSRV and ENTV Envs are essential for cell 
transformation, here we have found that restoration of this motif into the 
endogenous JSRV Env was unable to induce transformation, implying that 
other regions of JSRV and ENTV CTs are also important. Indeed, using 
serial truncation mutants we were able to identify a dileucine motif in the C-
terminus of JSRV Env CT to be critical for transformation. Structural 
analysis predicted that this dileucine motif is located at the immediate end 
of an extended alpha helix formed by the N-terminus of Env CT, separating 
it from the C-terminal random coils. Identification of cellular binding 
partners that directly interact with the JSRV and ENTV CTs will be crucial 
for fully understanding the mechanisms of JSRV/ENTV Env oncogenesis. 
 173 
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The HIV-1 cellular cofactor LEDGF/p75 is required for efficient viral DNA 
integration. Analysis of the HIV-1 cofactor activity of LEDGF/p75 mutants 
supports a chromatin tethering model, indicating that LEDGF/p75 acts as a 
molecular tether that interacts with HIV-1 integrase targeting the HIV-1 
pre-integration complex to the host chromatin. Our data have expanded this 
model by evidencing an active role of integrase during LEDGF/p75-
mediated chromatin tethering as well as by demonstrating the implication of 
chromatin tethering-independent mechanisms in the HIV-1 cofactor activity 
of LEDGF/p75. We have observed that deletion of the PWWP domain 
(PWWP) of LEDGF/p75 negligibly alters its HIV-1 cofactor activity 
despite decreasing its chromatin binding strength. A molecular explanation 
for these results comes from the analysis of the chromatin binding strength 
of the LEDGF/p75-integrase complex. Co-expression of LEDGF/p75 wild 
type or PWWP with HIV-1 integrase increased the chromatin binding 
strength of these cellular proteins. In the case of LEDGF/p75 PWWP, 
HIV-1 integrase rescued its chromatin binding strength to levels observed 
with the full-length protein. These evidences indicate that integrase can 
modulate the interaction of the LEDGF/p75-integrase complex with 
chromatin facilitating the HIV-1 cofactor activity of LEDGF/p75 PWWP. 
In support of the chromatin tethering-independent mechanism of 
LEDGF/p75 in HIV-1 DNA integration, we have observed that mutations in 
the CR1 or CR3 regions of LEDGF/p75 decreased its HIV-1 cofactor 
activity without affecting the interaction of LEDGF/p75 with chromatin 
and/or HIV-1 integrase as evaluated by multiple assays. In summary, our 
data illustrate the complexity of the molecular mechanism of LEDGF/p75 
in HIV-1 DNA integration. 
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We recently found and reported that the HIV-1 accessory protein Vpu is 
responsible for the known pseudotyping restriction between HIV-1 and the 
gibbon ape leukemia virus (GaLV) Envelope (Env) protein. Here we 
characterize factors required for this newly described restriction by Vpu. 
First, we investigated whether GaLV Env restriction is Gag dependent. 
Because we previously observed restriction in the context of HIV-1 and not 
MLV particles, we determined the sensitivity of another lentivirus, simian 
immunodeficiency virus (SIV), and an additional gammaretrovirus, RD114. 
In the presence of Vpu, GaLV Env pseudotyping was restricted with SIV 
particles but not RD114 particles. Because the matrix (MA) region of Gag 
is thought to interact with Env, we next tested the sensitivity of an MLV 
Gag chimera that contained the MA domain from HIV-1. This construct 
(HIV-1-MA/MLV) displayed HIV-1 like sensitivity to Vpu in our GaLV 
Env model. These data suggest that Vpu restriction occurs in a Gag 
dependent manner and that the MA domain contributes to this restriction. 
Second, we sought to determine the minimal regions of Vpu required for the 
GaLV Env incompatibility. Based on a series of Vpu cytoplasmic 
truncations and mutations, we found that removal of the Vpu C-terminal 
alpha-helix restored infectivity in GaLV Env/HIV-1 particles. We then 
tested a Vpu serine mutant (Vpu52/56) and a Vpu with a “scrambled” 
transmembrane domain (VpuRD) known to disrupt Vpu’s antagonism of 
CD4 and tetherin (BST-2), respectively. In our GaLV Env model, we found 
VpuRD, but not Vpu52/56, restricted infectious particle production. Previously 
we have shown that Vpu leads to a partial reduction in cellular GaLV Env 
protein, possibly the result of degradation. However, treatment of cells with 
either proteosomal or lysosomal inhibitors failed to restore the production 
of infectious particles, suggesting that degradation cannot fully explain 
incompatibility. However, like CD4, we found Vpu requires poly-
ubiquitination for GaLV Env restriction, although it is unknown whether 
GaLV Env is directly poly-ubiquitinated. Collectively, our findings indicate 
that Vpu’s mechanism for GaLV Env downmodulation appears to be 
distinct from the pathways previously described for modulation of CD4 and 
tetherin. 
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HIV-1 infected macrophages and microglia are long-lived viral reservoirs 
that persistently produce viral progenies. We previously demonstrated that 
HIV-1 infection promotes the stress-induced activation of the PI3K/Akt cell 
survival pathway in primary human macrophages, which extends the life 
span of these cells. This led us to determine whether various Akt inhibitors 
could affect survival of HIV-1 infected cells. Here, we examined the effect 
of one such class of drugs, alkylphospholipids (ALPs), on apoptotic cell 
death in human macrophages and a human microglial subline, CHME5, 
transduced with HIV-1 vector. We also explored Akt cell survival signals in 
transduced CHME5 cells, as well as the effect of ALPs on HIV-1 
production in human macrophages. Our findings revealed that the ALPs 
perifosine and edelfosine specifically induced death of HIV-1 infected 
primary human macrophages and CHME5 cells. Furthermore, these two 
compounds reduced phosphorylation of both Akt and GSK3β, a 
downstream substrate of Akt, in the transduced CHME5 cells. Additionally, 
we observed that perifosine effectively reduced viral production in HIV-1 
infected primary human macrophages. These observations confirm that the 
ALP compounds tested are able to inhibit the action of the PI3K/Akt 
pathway, therefore promoting cell death in HIV-1 infected macrophages and 
CHME5 cells transduced with HIV-1 vector. Pharmacological treatment 
with ALPs in HIV-1 infected patients would introduce the possibility of 
reducing the survival capacity of macrophage and microglial reservoirs, 
consequently decreasing viral production and release.  
 
*Authors contributed equally  
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Purified retroviral Gag protein can assemble in vitro to yield immature 
virus-like particles (VLPs). Despite little amino acid (AA) sequence identity 
in Gag, we show by electron cryo-tomography that the RSV Gag lattice is 
very similar to that previously reported for HIV-1 [1,2]. In both viruses, a 
prominent stalk-like density feature is apparent underneath the Gag 
hexamer, apparently formed by AAs just downstream of the folded CA-
CTD. We showed previously that in RSV, a 24 AA segment including the 
spacer peptide (SP) is critical for immature virus particle assembly. [3]. 
Secondary structure algorithms predict that this SP assembly (SPA) domain 
is an amphipathic helix, similar to predictions made earlier for HIV-1 [4]. 
We hypothesize that the stalk-like density feature corresponds to the SP 
assembly domain and that it holds the Gag hexamer together. 
 
To address this hypothesis, we have mutated individual AAs in the SPA 
domain to either Ala or Cys and assessed their role in in vitro assembly. The 
mutant proteins were expressed in E. coli, purified, and scored for their 
ability to assemble into VLPs. Mutations that abolish in vitro assembly are 
presumed to contribute to higher-order structures in VLPs. So far, the 
hydrophobic residues in the SPA domain do not tolerate mutations, but 
small, polar residues can be mutated without compromising assembly. 
These results are consistent with the hypothesis that the SPA domain forms 
a helix that interacts with adjacent SPA helices via hydrophobic 
interactions. We have modeled these interactions as a six-helix bundle like 
that in cucumber mosaic virus [5], as suggested originally by Wright et al 
[3]. Cysteine cross-linking and chemical modification experiments are in 
progress to test this model. 
 
1. Wright et al. (2007) EMBO J 26:2218; 2. Briggs et al. (2009) PNAS 106:11090; 
3. Keller et al. (2008) J Virol 82: 6788; 4. Morellet et al. (2005) Protein Sci 14:375; 
5. Smith et al. (2000) J Virol 74:7578. 
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We have recently shown that an LLDL sequence at the extreme C-terminus 
of FIV Gag is not required for virus release. However, we observe that FIV 
Gag LLDL mutants consistently fail to replicate efficiently in either feline 
kidney (CrFK) or T lymphocyte (MCH5-4) cell lines. Selection for second-
site revertants has revealed mutations in FIV Gag and Env that may restore 
virus replication. VSV-G-pseudotyped FIV Gag LLDL mutants exhibit a 
profound defect in specific infectivity when VLPs are produced in CrFK or 
HeLa cells, but, curiously, this infectivity defect is lost if virus is produced 
from 293T cells. Although no significant difference in VLP production is 
observed when the LLDL sequence is mutated, levels of RT detected in 
virions are consistently 2 to 3-fold lower than those in wild-type VLPs. 
Interestingly, the LLDL sequence fits the consensus for a canonical 
clathrin-binding motif found in many other proteins, including the β subunit 
of clathrin-adaptor proteins (AP-1,-2,-3) and HIV proteins (Nef, Vpu). 
However, the ability of FIV Gag to bind clathrin has not yet been 
demonstrated. To determine whether clathrin may play a role in virus 
infectivity or possibly virus production, we have found that siRNA-
mediated knockdown of clathrin heavy chain in HeLa cells inhibits both 
FIV and HIV-1 release efficiency by approximately 3-fold. Since the 
potential clathrin-binding LLDL motif of FIV Gag is not involved in virus 
release, this effect may rely on an unidentified clathrin-binding domain in 
FIV or HIV-1 Gag or is possibly an indirect effect. Thus, we propose that 
clathrin may be involved in FIV infectivity via the LLDL motif, and virus 
production in both FIV and HIV-1 through an unknown mechanism that is 
currently being defined. 
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Overall, at least 35 species of African nonhuman primate species are 
naturally infected with SIV, with a seroprevalence ranging from 10% to 
60% in the wild. Thus, African monkey species is the largest SIV reservoir 
and could represent a potential risk for the introduction of new retroviral 
zoonoses into the exposed human population. Indeed, it is now clearly 
demonstrated that the HIV epidemic originated quite recently from zoonotic 
transmission of viruses from chimpanzees and sooty mangabeys in Africa.  
The host range of retroviruses is influenced by antiviral proteins such as 
TRIM5a, a restriction factor that recognizes and inactivates incoming 
retroviral capsids (CA).  
Here, we wanted to investigate whether SIV (SIVgsn, SIVmus, SIVmon, 
SIVmnd1, SIVcol and SIVtal) found in primate bushmeat from Cameroon 
are sensitive to TRIM5 restriction.  
For this purpose, we swapped the fragment of the capsid that spans the 
CypA binding loop in a gag-pol SIVmac expression vector with that of SIV 
isolates from the SIVgsn lineage (SIVmon, SIVgsn and SIVmus), 
SIVmnd1, SIVcol and SIVtal. Gag expression was determined by 
immunoblotting. Stable CHO cells expressing distinct TRIM5 were 
obtained by transduction with primate TRIM5 of different origins. We then 
evaluated by single-round infectivity assays the restriction of these CA 
chimeras into CHO cells and CHO cells stably expressing either different 
TRIM5a (human, chimpanzee, African green monkey, and rhesus macaque) 
or the owl monkey TRIM-Cyp. Infectivity was assayed by FACS 48 hours 
post-infection. 
 
We observed that human and chimpanzee TRIM5a? did not restrict any of 
the SIV CA we tested. However, some SIV CA were restricted by agm-
TRIM5a (SIVmon, SIVmnd-1) or slightly restricted by rh-TRIM5a 
(SIVgsn, SIVmon). 
 
Interestingly, we found that SIVmnd1 and SIVgsn CA, and not SIVmon and 
SIVmus CA, were targeted by owl monkey TRIM-Cyp, suggesting that the 
interaction between cyclophilin A and lentiviral CA is not limited to HIV-1. 
On the other hand, TRIM5a does not seem to constitute a natural barrier to 
SIV infection of humans. 
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HIV-1 RNA is alternatively spliced to produce completely spliced 1.8kb or 
incompletely spliced 4.0kb classes of RNA. Nearly half of the HIV-1 RNA 
remains as unspliced RNA, which is used to encode Gag and Gag-pol 
protein and to serve as genomic RNA (gRNA). HIV-1 RNA splicing is 
tightly regulated to optimize gene expression and efficient virus replication. 
Our laboratory has previously shown that HIV-1 mutations that cause 
excessive splicing of HIV-1 RNA results in a severe reduction in virion 
production and defective Gag processing. Studies with one of the 
oversplicing mutant by confocal microscopy have shown that Gag 
expressed by the wild-type virus (WT) is mainly associated with plasma 
membrane whereas Gag expressed by the oversplicing mutant is mainly 
cytoplasmic, suggesting that the excessive splicing causes the Gag assembly 
and membrane localization defect. Overexpression of Gag protein alone was 
unable to rescue the defect, but co-transfection of WT virus along with the 
mutant showed significant rescue of both mutant Gag processing and virion 
production. Deletion of packaging sequence/s from WT virus resulted in 
inefficient rescue of Gag processing by the oversplicing mutant virus. These 
results suggest that co-packaging of WT RNA is necessary to restore the 
Gag processing and assembly defect of the oversplicing mutant.  
We have further shown that excessive splicing and Gag processing defect 
can be induced in wild-type HIV-1. Virus replication was inhibited using 5’ 
end modified U1 snRNAs that bind strongly to weak 5’splice donor sites 
downstream of either 3’splice acceptor site (3’ss) A1 or A2. Splicing was 
also promoted by expression of modified U1 snRNAs targeted to conserved 
sequences downstream of 3’ ssA3. Expression of modified U1 snRNAs to 
induce excessive splicing may have potential as a therapeutic approach for 
inhibition of virus replication.  
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Many models for HIV latency utilize minimal genomes that lack various 
accessory proteins such as Nef, Vpr and Vif. Our previous work using 
lentiviral vectors that express Tat and Rev in cis but lack Nef has shown 
that epigenetic silencing of the proviral genome alters chromatin structures 
on the provirus and restricts initiation and elongation of proviral DNA. To 
evaluate the potential role of Nef gene in the establishment and maintenance 
of latency, we developed modified vectors that encode Nef under the 
control of an IRES sequence and inserted downstream of fluorescent 
reporter gene (LTR-Δgag-pol-Rev-Env-EGFP-IRES-Nef-LTR TatH13L). 
Jurkat cells infected with the lentivirus carrying Nef gene (Nef wt) are 
silenced faster than cells infected with viruses carrying a Nef knockout (Nef 
ko) or mutations in the myristoylation site of Nef (G2A) or tyrosine kinases 
binding domain of Nef (PXXP). Cells infected with viruses expressing Nef 
also showed a higher proportion of completely silenced cells that harbor 
latent proviruses. To evaluate the impact of Nef on proviral induction, we 
isolated representative clones of latently infected cells carrying the Nef wt, 
Nef ko and Nef mutants. As expected, the Nef wt cell clones, showed 
dramatically decreased MHC class I expression on cell surface following 
TNF-α stimulation. Interestingly, although both types of cell clones are able 
to be reactivated through stimulation of the T-cell receptor by anti-
CD3/anti-CD28 stimulation, the Nef wt clones show enhanced expression 
of EGFP as monitored by flow cytometery analysis. We are currently 
performing a detailed analysis of the proviral reactivation in the presence of 
Nef using high resolution chromatin immunoprecipitation assays to monitor 
RNAP II and transcription factor recruitment to the proviral genome. In 
conclusion, we have demonstrated two distinct ways that Nef impacts HIV 
latency. First, following the initial infection, expression of Nef appears to 
enhance the rate at which cells are able to become latent, perhaps because of 
interference with cell signaling pathways due to the downregulation of 
surface receptors. Second, during the restimulation of latently infected cells 
Nef appears to enhance proviral transcription, perhaps by activating specific 
kinases. 
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Lentiviruses are able to infect non-dividing cells, and thus likely utilize a 
mechanism whereby the preintegration complex (PIC) traverses the nuclear 
membrane through the nuclear pore complex (NPC). Although the viral and 
cellular factors involved in this process remain largely uncharacterized, recent 
results have suggested that the capsid (CA) protein, and thus perhaps viral core 
uncoating, are significant determinants of nuclear import. Furthermore, recent 
genome-wide RNA interference screens have highlighted numerous nuclear 
transport factors, including the karyopherin beta protein TNPO3 as well as a 
number of nucleoporins (NUPs) that comprise the NPC, as host-factors for 
HIV-1 infection. Follow-up results indicated that depletion of these proteins 
blocks HIV-1 infection at nuclear import or integration, and we moreover 
recently reported that the dependency on TNPO3 during infection maps to the 
HIV-1 CA protein. 
 
To verify the importance of additional transport factors identified in the 
genome-wide screens, HeLa cells transfected with specific siRNAs were 
challenged with HIV-1 vectors, and resulting infectivities were normalized to 
those obtained in cells transfected with non-targeting siRNA controls. These 
results highlighted important roles for NUP153 and NUP358 in addition to 
TNPO3 during HIV-1 infection. Challenging the different knockdown cells 
with an expanded set of retroviral vectors indicated that primate lentiviruses 
including HIV-2 and several SIV strains were also significantly inhibited by 
TNPO3, NUP153, or NUP358 depletion whereas Moloney murine leukemia 
virus (MoMLV) and FIV were largely unaffected. By testing a panel of 
chimeric HIV-1 vectors encoding MoMLV matrix, CA, or integrase in place of 
their respective HIV-1 counterparts, we determined that substitution by 
MoMLV CA rendered the virus insensitive to NUP153 or NUP358 depletion. 
Furthermore, various HIV-1 CA missense mutants were differentially 
susceptible to NUP153 versus NUP358 knockdown; the cyclophilin A binding 
loop mutants G89V and P90A were insensitive to NUP358 knockdown, 
whereas the core-stabilizing mutant E45A appeared less sensitive to knockdown 
of NUP153 or TNPO3. Interestingly, NUP153 and TNPO3 depletion appeared 
to affect a similar set of CA mutant viruses, suggesting that these proteins may 
function in a common pathway during HIV-1 infection. Though an interaction 
between NUP153 and HIV-1 integrase was recently reported to be important for 
infection, our data instead highlight the CA protein as the dominant viral factor 
that determines the dependence on numerous nuclear transport factors including 
NUP153, NUP358, and TNPO3 during HIV-1 infection. 
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It is puzzling that so many viral auxiliary proteins exert pleiotropic activities 
despite their small size. Recent advances in the study of HIV-1 Vpu protein 
highlight a relevant mechanism whereby the viral protein bridges a host E3 
ubiquitin ligase complex to distinct target proteins that are thus labeled for 
subsequent degradation. Similarly to Vpu, Vpr recruits a cullin-based ubiquitin 
ligase termed CRL4 through the DCAF1 adaptor subunit. This mechanism 
underlies the ability of Vpr to arrest cell cycle progression at the G2/M 
transition, leading to apoptotic cell death. Here we addressed whether Vpr-
mediated effects other than G2 arrest might also rely on DCAF1 recruitment. 
We developed a clonogenic assay based on the expression of wild-type and 
mutant versions of Vpr using an EBV-based episome carrying the selectable 
marker hygromycin. Expression of the wt Vpr protein abrogated the formation 
of hygromycin-resistant cell colonies, confirming that long-term expression of 
Vpr is lethal in dividing cells. Intriguingly, two HIV-1 Vpr mutants, which are 
devoid of G2 arrest properties but conserve DCAF1 binding, strongly reduced 
the formation of hygromycin-resistant cell colonies. These mutants trigger 
apoptosis through caspase-3 activation but do not show any block in cell cycle 
progression. Thus Vpr expression can cause cell death independently of its G2 
arrest activity as suggested by several studies. Disruption of the DCAF1-
binding function of Vpr restored efficiency of colony formation indicating that 
recruitment of DCAF1 is required for this second cytotoxic activity of Vpr. 
However, DCAF1 binding is not sufficient to confer cytopathicity since Vpx 
from HIV-2/SIVsm, which also efficiently binds DCAF1, does not impair 
colony formation. 
Altogether, our data indicate that Vpr exhibits two distinct cytotoxic activities 
in dividing cells which both require the recruitment of DCAF1. Based on the 
current view of its mechanism of action, Vpr likely induces the proteasome-
mediated degradation of two host proteins independently required for proper 
cell growth and viability. 
 
This work was supported by grants from ANRS, Sidaction, Fondation de France 
and Mairie de Paris. 
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We have previously described intron regulated retroviral reporter vectors 
that allow the quantitative measurement of cell-to cell transmission. We 
have shown that HTLV-1 infection is strongly dependent of producer-target 
cell contact, Tax expression, Env and cell type. Cell surface molecules 
involved in the formation of the virological synapse and viral transmission 
have been studied extensively by microscopy. However, their quantitative 
contribution to HTLV-1 replication remains poorly defined. In order to 
better characterize new or known cell surface antigens involved in cell-to-
cell infection, we generated a panel of mouse monoclonal antibodies against 
Jurkat T cells and screened them in HTLV-1 and HIV-1 cell-to-cell 
infection assays. Among six inhibitory mAbs, three IgM class antibodies 
significantly decreased HTLV-1 cell-to-cell infection with no effects on 
HIV-1 infection. Immunoblot and mass-spectrometry analysis of proteins 
precipitated with these mAbs revealed that they recognize CD43 as well as 
CD45. Since both of these antigens are heavily O-glycosylated, we tested 
the mAbs in binding assays with synthetic saccharides and determined that 
they selectively bind Tn antigen. The Tn antigen is a monosaccharide N-
acetylgalactosamine attached to serine or threonine residues in polypeptide 
chains. Normally this antigen determinant is masked by the elongation of 
the carbohydrate chain catalyzed by T-synthase, and as a result, most cells 
do not present Tn antigen. However, Jurkat cells bear a mutation in the gene 
C1GALT1C1 (COSMC), encoding T-synthase specific chaperon that is 
necessary for the proper folding of T-synthase. Consequently, O-
glycosylation of proteins in Jurkat cells is interrupted. When we restored O-
glycosylation in Jurkat cells by expression of wild type Cosmc, HTLV-1 
cell-to-cell infection was enhanced 10 fold. Whether CD43 or/and CD45 
antigens are critical for HTLV-1 infection will be determined in knock-
down experiments. These findings imply a new role of heavily O-
glycosylated proteins in cell-to-cell infection of HTLV-1 and are consistent 
with the recent data demonstrating that T lymphocytes transiently store 
HTLV-1 viral particles as carbohydrate rich extracellular assemblies. 
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Sprouty2 (Spry2) is a PI(4,5)P2-binding protein that cooperates with Alix 
but interferes with Tsg101 function in modulation of cell surface receptor 
down-regulation. Since PI(4,5)P2 targets HIV-1 Gag to the plasma 
membrane, where Tsg101 or Alix facilitate Gag release, we determined 
whether Spry2 affected Gag trafficking. Here, we show that efficient release 
of the virus-like particles assembled from Gag required the steady-state 
level of endogenous Spry2. Moreover, in Cos-1 cells expressing Gag, 
adventitiously expressed Spry2 was translocated to the plasma membrane in 
a PTAP-dependent manner, implicating the Tsg101 bound to Gag in the 
recruitment. Gag and Spry2 co-localized at the periphery of some cells. 
However, under these conditions, much of the Gag was sequestered in the 
cell interior and release of the virus-like particles (VLPs) assembled by Gag 
was inhibited. The inhibition was relieved by mutation of the determinant of 
PI(4,5)P2 binding in Spry2, suggesting that Gag and Spry2 compete for this 
phospholipid. Surprisingly, the inhibition of Gag release observed in the 
presence of Spry2 was relieved by disruption of the PTAP motif in Gag. 
The determinant of PI(4,5)P2 binding in Spry2 and the YPX(n)L motif in 
Gag that recognizes Alix were required for this rescue. Co-
immunoprecipitation, confocal microscopy and in vitro capture assays all 
indicated that Spry2 associates with ESCRT 2 factors and can interfere with 
their recruitment of ESCRT-1. The results identify Spry2 as a novel 
regulator of HIV-1 release that may facilitate Tsg101 and Alix interaction 
with ESCRT-3 by sequestering factors in the ESCRT-2 complex. 
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HIV-1 infection is inhibited by target cell expression of the integrase 
binding domain (IBD) of the HIV-1 integration cofactor LEDGF. The 
structural requirements and mechanism for this dominant interference (DI) 
are unclear. More generally, it is not known whether integrase or other 
constituents within the Capsid-enclosed viral core become accessible to 
functional interaction with host cell proteins during cytoplasmic transit to 
the nucleus. Here we characterized parameters that determine DI protein 
activity and identified intracellular location effects with implications for the 
post-entry structural evolution and uncoating of HIV-1 particles. We 
determined that fusions of GFP to multiple IBD-containing segments of 
LEDGF inhibit HIV-1 replication, but a minimal GFP-IBD chimera, which 
distributes cell-wide, is most effective. Combining DI with endogenous 
LEDGF depletion using single step knockdown/re-expression lentiviral 
vectors was clearly multiplicative in effect, inhibiting single cycle 
infectivity by > 4 logs and completely blocking high (5.0) MOI viral 
replication in CD4 + T cell lines. We then sought to define when in the 
post-entry infection process integrase becomes accessible to GFP-IBD 
binding, by restricting the protein to specific intracellular locations. The 
protein retained potent antiviral activity when we confined it to either the 
nuclear envelope or to the cytoplasm. Moreover, the block triggered by a 
cytoplasm-confined DI protein manifests post-nuclear entry, at the level of 
integration. Certain other sub-cellular targetings caused loss of antiviral 
activity. These experiments demonstrate that LEDGF depletion and 
dominant interference target different temporal stages of the HIV-1 
integration process and demonstrate that PIC integrase becomes accessible 
to cellular protein engagement in the cytoplasm. 
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HIV-1 preintegration transcription is the earliest viral transcriptional 
activity that generates three viral regulatory proteins, Tat, Nef, and Rev. 
Among them, Tat, the transactivator of transcription, is required for 
efficient viral transcription from the provirus, but its function in 
preintegration transcription remains largely unknown. To determine the 
involvement of Tat in preintegration transcription, we established an HIV-1 
double mutant construct, pCMVΔ8.3(D116N/Δtat), a Tat expression vector, 
and an LTR-driven luciferase lentiviral vector. These constructs were used 
to assemble virion particles to characterize preintegration transcription. 
Using this system, we demonstrated that Tat is likely a part of the virion 
particle, and the virion-associated Tat is involved in the synthesis of non-
integrated viral DNA. In addition, we also constructed a doxycycline-
inducible Tat expression system. When introduced into HeLa cells, upon 
Tat induction, the Tat-mediated transcriptional activation predominantly 
acted on integrated proviral transcription, which exhibited a 12.5-fold 
increase in response to Tat; however, when non-integrated viral DNA 
template was identically tested, it displayed a significantly lower response, 
a merely 1.5-fold increase in reaction to Tat stimulation. Based on these 
results, we concluded that the virion-associated Tat is involved in viral 
DNA synthesis, but the early Tat protein synthesized from non-integrated 
viral DNA minimally stimulates preintegration transcription itself. The 
possible function of the early Tat protein is likely to stimulate viral 
transcription from subsequently integrated provirus. 
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Nef, an accessory protein expressed early during the replication cycle of the 
primate lentiviruses (HIV and SIV), plays an important role in viral 
infectivity and disease progression by a still not completely understood 
mechanism. Although many studies have described the role of Nef on the 
early stages of HIV-1 replication cycle, its contribution on the late stages is 
less explored. Our group has previously demonstrated that Nef interacts 
with GagPol by its p6*-PR region. Since both p6* and PR are involved with 
protein processing, we are now exploring Nef’s role on maturation and viral 
protease activity. To assess the level of protease activity in the presence or 
absence of Nef, Hek293T cells were transfected with HIV-1 NL4-3 WT or 
deltaNef in the presence of Lopinavir (LPV), a HIV-1 protease inhibitor, at 
increasing concentrations or at a fixed concentration at different time points. 
Then, we observed the level of Gag processing in cell lysates and VLP’s. 
We also assessed virus infectivity by the TZM-bl indicator cell line assay. 
In our experiments, NL4-3deltaNef was at least 10 times less sensitive to 
LPV than its WT counterpart, besides showing an abnormal processing 
profile and kinetics. The VLP’s analyses also showed that NL4-3deltaNef 
has less unprocessed Gag. Our results indicate that in the absence of Nef the 
protease activity is increased, however, this event is deleterious to the virus, 
since NL4-3deltaNef is about 5 times less infectious than WT. Therefore, 
we suggest that premature activation of protease can lead to abnormalities, 
for instance in the ratio of proteins in the budding virus. This could indicate 
a regulatory role of Nef on HIV-1 Protease activity. 
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As an obligate intracellular parasite, HIV-1 recruits host proteins and 
machineries to ensure abundant virus production and transmission to 
uninfected cells. Although host proteins involved in the transport of viral 
components towards the plasma membrane have been well investigated, the 
dynamics of this process remain incompletely understood. Previously we 
have shown that the dsRNA-binding protein, Staufen1 interacts with HIV-1 
Gag and regulates its multimerization and assembly on membranes. In 
addition, Staufen1 is found in the context of a ribonucleoprotein (RNP) that 
contains the HIV-1 genomic RNA, Gag and several other host RNA-
binding proteins such as NMD factor, Upf1, IMP1 and ABCE1. The 
formation of the HIV-1 RNP is dynamic and likely central to the fate of the 
genomic RNA during the late phase of the HIV-1 replication cycle.  
In this work, we used bimolecular and trimolecular fluorescence 
complementation (BiFC and TriFC) to directly visualize the localization of 
protein-protein and protein-protein-RNA interactions in living cells. We 
show that wild type (wt)Gag and Staufen1 as well as wtGag and IMP1 
interact in cells. These virus-host associations were not only present in the 
cytoplasm but were also found at GM-1-containing lipid raft domains at the 
plasma membrane. Importantly, in live and fixed cell assays, wtGag 
specifically recruited Staufen1 to the detergent insoluble membranes 
supporting a key function for this host factor during Gag assembly. In 
complementary TriFC experiments in which Gag was tethered to reporter 
mRNAs, strong interaction between both Gag-Staufen1 and the Gag-IMP1 
was predominantly observed in the cytoplasm suggesting an active 
recruitment of host proteins when bound to mRNA.  
The present work provides detailed information about where components of 
the HIV-1 RNP interact in cells and bring to light how HIV-1 recruits and 
co-opts RNA-binding proteins during the assembly of infectious particles. 
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We identified the RNase H of retroviruses and HIV as an essential enzyme 
for retroviral replication(1,2). It is specific for cleavage of RNA in RNA-
DNA hybrids and required for removal of the viral RNA genome during 
DNA synthesis. We validated it as a target for drug design. Out of the four 
known retroviral enzymes it is the only one not yet targeted for by 
antiretroviral therapy. Reverse Transcriptase (RT) and RNase H resemble in 
structure and function PAZ and PIWI, components of RISC for antiviral 
defence by siRNA silencing (3). We are targeting the RNase H inside cell-
free virus particles by the application of a short hairpin-looped 
oligodeoxynucleotide (ODN) driving HIV into suicide. A short local RNA-
DNA hybrid forms as substrate for the RNase H which cleaves the viral 
RNA. This renders the particles non-infectious including HIV from patients 
and multi-drug-resistant strains (4-6). In a mouse with the oncogenic 
retrovirus, Spleen Focus Forming Virus, SFFV, intravenous treatment with 
ODN reduced the virus load, delayed disease progression or completely 
prevented infection (7). We also reduced the HIV load in the blood of 30 
primary patients’ isolates from Zurich and Africa by ex vivo treatment with 
ODN in more than 30% by 1000fold (8). Also the viral load in a mouse 
vagina can be significantly reduced in a prophylactic as well as therapeutic 
treatment (9). Humanized SCID mice are under study with HIV and ODN. 
Our approach is distinct from siRNAand antisense treatment in respect to 
mechanism, kinetics, and efficiency. It may prevent HIV infection during 
sexual or mother-to-child transmission or against multidrug-resistant 
viruses. 
Also other viruses and cancer cells can be treated by activation of cellular 
RNases H. 
 
(1,2) Moelling et al., Nature (1971), EMBO (1988) (3) CSH Symp.71 (2006); (4,5) 
Jendis et al., ARHR(1996, 98); (6) Matskevich et al., ARHR(2006); (7) Matzen et 
al., Nature Biotechnology (2007) (8) Heinrich et al J AIDS (2008), (9) Widmer et al 
Antiviral Res (2009 (10) Noreen et al Oligonucleotides (2009)  
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We have shown that semen contains fragments of prostatic acid 
phosphatase that form amyloid aggregates termed SEVI (Semen derived 
Enhancer of Viral Infection), which interact with viral and cellular 
membranes and potently enhance HIV-1 infection by promoting viral 
attachment. Here, we further analyzed the mechanism underlying SEVI-
mediated enhancement of virus infection. Predictably, SEVI had no effect 
on the infections rates of naked viruses. In strict contrast, SEVI drastically 
increased the infectiousness of HIV-1, HIV-2, various SIVs, FIV, KoRV, 
PERV, FeLV, MLV, XMRV as well as Marburg virus. Somewhat 
unexpectedly, however, SEVI only slightly enhanced infection by HSV-1, 
HSV-2, CMV, HBV, HCV, Dengue, RSV, VSV and Measles virus. Close 
examination revealed that all of the latter viruses contain a tightly packed 
glycoprotein shield that might render the viral membrane inaccessible for 
SEVI. In contrast, the membrane of retroviruses, such as HIV-1, contains 
only a low number of envelope (Env) glycoprotein spikes. To further assess 
the role of Env density on the virions for SEVI-mediated enhancement of 
viral infectivity we analyzed HIV pseudoparticles containing various 
amounts of heterologous VSV-G. We found a highly significant inverse 
correlation between the quantity of VSV-G on the virions and the 
magnitude of infectivity enhancement by SEVI. These results were 
confirmed using SIV particles carrying low, median and high amounts of 
SIV Env glycoproteins. Our results show that SEVI is a broad-based but not 
a general enhancer of enveloped viruses infection and suggest that the 
accessibility of the viral membrane is a prerequisite for effective SEVI-
mediated infectivity enhancement. 
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HIV integrase strand-transfer inhibitors like raltegravir are a new promising 
class of anti-retroviral compounds. As with all anti-HIV drugs, treatment 
with raltegravir sometimes leads to evolution of drug-resistance mutations 
(DRMs). Three pathways of raltegravir resistance have been reported, each 
with a different primary mutation. In this work, we investigated patients in 
whom limited clonal sequencing revealed that the viral population 
underwent pathway switches upon raltegravir administration. Deep 
sequencing with the 454/Roche pyro-sequencing technology was performed 
to gain more insight into the evolutionary dynamics of the DRM switch. We 
recovered 4058 sequences, from two patients analyzed longitudinally, 
corresponding to the HIV integrase coding region spanning most of the 
known integrase inhibitor DRMs. The sequences were condensed into 
operational taxonomic units (OTUs) following error-correction by 
pyronoise. In both patients, we confirmed the switch from the N155H to the 
more resistant Q148H + G140S pathway. In one patient this happened 
around 4 months while in the other this occurred around 12 months 
following treatment initiation. We found the primary mutations on multiple 
genetic backgrounds, indicating either multiple independent de novo 
generation or reassortment onto different backgrounds by recombination. 
Q148H-G140S eventually swept through the population in both subjects. In 
none of the patients were we able to detect any pre-existing polymorphism 
at codon positions 155 or 148 that could have been selected at later times. 
Finally even with high-resolution sequencing, we were unable to identify 
any double mutant N155H-Q148H variant. These findings emphasize the 
relatively greater fitness of the Q148H-G140S virus in the presence of 
raltegravir and document the evolutionary steps leading to the final resistant 
population. 
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APOBEC3 cytidine deaminases inhibit the replication of HIV-1 to different 
degrees in the absence of the viral protein Vif. For example, APOBEC3F 
(A3F) suppresses viral infectivity to a lesser degree than APOBEC3G 
(A3G) but it is more resistant to HIV-1 Vif-induced degradation. Multiple 
APOBEC3 molecules are expressed simultaneously in HIV-1 susceptible 
target cells but their individual contribution to viral suppression when 
expressed at endogenous levels remains largely unknown.  
We used a replication competent HIV-1 NL4-3 molecular clone carrying 
Vif mutant W11R, which selectively counteracts A3G but not A3F, to 
dissect the relative contribution of A3F on HIV-1 replication inhibition in 
primary human lymphocytes. Contrary to our expectations, the NL4-3 
W11R virus replicated to similar levels as NL4-3 WT in primary 
lymphocytes derived from five different healthy, HIV-1 negative blood 
donors. We sequenced A3F of these donors to assess for the presence of 
inactivating (partial or total) single nucleotide polymorphisms. We found 
three different A3F haplotypes, one of which showed substantially lower 
antiviral activity when compared to the two others in single cycle infection 
experiments. However, when we quantified the A3F mRNA expression in 
the same PBMC samples by qPCR, we observed low expression levels in all 
5 donors. 
Taken together our data indicate that despite differences in antiviral activity 
among A3F haplotypes, the endogenous A3F expression in primary 
lymphocytes is limited to the extent that its neutralization is dispensable for 
spreading infection of HIV-1. 
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Our aim was to characterize the RhoGTPases and cell signaling pathways, 
which are specifically modulated by the process of HIV-1 assembly and 
production. Along this line, it has been proposed that these steps involve 
membrane and actin cytoskeleton remodeling which is regulated by the small 
RhoGTPases. In fact, a number of data suggests the implication of such proteins 
in HIV-1 production. Indeed, the use of toxin B, a drug which suppresses Rho 
GTPase activity, decreases HIV-1 release. In addition, HIV-1 virions contain 
some RhoGTPases and actin-binding proteins.  
Our preliminary results reveal that Rac1 and RhoA GTPase proteins can impact 
on HIV-1 Gag membrane attachment and localization, and viral production. 
Thus, Gag assembly and viral production might require a transitional regulation 
of cell signalling pathways mediated by RhoGTPases. However, the molecular 
mechanism underlying this effect is not yet understood. What is the role of the 
RhoGTPases in HIV-1 assembly and budding?  
Gag assembly takes place at the level of membrane microdomains such as the 
tetraspanin CD81-enriched microdomains at the plasma membrane, the raft or 
the PI(4,5)P2 microdomains where HIV-1 virions are released by budding. In 
addition, these microdomains are the sites where activated RhoGTPases can be 
anchored, and which determine cell endocytosis and migration, and membrane-
cytoskeleton regulation via actin-mediated cell signaling. During Gag 
interaction with these membrane microdomains, the Gag proteins could well 
recruit and modulate the activity of RhoGTPases, such as the main Rac1, Cdc42 
and/or RhoA GTPases, in order to facilitate virus assembly and release.  
We, thus, studied the implication of these RhoGTPases in virus assembly and 
release. In HIV-1 producing cells, the RhoGTPases of interest were either 
suppressed or overexpressed and for each conditions, we analysed the 
intracellular Gag localization, viral assembly and maturation, and viral 
production by several methods (RT test, immunoblots, membrane flotation 
assays) and by cellular imaging (confocal microscopy). The overexpression of 
Rac1 or RhoA Dominant Negative mutant proteins reduces viral production, 
modifies intracellular Gag localization and reduces Gag membrane attachment. 
In addition, the overexpression of Rac1 or RhoA WT or Dominant Positive 
mutant proteins enhances viral production while inhibition of endogenous Rac1 
and RhoA by siRNA or by specific drugs impacts viral production.  
Our results show that regulation of cell signaling by RhoGTPases is required for 
HIV-1 assembly and release. We will thus determine which are the cellular 
RhoGTPase mediated pathways and their interactions with viral components 
involved in HIV-1 assembly and release.  
   Work supported by INSERM, CNRS, FINOVI and SIDACTION.  
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The colonization of the sheep genome by JSRV-related endogenous 
retroviruses (enJSRVs) is a process that is still ongoing at the present time. 
Several of the recent enJSRV proviruses are insertionally polymorphic, 
maintain an intact genomic structural organization and are able to release 
viral particles in vitro. enJSRVs are abundantly expressed in the uterus 
during pregnancy, proving essential for conceptus development and 
placental morphogenesis. Interferon tau (IFNT), a type I interferon, is the 
pregnancy recognition signal secreted by the ovine developing conceptus 
prior to implantation. Previously, we have shown that bone marrow stromal 
cell antigen 2, (BST2/tetherin) is upregulated by IFNT in sheep cells 
(Arnaud et al, JVI 2010, Feb 24). We have also found that enJSRVs and 
oBST2 expression peak simultaneously during pregnancy but they are 
expressed in different cellular compartments of the sheep uterus. By 
transient transfections we showed that oBST2 inhibits viral particle release 
of enJSRVs and we proposed that oBST2 may have been an important 
factor in shaping the co-evolution of enJSRVs with their host.  
Interestingly, we found that oBST2 is duplicated both in the sheep and 
cattle genome. oBST2-A appears to have a stronger antiviral activity than 
oBST2-B. oBST2-A and oBST2B display a different intracellular 
distribution as assessed by immunofluoresence. In addition, the enJSRVs 
Env displays a different intracellular distribution whether expressed in the 
presence of oBST2A or oBST2B. The biological significance of the 
differences observed in oBST2A and oBST2B and the possibility of 
ruminant-specific antiviral mechanisms are currently being investigated. 
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The HIV-1 nucleocapsid (NC) domain of Gag has both specific and more 
general nucleic acid (NA) binding properties. NC recognizes the specific Ψ 
packaging signal on the genome, thereby ensuring that unspliced viral RNA is 
packaged into virus particles. In addition, NC acts as a general NA chaperone to 
facilitate reverse transcription by annealing/aggregating NAs via its highly 
positive character, and by destabilizing NA secondary structure via its two 
CCHC zinc finger (ZF) motifs. Interestingly, it has recently been reported that 
ZF deletion or mutation to CCCC results in production of virions containing 
DNA instead of RNA, rendering them noninfectious (1, 2). Thus, an additional 
role of NC is to prevent premature reverse transcription from occurring before 
or during assembly. Here, we probe the in vitro NA binding and chaperone 
properties of Gag variants containing the same ZF mutations or deletions tested 
in the cell-based assays. Fluorescence anisotropy equilibrium binding 
measurements reveal that mutation or deletion of both ZFs results in a modest 
reduction (~ 3-fold) in binding to the Ψ SL3 stem-loop relative to WT Gag, 
whereas binding to nonspecific single-stranded NAs is largely unaffected. 
Similarly, Gag’s ability to aggregate NAs or to facilitate tRNALys3 annealing 
to the primer-binding site, two functions of Gag during viral assembly, was only 
moderately affected (~ 3-fold) upon ZF mutation or deletion. A time-resolved 
fluorescence resonance energy transfer assay was used to monitor hairpin stem 
opening of a doubly dye-labeled TAR DNA construct. Surprisingly, single 
CCCC and ZF deletion variants were more effective at opening the TAR hairpin 
than WT Gag, and Gag variants in which both zinc fingers were mutated or 
deleted showed even greater duplex destabilization capability than the single ZF 
variants. Previous studies with the freestanding NC domain of Gag indicated 
that NC’s duplex destabilization activity depended on the ZF structures. Our 
new results suggest that in the context of Gag, disruption of the ZFs leads to 
enhanced duplex destabilization and additional studies to confirm these findings 
are underway. 
 
1. Thomas et al., J. Virol. 82: 9318-9328, 2008 
2. Houzet et al., Nucleic Acids Res. 36: 2311-19, 2008 
 196 
VRNA AND PI(4,5)P2 DRIVE POLYHEXAMERIC 
OLIGOMERIZATION OF RSV GAG 
 
Shorena Nadaraia-Hoke*, Nicole Gudleski*, John Flanagan, Leslie Parent  
 
Penn State College of Medicine, Department of Medicine, Hershey, PA, 17033 
 
Rous sarcoma virus (RSV) assembly depends on a series of spatio-temporally 
coordinated steps that culminate in the budding of spherical particles from the 
plasma membrane (PM). Assembly begins with Gag:viral RNA (vRNA) 
binding, followed by multimerization of Gag into a hexameric lattice at the PM. 
Here, we report that Gag binding to vRNA in vitro promotes poly-hexameric 
complex formation; however, Gag:vRNA interaction is not sufficient to trigger 
spherical particle formation at neutral pH. To determine whether an additional 
cellular factor was required, we investigated the role of PM-localized 
phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2], previously implicated in 
targeting of the HIV-1 and MuLV Gag proteins.  
 
To test whether PI(4,5)P2 is required for RSV Gag PM localization and 
budding, 5-phosphataseIV (5ptaseIV) was expressed to deplete intracellular 
levels of PI(4,5)P2. In cells that co-express the RSV genome and 5ptaseIV, Gag 
accumulated in cytoplasmic foci and virus particle production was decreased. In 
vitro binding experiments revealed that Gag and the isolated MA protein bound 
directly to PI(4,5)P2 with high affinity (Kd=74nM and 147nM respectively). 
Additionally, PI(4,5)P2 binding induced a conformational change in both MA 
and Gag. Surprisingly, PI(4,5)P2 changed the oligomeric state of MA from 
monomer to hexamer, suggesting that MA-membrane interactions promote 
formation of the hexameric lattice. In contrast, Gag:PI(4,5)P2 remained 
monomeric unless vRNA was added, resulting in polymerization into tube-like 
structures apparently composed of hexameric rings.  
 
In conclusion, we show that targeting of RSV Gag to the PM is mediated by 
PI(4,5)P2 and vRNA interactions, in contrast to myristylated HIV Gag, which 
requires structural rearrangement of the myristate moiety and PI(4,5)P2 binding. 
Furthermore, PI(4,5)P2 and vRNA binding have a synergistic effect on Gag 
polymerization in vitro, driving the formation of an apparent hexameric lattice. 
We propose that upon binding to vRNA, Gag forms hexameric complexes that 
migrate to the PM where tight binding to PI(4,5)P2 occurs. 
Gag:vRNA:PI(4,5)P2 binding induces conformational changes that might 
recruit other Gag molecules to form complete virus particles. 
Gag:vRNA:PI(4,5)P2 forms tubes rather than spheres, possibly due to the lack 
of an additional host factor or a curved membrane surface. Future experiments 
will test these possibilities, leading to a deeper understanding of the 
biochemical interactions that drive retrovirus particle assembly.  
 
*These authors contributed equally to this work.  
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Background: TRIM5α contains RING domain, which is frequently found 
in E3 ubiquitin ligases. It was reported that mutations disrupting RING 
domain function of rhesus monkey (Rh) TRIM5α only partially diminished 
its anti-HIV-1 activity. Although it has been proposed that Rh TRIM5α 
restricts HIV-1 via proteasome-dependent and -independent pathways, the 
precise role of RING domain in retroviral restriction remains unclear. 
Methods: We constructed mutant TRIM5αs in which Zn-binding sites of 
RING domain were disrupted and examined the effects of these mutations 
on retrovirus restriction by TRIM5α in various combinations of virus and 
host species. 
Results: SIVmac successfully avoided attacks by RING mutants of African 
green monkey (AGM) TRIM5α that could still somewhat restrict HIV-1 
infection. Addition of proteasome inhibitor MG132 did not affect the anti-
HIV-1 activity of AGM TRIM5α at all, whereas it disrupted at least partly 
the anti-SIVmac activity. These results indicated that AGM TRIM5α 
restricted SIVmac mainly via the proteasome dependent pathway, whereas 
HIV-1 restriction by AGM TRIM5α was both proteasome dependent and 
independent. In the case of human TRIM5α carrying proline at the position 
332 (Hu-R332P), however, both HIV-1 and SIVmac restrictions were 
completely eliminated by RING domain mutations. Furthermore, a 
proteasome inhibitor could also disrupt both anti-HIV-1 and anti-SIVmac 
activities of Hu-R332P. These findings indicate that Hu-R332P restricts 
both HIV-1 and SIVmac mainly via the proteasome dependent pathway. 
When we measured levels of reverse transcribed (RT) products of HIV-1, 
both late RT products and 2 LTR forms were severely suppressed in cells 
expressing parental TRIM5αs while those in cells expressing RING 
mutations of AGM and Hu-R332P TRIM5αs were significantly recovered.  
Conclusion: The mechanisms of retrovirus restriction by TRIM5α vary 
depending on the combination of host and virus species.  
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Treatment of HIV infection in vivo is complicated by the rapid evolution of 
drug resistance mutations. Attempts to model the evolution of HIV fall into 
two general categories, deterministic for large populations and stochastic 
for small populations. Importantly, it is not the census population size but 
the effective population size (Ne) that is the relevant parameter in these 
models. Ne is difficult to directly measure because it is influenced by 
bottlenecks, metapopulation structure, variance in progeny number, etc., but 
can be inferred by calibrating the predictions of a reference model, in which 
Ne is a parameter, to observable behavior in an experimental system. 
 
We developed a tissue culture based system using ALV that closely meets 
the assumptions a simple model to describe the evolution of a population 
containing two variants, which differ in fitness due to a single point 
mutation in env with a choice of two alleles. A defined mixture of the two 
viruses is passed repeatedly in culture, and their relative frequency as a 
function of passage number is assessed by allele-specific PCR. By making 
the better-fit virus increasingly rare at the start of the competition we are 
able to observe the evolution of the population shift from deterministic to 
stochastic evolution, as indicated by the increasing variance of the rate of 
fixation of the more fit variant, a behavior described by the model. We 
found that the magnitude of stochastic behavior is a function of the 
selection coefficient between the two competing viruses, another prediction 
made by the model. 
 
We propose that the ratio of Ne to N (i.e., the effective to the census 
population size) that describes this simple experimental system will provide 
an upper bound to inferences of Ne when this model is applied to the more 
the complicated system of HIV infection in vivo. 
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HIV uses RNA structures in its genome, including the RRE, TAR and 
dimerization sequences, to modulate and regulate its replication cycle. The 
structure of a full length genomic RNA of the NL4-3 molecular clone of HIV 
was recently described (Watts et al. Nature 2009). Interestingly, the relatively 
unstructured protein sequences linking autonomously folding protein domains 
were found to be encoded by highly structured regions in the RNA genome. 
This distribution of RNA structure suggested a model in which these structures 
facilitate native folding of HIV proteins. 
As, in HIV, RNA structures have also been associated with the promotion of 
recombination in mechanistic studies, creating local recombination hot spots, 
we compared the distribution of RNA structure to the variations in 
recombination rates in the envelope gene. We observe that the recombination 
pattern in env, obtained using primary isolates of different HIV-1 subtypes in a 
system where recombination is analyzed in the absence of selection (Simon-
Loriere et al, PLoS Path. 2009), is clearly recaptured by the presence of RNA 
structures. The pattern of RNA structure is thus a strong predictor of genome 
regions with high levels of recombination in HIV-1. 
If this observation, made in env in absence of selection, can be extended to the 
rest of the genome, then traces of the distribution of RNA structure should be 
observed in the pattern of recombinant breakpoints observed in nature. This is 
particularly true in regions of the genome where recombination presents a lower 
risk of disrupting intra-gene interaction networks such as in regions between 
genes or proteins, or between protein domains. 
We do observe significantly higher levels of breakpoints in structured regions of 
the RNA genome and in intergenic regions; breakpoints in the former category 
clearly dominating on the second. In parallel, we also observe a noticeable trend 
for an enriched presence of structured RNA regions to be located preferentially 
in intergenic regions. Recombination is thus oriented such that the probability 
that recombination results in functional proteins is maximized. As a result, 
recombination between divergent sequences, such as between genomes 
belonging to different HIV-1 subtypes, tends to result in the transfer of entire 
genes to a different genetic background, rather than creating chimeric genes. 
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Antagonism of tetherin/CD317-mediated restriction of retroviral particle 
release by the HIV-1 accessory protein Vpu results in the downregulation of 
tetherin levels from the cell surface and its degradation. Vpu-induced 
tetherin degradation, but not downregulation of cell surface levels, can be 
rescued by proteasome inhibition indicating it is an ubiquitin (Ub)-driven 
process, although whether its ultimate destruction occurs in the lysozome or 
after dislocation to the cytoplasm remains unclear. The cytoplasmic tail of 
human tetherin contains two membrane proximal lysine residues (K18 and 
K21) that could serve as potential Ub-acceptors. Indeed K18 is essential for 
the targeting of tetherin for ESCRT-dependent degradation by K5, a RING-
CH E3 ligase encoded by Kaposi’s sarcoma-associated herpesvirus 
(KSHV). Ubiquitinated species of tetherin can be detected in Vpu-
expressing cells, and this is dependent on the presence of K18 and K21. 
Using HT1080 cells stably co-expressing tetherin mutants and Vpu, we can 
show that degradation of tetherin by Vpu depends primarily on K21, 
although K18 mutants display partial resistance to degradation. K21R 
mutants of tetherin were also poorly downregulated from the cell surface. 
Despite these defects in degradation and downregulation of tetherin K-
mutants, there was little or no difference in the abilities of these proteins to 
restrict HIV-1 particle release, or their sensitivity to Vpu-mediated 
antagonism. Thus Vpu-induced ubiquitination and degradation of tetherin is 
dispensable for blocking its antiviral activity. 
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     Two views have dominated the discussions on the etiology of multiple sclerosis 
in recent decades: It could be a genetic disease, or it could be a disease caused by an 
infectious agent. The genetic view is most clearly expounded by studies of twins, 
showing that concordance among monozygotic twins is approximately 25 percent, 
while concordance among dizygotic twins is only 2 - 3 percent. The alternative 
view, that multiple sclerosis is caused by an infectious agent, is most clearly backed 
by animal studies. The obvious intersections of a genetic and a viral etiology are the 
human endogenous retroviruses.  
     48 intact or near-intact human endogenous viruses were treated as Mendelian loci 
in an analysis based on genetic epidemiology. We investigated DNA from 350 
patients with verified multiple sclerosis living as well as DNA from 500 persons 
without sclerosis from the same part of the country. Females constituted 62 percent 
of cases and 67 percent of the controls. A total of 220 markers were tested. A 
particularly striking cluster of significant markers occurred on chromosome X at 
approximate chromosome position 97100000 around the HERV-F(c)1 proviral locus 
(NCBI genome build 37.1). The marker rs391745 was lowest with a p-value of 
4*10-6 (2-sided) for association with disease, when calculating on the basis of C-
allele carriers. This value remained significant after Bonferroni correction (p = 
0.0009).  
     We retested the association of rs391745 and multiple sclerosis in another cohort 
of 542 verified cases and 1160 controls, making sure that there were no overlaps 
between the two cohorts. Females constituted 66 percent of cases and 65 percent of 
the controls. Rs391745 was again associated with MS. Finally, we tested a third 
smaller cohort of verified multiple sclerosis in Eastern Danes. In this cohort women 
constituted 70 and 63 percent among cases and controls, respectively. We could not 
find any association of rs391745 with multiple sclerosis, and do not know why the 
association was absent. The p-value for all 3 cohorts combined was 0.00001 (2-
sided) and thus significant after Bonferroni correction (p = 0.003).  
    We performed a scan of the region surrounding the HERV-F(c)1. It was clear that 
the association occurred in a 20 kb region around the provirus. In contrast, the 
nearest known genes lie 141 kb upstream, and 57 kb downstream, respectively.  
     By treating the endogenous retroviruses as Mendelian loci, we have brought the 
formidable knowledge of human genetics to bear on their role in disease, and 
avoided the difficulties of establishing the causality of a ubiquitous agent. 
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HIV-1 recombination events are a major contributor to creating viral 
diversity. Recombination happens approximately 20% of the time between 
the two single stranded RNA genomes of HIV-1 during reverse 
transcription (Onafuwa-Nuga et al. 2008). We are searching for viral 
mutations that affect the strand transfer activity of HIV-1 RT known to 
mechanistically contribute to viral recombination. For this, two RT clinical 
isolates, a pre-drug RT isolate and post-drug RT isolate from a single 
patient before and after multiple NRTI treatments, respectively, were used 
to study strand transfer efficiency with different RNA substrates during 
reverse transcription. The RNase H activities and RNA template 
degradation of these two RT isolates during reverse transcription were also 
assayed to coincide with strand transfer activity observed in both RT 
isolates. We found that the post drug RT isolate containing multiple 
thymidine analog mutations (TAMs) along with a dipeptide finger insertion 
mutation SG at positions 69 and 70 have increase strand transfer efficiency 
during reverse transcription compared to the pre-drug RT isolate. There 
were also more primary and secondary cuts generated from the post drug 
RT isolate in the RNase H assay. We hypothesize that the post drug RT 
isolate having the finger dipeptide insertion along with the background 
TAMs alters its interaction with the template, and possibly affects strand 
transfer of HIV-1 RT. This enhancement in strand transfer frequency of 
HIV-1 may allow the virus to effectively combine various existing 
mutations in a round of replication, ultimately promoting the evolution and 
escape of HIV-1 from multiple anti-viral selective pressures. 
 203 
A NOVEL HOST FACTOR, UBIQUITIN-CONJUGATING ENZYME E2 
VARIANT 1 (UBE2V1), INFLUENCES HIV-1 INFECTION IN HUMAN 
MONOCYTIC CELLS 
 
Nidhanapati K Raghavendra, Heather L Hoy, Li Wu  
 
Department of Veterinary Biosciences, The Ohio State University, 1900 
Coffey Road, Columbus, OH, 43210 
 
Host factors play a critical role in HIV-1 replication and cellular restriction 
of viral infection. Studying the mechanisms of HIV-1 interaction with host 
factors can facilitate our understanding of viral pathogenesis. The cell-type 
specific signaling pathways and the associated transcription factors can 
influence the infection by HIV-1. In our effort to explore postentry 
restriction of HIV-1 infection in undifferentiated human monocytes, we 
identified a novel host factor, ubiquitin-conjugating enzyme E2 variant 1 
(UBE2V1), which significantly influences HIV infection in certain cell 
types. UBE2V1 belongs to the subfamily of ubiquitin-conjugating E2 
enzyme variant proteins, which are catalytically inactive forms of E2 
enzymes. The role of UBE2V1 in HIV-1 infection has been analyzed using 
a human promonocytic cell line, U937. Compared to parental U937 cells, a 
stable small hairpin RNA (shRNA) based knock-down of UBE2V1 in U937 
cells resulted in a 10±1 fold increase in HIV-1 gene expression upon 
infection with a single-cycle, vesicular stomatitis virus G protein (VSV-G) 
pseudotyped NL4-3 luciferase reporter virus. Moreover, infection with a 
replication-competent NL4-3 ∆nef-luciferase HIV-1 resulted in greater than 
a 40-fold increase in the luciferase gene expression. The fold increase in 
HIV-1 infection levels is observed to be independent of the multiplicity of 
infection. In contrast, shRNA-based stable knock-down of UBE2V1 in 
human CD4+ T cell line Sup-T1 did not significantly affect the infection 
with the replication-competent virus. There is a slight decrease (20±5%) in 
luciferase expression in the Sup-T1 cells infected with the single-cycle 
HIV-1. The role of UBE2V1 in HIV-1 infection of primary monocytes, 
macrophages, and CD4+ T cells is under investigation. A UBE2V1/UBE2N 
heterodimer is known to have a role in the signaling by TNF receptor 
associated factor 6 (TRAF-6), transcriptional activation of target genes, and 
cell cycle and differentiation. Details of the events in HIV-1 life-cycle that 
are influenced by UBE2V1 will be presented. Our results suggest that 
UBE2V1 may act as a cellular regulator for HIV-1 gene expression in 
certain cell types. 
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High rates of HIV-1 recombination generate diversity in circulating strains 
and allow the virus to escape immune responses and develop drug 
resistance. We previously showed that the dimerization initiation signal 
(DIS) identity affects the copackaging efficiency of RNA derived from 
different proviruses. For example, HIV-1 subtypes B and C have different 
DIS sequences and their RNAs are copackaged less efficiently than those 
with the same DIS. These conclusions came from studies using the 
reconstitution of a functional green fluorescent protein gene (gfp) during 
recombination as a surrogate. We have now established a dual-marker 
system that uses the reconstitution of a functional Gag (capsid) protein, in 
addition to gfp, to directly detect recombination in the viral genome.  
 
Using this system, we have shown that recombination occurred more 
frequently in the gag gene between two viruses of the same subtype (B/B 
and C/C) than between viruses of different subtypes (B/C), even when the 
viruses contained the same DIS. These results revealed that aside from DIS 
identity, there were other barriers to HIV-1 intersubtype recombination.  
 
In addition to group M viruses, which includes both subtype B and C 
variants, there are three other HIV-1 groups, O, N, and P. Despite the high 
genetic diversity, group M and group O recombinants have been previously 
reported in clinical samples. We are currently studying the barriers to 
intergroup HIV-1 recombination. Our preliminary results suggest that when 
containing the same DIS, group O RNA copackages less frequently with 
group M RNA compared to RNAs from two different viral subtypes. 
Additionally, recombination in the gag gene occurs less frequently between 
group O and group M viruses than between two subtype B or two subtype C 
viruses. Therefore, multiple barriers exist in the generation of intergroup 
HIV-1 recombination.  
 
* Equal contribution 
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The complex and still obscure etiology of Multiple Sclerosis (MS) seems to 
involve hereditary and environmental, probably infectious, factors alike. 
Human endogenous retroviruses (HERVs), inherited as mendelian genes, 
could be the link between these factors.  
A recent association study in our group investigated association between 
Multiple Sclerosis and all HERVs with potential for (or close to) protein 
expression. This analysis revealed association in a region of chromosome X 
containing HERV-F(c)1.  
The HERV-F(c)1 sequence contains the general retrovirus structure of 
LTR-elements and the three genes Gag, Pol and Env. The Env gene seems 
intact with an open reading frame, whereas the Gag and Pol frames are 
interrupted by two premature stop-codons and a frameshift mutation. Thus, 
we suspect that only three point mutations keep this provirus remnant from 
having expression potential for all three viral proteins. In order to gain more 
knowledge about the capacity of the virus and particles derived from it, we 
decided to reconstruct the potential for Gag-Pol polyprotein expression of 
HERV-F(c)1 by means of site-directed mutagenesis. 
BLAST-search comparison with other viral sequences indicated the most 
probable nucleotides for substitution (point-mutation) or deletion 
(frameshift). The sequences for HERV-F(c)1 Gag-Pol and Env were cloned 
into two different expression vectors respectively. This minimizes the risk 
of replication competent retrovirus (RPR) production upon concurrent 
expression and virion production. The expression vectors allow for various 
future studies revealing the nature 
of this virus upon reactivation.  
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We and others have shown that fusion proteins in which the PWWP domain 
and AT hooks of LEDGF are replaced by other chromatin binding domains 
redirect HIV-1 integration. There are two reasons to continue to pursue this 
technology 1) to control the specificity of integration for safer gene therapy 
2) to understand the binding specificity and distribution of chromatin 
binding proteins. We have prepared several new LEDGF fusions that alter 
the integration pattern of HIV DNA in KO mouse cells that lack normal 
LEDGF. We previously showed that a PHD finger from ING2 (which binds 
H3K4Me3) fused to the integrase binding domain of LEDGF preferentially 
directs integrations near the transcriptional start sites (TSSs) of expressed 
genes. We now show that a PHD finger from JARID1α (which also binds 
H3K4Me3), causes a similar distribution and, with some interesting 
exceptions, favors integrations in the same genes. In contrast, a fusion with 
a domain from MLL containing both a PHD finger that binds H3K4Me3 
and an atypical bromodomain, directs integrations near the TSS of a very 
different group of expressed genes than the ING2 and JARID1α PHD finger 
fusions. We reported the distribution of integrations directed by the 
chromodomain of HP1α. We now show that a fusion with the 
chromodomain from Cbx7, which recognizes a related set of histone 
modifications, directs a pattern of integration that is distinct from the HP1α 
fusion. These new data extend our previous work and show that a 
combination of domains with different chromatin binding specificity can 
lead to novel patterns of integration, a result that holds promise both for 
gene therapy and for the study of the specificity of chromatin binding 
proteins. 
 207 
RECOMBINANT TY3 INTEGRASE MEDIATES BRF1C-DEPENDENT 
AND SEQUENCE-SPECIFIC STRAND TRANSFER IN VITRO  
 
Xiaojie Qi, Kim Nguyen, Heather Hatzis, Suzanne Sandmeyer  
 
University of California Irvine, Department of Biological Chemistry, Irvine, 
CA, 92697 
 
Ty3 is a long terminal repeat retrotransposon in the budding yeast 
Saccharomyces cerevisiae. Ty3 integration occurs preferentially at the 
transcription initiation sites of genes transcribed by RNA polymerase III 
(Pol III). Two general transcription factors, TFIIIB and TFIIIC are required 
by Pol III in vivo; however, in vitro at the SNR6 gene, which contains an 
upstream TATA element, TFIIIB is sufficient to support transcription on a 
naked DNA template. Previously, using Ty3 VLPs as the source of 
integrase (IN) and cDNA, our laboratory showed that Ty3 integrated at low 
but detectable frequencies in the presence of TFIIIB subunits Brf1 and 
TATA-binding protein (TBP). In this study, we purified recombinant Ty3 
IN and characterized its catalytic activity. A Brf1n-TBPcore-Brf1c triple 
fusion protein (TFP) was shown to be able to replace Brf1 and TBP for 
TFIIIC-independent transcription [1]. Using the TFP construct, a novel 
integration assay was developed in which recombinant IN mediated strand 
transfer of oligonucleotide duplexes representing the Ty3 termini to sites of 
TFP binding. Electrophoretic mobility shift assay (EMSA) showed the 
formation of a complex consisting of IN, TFP, and a TATA box-containing 
DNA in the presence of Mg2+. GST pull-down assays were used to show 
that the interaction was between the Brf1c domain of TFP and the C-
terminal domain of IN. When Mn2+, an alternative cofactor for retrovirus 
IN, was supplied in the reaction, TFP targeting was abolished but new 
insertion sites were found to concentrate in an upstream region. 
Examination of nearby sequences in that region revealed an 8-bp stretch 
almost identical to Ty3 LTR end sequence. Based on this result, we 
hypothesize that in the absence of targeting factors, Ty3 IN may bind to 
target sequences resembling its own termini and have weak strand-transfer 
activity.  
 
 
1. Kassavetis GA, Soragni E, Driscoll R, Geiduschek EP. Reconfiguring the 
connectivity of a multiprotein complex: fusions of yeast TATA-binding protein with 
Brf1, and the function of transcription factor IIIB. Proc Natl Acad Sci U S A. 2005. 
102: 15406-11. 
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The M-MuLV IN protein is a 45kDa protein, and thus encodes insertions 
beyond the three conserved domains: HHCC zinc binding domain at the N-
terminus, the catalytic core, and the C-terminal domain. Of particular 
interest was the MuLV IN N-terminal domain (NTD: amino acids 1-105). 
Using NMR, X-ray crystallography, and SAXS analysis, we find that in 
addition to the structurally conserved HHCC zinc binding region, the NTD 
contains an N-terminal extension domain (NED) similar to PFV IN. While 
the NED is not conserved among many retroviruses, this region is essential 
for M-MuLV integration, both in vitro and in vivo. In solution, the M-
MuLV IN NTD forms a dimer with a Kd of ~650 nM. A selective labeling 
strategy, including the production of asymmetrically labeled dimers, has led 
to the elucidation of residues involved in the dimer interface. While the X-
ray and NMR structure display concordance within the monomer, a similar 
dimer is not present in the X-ray crystal structure. To further characterize 
the dimer SAXS analysis was performed. Mutational analysis, based on the 
structure of the NTD, has highlighted critical amino acids required in vivo 
for viral infection, where were previously found non-essential for in vitro 
integration assays. Comparison of these structures, as well as with the 
structure of the NED/NTD of the PFV IN in complex with DNA will be 
presented. 
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During HIV-1 replication the cellular cofactor LEDGF/p75 (Lens 
Epithelium Derived Cofactor/p75) binds HIV-1 integrase and targets viral 
integration preferentially into active genes. Several strategies were used to 
show the important role of LEDGF/p75 in viral replication. After RNAi-
mediated knockdown of LEDGF/p75, residual replication was observed 
possibly supported by minute LEDGF/p75 protein levels. Mouse knockout 
fibroblasts were generated enabling analysis of high titer single round 
lentiviral vector transduction but not of multiple round replication. To 
enable evaluation of multiple round replication in the complete absence of 
LEDGF/p75, a human LEDGF/p75 somatic knockout cell line was 
generated (-/-) leaving the p52 splice variant intact.  
By homologous recombination in the pre-B-cell line Nalm-6, exons 10 to 
13, coding for the LEDGF/p75 integrase binding domain (IBD) were 
deleted. As a result a truncated protein was formed in which the C-terminal 
region of LEDGF/p75 (aa 325-530) was replaced by a new 9 aa tail. Correct 
homologous recombination was verified by southern blot analysis and DNA 
sequencing. Absence of LEDGF/p75 specific mRNA was verified by Q-
PCR. Western blot analysis revealed the presence of the truncated protein. 
Multiple round HIV replication in LEDGF/p75 -/- and +/- cells was delayed 
for 2 weeks in the LEDGF/p75 null cells. Using 454 sequencing the HIV 
and EIAV integration site profile was determined. In LEDGF/p75 +/+ cells 
74 % of the HIV integration sites were found in Refseq genes compared to 
48 % in the -/- cells. For EIAV integration, these numbers were 60 % and 
37 %, respectively. In addition, upon knockout of LEDGF/p75, HIV-1 and 
EIAV integration around CpG islands (1 kb) increased 6- and 4-fold, 
respectively. These results are in line with earlier reports investigating 
integration site preference in human LEDGF/p75 knockdown cells or 
mouse knockout cells. 
Our results corroborate LEDGF/p75 as a critical, but not essential cofactor 
for HIV replication in human cells. We are currently evaluating 
LEDGF/p75 knockout escape mutants to understand how HIV is capable to 
replicate in human cells in the complete absence of LEDGF/p75. 
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Recent siRNA screens have identified numerous human genes whose 
expression is necessary for efficient HIV infection. A number of identified 
factors are required for nuclear import and/or integration of the virus, and it 
has been suggested that these steps may be mechanistically coupled. We 
have investigated the role of several nuclear factors in HIV integration 
using siRNA to deplete protein levels and 454-pyrosequencing of 13,329 
unique integration sites to map proviral distribution. Genomic sequences 
flanking proviruses were aligned to the hg18 draft human genome sequence 
and compared to annotated features including genes, exons, GC content, 
and CpG islands. Depletion of TNPO3, RANBP2 (NUP358), ANAPC2, and 
SNW1 significantly reduced HIV integration targeting to gene-rich and G/C 
rich regions, compared to wild-type HIV integration sites. This pattern was 
distinct from that seen when PSIP1/LEDGF/p75 is depleted. As a control, 
we investigated integration targeting of MuLV, which is not thought to 
traverse the nuclear pore, and whose integration steps are LEDGF-
independent. The distribution of MuLV proviruses was not altered with 
respect to gene or G/C density when TNPO3, ANAPC2, and SNW1 were 
depleted. In agreement with previous reports, depletion of these three 
factors inhibited HIV infection while only the latter two reproducibly 
prevented MuLV infection. Effects of knockdown on infectivity and 
integration targeting were partially rescued by expression of siRNA-
insensitive alleles of TNPO3 and ANAPC2. Given that TNPO3 and 
RANBP2 are components of nuclear import pathways, their necessity for 
normal integration targeting of HIV but not MuLV is consistent with a 
model of linked import and integration. Our data is in agreement with 
concurrent studies with collaborators showing that capsid mutants defective 
in binding RANBP2 also have altered integration site selection. How these 
factors interact with the PSIP1/LEDGF/p75 pathway, which also affects 
targeting, is under investigation. These data are consistent with a model in 
which a large collection of host proteins contribute to coupled nuclear 
import and subsequent integration in gene dense regions. 
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Upon cell invasion retroviruses generate a DNA copy of their RNA genome and 
integrate retroviral cDNA within host chromosomal DNA. These 
retrotransposition steps are essential and conserved features of retroviral 
replication. Integration occurs throughout the host cell genome but target site 
selection is not random and each subgroup of retrovirus is distinguished from 
the others by attraction to particular features on chromosomes. Despite 
extensive efforts to identify host factors that interact with retrovirion 
components, or chromosome primary structure and epigenetic markers 
predictive of integration, little is known about how integration sites are selected. 
 
We attempted to identify markers predictive of retroviral integration by 
exploiting ChIPSeq (high-throughput sequencing technology combined with 
standard chromatin immunoprecipitation) and borrowing statistical concepts 
from the field of Information Retrieval. ChIPSeq produces genome-wide, 
chromosome-associated factor sitemaps of higher density than previously 
attainable. Precision-Recall methods developed for extracting information from 
highly skewed datasets were exploited to discriminate between individual 
chromatin-associated markers for retroviral integration and to combine the 
predictive power of multiple factors. Markers with F scores between 0.5 and 1.0 
were considered to be associated with integration sites. 
 
Currently, the best chromosomal markers for integration site selection are CpG 
islands and transcription start sites (TSS) associated with gammaretroviruses. 
21 to 27% of MLV integration sites fall within 2 kB of these markers with F 
scores of 0.36 to 0.51. The F score for HIV-1 is 0.11. Then we compared 
ChIPSeq datasets for more than 70 factors with 12 retroviral integration data 
sets for HIV-1, MLV, HIV/MLV chimeras, PERV, XMRV, HTLV1, ASLV, 
and Foamy virus. When compared with MLV, PERV or XMRV integration 
sites, F scores >0.80 were observed with acetylation of H3 and H4 at several 
positions, methylation of H2AZ, H3K4 and K9, and STAT1. H3K4me3 vs 
MLV, for example, gave an F score of 0.84, while HIV-1 was only 0.21. The F 
score for a chimera in which HIV-1 gag and IN was replaced with those from 
MLV was 0.82. By combining highly specific markers, we generated a 
supermarker that, 1) predicts >70% of MLV integration site within 2 kB, 2) 
predicts the average number of proviruses within a specific chromosomal region 
of a specific cell line, 3) explain why some oncogenes are activated in certain 
cell and not in others.  
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The intasome is the basic recombination unit of retroviral integration, 
comprised of the integrase (IN) protein and ends of the cDNA made by 
reverse transcription. Clinical IN strand transfer inhibitors (InSTIs) 
preferentially target the DNA bound form of IN as compared to the free 
protein, highlighting the critical requirement for detailed understanding of 
HIV-1 intasome structure and function. Though biochemical studies have 
identified a tetramer of HIV-1 IN as the active form of the enzyme, 
structural details of protein and DNA interactions are lacking.  
 
The crystal structure of the related prototype foamy virus (PFV) intasome 
has been solved recently, revealing numerous details of the retroviral 
integration machinery. Structures of drug-bound PFV intasome complexes 
moreover shed significant light on the mechanism of InSTI action. Herein 
we present a model for the HIV-1 intasome built using the PFV structure as 
template. Analysis of critical IN-IN and IN-DNA interactions seen in the 
HIV-1 intasome and their comparison with previous results further 
validated our model. The roles of novel IN-DNA contacts are being 
assessed using a variety of biochemical assays. 
 
Models for clinical InSTIs bound at the HIV-1 IN active site were also 
constructed and compared to results of previous studies. These data 
highlight key attributes of drug resistance and underscore interactions 
between halobenzyl moieties common to InSTIs and the invariant CA/GT 
residues at the end of the viral DNA substrate.  
 
Our models highlight the structural basis for HIV-1 integration, define the 
mechanism of inhibitor action, and therefore should help to formulate new 
drugs to inhibit viruses resistant to first-in-class compounds. 
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We have used atomic force microscopy to study stable complexes formed 
between HIV-1 integrase and viral DNA. A tetramer of integrase stably 
bridges a pair of viral DNA ends, consistent with previous analysis by gel 
electrophoresis. This intasome is highly stable to high ionic strength that 
strips more loosely associated integrase from internal regions of the viral 
DNA. We also observe tetramers of integrase associated with single viral 
DNA ends and time course experiments suggest that these Single End 
Complexes (SECs) are intermediates in intasome assembly. Strikingly, 
integrase tetramers are only observed in tight association with viral DNA 
ends and not at internal regions of the viral DNA. Dimers of integrase were 
never observed bound to viral DNA ends. The self-association properties of 
intasomes suggest that the integrase tetramer within the intasome is 
different from the integrase tetramer formed at high concentration in 
solution in the absence of viral DNA. Finally, the integration product 
remains tightly bound by the integrase tetramer, but the 3' ends of the target 
DNA in the complex are not restrained and are free to rotate resulting in 
relaxation of initially supercoiled target DNA. The crystal structure of the 
prototype foamy virus intasome1 suggests that some integrase domains 
within the tetramer may be dispensable for intasome assembly. We are 
currently testing this hypothesis. 
 
Reference: 
1. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Nature, 
published online 31 January 2010. 
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A tetrameric form of HIV-1 integrase (IN) stably associates with two viral DNA 
ends and catalyzes integration of the viral genome into the host chromosome, a 
process essential for retroviral replication. We and other groups have 
demonstrated that LEDGF also stabilizes a tetrameric form of IN. However, our 
mass spectrometric footprinting experiments and functional assays have 
suggested that IN tetramers formed in IN-viral DNA and IN-LEDGF complexes 
are not identical. For example, mass spectrometric footprinting experiments 
have indicated that IN undergoes significant conformational change upon 
interactions with DNA substrates but not with LEDGF. Furthermore, we and 
other groups have demonstrated that the pre-assembled IN-LEDGF complex is 
active in 3’-processing and single-end integration reactions but fails to catalyze 
the biologically relevant concerted integration of both ends. In contrast, pre-
incubation of IN with vDNA and subsequent addition of LEDGF ensures 
effective concerted integration. In the present study we have examined a 
hypothesis that direct binding of LEDGF differentially modulates structural 
conformations and functions of the pre-formed IN-viral DNA complex and 
unliganded IN. To compare IN tetrameric forms in the IN-viral DNA and IN-
LEDGF complexes we employed protein-protein FRET. For this, two separate 
preparations of IN were site-specifically labeled with donor and acceptor 
fluorophore. The results indicate that the IN tetramers adopt distinct 
conformations in the IN-LEDGF and IN-viral DNA complexes. In particular, 
the two IN active sites are positioned significantly closer together in the IN-
viral DNA complex than the IN-LEDGF complex. FRET measurements suggest 
optimal organization of individual IN subunits within IN-viral DNA complex, 
while LEDGF stabilizes suboptimal conformation of IN tetramer. Furthermore, 
the order of addition experiments indicated that binding of LEDGF to the pre-
formed IN-viral DNA complex allows maintenance of the fully functional 
conformation of the nucleoprotein complex, whereas preincubation of LEDGF 
and IN first and subsequent addition of viral DNA yield a distinct conformation 
of the IN tetramer which is defective for concerted integration. These findings 
provide new and important insight into the structural organization of IN in the 
functional ternary IN-viral DNA-LEDGF complex and highlight the importance 
of the sequential interactions of viral DNA and LEDGF for productive HIV-1 
integration. 
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Integration of HIV-1 DNA into chromosomes by the viral integrase (IN) is 
essential for virus replication. Upon reverse transcription, a preintegration 
complex (PIC) is formed wherein IN removes two nucleotides from the 3’-
OH blunt-ends of linear cDNA. After nuclear transport, IN inserts the two 
recessed DNA ends into chromosomes via a concerted integration 
mechanism. In-vitro, IN juxtaposes two viral DNA ends forming the 
synaptic complex (SC), a transient intermediate in the concerted integration 
pathway. Here, we show Raltegravir (RAL) and other strand transfer 
inhibitors (STI) possessing diverse structures bind to and inactivate SC. The 
inactivated or trapped SC is unable to bind target DNA thereby inhibiting 
the formation of concerted integration products. Efficiency of a particular 
inhibitor to form trapped SC correlates with its potency to inhibit concerted 
integration. 
We detected a new major IN-single viral DNA-inhibitor complex on native 
agarose above 200 nM STI, termed inhibitor-single DNA (ISD) complex. 
IN dimers in ISD complex bind to the terminal ~30 bp on U5 and U3 DNA 
ends. Formation of ISD was time, temperature, and STI concentration 
dependent. With RAL, MK-2048, and diketo acid L-841,411, ~20-30% of 
the input DNA substrate was incorporated into the ISD complex. Most of 
other seven STI investigated including Elvitegravir weakly produced ISD 
(≤5% of the input DNA). RAL resistant mutant N155H weakly formed the 
ISD complex with RAL at 25% level of wild type IN which correlates with 
the ~3 fold increase in the IC50 value for inhibition of concerted integration 
by N155H. The ISD complex may be valuable in the biochemical 
evaluation of newly identified STI, drug-resistant IN mutants, and atomic 
structural analysis. 
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Exploring the dynamic interplay between HIV-1 and host cell factors is 
essential to understand the molecular mechanisms underlying diverse 
physiological aspects of the HIV-1 life cycle. During early steps, viral 
components, as part of the pre-integration complex (PIC), have to travel 
from the plasma membrane and then cross the nuclear pore to finally 
integrate viral cDNA into the host cell genome. This latter event is 
controlled by the viral enzyme integrase (IN), which has to interact with 
both viral and cellular proteins to achieve integration. Because IN is one of 
the components that remains constantly associated with PIC until reaching 
its chromosomal target it is particularly suited for studying interactions 
between PIC and cellular factors.  
In this study, we developed a biochemical approach to further explore the 
dynamics of interactions that IN engaged with its cellular and viral partners 
at early time points post-infection. We took advantage of the HIV-1 Bru 
virus carrying an IN tagged with an HA epitope to purify and characterize 
IN complexes during the course of T-lymphocyte infection. At two hours 
post-infection (h.p.i.), the majority of IN co-eluted with viral DNA within a 
high molecular mass (IN-HMM) complex, as analyzed by gel-filtration 
chromatography. This complex is dramatically reduced at later time points, 
while several low molecular mass IN complexes (IN-LMM) are still 
detectable. These IN-LMM complexes were found to co-fractionate with 
cellular cofactors LEDGF/p75, VBP1 and TNPO3. Furthermore, interaction 
between IN and LEDGF/p75, VBP1 and TNPO3 could also be detected at 6 
h.p.i. Overall, our results indicate a dynamic recruitment of cellular 
cofactors by IN during the early steps of HIV replication.  
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Human endogenous retroviruses (HERVs) result from viral infections in the 
germ line and constitute about 8% of the human genome. The HERV-K 
(HML-2) group includes the most recently integrated human proviruses, 
some of which are expressed in normal and cancer tissue. Examples of 
HERV-K expression, ranging from RNA transcripts to virus particles 
visible in electron micrographs, have been observed in mammary tumors. 
Since HERVs represent a significant fraction of the human genome, 
endogenous proviruses might play an important role in the regulation of 
cellular gene expression leading to tumor formation. Identification of 
HERV loci may also provide useful indicators of altered gene expression 
from various cellular DNA regions as well as understanding the underlying 
mechanisms of tumorigenesis. 
 
To assess these possibilities, we have examined HERV-K (HML2) 
expression patterns in a set of breast cancer cell lines, as well as primary 
mammary epithelial and tumor cells. We have identified a subset of HML-2 
proviruses that is expressed uniquely in tumor cells of various types, but not 
in normal mammary epithelium. From these proviruses, we have analyzed 
published microarray data to determine whether their expression is linked to 
expression of genes implicated in tumorigenesis through local changes in 
chromatin structure or through shared promoter elements. Identification of 
provirus-linked genes that are significantly upregulated in tumor samples 
which will provide important insights into the mechanism of tumorigenesis 
and may identify putative anti-tumor targets. Finally, we have shown that 
envelope (Env) proteins encoded by HERV-K proviruses are expressed in 
all tumor cell lines examined but not in normal lines, enhancing the 
prospect of using Env as a possible biomarker for tumorigenesis. 
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Epigenetic silencing of retroviral DNA may occur through either stochastic 
or active processes. Stochastic processes include integration site position 
effects, while active processes may reflect a cellular antiviral response. We 
have been investigating the mechanisms that underlie the rapid, and high 
frequency epigenetic silencing of avian sarcoma virus in human cells, using 
RCAS/RCAN vectors that encode GFP reporter genes under control of the 
LTR or heterologous promoters. We show that epigenetic silencing 
proceeds through two steps: initiation and maintenance. Initiation appears to 
be an active process, whereby host factors engage the incoming viral DNA. 
We had previously discovered such an inhibitory role for the ubiquitous 
host protein Daxx, a transcriptional repressor. Daxx is now recognized to 
have broad antiviral roles, with repressive activities mediated via its binding 
partners, histone deacetylases (HDACs) and DNA methyl transferases 
(DNMTs). Our recent studies address the roles of these factors, and show 
that proviral DNA methylation occurs very rapidly, post-infection. 
Furthermore, knockdown of Daxx prior to infection results in increased 
GFP expression, consistent with its proposed repressive role. 
 
To identify the cellular factors that maintain long term silencing, we 
previously developed an siRNA-based screening approach, in which 
knockdown of specific silencing factors results in viral GFP reporter 
reactivation. We identified functional roles for DNMT3A, as well as the 
histone methyltransferases KMT1E and KMT5C, which place the 
H3K9me3 and H4K20me3 repressive marks, respectively. Our recent 
findings indicate that these histone repressive marks, as well as CpG DNA 
methylation are widespread over the integrated proviral DNA. Our current 
data suggest a model in which the silencing machinery is recruited to viral 
DNA to initiate and maintain a heterochromatic state. This experimental 
system provides a robust approach for identifying cellular epigenetic 
silencing factors.  
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Previously we reported the results of a somatic cell genetic screen of 
insertionally mutagenized Chinese hamster ovary (CHO-K1) cells that 
identified ZASC1 as a novel transcriptional regulator of MLV transcription. 
ZASC1 was shown to be a sequence-specific DNA binding protein with 
three highly similar binding sites located within the MLV U3 promoter. 
Sequence homology analysis revealed that the HIV-1 promoter contained a 
highly conserved ZASC1 binding site located just upstream of the TAR 
element. EMSA analysis confirmed that ZASC1 bound the HIV-1 promoter 
and infection with HIV-1 vectors containing mutations in the U3 region that 
disrupt ZASC1 binding led to impairment of proviral transcription in newly 
infected CHO-K1 cells or human Jurkat T cells. The role of ZASC1 in HIV-
1 infection was confirmed using dominant negative ZASC1 mutants and 
gene-specific shRNAs that reduced the level of ZASC1 protein prior to 
virus challenge. Due to the close proximity of the ZASC1 binding site to the 
TAR element, we examined the potential role of ZASC1 in TAT mediated 
activation of transcription. In transient transfection assays, TAT mediated 
stimulation of promoters lacking ZASC1 binding sites was significantly 
lower than that seen with WT promoters. In contrast to ZASC1 effects on 
the MLV promoter, expressing exogenous ZASC1 did not, by itself, 
stimulate the HIV-1 promoter. However, TAT and ZASC1 co-expression 
significantly increased TAT activation, and this stimulation of TAT activity 
was dependent upon the ZASC1 binding sites in the viral promoter. 
Mammalian two-hybrid and co-immunoprecipitation experiments 
demonstrated a physical interaction between ZASC1 and TAT. These data 
demonstrate that ZASC1 is a new transcriptional regulator of HIV-1 gene 
expression that binds to DNA sequences in the HIV-1 promoter, interacts 
with TAT and stimulates TAT-mediated activation of viral transcription. 
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Nuclear retention of RNA is implicated in the regulation of several 
pathways of gene expression. A good model of functional nuclear RNA 
retention comes from the human immunodeficiency virus type 1 (HIV-1) 
where the generation of infectious virions requires the synthesis of two 
classes of viral transcripts: the spliced and the non-terminally spliced HIV 
RNA. The former is efficiently processed and exported to the cytoplasm. 
The latter remains unspliced or partially spliced and it is retained in the 
nucleus by unknown mechanism until the viral Rev protein mediates its 
export for the expression of structural proteins and for the production of 
full-length genomic RNAs.  
A major mechanism of nuclear RNA retention involves hyperediting by 
adenosine deamination. We show that hyperediting is not obligatory for 
retention of viral unspliced RNA and we characterize an alternative 
pathway. 
To this end we explored the proteome associated with the unspliced HIV-1 
RNAs that are retained in the nucleus until the viral Rev proteins mediate 
their export. We demonstrate that the viral unspliced RNA is associated 
with the host factors PSF, p54nrb and MATR3. PSF/p54nrb complex binds 
the viral RNA co-transcriptionally but MATR3 defines a subnuclear 
compartment where the viral RNA is delivered. This pathway is required 
for the activity of Rev on unspliced HIV-1 RNA. Interestingly PSF/p54nrb 
binding and localization to MATR3 foci occur independently of RNA 
hyperediting.  
Our findings reveal a novel cellular mechanism of nuclear RNA retention 
that is hijacked by a virus. 
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Mouse mammary tumor virus (MMTV) is a complex murine retrovirus that 
encodes an HIV Rev-like export protein, Rem, from a doubly spliced 
version of envelope (env) mRNA. Previously, the N-terminal 98 amino 
acids of Rem, which is identical to Env signal peptide (SP), and full-length 
Rem were shown to be functional in a reporter assay and localized to the 
nucleolus. The reporter assay is based on the Renilla luciferase gene, which 
has been inserted into the 3’ end of the MMTV genome. Luciferase activity 
is responsive to Rem or Env expression and requires a functional nuclear 
localization sequence in the SP from either protein. Rem-responsiveness 
also requires a Rem-responsive element (RmRE) on the reporter vector. 
MMTV-infected cells or cells transfected with rem or envelope cDNAs 
express SP. Signal peptides generally function to direct translation of viral 
or cellular glycoproteins to the endoplasmic reticulum (ER). Signal 
peptidase, a protease located in the ER lumen, then cleaves the signal 
peptide, which is believed to be degraded by cytosolic proteasomes. 
Mutations that block Rem or Env cleavage by signal peptidase eliminate 
both detectable SP and functional activity in reporter assays. Fluorescence 
microscopy revealed that GFP-tagged cleavage site mutants are unstable 
and lack fluorescence compared to GFP-tagged wild-type Rem, suggesting 
improper folding. Uncleaved Rem is partially glycosylated, yet mutations in 
both glycosylation sites within the C-terminus prevented Rem function. 
Proteasome inhibitors allowed accumulation of uncleaved Rem relative to 
SP and increased reporter activity, consistent with SP retrotranslocation and 
proteasomal escape prior to nuclear entry. Expression of a dominant-
negative p97 ATPase did not alter levels of unprocessed Rem and SP, but 
decreased reporter activity, suggesting p97-dependent retrotranslocation of 
SP. Our results provide the first example of a SP that is processed by signal 
peptidase and retrotranslocated to allow nuclear localization and function. 
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Human Immunodeficiency Virus Type 1 uses a complex regulatory 
mechanism, involving both viral and cellular genes, to control gene 
expression. In case of HIV-1 a single transcript in its unspliced and spliced 
forms directs the synthesis of all viral proteins. Normally the nuclear export 
of intron containing / unspliced RNA transcripts is inhibited in all 
eukaryotic cells. However, post-transcriptional regulatory systems 
involving viral elements like Rev/RRE and CTE have been shown to 
overcome the restrictions of cellular RNA export mechanisms. HIV-1 has 
evolved the viral Rev protein to overcome this restriction for viral 
transcripts. RNA capping and cap-methylation occur co-transcriptionally at 
the start of transcription and 5’- mRNA capping has important 
consequences for events such as pre-mRNA synthesis / splicing, RNA 
cytoplasmic transport, mRNA translation and turnover. In eukaryotes, a 7-
methylguanosine (m7G) cap is added to newly transcribed RNA polymerase 
II (RNAP II) transcripts. A subset of RNAP II transcribed cellular RNAs, 
including small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), 
and telomerase RNA, are additionally hypermethylated at the exocyclic N2 
of the guanosine cap. These RNAs, different from m7G-RNA, are exported 
from the nucleus through the CRM-1 pathway. The CRM-1 pathway is also 
used by HIV-1 to export Rev/RRE-dependant RNAs into the cytoplasm and 
previously, it was considered that the HIV-1 Rev protein and the cis-acting 
viral RRE were sufficient for dictating export specificity through CRM-1. 
Here, we report that HIV-1 Rev/RRE-dependant RNA, like snRNA and 
snoRNA, has a trimethylguanosine (TMG) cap. We identify the 
trimethylating methyltransferase as the human PIMT (PPAR-interacting 
protein with methyltransferase domain) protein and show that PIMT-
mediated TMG modification specifies CRM-1 export of Rev/RRE-
dependent RNA. 
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Retroviruses rely on host RNA binding proteins to modulate various steps 
in their replication. Many retroviruses require Dhx9/RNA helicase A 
(RHA) for efficient virion production. In HIV-1, RHA is a necessary host 
factor for efficient translation of viral mRNA, and RHA assembled into 
progeny virions promotes infectivity of these virions. Biophysical and 
genetic approaches defined features of RHA necessary for selective 
interaction with retroviral target RNA. Site-directed mutagenesis 
determined that helicase activity associated with the central DEIH helicase 
core is necessary for HIV-1 and HTLV-1 translation activity; the C-terminal 
RGG-rich domain is necessary for nuclear localization of RHA and protein-
protein interactions necessary for translation activity, but not RNA 
recognition. The N-terminal RNA binding domain directs specific 
recognition of retroviral target RNA. Substitution mutations identified 
critical N-terminal Lysine residues; their mutation is sufficient to eliminate 
target RNA affinity. Mutation or deletion of N-terminus eliminates RHA 
translation activity. Furthermore, expression of the RHA N-terminus is 
sufficient to block RHA-dependent translation activity. Our results support 
the expectation that host modification of RHA is sufficient to downregulate 
RHA-dependent translation of viral and host genes. The results suggest 
RHA is the nexus of a newly appreciated antiviral response mechanism. 
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Unspliced retroviral RNAs function as genomes (gRNA) for packaging and 
mRNAs for translation. Where and when gRNAs initially form dimer 
partner associations or are recruited for packaging likely differs among 
retroviruses. For Moloney murine leukemia virus (MLV), previous findings 
with actinomycin D treated cells suggest that MLV unspliced RNAs sort 
into non-equilibrating pools of gRNAs and mRNAs. Prior work from our 
lab and others on the randomness of gRNA dimer populations suggests that 
unlike HIV-1, MLV gRNA dimer partner selection may occur before RNAs 
exit the nucleus, suggesting that the bisection in gRNA and mRNA fates 
occurs before nuclear egress. Here, tetracycline-regulated MLV 
transcription was used to repress MLV transcription in a more targeted 
fashion in order to re-address the two pool phenotype of MLV unspliced 
RNA. Specific repression of MLV transcription led to a more rapid decline 
in gRNA packaging than virion production which is consistent with earlier 
findings where transcription was inhibited globally with actinomycin D. 
Additionally, packaged gRNA dimer populations were analyzed at various 
time points after both specific and general transcription inhibition. The 
results indicated that transcription inhibition led to increased randomness in 
gRNA dimer partner associations and a parallel increase in recombination 
under both conditions, albeit with residual biases consistent with an ongoing 
partitioning between mRNAs and genomes. These data suggest that the 
small population of heterodimers in MLV co-expression studies arise from 
a subset of gRNAs that escape early dimer partner associations and form 
dimer associations more randomly later. Together, our observations suggest 
that MLV unspliced RNA fates are determined early in the host cell nucleus 
and support the early separation of MLV unspliced RNAs into two largely 
non-equilibrating pools. 
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An emerging unified model of nonsense-mediated decay (NMD) suggests that 
long 3' untranslated regions (3' UTRs) render mRNAs susceptible to NMD in 
mammalian cells. Retroviruses, which invariably express mRNAs containing 3' 
UTRs spanning several kilobases, have a complex relationship with the NMD 
surveillance machinery. For example, avian retroviruses have evolved RNA 
elements that suppress degradation of messages harboring premature 
termination codons, while it has been reported that the core NMD factor Upf1 is 
a positive regulator of HIV RNA stability.  
 
We are using affinity purification of mRNP complexes containing tagged RNAs 
to identify proteins associated with the 3' UTRs of HIV mRNAs. In the course 
of these experiments, we observed enrichment of Upf1 on transcripts containing 
HIV 3'LTR sequences. We find that the association of Upf1 with HIV 3’LTR-
containing mRNAs is not sequence-specific but instead correlates with UTR 
length. To better understand the functional significance of Upf1 recruitment to 
transcripts with long UTRs, we analyzed Upf1 binding to model mRNAs 
containing 3'UTRs known to be either susceptible or resistant to NMD. We 
observed some Upf1 association with all transcripts tested, but mRNAs with 3’ 
UTRs known to undergo Upf1-dependent decay co-purified substantially higher 
levels of Upf1 protein than those resistant to NMD, in a manner independent of 
ongoing translation and functional NMD. Together, these findings suggest that 
nonspecific RNA binding by Upf1 may allow it to act as an intrinsic sensor of 
UTR length in the process of premature termination codon surveillance. 
 
The Moloney murine leukemia virus (M-MLV) readthrough-promoting 
pseudoknot causes misincorporation of an amino acid at the gag termination 
codon at 5-10% frequency. Using the M-MLV pseudoknot to modulate 
translation termination at an NMD-triggering premature termination codon, we 
find that readthrough disrupts steady-state Upf1 association with transcripts 
containing long UTRs. Surprisingly, we also demonstrate that either 
readthrough or frameshifting by retroviral RNA structures can robustly inhibit 
NMD. In fact, even M-MLV pseudoknot variants causing levels of readthrough 
insufficient to disrupt Upf1 association with long UTR-containing RNAs can 
stabilize NMD targets. By modulating readthrough efficiency, we are thus able 
to separate Upf1 recognition of long UTR-containing RNAs from downstream 
RNA decay, giving valuable insight into the in vivo dynamics of transcript 
surveillance and decay by the NMD pathway. In addition, this work uncovers a 
potential role for recoding elements in the evasion of NMD by retroviruses. 
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The Rous sarcoma virus (RSV) Gag protein coordinates the assembly and 
release of virus particles from the plasma membrane. Previously, we 
demonstrated that RSV Gag undergoes transient nuclear localization prior to 
membrane binding. Nucleocytoplasmic shuttling of Gag is intrinsic to the virus 
assembly pathway. If Gag bypasses the nuclear trafficking step, virion 
incorporation of genomic RNA (gRNA) is severely impaired, although re-
establishing Gag nuclear transport restores gRNA encapsidation. Taken 
together, these results strongly suggest that Gag nuclear trafficking is involved 
in the recognition and selective encapsidation of RSV gRNA.  
 
To directly test whether we could visualize Gag-gRNA interactions within the 
nucleus, we adapted the MS2-phage labeling system to tag the viral RNA with a 
fluorophore. We engineered an RSV provirus containing 24 repeats of MS2-
RNA stem loops (RC-24x). The MS2 coat protein fused to YFP (MS2-YFP) 
recognizes this RNA stem loop structure and selectively binds it, allowing the 
detection of gRNA in live cells. Incorporation of 24 copies of the MS2 stem 
loops into the RSV genome did not disrupt productive infection in avian cells.  
 
To visualize where Gag interacts with the gRNA in living cells, we expressed 
Gag-CFP in trans. MS2-YFP, which harbors a strong nuclear localization 
signal, remains diffuse throughout the nucleus when co-expressed with an RSV 
provirus lacking the MS2 loops (RC-wt), and little MS2-YFP was seen outside 
the nucleus. When the RC-24x provirus was expressed, MS2-YFP formed 
discrete puncta in the nucleoplasm as well as foci just outside the nucleus, in the 
cytoplasm, and at the plasma membrane that colocalized with Gag.  
 
To study Gag-gRNA interactions in the nucleus, cells expressing RC-24x or 
RC-wt, MS2-YFP, and Gag-CFP were treated with leptomycin B (LMB) to 
inhibit Gag nuclear export. In LMB treated cells, MS2-YFP formed larger 
intranuclear puncta that were localized at or near foci of Gag-CFP with RC-24x 
but not RC-wt. Colocalization of Gag with the MS2-tagged gRNA suggests that 
RSV Gag binds its genome in the nucleus. To better characterize these 
intranuclear binding events, we will use a nuclear-export deficient mutant of 
Gag (L219A) to study the mobility of Gag-gRNA nuclear foci. Furthermore, we 
will use time-lapse experiments to follow the MS2-tagged gRNA puncta from 
the nucleus, through the cytoplasm, and to the plasma membrane for particle 
release.  
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We recently developed a system to directly examine the RNA content of 
individual HIV-1 particles, using fluorescent protein (FP)-tagged RNA-
binding proteins that specifically recognize stem-loop structures engineered 
into the viral genome. We have now applied a similar strategy to study the 
mechanisms of HIV-2 RNA packaging, which has been proposed to be 
different from that of HIV-1; specifically, HIV-2 Gag packages the RNA in 
cis and only RNA that encodes full-length functional Gag can be efficiently 
packaged.  
To delineate the efficiency of HIV-2 genome encapsidation and explore the 
mechanisms of HIV-2 RNA packaging, we modified HIV-2 genomes, 
coexpressed these genomes with FP-tagged RNA-binding proteins, 
harvested virus-like particles, and directly examined the RNA content of 
each particle by fluorescence microscopy. We observed that >90% of the 
HIV-2 particles contained full-length viral RNA. Using two different tagged 
RNA-binding proteins, we found that heterozygous particles, which 
contained RNAs from two different viruses, were generated efficiently. 
Furthermore, the ratio of the heterozygous particles in the viral population 
could be altered by changing the dimerization initiation signal (DIS) in the 
5′ untranslated region, suggesting that HIV-2 Gag packages one dimeric 
RNA rather than two monomeric RNAs.  
To further explore whether HIV-2 packages RNA in cis, we generated gag 
mutants that do not encode functional proteins and used a competition assay 
to compare the packaging efficiencies of RNAs from viruses encoding wild-
type or mutant Gag. Our preliminary results showed that mutant Gag-
encoding RNAs were efficiently packaged into particles.  
Together, these findings indicated that HIV-2 RNA is encapsidated into 
particles at a high efficiency, HIV-2 Gag packages dimeric RNA, and 
efficient HIV-2 packaging does not require RNA that encodes full-length 
functional Gag.  
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All retroviral genomic RNAs contain a cis-acting packaging signal, termed 
ψ, but the mechanism by which ψ-containing RNAs are selectively 
packaged into nascent virions is not understood. Ψ could contain a high-
affinity binding site for Gag; however, it is equally possible that ψ directs 
the RNA to a cellular compartment where it will encounter Gag before Gag 
can interact with cellular mRNAs (which can also be packaged). Retroviral 
RNAs are packaged as dimers and it has been suggested that dimerization is 
essential for selective packaging. Using the SHAPE method of high-
throughput analysis of RNA secondary structure, we have studied the 
structure of Moloney murine leukemia virus (MLV) RNA within the 
authentic virus particle and compared this structure to that of naked viral 
RNA. We also analyzed the binding of recombinant MLV Gag protein (the 
structural protein of the virus) and NC protein (the nucleic acid-binding 
protein within mature MLV particles) to dimeric RNA in vitro. These 
experiments indicate that both Gag and NC bind specifically to the 
sequence UCUG-UR-UCUG and interact most strongly with the first U and 
final G in each tandemly repeated UCUG element. The context surrounding 
these ten nucleotides is also important, as highest affinity binding requires 
the presence of base-paired regions flanking this motif. Two of these motifs 
are partially base-paired in monomeric MLV RNA, but are unpaired in 
dimeric RNA. We tested the possibility that this high-affinity binding 
structure, specifically created upon dimerization of MLV RNA, is important 
in packaging. We found that a mutant in which all 4 of the G residues in the 
two motifs are replaced by A nucleotides is packaged <1% as efficiently as 
the native sequence. Thus, this motif is a crucial element in ψ. To our 
knowledge, this is the first time that alteration of a small number of bases 
has had such a dramatic effect on the packaging of a retroviral RNA. The 
results support the general hypothesis that ψ is a high-affinity binding 
structure for the homologous Gag protein.  
 
This research was supported in part by the Intramural Research Program of the NIH, 
National Cancer Institute, Center for Cancer Research and by NCI contract no. 
HHSN261200800001E with SAIC-Frederick.  
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HIV-1 assembles inefficiently in murine cells, reflecting weak expression of 
the Gag/Gag-Pol structural proteins and a cellular defect in Gag targeting to 
the plasma membrane. Mouse-human cell fusions or hybrids can provide for 
infectious virus production, suggesting that murine cells lack one or more 
human factors necessary for HIV-1 assembly. We previously demonstrated 
that HIV particle production in murine cells is restored after replacing the 
Rev-response element (RRE) in Gag/Gag-Pol transcripts with four copies of 
the constitutive transport element (CTE) from Mason-Pfizer monkey virus. 
The RRE confers nuclear export of unspliced and partially spliced viral 
transcripts using the HIV Rev/Crm1-dependent pathway, while the CTE 
directs export through the NXF1/NXT pathway used by the bulk of cellular 
mRNAs. This result suggests a mechanistic link between transport of the 
viral genome, serving as the mRNA encoding Gag/Gag-Pol, and Gag 
assembly competency. Subsequently, we have designed RNA transcripts 
encoding Gag/Gag-Pol and various Gag mutants under the control of 
different nuclear export elements and have used these to study the vertical 
integration of HIV-1 gene expression as well as to identify and characterize 
human cellular factors that may contribute to the HIV-1 assembly pathway. 
These studies have identified multiple cellular factors that, when expressed 
transiently, markedly improve Gag/Gag-Pol expression and virus particle 
production. A subset of these factors, most notably members of the SR 
family of RNA binding proteins, result in robust increases to Gag/Gag-Pol 
expression specifically from HIV-1 RNAs. However, when controlled for 
expression level, SR proteins do not overcome the defect to Gag assembly 
competency. By contrast, other factors such as Sam68 both boost Gag/Gag-
Pol expression and improve Gag assembly competency in murine cells. We 
are currently asking if these proteins may contribute to restoring virus 
replication in murine cells 
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Retroviral assembly and release are highly coordinated events mediated via 
specific interactions between the viral Gag protein and the host cell 
machinery. Previous work from our lab demonstrated the involvement of 
Golgi-localized, γ-ear-containing, Arf-binding proteins (GGAs) and ADP 
ribosylation factor (Arf) proteins in HIV-1 assembly and release. In this 
study, we identified the cellular protein growth arrest-specific 7 (Gas7) as a 
novel candidate host cofactor in HIV-1 replication. Gas7, a Pombe cdc15 
homology (PCH) protein harboring functional determinants like F-BAR, 
WW, and SH3-domains, interacts not only with HIV-1 Gag but also with 
cellular cofactors that have been implicated in the late stages of retroviral 
replication (e.g., GGA1, Tsg101, and SH3GL1). The F-BAR domain of 
Gas7 is known to bind to actin and induce plasma membrane outgrowths, 
while the WW-domain is reported to be essential for Gas7-mediated 
microtubular maintenance. We observe that exogenously expressed, full-
length Gas7b is incorporated into virions and subsequently processed by the 
viral protease. In contrast, the Gag-binding F-BAR domain by itself is 
excluded from virions. This apparent WW-domain dependence of virion 
incorporation is further supported by our observation that the Gas7-binding 
protein PSTPIP1, a WW-domain deficient but F-BAR domain-harboring 
member of the same family, is excluded from virions. Bimolecular 
fluorescence complementation (BiFC) assays, in addition to providing 
evidence for direct interaction of Gas7 with HIV-1 Gag and GGA1, enabled 
visualization of plasma membrane-localized actin tail-like structures 
resulting from BiFC between Gas7 and HIV-1 Gag. We also obtained 
evidence by BiFC that Gas7 binds EIAV Gag in living cells. Interestingly, 
we observed an interaction between Gas7 and the WASP-interacting protein 
(WIP) in yeast two-hybrid assays, and a recent report demonstrated a direct 
interaction between Gas7 and N-WASP via the WW-domain. These 
findings imply a role for WIP:WASP:Arp2/3 pathway in Gas7-mediated 
membrane remodeling events that could potentially modulate retroviral 
assembly and release at the plasma membrane. The reported enhancement 
of Gas7 expression levels in polarized monocyte-derived macrophages and 
the generation of tubule-like structures upon Gas7 dimerization in our BiFC 
assays also suggest additional roles for Gas7 such as in intercellular transfer 
of retroviruses. Data deciphering the functional role of Gas7 and its cellular 
partners in retroviral replication will be presented. 
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In the last years, biochemical and structural studies have indicated the crucial 
involvement of host cell ESCRT components during the HIV-1 budding 
process. The AAA ATPase SKD1 (Vps4) acts in the final stage of ESCRT 
function, resolving the ESCRT III complex in order to recycle its components.  
 
Using fluorescently labelled SKD1, we have directly visualized the dynamics of 
SKD1 activity during the Gag assembly and release process by fluorescence 
live-cell imaging over 1-2 hours at 37°C. SKD1eGFP coexpressed with 
GagmCherry and Gagwt showed fluorescence bursts at the plasma membrane of 
living cells, colocalizing with viral assembly sites. Specific recruitment of 
SKD1 to Gag assembly sites was verified by the absence of SKD1 bursts if no 
Gag or Gag late- mutants were expressed. Moreover, the number of bursts 
increased with the number of Gag assembly sites connecting those bursts to 
SKD1 activity. Coexpression of the SKD1E228Q mutant, which prevents ATP 
hydrolysis and has been reported to arrest SKD1 in its multimeric ring structure, 
resulted in frozen bursts at the plasma membrane, largely not colocalizing with 
Gag assembly sites. By tracking individual assembly sites, we could establish 
the timing of the SKD1 interaction with respect to the three phases of HIV-1 
budding established in earlier studies (PLOS Pathogen 5(11), 2009). SKD1 
bursts appeared mainly at the beginning of phase II when the Gag lattice had 
been completed and these bursts lasted in the order of one minute. On average, 
less than one burst was detected per assembly site, indicating that not every 
assembly site interacts with SKD1 (at least on the timescale of the two-hour 
measurement). Those assembly sites that did interact with SKD1 showed either 
a single burst or a low number of bursts. Mobility of Gag particles often 
increased or they disappeared on a delayed time scale after SKD1 bursts 
indicating that SKD1 recruitment is not immediately followed by virus release. 
 
These studies provide direct information regarding the interaction of the cellular 
component SKD1 with nascent HIV-1 assembly sites. Such live-cell imaging 
experiments provide great promise in elucidating more details of the viral life 
cycle. 
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The HIV-1 capsid (CA) protein assembles mature cylindrical and conical 
cores during viral morphogenesis in vivo, and can be induced to assemble 
cones, spheres and cylinders (tubes) in vitro. CA proteins are composed of 
N-terminal domains (NTDs), which have an amino-terminal β-hairpin and 
seven α helices (H1-H7); and a C-terminal domain (CTD), which folds to 
yield a short 310-helix followed by four α helices (H8-H11). Within capsid 
assembly products, CA proteins organize as hexamers, featuring NTD-NTD 
contacts mediated through H1-H3, intermolecular contacts between NTD 
H4 and a CTD groove, and interlinking of hexamers via the CTD dimer 
interface (H9). We have examined the determinants of HIV-1 capsid 
assembly in vivo and in vitro. Not surprisingly, we have found that 
perturbation of NTD β-hairpin, H1 and H2 residues impairs tube assembly; 
and that while deletion of the NTD cyclophilin loop (between H4 and H5) 
fosters assembly in vitro, the mutation yields assembly competent, but non-
infectious virus. Interestingly, we also have identified mutations in H6 that 
alter assembly morphologies, suggesting a β-hairpin-H6 interaction that 
regulates core morphogenesis. Additional experiments have led to the 
identification of second site revertants of NTD H4 mutations that map to the 
CTD, but not directly to residues at the CTD groove. These results support a 
more complicated model of intermolecular NTD-CTD interactions than 
previously reported. Yet other experiments show that capsid assembly can 
be triggered via the addition of low concentrations of RNA and capsid-
nucleocapsid (CANC) proteins, demonstrating a two step nucleation-growth 
mechanism for core assembly. Finally, in examining the effects of peptide 
inhibitors of capsid tube assembly, we have found that whereas the known 
inhibitor CAI blocks tube assembly, and can dismantle assembled tubes; 
two other peptides substantially alter the morphologies of the CA tubes. Our 
results identify new CA assembly determinants that may be targeted for the 
inhibition of HIV. 
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HIV-1 Gag assembles into virus particles predominantly at the plasma 
membrane (PM). The MA domain promotes binding to the PM via myristic 
acid moiety at the N terminus and the highly basic region (HBR) (the 
residues 17-31) in MA. In addition, MA is involved in envelope 
incorporation into virions and early post-entry process, both of which affect 
infectivity of progeny virions. Previously, we observed that 
phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] interacts with HBR and 
that this interaction is essential for Gag binding to the PM and virus release 
in HeLa cells. However, it is still unknown whether PI(4,5)P2 is similarly 
required in T cells. 
In this study, we demonstrate that PI(4,5)P2 also facilitates Gag binding to 
the PM and efficient virus release in T cells. In the presence of active 
polyphosphoinositide 5-phosphatase IV (5ptaseIV) that depletes cellular 
PI(4,5)P2, Gag localization at the PM was reduced, and instead, 
mislocalized to intracellular compartments or remained in the cytosol. 
Consistent with this observation, virus particle production was reduced in 
A3.01 T cells expressing 5ptaseIV. Serial passage of HIV-1 in an A3.01 
clone that expresses 5ptaseIV upon infection yielded an adapted mutant 
virus that has an L to R change at the MA residue 74 (74LR). The 74LR 
mutation accelerated the virus replication in T cells expressing 5ptaseIV 
relative to WT. However, single-cycle experiments revealed that the 74LR 
mutant was less efficient in virus release from parental A3.01 than WT, and 
in 5ptaseIV-expressing clones, release of the 74LR mutant is not more 
efficient than that of WT. Thus, accelerated replication of the 74LR mutant 
relative to WT in 5ptaseIV-expressing clones is not likely due to improved 
virus release. Instead, we found that the 74LR mutation increased the virus 
infectivity and compensated for the lack of PI(4,5)P2-dependent virus 
release enhancement. Altogether, these results indicate that PI(4,5)P2 
enhances Gag-membrane binding, Gag targeting to the PM and virus release 
efficiency in T cells, which in turn likely promotes efficient virus spread in 
T cell cultures. In the absence of PI(4,5)P2, however, the inefficient virus 
particle production can be compensated for by a mutation that enhances the 
virus infectivity. 
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HIV-1 Gag contains two late (L) domains: PTAP and LYPXnL that recruit 
members of the host’s fission machinery (ESCRT) to facilitate HIV-1 
release. Other retroviruses gain access to the ESCRT pathway by utilizing a 
PPXY-type L domain that interacts with cellular Nedd4-like ubiquitin 
ligases. Despite the absence of a PPXY motif in HIV-1 Gag, interactions 
with Nedd4-2 were recently shown to stimulate HIV-1 release. Here we 
show that the ubiquitin ligase Nedd4-1 corrected release defects resulting 
from the disruption of PTAP (PTAP-), suggesting that HIV-1 Gag might 
also recruit Nedd4-1 to facilitate virus release. Notably, Nedd4-1 
remediation of HIV-1 PTAP- budding defects is independent of cellular 
Tsg101, suggesting that Nedd4-1 function in HIV-1 release does not 
involve ESCRT-I components and is therefore distinct from that of Nedd4-
2. Consistent with this finding, deletion of the p6 region decreased Nedd4-
1-Gag interaction, and disruption of the LYPXnL motif eliminated Nedd4-
1-mediated restoration of HIV-1 PTAP-. This result indicated that both 
Nedd4-1 interaction with Gag and function in virus release occur through 
the Alix-binding LYPXnL motif. Furthermore, mutations of basic residues 
located in the NC domain of Gag that are critical for Alix’s facilitation of 
HIV-1 release, also disrupted release mediated by Nedd4-1, further 
confirming a Nedd4-1-Alix functional interdependence. In fact we found 
that Nedd4-1 binds Alix in both immunoprecipitation and yeast-two hybrid 
assays. In addition, Alix rescue of HIV-1 PTAP- required cellular Nedd4-1 
supporting the notion that Alix must recruit Nedd4-1 to promote HIV-1 
production. To promote virus release, Nedd4-1 also requires its catalytic 
activity, and RNAi knockdown of cellular Nedd4-1 inhibited Alix 
ubiquitinationin in the cell. Together our data support a model in which 
Alix recruits Nedd4-1 to facilitate HIV-1 release mediated through the 
LYPXnL/Alix budding pathway via a mechanism that involves Alix 
ubiquitination. 
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The mature capsids of HIV-1 and other retroviruses are fullerene protein 
shells that package the viral RNA for delivery into new host cells and 
facilitate proper reverse transcription of the genome. Retroviral capsids are 
composed of around 250 hexamers and exactly 12 pentamers of the viral 
CA protein, which are arranged on a variably curved hexagonal lattice. The 
lack of strict global symmetry in retroviral capsids has precluded traditional 
high-resolution structural analyses. Studies of these capsids have therefore 
employed symmetric model systems, derived from pure recombinant 
proteins in vitro. 
 
We have previously used a disulfide crosslinking strategy to facilitate the 
purification and crystallization of soluble HIV-1 CA hexamers. The 
resulting structures revealed in atomic detail the quaternary interactions that 
stabilize the hexamer, and the structural variations required to form a 
variably curved hexagonal lattice. We have recently used a similar strategy 
to determine X-ray crystal structures of the HIV-1 CA pentamer at 2.5 Å 
resolution. The new structures reveal that indeed, the CA pentamer and 
hexamer are quasi-equivalent. The same protein surfaces are used to form 
both oligomers, with the N-terminal domain of CA forming hexameric or 
pentameric rings, and the C-terminal domain forming a mobile belt around 
the central ring. Pentamer formation appears controlled by electrostatics, 
and may involve a balancing of attractive and repulsive ionic interactions 
between the N-terminal domains. 
 236 
SERINE RESIDUES IN THE P6 PROTEIN OF HIV-1 ARE 
PHOSPHORYLATED BY PKC AND REGULATE VIRAL CORE 
ASSEMBLY 
 
Jörg Votteler1, Liane Neumann1, Friedrich Hahn1, Sabine Hahn1, Kerstin 
Schmidt1, Nicole Studtrucker2, Peter Henklein3, David E Ott4, Gudrun 
Holland5, Norbert Bannert5, Ulrich Schubert1,2  
 
1Friedrich-Alexander-University , Institute of Virology, Erlangen, 91054, 
Germany, 2Virologik GmbH, Abt. HIV/AIDS, Erlangen, 91052, Germany, 
3Humboldt University, Institute of Biochemistry, Berlin, 10117, Germany, 4 
National Cancer Institute, SAIC-Frederick, Frederick, MD, 21702-1201, 
5Robert Koch-Institute, AIDS Immunopathogenesis and Vaccine 
Development, Berlin, 13353, Germany 
 
The p6 protein of HIV-1 Gag contains the two late assembly (L-) domains 
that recruit certain host cell factors in order to facilitate the release of 
nascent virions from infected cells. In addition, HIV-1 p6 has been 
characterized as the major phosphoprotein in virus particles. It was further 
observed that p6 can be modified at Thr, Ser, and, to a smaller extent, at Tyr 
residues indicating that p6 should be a substrate for several kinases. 
Originally, the mitogen-activated protein (MAP)-kinase ERK-2 was 
identified to mediate the phosphorylation of p6 in position Thr-23, a 
modification that was suggested to regulate the assembly and release of 
progeny virions.  
In the present study, we identified p6 as a substrate of the protein kinase C 
(PKC) that phosphorylates Ser residues in positions 14, 25, and 40. 
Individual substitution of all Ser residues in p6 revealed that only Ser-40 is 
important for virus replication in T-cell lines and in human lymphocyte 
tissue cultivated ex vivo, while combined mutation of all three PKC-sites 
completely abrogated replication. Most intriguingly, mutation of the PKC 
sites had no influence on L-domain mediated virus release. In contrast, the 
specific infectivity of the virions was reduced when Ser-40 was exchanged 
and completely lost when all PKC sites were mutated. Furthermore, it was 
observed that the integrity of the PKC sites is crucial for the final 
processing of CA from p25 to p24. Electron microscopy revealed that this 
defect in CA processing in turn leads to an irregular morphology of the 
virus core and the formation of an electron dense extra core structure. Thus, 
the cumulative results support a novel function of p6 that does not affect 
virus release but stimulates maturation of CA in a process that might be 
governed by PKC phosphorylation. 
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PPxY-type L domains are thought to promote retroviral budding through 
the recruitment of Nedd4 family ubiquitin ligases. Surprisingly, the budding 
and infectivity of HIV-1 L domain mutants is potently enhanced by ectopic 
Nedd4-2s, even though HIV-1 Gag lacks PPxY motifs. Nedd4-2s is a 
Nedd4-like ubiquitin ligase that associates with HIV-1 Gag via a naturally 
truncated C2 domain. In addition, Nedd4-2s harbors four ligand-binding 
WW domains and a catalytic HECT domain. We now find that the truncated 
C2 domain of Nedd4-2s can be functionally replaced by cyclophilin A 
(CyPA), which binds to the CA domain of HIV-1 Gag. Furthermore, when 
targeted to Gag through CyPA, or alternatively through the truncated 
Nedd4-2s C2 domain, the HECT domains of most but not all members of 
the Nedd4 ubiquitin ligase family were sufficient to efficiently rescue HIV-
1 budding. Notably, chimeras based on ubiquitin ligases with exquisite 
specificity for the synthesis of K63 ubiquitin chains were active, indicating 
that the synthesis of K48 chains is not required to function in viral budding. 
Interestingly, certain HECT domain fusion proteins and intra-HECT domain 
chimeras induced comparable levels and patterns of HIV-1 Gag 
ubiquitination, even though they differed dramatically in their ability to 
rescue HIV-1 budding. Thus, our results strongly argue against the 
possibility that Gag is the functional target of HECT domain-induced 
ubiquitination. 
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HIV-1 buds out from the infected cell in an immature, non-infectious form. 
Immature virions contain a partial spherical shell with Gag organized as a 
hexameric lattice. This lattice is well ordered at the CA level, and is linked via 
rod-like densities to an inner, disordered layer that corresponds to NC-RNA [1]. 
Maturation requires proteolytic cleavage of the Gag polyprotein at five 
positions, leading to a dramatic change in the organization of the CA domain 
and formation of the conical core. To shed light on the maturation process we 
analyzed viral variants containing point mutations abolishing cleavage at 
individual or multiple Gag cleavage sites [2]. For each variant we used cryo-
electron tomography and subsequent subtomogram averaging to resolve the 
structure of the Gag lattice.  
Mutation of all proteolytic sites in Gag gave rise to particles that were 
structurally indistinguishable from immature virions due to a non-functional or 
inactivated protease. If only a single cleavage site between MA and CA was 
retained, there was also no change in the structure of the Gag lattice, but the 
distance between the CA layer and the membrane became more variable. If all 
cleavage sites downstream of SP1 (NC-SP2-p6) could be processed leaving an 
uncleaved MA-CA-SP1 product, the CA lattice and rod like densities were 
maintained, while the NC-RNA complex condensed in the particle centre. If 
only the cleavage site between MA and CA was mutated, processing at the 
wild-type downstream site between CA and SP1 was also reduced. Despite 
partial cleavage at this junction, the hexagonal immature lattice and the rod-like 
structures were retained. Mutating only the cleavage site between CA and SP1 
produced virions with a condensed NC-RNA complex that contained no visible 
immature Gag lattice.  
These results indicate that disassembly of the immature Gag lattice requires 
cleavage both upstream and downstream of CA. Furthermore, the rod-like 
densities protruding below the CA layer maintain their structure even if the NC-
RNA complex has condensed, and the CA-SP1 junction has been partially 
cleaved, suggesting that they represent a stable assembled oligomeric structure. 
 
 
1. Briggs JAG, Riches JD, Glass B, Bartonova V, Zanetti G, et al. (2009) Structure 
and assembly of immature HIV. Proc Natl Acad Sci USA 106: 11090-11095. 
2. Müller B, Anders M, Akiyama H, Welsch S, Glass B, et al. (2009) HIV-1 Gag 
processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol 
Chem 284: 29692-29703. 
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To establish and maintain productive infection in host species, retroviruses 
employ numerous host factors for replication. We used a mass spectroscopy 
approach and highly purified HIV-1 virus-like particles to identify host 
proteins that might be involved in particle morphogenesis. 
 
We identified clathrin as a component of highly purified protease-defective 
HIV-1 virus-like particles (VLPs). Notably, clathrin was exceptionally 
abundant in these particles, and was present at almost the same levels as the 
Pol protein. Moreover, clathrin incorporation was highly specific – it was 
completely absent from particle generated using the HIV-1 Gag protein 
alone. This specificity of incorporation was further confirmed by the fact 
that clathrin incorporation was almost undetectable in particles generated by 
GagPol proteins bearing point mutations in the RT or IN domains of Pol. 
Remarkably, several other retroviruses (SIVmac, MLV and M-PMV) also 
packaged clathrin into virions. However in each of these cases, Gag rather 
than Pol was responsible for recruiting Gag into virions. Additionally, for 
all three retroviruses we could identify specific peptide sequences encoded 
within the Gag protein that mimicked sequences found in cellular clathrin 
adapter proteins and were entirely responsible for clathrin incorporation. 
Correspondingly, the amino-terminal beta-propeller domain of the clathrin 
heavy chain (HC) that is normally responsible for binding to clathrin 
adapters was sufficient for clathrin incorporation into VLPs. 
 
Mutations in viral proteins that blocked clathrin incorporation, or 
perturbation of cellular clathrin had several effects on virion morphogenesis 
that differed according to which particular virus or viral protein was 
analyzed. Deleterious effects on viral protein stability, the assembly and 
release of virions and/or virion infectiousness could be induced by 
perturbing clathrin recruitment. Collectively, these data suggest an 
important role for clathrin-Gag and/or clathrin-Pol interactions in the 
genesis of retroviral particles. 
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HIV capsid assembly is a late essential step in the retroviral life cycle and is 
not targeted by current antiretrovirals. We employed an in vitro translation 
system, which faithfully models HIV assembly in living cells, to screen a 
small molecule library for HIV-1 capsid assembly inhibitors. Several hits 
were obtained in this screen. Here, we report the antiviral activity of 
selected compounds and provide insights into their mechanism of action.  
Several compounds found to be active in the cell free system also 
suppressed HIV-1 replication in a T cell line, indicating that the 
experimental system is suitable to identify antivirals. Six compounds, 
representing 5 chemical scaffolds, with CC50 and IC50 values in the lower 
micromolar range, were selected for further characterization. All of the 
selected compounds showed pan-lentiviral activity with similar IC50 values 
for HIV-1, HIV-2 and SIV, but inhibited different stages of the viral life 
cycle. Compound 4.1 showed a strong potential to inactivate cell-free virus 
which might account for its early effect on HIV-1 infection. It could be 
shown that compound 4.1 does not interfere with virus release from 
chronically infected Jurkat cells, but diminishes the infectivity of released 
virions. A FACS-based FRET assay revealed that compound 4.1 disturbed 
Gag-Gag interactions, and Gag processing intermediates, which were 
recently shown to inhibit viral infectivity, were detected in virion 
preparations treated with compound 4.1. In agreement with these 
observations, a preliminary electron microscopy analysis suggested that 
treatment of infected cells leads to release of virions with aberrantly formed 
capsids. Collectively, our results indicate that compound 4.1 might interfere 
with appropriate Gag folding, and might thereby inhibit formation of 
infectious particles.  
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HIV-1 is an enveloped virus and the incorporation of Env is crucial for the 
viral infectivity. Although under extensive study for decades, the cellular 
locations and molecules involved in Env incorporation have not been 
clearly defined. We propose that intracellular trafficking of Env through 
recycling pathways is an essential determinant of the specific virion 
incorporation of Env. To test this hypothesis, we expressed dominant-
negative and constitutively-active forms of Rab11a, and monitored Env 
incorporation at the budding site and on released viral particles. Dominant-
negative Rab11a did not alter Env incorporation, which seemed to 
contradict our hypothesis. Surprisingly, however, we found that expression 
of a constitutively active form of Rab11a reduced Env incorporation 
dramatically. Particle infectivity was correspondingly decreased by this 
intervention. Next, we examined the effect of constitutively-active Rab11a 
on Env lacking the long cytoplasmic tail. Constitutively-active Rab11a had 
no effect on incorporation on NL4.3 del144 Env incorporation, indicating 
that the specific incorporation defect could be mapped to the Env 
cytoplasmic tail. EM analysis of particles released in the presence of 
constitutively active Rab11a revealed markedly-diminished Env 
incorporation. We conclude that altered recycling or rapid recycling from 
the pericentriolar recycling compartment prevents Env from reaching the 
particle assembly site and shunts it toward alternative intracellular sites. 
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The cross-species restriction factor TRIM5α is a member of the tripartite 
motif (TRIM) family of proteins and affects the retroviral life cycle. Human 
TRIM5α (TRIM5αhu) potently restricts N-MLV infection, but not N/B-
MLV infection, while rhesus monkey (TRIM5αrh) blocks both early and 
late phases of the HIV-1 life cycle, but does not block SIV infection or 
production. Detailed mechanisms involved in the TRIM5α-mediated 
retroviral restriction still remain elusive. To better understand the 
mechanisms of TRIM5α mediated antiviral activities, we first examined a 
cellular binding partner of TRIM5αrh. Immunoprecipitation of HA-tagged 
TRIM5αrh and subsequent MS analysis identified the membrane raft-
associated protein flotillin-1/reggie-2 as a potential TRIM5αrh interaction 
partner. Immunohistochemistry studies confirmed the co-localization of 
TRIM5αrh cytoplasmic bodies with flotillin-1/reggie-2, as well as another 
lipid raft marker caveolin-1. A detergent-free protein flotation assay on HA-
tagged TRIM5α identified TRIM5α in flotation fractions alongside lipid 
microdomain-associated proteins, including flotillin-1/reggie-2. Moreover, 
lipid depletion disrupted prominent TRIM5αrh cytoplasmic body formation. 
These observations suggest the association of TRIM5αrh with subcellular 
lipid microdomains, and a possible role of flotillin-1/reggie-2 or cellular 
lipids in TRIM5α-mediated antiviral activities. Next, we examined the 
influence of flotillin-1/reggie-2 knockdown and cellular lipid depletion on 
TRIM5α-mediated retroviral restriction. Although knockdown of flotillin-
1/reggie-2 expression in rhesus monkey FrhK4 cells showed no significant 
effects on TRIM5αrh-mediated early and late restriction of HIV-1 
replication, depletion of cellular lipids impaired the TRIM5αrh-mediated 
late restriction of HIV-1, but not SIVMAC. Moreover, lipid depletion prior 
to infection strongly increased infectivity of N-MLV, but not N/B-MLV, in 
human TE671 cells, suggesting that lipid depletion impairs TRIM5αhu-
mediated N-MLV restriction. Importantly, lipid repletion prior to infection 
partially restored the TRIM5αhu-mediated N-MLV restriction. Our data 
therefore demonstrated the critical role of cellular lipids for efficient 
TRIM5α-mediated antiviral activities. 
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Several single nucleotide polymorphisms (SNPs) have been mapped to the 
coding regions of each of the seven human APOBEC3 (A3) but their 
functional impact remains to be explored. Recently, we and others have 
found that the single domain cytidine deaminase A3H is polymorphic in 
sequence. One of the haplotypes (A3H HapII-RDD) displays a strong 
antiviral activity. The goal of this study was to elucidate the mechanisms 
underlying the differences in activity between A3H haplotypes.  
In addition to the naturally occurring A3H HapI-GKE and HapII-RDD 
proteins (which differ at three amino acid positions) we constructed a panel 
of 6 site-directed mutants that contain all possible combinations of the 
mutations. A series of transfections, infections and GST pull-down 
experiments was performed to assess A3H protein stability, the 
requirements for A3H-Gag interactions and A3H virion incorporation. The 
catalytic activity of each A3H variant was assessed using an E. coli mutator 
assay.  
A3H HapII-RDD restricts HIV-1 NL4-3 ~10-fold more efficiently than 
HapI-GKE. Since this difference in antiviral activity strongly correlates 
with protein expression levels in the producer cell we anticipated to observe 
differences in the amount of A3H being packaged. Contrary to our 
expectations, incorporation of A3H into the HIV-1 virions was equally 
efficient for all the variants. When tested in a bacterial mutator assay, both 
A3H haplotypes showed similar deaminase activity upon normalization for 
differences in expression. GST pull-downs and virion incorporation 
experiments using Gag deletion mutants demonstrated that each A3H 
haplotype interacts with a different Gag region; A3H HapII-RDD associates 
with nucleocapsid (NC) in an RNA dependent manner whereas A3H HapI-
GKE interacts exclusively with capsid.  
A3H is the first human cytidine deaminase for which haplotypes with 
distinct antiviral activity have been described. Our results suggest that the 
single deaminase domain of A3H is both catalytically active and functions 
in RNA binding/virion incorporation. However, the interaction of A3H 
HapI-GKE with Gag capsid but not NC likely prevents its access to the 
reverse transcription complex and thereby limits its antiviral activity.  
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Prior assembly studies suggest that three interactions drive the assembly of 
HIV-1 Gag into particles: Gag-binding to an RNA scaffold that promotes 
Gag multimerization, Gag multimers binding to the plasma membrane that 
form larger complexes, and Gag-Gag interactions which condense these 
loose structures into a tightly knit particle shell. Despite much progress in 
identifying these processes, it is not clear whether they act discretely or 
cooperatively. Previously, we found that Gag required one of two RNA 
binding sites, either NC or a basic region of MA within Gag for efficient 
particle formation (Ott et al., J. Virol. 79:13839), supporting the RNA 
scaffold model. A follow-up study of the kinetics of wild-type and NC 
mutant Gag particle production indicated that NC-mediated binding of RNA 
is an initiating event in Gag assembly (Ott et al., J. Virol. 83:7718), 
confirming a prediction of the RNA scaffold model. To examine the 
interdependence of RNA binding and plasma membrane binding during 
Gag assembly, we co-expressed our MXNX proviral mutant construct, 
which contains a mutated MA RNA-binding site and a nearly complete NC 
deletion, with a myristylation mutant (myr-). Neither of these mutants 
efficiently produces particles by themselves, yet particle incorporation for 
each is readily complemented by wild-type Gag. Co-transfection 
experiments between these two constructs revealed that MXNX and myr- 
could not rescue each other, indicating that RNA binding and plasma 
membrane binding are mutually dependent. In contrast each mutant alone, 
carrying either the MA mutation (MX) or the NC deletion (NX) could 
rescue myr- Gag. These data indicate that RNA binding and membrane 
binding are coordinated events that function together during HIV-1 Gag 
assembly. 
 
(This project has been funded in whole or in part with Federal funds from the 
National Cancer Institute, National Institutes of Health, under Contract No. 
HHSN261200800001E.)  
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In Old World monkeys, HIV-1 encounters blocks mediated by the 
restriction factors TRIM5α, APOBEC3G and tetherin. Overcoming these 
blocks may allow the development of HIV-1-like viruses that infect 
macaques. In the present work, we used a protocol previously employed to 
adapt HIV-1 to replicate in CD4-negative cells [1] and in cells expressing 
common marmoset CD4 and CXCR4 [2]. We successfully adapted an HIV-
1 isolate to replicate in HeLa-CD4 cells expressing rhesus monkey TRIM5α 
(rhTRIM5α). A single residue change that arose during the first passage of 
the virus, and is located in the base of the CypA-binding loop of the capsid 
protein, was sufficient to allow the virus to replicate in HeLa-CD4 cells 
stably expressing rhTRIM5α. Competition assays with virus-like particles 
and assays directly measuring rhTRIM5α binding to CA-NC tubes 
demonstrate that the mechanism of escape of this capsid mutant involves a 
reduced binding affinity for rhTRIM5α. Cyclophilin A binding to the 
adapted virus capsid protein was comparable to that of the wild-type capsid. 
The combination of this capsid mutant with other changes designed to 
overcome restriction might help to generate a more HIV-1-like virus able to 
replicate in macaques.  
 
 
1. Kolchinsky, P., et al., Adaptation of a CCR5-using, primary human 
immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol, 
1999. 73(10): p. 8120-6.  
2. Pacheco, B., et al., Adaptation of the human immunodeficiency virus type 1 
envelope glycoproteins to new world monkey receptors. J Virol, 2008. 82(1): p. 346-
57.  
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Human APOBEC3B (A3B) has been described as a potent inhibitor of 
retroviral infection and retrotransposition. However, we found that the 
predominantly nuclear A3B did not restrict infection by HIV or HIVDvif, 
while significantly inhibiting LINE-1 retrotransposition. A chimeric mutant 
A3G/B, in which the first 60 amino acids of A3B were replaced with those 
of A3G, was able to restrict HIV, HIVDvif and HTLV-1 infection, as well 
as LINE-1 retrotransposition. In contrast to the exclusively cytoplasmic 
A3G, which is inactive against LINE-1 retrotransposition, A3G/B protein, 
while mainly localized to the cytoplasm is also present in the nucleus. 
Further mutagenesis analyses revealed that residues 18, 19, 22 and 24 in 
A3B are the major determinants for nuclear vs cytoplasmic localization and 
anti-retroviral activity. HIVDvif packages A3G, A3B and A3G/B with close 
to equal efficiencies into particles. As in A3B, mutations E68Q and E255Q 
in the active centers of A3G/B resulted in loss of the inhibitory activity 
against HIVDvif while retaining activity against LINE-1 retrotransposition. 
The low inhibition of HIV vif by A3B correlates with a low mutation rate 
in viruses transmitted in the presence of A3B. In contrast, viruses, which 
had been exposed to A3G/B, showed a high number of G to A transitions. 
The mutation pattern was similar to that previously reported for A3B with a 
preference of the TC context (84%) followed by CC (16 %). In summary, 
these observations suggest that the nuclear localization of A3B targets it to 
inhibit transposition of LINE-1 and LINE-1 dependent retro-elements, and 
that redirecting it to the cytoplasm enables it to restrict retroviruses. 
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Infection of the germ line by retroviruses has led to endogenous proviruses, 
most of which have become inactivated due to mutations. Nonecotropic 
murine leukemia viruses (MLVs) are endogenous gammaretroviruses and 
can be subdivided into three groups: xenotropic (XMV), polytropic (PMV), 
and modified polytropic (MPMV). Previous work in our laboratory has 
identified 49 nonecotropic MLV proviruses in the sequenced genome of 
C57BL/6J inbred mice. This work also found evidence for editing by 
APOBEC3 (mA3), a host defense mechanism that caused G-to-A mutations 
during viral DNA synthesis at the time of integration of PMV and MPMV, 
but not in XMV proviruses. Since inbred mice were derived from crosses of 
several different wild subspecies of mice (Mus musculus domesticus and M. 
m. molossinus, itself a natural hybrid between M. m. musculus and M. m. 
castaneus), which may differ in A3 activity, we sought to identify and 
characterize endogenous MLV proviruses and their integration sites in wild 
mouse species.  
 
We used PCR primers to amplify fragments representing specific 
proviruses, solo LTRs, and unoccupied integration sites identified in the 
C57BL/6J mouse genome. Only 7 proviruses were found at the same 
location in wild mouse species, indicating that integration occurred 
relatively recently in the lineage or lineages that gave rise to inbred lines. 
No such proviruses were found in M. m. domesticus, but we identified 7 
XMV and MPMV proviruses in M. m. molossinus, M. m. musculus, and M. 
m. castaneus integrated in the same locations in the genomes as in the 
inbred strain. The presence of proviruses varies among individuals of M. m. 
molossinus, indicating that they integrated after the origin of this subspecies 
and are not yet fixed in the population sampled. The 5’ and 3’ LTRs of 
these identified proviruses were identical in sequence to one another and to 
the corresponding LTRs in the B6 genome, indicating that these integrations 
occurred quite recently. We are currently identifying and sequencing more 
proviruses in the genomes of both M. m. molossinus and other wild mouse 
species using primers targeting provirus-specific regions and B1 repetitive 
DNA elements. We are also examining the APOBEC3 gene in the various 
species to explore the possibility that APOBEC3 function may differ in 
certain wild mice species and to see if differences correlate with the 
proviruses present in their genomes.  
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The Nef protein is a critical factor for AIDS pathogenesis that substantially 
increases HIV replication in vivo via the modulation of multiple host cell 
transport and signal transduction processes. In T lymphocytes, Nef is well 
known to affect actin remodeling and chemotaxis as well as to modulate 
cell surface exposure of transmembrane receptors. In addition, Nef also 
causes pronounced intracellular accumulation of the Src kinase Lck that is 
only peripherally associated with the inner plasma membrane leaflet; the 
underlying mechanism and functional consequences of this highly 
conserved Nef activity are currently unclear.  
Using spinning disc confocal and immuno-electron microscopy we identify 
the intracellular compartment in which Lck accumulates in the presence of 
HIV-1 Nef as the Trans Golgi network. Real time imaging reveals that Nef 
potently inhibits the otherwise highly dynamic intracellular transport of Lck 
from intracellular membranes to the plasma membrane. While this effect 
relies on the SH3 domain binding motif in Nef and acylation of Lck, known 
protein interaction motifs of the kinase and colocalization with Nef are 
dispensable. Consistent with a more general effect on membrane trafficking, 
Nef also induces intracellular accumulation of other Src kinase family 
members. Kinetic analysis of Lck transport demonstrates that Nef 
selectively acts on newly synthesized Lck molecules to prevent their initial 
targeting to the plasma membrane. Functional studies indicate that this 
block in plasma membrane translocation of Lck is the mechanism by which 
Nef in T lymphocytes prevents recruitment of Lck to contact sites with 
antigen presenting cells. Together, these findings unravel a novel 
mechanism by which Nef affects plasma membrane targeting of membrane-
associated host cell factors to optimize the environment in HIV-1 infected T 
lymphocytes.  
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Zoonosis of SIVcpz has given rise to both pandemic (M) and non-pandemic 
(O and N) groups of HIV-1, as well as SIV infection of Gorillas (SIVgor). 
SIVgor itself may also have transmitted to humans giving rise to HIV-1 
group P. These lentiviruses encode accessory proteins, including Vpu, 
which has two important roles. Vpu removes CD4 protein from the cell 
membrane to prevent super-infection and aid virus release. Vpu from M 
group HIV-1 also improves virus release by antagonizing tetherin (CD317, 
BST2) which acts to tether newly formed virions to the infected cell 
surface. Here we show that Vpus from O group HIV-1 Ca9, BCF06 and 
BCF07 are not able to counteract human tetherin, although they are still 
able to remove cell-surface CD4. We hypothesize that an inability to 
antagonize human tetherin has contributed to O group viruses failing to 
transmit in humans to pandemic levels. Characterization of chimeric and 
mutant O groups Ca9 and BCF06, and M group Vpu domains demonstrated 
that the Vpu/tetherin interaction is complex and involves several domains. 
We have also identified specific residues within the Beta-TrCP recognition 
signal that are important for tetherin antagonism, as well as specific 
residues within the transmembrane domain that have been under positive 
selection. The specific localization of the various Vpus has also been 
studied. This work aims to shed light on the molecular details of how Vpu 
acquired anti-tetherin activity and led to a pandemic HIV infection of 
humans. 
 
This work is supported by the Medical Research Council and the Wellcome 
Trust. 
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The APOPEC3 family of cytidine deaminases (A3A-A3H) play an 
important role in host mediated antiviral defence against retroviruses and 
retroelements, including HIV-1. Although much has been discerned about 
the APOBEC3 proteins in terms of mechanisms of antiviral resistance, the 
cellular function of these proteins remains poorly defined. In an attempt to 
address this and further elucidate their anti-viral activity, several cellular 
proteins that interact with A3G have been identified. The most intriguing of 
these are the Argonaute protein family as they interact with A3G in a 
manner which is at least partially resistant to RNase treatment. The 
Argonautes are integral components of RISC, which is involved in miRNA 
mediated translational repression and mRNA decay. Components of this 
pathway, as well as A3G and silenced mRNAs have been shown to localise 
to discrete cytoplamic foci termed Processing (P) Bodies. We aim to better 
understand the extent of the associations between these two protein families 
and the relevance this may have to APOBEC3 cellular and/or anti-viral 
activities. 
We have carried out a detailed analysis of APOBEC3 family members in 
terms of interaction with the Argonautes and co-localisation to P-bodies. 
Our findings show that the most potent antiviral proteins, A3F, A3G and 
A3H are able to interact with several of the Argonaute proteins, while no 
detectable interaction was found with the rest of the APOBEC3 family. 
With regards to P-body localisation, once again, A3F, A3G and A3H all 
showed strong co-localisation with Ago2 as did A3D/E, which has a more 
modest anti-viral effect. The remaining APOBEC3 proteins displayed weak 
or no co-localisation. Therefore there appears to exist a correlation between 
the anti-viral activity of APOBEC3 family members and interactions with 
the Argonaute proteins. This specificity has led us to further investigate the 
functional consequences of this interaction. It has previously been reported 
that members of the APOBEC3 family are able to counteract the repression 
mediated by miRNAs implicating a role for these proteins in the regulatory 
control of cellular mRNA translation. We are attempting to extend these 
findings through the utilisation of miRNA based reporter assays and aim to 
further investigate any correlates which may be present between this 
potential cellular function of the APOBEC3 proteins, association with the 
Argonautes, localisation to P-bodies and anti-viral phenotypes.  
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Most gammaretroviruses encode a glycosylated transmembrane Gag 
molecule (glycogag) translated from a CUG initiation codon upstream and 
in-frame with gag. We have recently established that glycogag derived from 
murine leukemia virus is an infectivity factor able to fully rescue the 
defective infectivity of Nef-negative HIV-1. Nef and glycosylated Gag 
share major functional features. The activity of the two proteins similarly 
depends on the producer cell-type and the nature of the envelope 
glycoprotein. In addition, Nef and glycogag co-localize in intracellular, 
perinuclear compartments.  
We have now further characterized the functional similarity between the 
two retroviral factors. Nef and glycogag affect an equally early step of the 
retroviral life cycle. In addition, the activity of glycogag on infectivity is 
inhibited by agents which impair also the function of Nef. Altogether, our 
data strongly suggest that the two retroviral factors represent a case of 
convergent evolution.  
We have established that the activity on retrovirus infectivity resides within 
the intracellular portion of glycogag. We have evidence that only the 
transmembrane-proximal region is required for this function. Intriguingly, 
comparative analyses of glycogag sequences derived from different gamma-
retroviruses shows that this region is highly divergent and the least 
conserved within glycogag. We are now testing the ability of different 
glycogag alleles to replace the activity of Nef on HIV-1 infectivity. This 
will establish whether the activity on infectivity is conserved across 
glycogag-encoding gammaretroviruses and will identify molecular 
determinants crucial for this function.  
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Species-specific restriction factors (RFs) may have therapeutic potential. 
FIV is restricted by several primate TRIM5α & TRIMCyp proteins, 
unusually including both aotus and macaca genus TRIMCyps, and there are 
no feline orthologs. If transgenesis with RF genes were feasible, domestic 
cat models could have potential for a number of goals, including testing 
hypotheses that introducing a RF can render a species genetically immune 
to a lentivirus, reduce in vivo replication or prevent AIDS. 
We have now achieved transgenesis in the domestic cat, using single cell 
embryo microinjection of lentiviral vectors that co-encode a RF & GFP. We 
first compared FIV restriction of primate TRIM5α & TRIMCyp alleles in 
cultured feline cells. M. mulatta TRIMCyp (rhTC) was potent, reducing 
FIV infectivity > 3 logs. Vector and feline-specific reproductive 
biotechnology parameters were optimized iteratively to enable transgenesis. 
Microinjecting before or after fertilization had no effect on embryo 
development or transgene expression. Pre-fertilization injection produced 
less mosaicism. Expressing GFP + rhTC (rhTC.GFP vector) or GFP alone 
showed that adding rhTC had no deleterious effects on feline blastocyst 
development. 
Transfer of rhTC.GFP vector-microinjected embryos into reproductive 
tracts of 6 queens using empirically optimized queen pre-conditioning and 
embryo transfer protocols resulted in two live, healthy male transgenic (TG) 
kittens. Southerns & PCR on tail & PBMC DNA demonstrated each cat has 
several insertions. TG but not control PBMCs were GFP-fluorescent. WB 
revealed GFP and rhTC in TG but not control PBMCs. 2 other pregnancies 
resulted in premature birth of 6 fetuses, all TG, and a full-term, 
morphologically normal TG kitten that died of obstetrical complications. 
Autopsies showed transgene expression in multiple organs. We conclude 
that feline-optimized lentiviral transgenesis methods can generate multi-
gene TG domestic cats. RF-TG cats are being bred, sperm-banked, and 
challenged with animal-titered FIV. Further transfers are in progress with 
different RFs, promoters. The approach will aid analysis of RF biology in 
vivo and RF-based gene therapy. In addition to potential for conferring 
immunity against this lentivirus, transgenesis in this accessible species may 
foster modeling of other diseases. 
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NON-PRODUCTIVE REPLICATION OF HIV-1 IN RENAL 
PODOCYTES: IMPLICATIONS FOR HIVAN PATHOGENESIS. 
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HIV-1 associated nephropathy (HIVAN) is a renal disease almost entirely 
limited to individuals of African descent. Genome–wide association studies 
have recently identified MYH9 as a candidate gene associated with the high 
risk for development of HIVAN in African Americans. The cellular target 
involved in the development of HIVAN is the renal epithelium, most 
notably podocytes and tubular cells. Since podocytes are the critical 
components of the blood filtration barrier, loss of podocytes into urine as a 
result of HIV-1 infection may promote glomerular diseases including 
HIVAN. However, the mechanism of podocyte infection in HIVAN is 
controversial. One of the current hypotheses is that productive infection of 
podocytes by HIV-1 and expression of HIV-1 accessory genes causes the 
cellular injury. However, prior our study, this hypothesis was never tested 
in vitro using podocytes and wild-type HIV-1. The reported lack of classical 
HIV-1 entry receptors CD4, CXCR4, or CCR5 in podocytes suggests that 
virus entry through this pathway is unlikely. We have shown that 
transfection of podocytes with CD4 and CXCR4 expression vectors restored 
productive replication of X4 HIV-1 to the levels observed with VSV-G 
pseudotyped HIV-1, confirming that lack of entry receptors is a major 
barrier to establishing productive infection in podocytes. Further, we have 
shown that wild-type HIV-1 readily enters podocytes through a dynamin-
dependent endocytosis and partially colocalizes with recycling endosomes 
and late endosomes/lysosomes. However, the majority of the internalized 
virus escapes degradation and is released back to the culture medium as a 
fully infectious virus. We have detected only a limited and transient 
accumulation of HIV-1 reverse transcription DNA products, suggesting that 
HIV-1 is unable to establish productive infection in podocytes. This was 
further confirmed by detection of HIV-1 Gag and unspliced HIV-1 RNA 
only very early in infection, indicating they originate from virion-associated 
endocytosed HIV-1 particles rather than de novo synthesis. We conclude 
that the reported in vivo detection of HIV-1 nucleic acids and proteins in 
glomerular podocytes from HIVAN individuals may reflect endocytosed 
virions rather than productively replicating virus. A new mechanism 
describing an abortive HIV-1 infection leading to podocyte injury in 
HIVAN will be discussed. 
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TRIMCyps are anti-retroviral proteins that have arisen independently in 
New World and Old World primates. All TRIMCyps comprise a CypA 
domain fused to the tripartite domains of TRIM5α but they have distinct 
lentiviral specificities, conferring HIV-1 restriction in New World owl 
monkeys and HIV-2 restriction in Old World rhesus macaques. Here we 
provide evidence that Asian macaque TRIMCyps have switched restriction 
specificity between different lentiviral lineages during their evolution, 
resulting in species-specific alleles that target different viruses. Structural, 
thermodynamic and viral restriction analysis suggests that a single mutation 
in the Cyp domain, R69H, occurred early in macaque TRIMCyp evolution, 
expanding restriction specificity to the lentiviral lineages, found in African 
green monkeys, sooty mangabeys and chimpanzees. Subsequent mutations 
in different species have enhanced restriction to particular viruses but at the 
cost of broad specificity. We reveal how specificity is altered by distant 
scaffold mutations that modify surface electrostatics and propagate 
conformational changes into the active site. Our results suggest that 
lentiviruses may have been important pathogens in Asian macaques despite 
the fact that there are no reported lentiviral infections in macaque 
populations. 
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SEROLOGICAL MARKERS OF XMRV INFECTION  
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Background: Xenotropic Murine Leukemia Virus-related Retrovirus 
(XMRV) is a human gammaretrovirus recently identified in prostate cancer 
tissue and in lymphocytes of patients with chronic fatigue syndrome. To 
establish the etiologic role of XMRV infection in human disease requires 
large scale epidemiological studies; development of serological assays to 
detect XMRV-specific antibodies (serological markers) would greatly 
facilitate such studies. An understanding of the dynamics of the antibody 
response elicited by infection with XMRV is essential for development of 
reliable serological assay(s).  
Methods: Three rhesus macaques (2 males, 1 female) were inoculated 
intravenously with XMRV; two were re-inoculated on day 158. Blood was 
collected throughout the course of infection. XMRV-specific antibody 
responses were monitored by Western Blot (WB) using XMRV lysate and 
recombinant viral proteins. In addition, prototype serologic assays to detect 
antibodies to env gp70, env p15E and gag p30 were developed using 
recombinant antigens on the high-throughput automated ARCHITECT 
instrument system (Abbott Diagnostics).  
Results: By WB analysis, all three macaques developed antibody responses 
to env and gag proteins during the second week of infection. Specific 
antibody responses to env gp70 and env p15E were detected at 9 days post 
infection; antibodies to gag p30 were detected by days 11-14. All three 
antibody responses persisted to 158 days and were substantially boosted by 
re-inoculation. Two macaques exhibited weak and transient antibody 
responses to gag p15 and gag p10. Based on WB analysis, antibody 
responses to env gp70, env p15E and gag p30 were identified as useful 
markers for serological assay development. The prototype ARCHITECT 
assays demonstrated 100% sensitivity by detecting all WB positive serial 
bleeds from the XMRV-infected macaques.  
Conclusions: This study characterized the dynamic process of antibody 
development in XMRV-infected macaques and identified serological 
markers useful for detection of XMRV infection. The prototype XMRV-
antibody assays will facilitate large-scale epidemiological studies.  
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ANTI-HIV-1 NUCLEOCAPSID RNA APTAMERS REVEAL A 
POSSIBLE CONSENSUS RNA MOTIF IN THE PACKAGING SIGNALS 
OF DIVERSE RETROVIRUSES 
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Genome encapsidation by HIV-1 involves specific recognition and subsequent 
packaging of two copies of the full-length viral genomic RNA in the cytoplasm 
of infected cells. This specific packaging is facilitated by an RNA sequence 
(known as ψ) in the 5’-UTR of the virus which is recognized by the 
nucleocapsid (NC)-domain in the Gag polyprotein. The interaction of the ψ− 
sequence of a retrovirus with its cognate NC protein is believed to be highly 
specific and cross-packaging between retroviruses is known to occur but at a 
low efficiency. 
 
We raised RNA aptamers against the HIV-1 Gag polyprotein and identified two 
aptamers that bound specifically to DP6-Gag (a version of HIV-1 Gag lacking 
p6) and the NCp7 protein. The two aptamers specifically bound to HIV-1 but 
not to SIVmac or RSV- Gag. In order to understand the nature of the interaction 
of the NC-specific aptamers with HIV-1 NC, we designed an in vitro 
competition assay where purified NC protein was incubated with a mixture 
containing radiolabeled aptamer RNA and increasing concentrations of 
unlabeled RNA transcripts encoding the ψ− RNAs from several retroviruses. 
While a robust competition for binding to NC was observed when ψ− RNA 
from HIV-1 was used as a competitor, control RNAs like yeast tRNA, an MA-
specific RNA aptamer or a ψ− RNA from RSV, an alpharetrovirus, were unable 
to compete for binding. Interestingly, HIV-2, SIV and MuLV ψ− RNAs also 
strongly competed with the aptamers for binding to HIV-1 NC similar to that of 
HIV-1 ψ−RNA. While HIV-1 NC has been shown to recognize the 
ψ−sequences from HIV-2 and SIVmac, it is not known to interact with the ψ−sequence of MuLV. Similar results were also obtained when HIV-1 NC in 
the binding assays was replaced with DP6-Gag. Our results suggest a novel 
possibility that the ψ− regions of diverse retroviruses contain a conserved RNA-
motif and discrimination between the genomic RNAs by HIV-1 NC might 
require a second signal unique to the virus. The results of our ongoing 
experiments to delineate the minimal binding domains of various retroviral ψ 
sequences necessary for this competitive binding will be presented. 
 
To determine if the aptamers could function as molecular mimics in vivo, we 
replaced the ψ-region (SL1- or SL3- stem loops) of pNL4-3.Luc.R-E- with the 
NC-specific aptamers. While the replacement of the ψ−sequence with the 
aptamer sequence did not inhibit viral protein processing or assembly, we 
observed that all of the viruses had reduced infectivity (3-10 fold) compared to 
wild-type viruses. We are currently examining the levels of genomic RNA 
encapsidated into these virions by quantitative RT-PCR to study if the aptamers 
could in fact mimic the ψ-region of HIV-1 in vivo. 
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Lentiviruses including HIV-1 can efficiently infect non-dividing cells, 
whereas gamma retroviruses require cell division. Though the details 
remains unclear this property is thought to be due an ability of lentiviruses 
to recruit host nuclear import proteins and traverse the nuclear pore. Here, 
we show that mutations in HIV-1 capsid (CA) that impact on the ability to 
infect non-dividing cells can lead to significant reduction of HIV-1 GFP 
infection in primary human monocyte-derived macrophages (MDM). 
Furthermore, the mutants are defective in a cell line specific way with 
certain cell lines being fully permissive to mutant viruses but other cell lines 
being rather non-permissive to the mutants as compared to wild type virus. 
We have also assessed whether the mutations impact on the ability of HIV-
1 to replicate in human macrophages and whether mutation impacts on the 
ability of HIV-1 to avoid activating pattern recognition and interferon 
signalling in these cells. Our data indicate that HIV-1 CA is an important 
determinant of HIV-1 infectivity impacting on the ability to infect naturally 
non-dividing targets of HIV-1 infection as well as cell lines in a cell line 
specific way. 
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Efficient retroviral budding is crucially dependent on the presence of L- 
(late) domains, short peptide motifs in Gag proteins that recruit components 
of the ESCRT (endosomal sorting complex required for transport) 
machinery. Ultimately, these interactions lead to the promotion of viral 
budding by engaging the membrane scission activity of ESCRT-III. One of 
these motifs, the PPXY L-domain present in viruses such as MLV (murine 
leukaemia virus) and HTLV-1 (human T-cell leukaemia virus 1), accesses 
the ESCRT pathway via interaction with HECT ubiquitin ligases. However, 
it remains unclear how recruitment of the ESCRT-III complex takes place 
in this context. In this project, arrestin-like proteins (ARRDC1, 2, 3 and 4 
(arrestin domain-containing) were tested for their ability to function as 
cellular adaptors between HECT Ubiquitin ligases and the ESCRT pathway 
in PPXY L domain mediated viral budding. We were able to show that 
arrestin-like proteins interact with both HECT Ubiquitin ligases (WWP1, 
WWP2 and Itch) and ESCRT components (ALIX and Tsg101). The 
involvement of this family of proteins in ESCRT mediated processes was 
supported by our finding, that ARRDC1 colocalises with a catalytically 
inactive form of the ESCRT component Vps4, a hallmark of proteins 
interacting with this pathway. Furthermore, we gained insights in the 
function of arrestin-like proteins by analysis of MLV particle production. 
These experiments revealed a PPXY specific reduction of infectious particle 
production in cells transiently expressing ARRDC1, ARRDC2 and 
ARRDC3. In support of a role in viral egress, confocal analysis showed that 
ARRDC1 could be recruited to the plasma membrane upon expression of 
MLV Gag. Together, these results support the hypothesis that arrestin-like 
proteins could be involved in the recruitment of the ESCRT machinery in 
PPXY mediated budding. 
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Retrovirus assembly is triggered by a nonspecific interaction between Gag 
and nucleic acids (NA). This is indicated both by encapsidation of cellular 
mRNAs into psi(-) virions and by the requirement for NA for assembly in a 
defined system in vitro. The NA requirement is, however, bypassed if the 
NC domain (the principal NA-binding domain of Gag) is replaced by a 
leucine-zipper oligomerization domain, raising the possibility that 
oligomerization of full-length Gag on NA leads to exposure of new 
interfaces for Gag-Gag interaction and thus to particle assembly. These new 
interfaces are very likely within the CA domain. The NC and CA domains 
in HIV-1 Gag are separated by a short linker region called SP1. It has been 
suggested that the N-terminal part of SP1 is α-helical, but NMR studies 
show that it has only a slight tendency to form helices in an aqueous 
solvent. On the other hand, it does form an α-helix in 30% trifluoroethanol 
(TFE). We have characterized SP1 in several ways. Extensive mutational 
studies show that proper assembly is exquisitely sensitive to changes in the 
sequence of the first 6-7 residues of SP1; for example, while the 4th residue 
(Met) can be replaced with Phe, replacement with Tyr completely destroys 
the ability of Gag to assemble correctly in 293T cells. Circular-dichroism 
measurements on free SP1 show that it does indeed undergo a concerted 
shift to a helical conformation as the TFE concentration is raised. To 
reconcile all of these observations, we propose the following model: SP1 is 
a random coil in free Gag, but when Gag oligomerizes, either on NA or via 
a leucine-zipper motif, the high local protein concentration creates a more 
nonpolar environment. This environment induces helix formation in the SP1 
domain. This change is then “propagated” into the CA domain, leading to 
exposure of new interfaces and assembly. Various approaches to test this 
hypothesis are now under way.  
 
This research was supported in part by the Intramural Research Program of the NIH, 
National Cancer Institute, Center for Cancer Research and by NCI contract no. 
HHSN261200800001E with SAIC-Frederick. 
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Vpx is an accessory protein found in the HIV-2/SIVsm/SIVmac lineage of 
primate lentiviruses and plays an important role in infection of non-dividing 
cells such as macrophages and dendritic cells. Pretreatment of monocyte-
derived dendritic cells (moDC) with SIVmac251-virus-like particles 
containing Vpx (Vpx-VLPs) also enhances HIV-1 transduction. Here we 
extended these observations by examining the effect of Vpx-VLPs on HIV-
1 infection in the presence of a type I interferon response. Following 
establishment of an antiviral state by treatment with type I interferon or 
pathogen recognition receptor (PRR) agonists, HIV-1 transduction of 
moDCs was nearly undetectable. Strikingly, despite the establishment of an 
antiviral state, Vpx-VLPs rescued HIV-1 transduction up to 1000-fold but 
not HIV-2 or SIVmac. By producing HIV-1 virions in the presence of Vpx 
and no other SIV factors, Vpx was shown to be sufficient for HIV-1 to 
overcome the antiviral state. In the absence of interferon, the boost to HIV-
1 infection of moDCs by Vpx-VLPs was associated with an increase in 
nascent HIV-1 cDNA. The larger boost to HIV-1 infection of interferon-
treated moDCs by Vpx-VLPs was associated with minimal additional 
increase in viral cDNA or 2-LTR circles; this suggests that the major effect 
of Vpx is executed within the target cell nucleus. Vpx-VLPs did not 
globally block the induction of interferon or of interferon-stimulated genes 
(ISGs), suggesting that the mechanism involves Vpx-mediated suppression 
of a particular interferon-induced activity. Vpx mutants that disrupt 
interaction with VprBP/DCAF1 and knockdowns of this protein in 
macrophages did not abrogate the observed effect suggesting a Cullin4 E3 
ubiquitin ligase independent mechanism. This complex has been reported to 
be essential for the enhanced HIV-1 transduction mediated by Vpx-VLPs in 
moDCs and macrophages. In ongoing experiments we are attempting to 
understand the mechanism by which Vpx rescues HIV-1 from the antiviral 
state. 
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FIV is a complex retrovirus belonging to the lentiviral genera that causes a 
disease similar to human acquired immunodeficiency syndrome in 
domesticated cats. FIV is a potential small animal model for AIDS, and FIV 
based vectors are also being pursued for human gene therapy. Recently, a 
series of studies have suggested that similar to the packaging determinants 
of the primate lentiviruses, human and simian immunodeficiency virus 
(HIV and SIV), and the packaging determinants of this non-primate 
lentivirus are complex and multipartite. Specifically earlier studies from our 
laboratories have mapped the FIV packaging signal to two or more 
discontinuous regions within the 5’ end 511 nucleotides (nt) of the genomic 
RNA (Mustafa et al., 2005, J Virol, 79:13817-21), and structural analyses 
have determined its secondary structure (Kenyon et al., 2008, RNA, 
14:2597-608). Using minimal free-energy structural predictions, 
biochemical probing, and phylogenetic analyses, we have demonstrated five 
conserved stem loops (SL1-SL5) and a conserved long-range interaction 
(LRI) between complementary heptanucleotides in R/U5 (nt 289 5’ 
CCCUGUC 3’ nt 295) and Gag (nt 644 3’ GGGACAG 5’ nt 638). In 
addition to the LRI, we have identified in stem loop 5 a prominent 10 bp (nt 
657 5’ AAUGGCCAUU 3’ nt 666) palindromic (pal) sequence within the 
Matrix coding region of Gag that may act as a viral dimerization initiation 
site. To establish the biological significance of different structural 
components of the proposed structure and to provide functional evidence 
for the existence of the LRI, and the role of pal in FIV RNA packaging, we 
introduced a series of mutations including deletions/substitutions and/or 
compensatory mutations in the proposed RNA secondary structure. These 
mutations were tested in a biologically relevant in vivo packaging and 
transduction assay to determine their effects on packaging and replication 
efficiency of FIV transfer vectors. The detailed results of the deletion and 
substitution mutational analysis will be presented, which will further 
validate the RNA secondary structure of the FIV packaging signal proposed 
by us earlier and establish the biological significance of different structural 
components in FIV RNA packaging. 
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SEVI (Semen-derived Enhancer of Viral Infection) was identified from a 
peptide library of pooled human semen as a factor that can greatly enhance 
HIV infection. SEVI corresponds to an amyloidogenic peptide fragment 
from prostatic acid phosphatase (PAP), an abundant protein in semen. The 
amyloid form of this peptide can enhance HIV infection up to 105-fold 
under conditions of limiting viral inocula. Although we have previously 
shown that synthetic versions of SEVI can enhance HIV infection, the 
extent to which endogenous SEVI contributes to the ability of semen to 
enhance HIV infection was unclear. To address this question, we generated 
antibodies against SEVI fibrils, and used them to probe relative SEVI levels 
in individual semen samples obtained from multiple donors. We observed a 
statistically significant correlation between the viral enhancing activity of 
semen and anti-SEVI reactivity. Conversely, the enhancing activity of 
semen was not correlated with levels of prostate specific antigen (PSA) or 
other proteins present in semen. Furthermore, when semen was depleted of 
HIV enhancing activity by incubation for prolonged periods at 37oC or by 
resin-mediated depletion of cationic proteins, we observed a reduction in 
anti-SEVI reactivity. These findings suggest that endogenous SEVI likely 
plays an important role in the ability of semen to enhance HIV infection. 
Microbicides targeting both HIV and SEVI might greatly reduce HIV 
transmission. 
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Recent studies suggest that a novel human retrovirus, XMRV, is associated 
with prostate cancer or chronic fatigue syndrome (3,4). The virus was found 
in prostate tumors of patients carrying a germline mutation of the HPC1 
gene locus, which encodes the antiviral gene RNase L. Previous studies 
have suggested that XMRV is susceptible to the Interferon (IFN)-induced 
antiviral state in DU145 prostate cells, but not in LNCaP prostate cells since 
these cells are deficient in IFN signaling. Reduction in RNase L by RNA 
interference (RNAi) slightly enhanced XMRV replication in the presence of 
IFN but had no effect in the absence of IFN (1). Moreover, recent studies 
indicated that well characterized IFN-induced retroviral restriction factors, 
such as tetherin and APOBEC3G, are capable of restricting XMRV 
replication (2). 
 
Despite these observations, it is still unknown what cellular factor is 
restricting XMRV in the context of an IFN induced antiviral state. To 
explore possible factors that might restrict XMRV, we reconstituted an IFN 
antiviral state in an IFN-signaling competent cell line (2fTGH cells - human 
fibrosarcoma) and tested the ability of XMRV to establish a spreading 
infection. XMRV replication and spread was completely blocked following 
IFN exposure, but preceded normally in cell lines deficient in various 
components of the IFN signaling pathway. Reduction of RNase L steady 
state protein levels by more than 90% failed to relieve the block imposed by 
IFN, suggesting that RNase L is not a limiting factor in the context of IFN. 
The same results were seen upon knockdown of tetherin, an IFN-induced 
gene product shown to have broad antiviral properties against retroviruses. 
Further investigations revealed that IFN blocks XMRV replication at early 
stage in the life cycle and it therefore remains possible that either an 
unknown factor or multiple known IFN-induced genes are responsible for 
inhibition of XMRV. 
 
 
1. Dong, B., S et al., 2007. Proc Natl Acad Sci U S A 104:1655-60. 
2. Groom, H.C. et al., 2010. Proc Natl Acad Sci U S A  
3. Lombardi, V.C. et al. 2009. Science 326:585-9. 
4. Urisman, A. et al., 2006. PLoS Pathog 2:e25 
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During viral maturation the HIV-1 virion typically forms an electron-dense 
conical core that houses the viral genome and replication proteins required 
for the subsequent round of infection. The outer surface of this core is the 
viral capsid which is compromised solely of the protein CA. Proper 
formation of this capsid is required for the virus to be infective. Studies of 
HIV-1 capsids composed of mutated CA proteins have found that mutations 
increasing or decreasing overall stability of the capsid have strong negative 
effects on viral infectivity. These findings have led to the theory that the 
HIV-1 capsid exists in an optimized “metastable” state that is required for 
full infectivity. 
Following fusion with the target cell, the viral capsid begins a process of 
disassembly that has been termed “uncoating”. Despite significant research 
over many years, the process of uncoating remains poorly understood. 
Mutations in CA or host cell restriction factors such as TRIM5α may alter 
the natural process of uncoating and decrease viral infectivity. The majority 
of mutations in CA can be classified as mutations that enhance capsid 
stability (hyperstable) or decrease capsid stability (hypostable). Host factors 
such as cyclophilin A (CypA) are also considered to play a role in HIV-1 
uncoating but the manner in which these proteins function is also not well 
characterized.  
Various assays can be utilized to determine the relative stability of a given 
HIV-1 capsid. Utilizing a panel of CA mutants we tested several uncoating 
assays to determine if variances in outcomes would occur between 
individual panel members depending in the assay chosen. We noted that 
certain CA mutants had divergent behaviors depending upon the assay 
utilized to determine the degree of uncoating. Based upon these 
observations we conclude that the definition of a given CA mutant as hyper- 
or hypostable is assay-dependent and the choice of assay used to make this 
determination can alter interpretation of experimental results. 
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The mechanism of gamma retrovirus integration site selection is not only an 
interesting scientific question, but also a topic of interest to the field of gene 
therapy. Integration of therapeutic genes into a host genome can and has led 
to adverse events in multiple therapeutic gene transfer studies. Both fields 
would benefit from an increase in knowledge of the interaction between the 
host cell and the gamma retrovirus pre-integration complex. In this study, 
we extensively analyze the integration site preferences of two gamma 
retroviruses, murine leukemia virus (MLV) and xenotropic murine leukemia 
virus-related virus (XMRV) in primary human CD4+ T lymphocytes. 
Generating these data sets in T lymphocytes will allow us to use 
bioinformatic methods to compare the integration site data set to previously 
published ChIP-Seq data with an exact match of cell type. As a result, our 
bioinformatic methods will be allow us to correlate certain genomic features 
to increased or decreased integration frequency, possibly leading to the 
identification of new integration site trends. 
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In this work we study the effect of HIV-1 nucleocapsid protein (NC) on the 
opening and closing kinetics of the TAR RNA hairpin by applying force to 
the ends of individual RNA molecules using optical tweezers. The TAR 
hairpin opens up as it is pulled by the ends and closes as it is relaxed, and 
the forces at which each transition occurs depend on the pulling/relaxation 
rate. Surprisingly, we find that in the presence of saturating NC, the average 
TAR opening force increases, and the effect is greater at higher pulling 
rates. However, extrapolation to zero force shows that the force-free 
opening rate is ~1000-fold greater in the presence NC. This result suggests 
that NC decreases the free energy barrier for TAR opening by ~4 kcal/mol. 
Moreover, we estimate that whereas 12 bp (out of 24 bp total) have to be 
unzipped by force to completely unfold the hairpin stem in the absence of 
NC, only about 6 bp must be opened prior to complete unfolding in the 
presence of NC. These results are consistent with the ability of NC to 
moderately destabilize DNA bps. While the TAR hairpin remains relatively 
stable in the presence of NC, its opening rate is significantly increased, 
illustrating the general nucleic acid chaperone activity of this protein. 
Future studies aimed at characterization of NC’s effect on the TAR closing 
rate will allow a complete understanding of the effect of HIV-1 NC on the 
kinetics and equilibrium stability of TAR RNA. 
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Intracisternal A-type particles (IAPs) are endogenous retroviral elements 
that have readily colonized the mouse genome with around two thousand 
copies. Most of them lie dormant and are lined with silent histone 
H3K9me3 marks, which we recently identified to be dependent on KAP1, 
the loss of which leads to the uncontrolled expression of IAP genes in 
embryonic stem (ES) cells and in early embryos. 
 
Interestingly, IAP elements are also heavily methylated in their DNA and 
remain so even throughout reprogramming in early embryos when other 
classes of retroelements are sensitive to genome-wide demethylation. It is 
thought that sequence-specific signatures maintain continuous methylation 
of IAPs to keep them silent, although the precise sequences and factors 
controlling this process are unknown. We propose KAP1 to be implicated 
since we have observed it to induce de novo CpG methylation of a reporter 
in early embryos. 
 
Our goal is to establish if KAP1 controls DNA methylation of IAP 
proviruses. We are investigating this question by using bisulphite 
pyrosequencing to measure the IAP methylation load globally as well as at 
specific loci. We are comparing DNA taken from embryos that are wild 
type or knockout for KAP1 to determine if KAP1 is able to protect IAP 
genomes from DNA demethylation. We are also testing the ability of 
introduced IAP cis-acting sequences to induce de novo methylation. These 
studies will characterise the mechanism of KAP1 silencing of endogenous 
retroelements during early embryogenesis. 
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Partitioning of membrane proteins into various types of microdomains is 
crucial for many cellular functions. Tetraspanin-enriched microdomains 
(TEMs) are a unique type of protein-based microdomain, distinct from 
membrane rafts, and important for several cellular processes such as fusion, 
migration, and signaling. TEMs also serve as sites of HIV-1 
assembly/egress and tetraspanins regulate HIV-1-induced membrane fusion. 
It is also well established that HIV-1 particles are enriched in raft lipids.  
Using different quantitative microscopy approaches, we investigated the 
dynamic relationship between TEMs, membrane rafts, and HIV-1 exit sites, 
focusing mainly on CD9. Our results demonstrate that this tetraspanin 
accumulates at HIV-1 assembly sites as expression of the major viral 
structural component, Gag, increases. Further, CD9 exhibited confined 
behavior and reduced lateral mobility at these sites, suggesting that Gag 
assembly locally traps tetraspanins. In contrast, the raft lipid GM1, while 
also recruited to budding/assembly sites, exhibited mostly normal mobility 
in these membrane areas. These results suggest that by actively regulating 
the local membrane environment at budding sites, HIV-1 creates a 
membrane milieu favorable for viral assembly and/or transmission to target 
cells. 
 269 
DOMAIN SPECIFIC CONTRIBUTIONS TO THE BIOLOGICAL 
PROPERTIES OF CHIMERIC SUBTYPE B AND C VPU PROTEINS 
 
Autumn Ruiz1, M. Sarah Hill2, Kimberly Schmitt1, Edward B Stephens2  
 
1University of Kansas Medical Center, Anatomy and Cell Biology, Kansas 
City, KS, 66160, 2University of Kansas Medical Center, Microbiology, 
Kansas City, KS, 66160 
 
Previously, we showed that a subtype C Vpu protein from a clinical isolate 
of HIV-1 displayed biological properties distinct from those exhibited by a 
laboratory-adapted subtype B Vpu (HXB2). Inoculation of pig-tailed 
macaques with a simian-human immunodeficiency virus (SHIV) expressing 
a subtype C Vpu protein (SHIVSCVpu) resulted in a more gradual loss of 
CD4+ T-cells compared to those inoculated with a SHIV expressing a 
subtype B Vpu (SHIVKU-1bMC33) (M.S. Hill et al., Virology 371(1):86-97, 
2008). In this study, we sought to determine the contributions of the N-
terminus/transmembrane domain and the cytoplasmic domain of each of 
these subtypes to the differences observed. We constructed chimeric Vpu 
expressing either the subtype B or subtype C N-terminal 
region/transmembrane domain and the opposing cytoplasmic domain. Both 
chimeric vpu genes were fused in frame with the gene for enhanced green 
fluorescence protein (EGFP). Our results indicate that the cytoplasmic 
domain is responsible for localization of the protein and the difference in 
molecular weight of the fusion proteins. Both proteins down-regulated CD4 
from the surface similar to the SCVpu. We constructed SHIV expressing 
either of the chimeric Vpu (SHIVVpuBC and SHIVVpuCB). SHIVVpuBC 
replicated with increased kinetics compared to both parental viruses 
(SHIVKU-1bMC33 and SHIVSCVpu) as well as to the SHIVVpuCB. SHIVVpuCB 
replicated with reduced kinetics compared to the SHIVVpuBC and the 
parental SHIVKU1b-MC33, however at a rate similar if not slightly increased 
from the parental SHIVSCVpu. Inoculation of three pig-tailed macaques with 
SHIVVpuBC resulted in a rapid loss of circulating CD4+ T-cells and high viral 
loads. Studies involving inoculation of pig-tailed macaques with SHIVVpuCB 
are ongoing. These results demonstrate the potential impact of the 
individual domains of the Vpu protein on biological properties, protein 
function and pathogenesis.  
This study supported by NIHAI51981.  
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HIV-1 encodes a polypeptide called Gag that is capable of forming virus-like 
particles (VLPs) in vitro in the absence of other cellular or viral constituents. 
During the late phase of HIV-1 infection, Gag polyproteins are transported to 
the plasma membrane (PM) for assembly. Gag trafficking and assembly on the 
PM of the infected host cells are essential to the production of new HIV virions. 
Great progress has been made in defining both the viral and cellular 
determinants of HIV-1 assembly and release. However, the trafficking pathway 
used by Gag to reach its assembly sites in the infected cell is poorly understood. 
There is mounting evidence that HIV-1 Gag interacts with several cellular 
proteins during the virus replication cycle and that these interactions are 
mediated by the MA domain. These include calmodulin (CaM), the suppressor 
of cytokine signaling 1 (SOCS1), the human adaptor protein-3 complex (AP-3), 
and tail-interacting protein (TIP47). CaM is a calcium-binding protein 
expressed in all eukaryotic cells. It can bind to and regulate a number of 
different protein targets, thereby affecting many different cellular functions. It 
can have different subcellular locations, including the cytoplasm, within 
organelles, or associated with the plasma membrane. Previous studies have 
revealed that CaM co-localizes with Gag in a diffuse pattern in the cytoplasm of 
infected H-9 cells, Gag-CaM interactions are dependent on calcium, and that 
these interactions are mediated by the MA domain. Coupled with recent 
evidence that intracellular calcium stimulates production of virus-like particles, 
we hypothesize that CaM-MA interactions are probably important for Gag 
trafficking and assembly. We have employed a set of structural, biochemical 
and biophysical methods to precisely elucidate the structural requirements of 
Gag-CaM interactions. Herein, we demonstrate that MA binds directly to CaM 
in a calcium-dependent manner with a 1:1 stoichiometry and dissociation 
constant (Kd) of 1.9 µM ± 0.1 µM. NMR, ITC and mutagenesis studies 
confirmed that MA binds preferentially to the C-terminal hydrophobic pocket of 
CaM in an entropically driven mode. Furthermore, our data show that the N-
terminal myristyl group of MA is not required for CaM binding. We hope that 
our studies will not only elucidate the structural requirements for Gag-CaM 
interactions but may establish a potential link between CaM cell signaling 
pathway and HIV replication and infectivity. Elucidation of the molecular 
interactions between the host cell and HIV are important for understanding the 
resulting viral replication and the subsequent cytopathogenesis in the infected 
cell, which will aid in the development of more efficient antiviral drugs. 
 271 
INVOLVEMENT OF SUPPRESSOR OF CYTOKINE SIGNALING 1 
(SOCS1) PROTEIN IN THE RHESUS MACAQUE TRIM5ALPHA 
MEDIATED LATE RESTRICTION 
 
Ryuta Sakuma1,2, Sayaka Sukegawa1, Seiga Ohmine2, Yasuhiro Ikeda2, 
Shoji Yamaoka1  
 
1Tokyo Medical and Dental University, Department of Molecular Virology, 
1-5-45 Yushima, Bunkyo-ku, 113-8519, Japan, 2Mayo Clinic, Department 
of Molecular Medicine, 200 First Street SW, Rochester, MN, 55905 
 
Old world monkey TRIM5α was originally identified as a host factor which 
restricts HIV-1 infection through recognizing the viral core by its 
B30.2(PRYSPRY) domain. We have reported that rhesus macaque TRIM5α 
(TRIM5αrh) also restricts HIV-1 production. The amount of HIV-1 Gag in 
producer cells was reduced by TRIM5αrh over-expression. TRIM5αrh’s 
encapsidation into virus like particles made by HIV-1 Gag poly-proteins 
suggested that the target of the late restriction is the Gag protein, not the 
core structure. Responsible residues for the late restriction locate to the N-
terminal region of coiled-coil domain, not in B30.2(PRYSPRY). TRIM5αrh 
restricts HIV-1 production in a cell line dependent manner, and the study 
using fused cells among supportive and non-supportive cell lines suggested 
that TRIM5αrh needs an additional host factor(s) to block HIV-1 
production. Here we found that SOCS1 bridges the interaction between 
TRIM5αrh and HIV-1 Gag protein. SOCS1 is known to enhance HIV-1 
production by rescuing HIV-1 Gag protein from lysosomal degradation 
(Ryo A et al. PNAS 2008). When SOCS1 was over-expressed in producer 
cells, HIV-1 production was rescued from the TRIM5αrh-mediated late 
restriction. In the presence of SOCS1, Gag poly-protein, but not 
matured/monomeric CA, co-immunoprecipitated with TRIM5αrh by an α-
HA pull-down. Human TRIM5α (TRIM5αhu) did not show the interaction 
with SOCS1 protein in producer cells, and HIV-1 Gag protein was not 
obtained by an α-HA (TRIM5α) pull down, even when SOCS1 was over-
expressed. Over-expression of SOCS1 reduced the amount of TRIM5αrh, 
but not TRIM5αhu, in transfected cells. Thus we hypothesized that 
TRIM5αrh restricts HIV-1 production through an interaction with SOCS1. 
Although this TRIM5αrh mediated late restriction still remains 
controversial and further study and discussion about the antiviral activity 
are required, our findings give new insight into understanding the role of 
TRIM5α in innate-immunity. 
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The viral protein Nef is a pathogenic factor present in Simian and Human 
Immunodeficiency Viruses (SIV and HIV). The absence of Nef reduces 
viral infectivity about 4-40 fold and disease progression both in humans and 
macaques. The mechanisms underlying the gain of infectivity conferred by 
Nef is still not fully understood. We analyzed the effect of complete and 
partial deletions of the nef gene for the replicative cycle of the 
SIVcpzGAB2 infectious clone. Disruption of the Nef ORF was achieved by 
mutagenesis of the start codon of nef which resulted in the complete 
absence Nef expression (SIVcpzΔNef), or by insertion of two nucleotides at 
position 218 which resulted in the expression of a truncated N-terminus of 
Nef (76aa peptide) (SIVcpz t-Nef). The SIVcpzΔNef was 2-4 fold less 
infectious than the wild type SIVcpz in TZM-bl cells and, after providing 
Nef in trans, the infectivity increased to the levels of the wild type virus. 
Infectivity of the SIVcpz t-Nef was completely abrogated in TZM-bl cells 
and was not rescued by providing Nef in trans. Analyses of Gag processing 
showed an accumulation of the p55Gag and the intermediate precursors and 
a reduction of p24CA levels both in cell lysates and viral particles. 
Furthermore, the truncated Nef peptide interfered with the infection of 
SIVcpzΔNef and HIV-1ΔNef. “Chase” assays of 293T transfected cells 
treated with 10mM of cycloheximide showed that in the absence of Nef the 
p55Gag had a faster kinetic of processing. These data confirm that Nef is an 
infectious factor for SIVcpz and suggest that Nef has a correlation with the 
viral protease during virus particle formation. 
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It has been shown that the hypermutated HIV-1 sequences from infected 
patients exhibit strong preferences for G-to-A. In 2003, human APOBEC3G 
was identified as an HIV-1 restriction factor, which edits nascent HIV-1 
DNA by inducing G-to-A hypermutations and debilitates the infectivity of 
vif-deficient HIV-1. On the other hand, HIV-1 Vif protein has the robust 
potential to degrade APOBEC3G protein. Although following 
investigations have revealed that lines of APOBEC3 family proteins have 
the capacity to mutate HIV-1 DNA, it remains unclear whether these 
endogenous APOBEC3s contribute to mutations of vif-proficient HIV-1 
provirus in vivo. 
In this study, we use a human hematopoietic stem cell-transplanted 
humanized mouse (NOG-hCD34 mouse) model and show that Vif is 
prerequisite for HIV-1 expansion. Notably, we demonstrate the 
predominant accumulation of G-to-A mutations in HIV-1 provirus 
displaying characteristics of APOBEC3-mediated mutagenesis in the 
presence of Vif. It was of interest that the frequency of APOBEC3-
associated HIV-1 G-to-A mutations leading to termination codons was 
significantly observed. Although it is now considered that endogenous 
APOBEC3s contribute to HIV-1 G-to-A hypermutation in patients, there 
are no investigations focusing on the influence of APOBEC3s on HIV-1 in 
vivo. Since the original sequence of HIV-1 in an infected individual is 
inaccessible, the previous observations of HIV-1 mutation in patients were 
mostly based on comparative analyses to prototypic HIV-1. Therefore, this 
is the compelling evidence indicating that endogenous APOBEC3s are 
associated with G-to-A hypermutation of HIV-1 provirus in vivo, which can 
result in the abrogation of HIV-1 replication. 
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The use of gene transfer as a means to deliver anti-HIV molecules to target 
cells provides a promising approach to control infection. The use of 
catalytic RNAs or ribozymes (Rzs) engineered to target HIV RNA is one of 
several approaches that can be used to generate HIV resistant cells with the 
potential to inhibit HIV replication. The hepatitis delta virus Rz (HDV-Rz) 
was the first self-cleaving Rz motif identified which naturally functions in 
human cells. In order to improve upon the limited target specificity of 
previous trans acting HDV-Rzs, Dr. Perreault’s Laboratory developed The 
Specific On/oFf Adaptor (SOFA) HDV-Rz motif (1).  
 
Our aim is to evaluate whether SOFA HDV-Rzs could be used to target 
HIV RNA and inhibit the production of new HIV virus in cells. Towards 
this aim we have generated SOFA HDV-Rzs targeting HIV RNA and have 
identified several which can both cleave HIV RNA in vitro and inhibit HIV 
expression in cell assays. Our results suggest that SOFA-HDV Rzs targeting 
HIV RNA could be a useful addition to the arsenal of anti-HIV gene 
therapy agents. 
 
Reference: 
1: Bergeron and Perreault. 2005. Target-dependent on/off switch increases ribozyme 
fidelity. Nucleic Acids Res. 33(4):1240-1248. 
 
This work is supported by the Canadian Institutes of Health Research 
 275 
CHARACTERIZATION OF THE RETROVIRAL SILENCING 
MACHINERY IN EMBRYONIC STEM CELLS 
 
Sharon Schlesinger, Gary Z Wang, Stephen P Goff  
 
Columbia University P&S, Biochemistry and Molecular Biophysics, New 
York, NY, 10032 
 
The pluripotency of Embryonic stem cells (ESC) mandates stringent 
mechanisms for maintaining genomic integrity, among them the ability to 
silence potentially genotoxic attacks by endogenous and exogenous 
retroelements. Although infection of ES and Embryonic Carcinoma (EC) 
cells by MMLV results in the successful integration of the proviral DNA 
into the genome, transcription from the viral promoter in the long terminal 
repeat (LTR) is potently silenced. This restriction is partly due to a large 
nuclear complex that binds to a conserved DNA element called the primer 
binding site (PBS). It was recently shown that the PBS of MMLV- PBSpro 
-binds a DNA binding Zinc-Finger protein called ZNF809, which further 
recruits TRIM28 (Kap1), a known transcriptional silencer. TRIM28 recruits 
several factors involved in transcriptional silencing and heterochromatin 
formation.  
The remarkable ability of ESC to potently suppress retroviruses constitutes 
a unique opportunity to decipher the molecular mechanisms underlying 
gene silencing used by these cells. Thus, in order to characterize the 
silencing machinery over time and at various developmental stages, we are 
using a reporter system that enables us to measure viral restriction in a live 
population of cells. In this system, MMLV LTR-PBS sequence is fused to 
GFP and is then used to infect cells. Repression mediated by the PBS can be 
relieved by replacing the PBSpro with a sequence complementary to 
glutamine (Gln) tRNA, and this PBSgln is used as our control virus. Using 
these viruses we show a high PBS-mediated restriction rate in EC and ES 
cells. However, when we knock down ZFP809 we see no PBS-mediated 
repression at all. This suggests that the PBS restriction mechanism plays a 
major role in the ESC specific silencing of viral expression. Strikingly, the 
silencing machinery is active immediately after viral DNA integration and 
is retained at the same efficiency for weeks. Moreover, even the small sub-
population of cells that escape silencing in a defined window of time are 
again silenced after one day. Interestingly, in cells infected with PBSgln or 
in ZFP809 KD cells the restriction efficiency of ES and EC cells is much 
higher than that seen in somatic cells. This implies the existence of an 
alternative silencing mechanism. Finally, we are mapping the correlation 
between differentiation and viral repression by looking at cells in different 
stages of development. 
These studies provide us with a better understanding of the specific features 
of the stem cells that allow for their genetic stability and resistance to viral 
replication.  
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Over the past decade, it has been established that the nucleolus is not just a 
site for ribosomal biogenesis; it is a multifunctional compartment involved 
in other processes such as cell cycle regulation, cell stress response, the 
processing and maturation of non-ribosomal RNAs, and viral replication. 
Distinct steps in viral RNA (vRNA) replication have been shown to occur 
in the nucleolus for both the Borna disease virus and the hepatitis delta 
virus. Picornaviruses and hepatitis C virus interact with the nucleolar 
protein nucleolin to stimulate translation. The herpesvirus saimiri 
nucleocytoplasmic shuttling protein ORF57 localizes to the nucleolus, 
recruits transcription/export proteins to the nucleolus, and is required to 
traffic through the nucleolus for vRNA transport.  
 
The HIV-1 regulatory protein Rev has also been demonstrated to localize to 
the nucleolus. Rev mediates the nucleocytoplasmic transport of intron-
containing vRNA by binding to a stem-loop structure, the RRE, and 
recruiting CRM1-dependent export machinery. It has been reported that 
Rev can induce the relocalization of CRM1, Nup98 and Nup214 to the 
nucleolus, suggesting formation of Rev:factor export complexes within the 
nucleolus. Furthermore, Rev can multimerize in the nucleolus and can 
actively bind and export nucleolar localized RRE-containing target RNAs. 
Collectively, these finding suggest that the nucleolus may have a functional 
role in the nuclear export and/or subsequent translation of Rev-directed 
RNAs. Nonetheless, whether this nucleolar localization plays a role in HIV-
1 vRNA export or expression remains controversial. Initial steps towards 
elucidating this role, we have analyzed the intracellular distribution of 
vRNA from proviral clones containing select mutations in Rev or the RRE 
using coupled fluorescence in situ hybridization followed by indirect 
immunofluorescence. Using a fluorescent resonance energy transfer assay, 
we have also analyzed the functional interactions of nucleolar proteins, 
previously identified as Rev cofactors, during Rev-mediated export of RRE-
containing vRNA from the nucleus to the cytoplasm. 
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Human APOBEC3G (hA3G) and APOBEC3F (hA3F) exhibit potent anti-
HIV-1 activity by restricting retroviral infection through the deamination of 
cytidine residues during minus strand DNA synthesis. Our studies indicate 
that rhesus APOBEC3G (rhA3G) is not incorporated into wild-type 
pathogenic simian-human immunodeficiency virus (SHIVKU-2MC4) while 
rhesus APOBEC3F (rhA3F) is readily incorporated. This result suggests 
that SIV Vif may not directly interact with rhA3F. In order to examine the 
determinants involved, we constructed vectors expressing human and rhesus 
A3F proteins in which the C-terminal domains were exchanged. 
Introduction of the rhesus C-terminal domain into hA3F resulted in 
decreased virion incorporation and viral restriction. We next sought to 
identify the specific residues responsible for this inhibition of function as 
well as determine if rhesus and/or pigtailed macaques expressed naturally 
occurring variants of APOBEC3F efficient in neutralizing Vif-deficient 
viruses. The rhA3F genes from five rhesus and pigtailed macaques were 
cloned and sequenced. Viral properties of each clone were assessed using 
infectivity, incorporation, and hypermutation assays. We found that the C-
terminus of rhesus APOBEC3F contains unique amino acid residues critical 
for APOBEC3F virion incorporation and decreased viral restriction. The 
results from this study further indicate that SIV Vif is a less potent inhibitor 
of rhA3F.  
 
This study supported by NIHAI084123-01  
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We previously identified clinical isolates with phenotypic resistance to the non-
nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) in the 
absence of known NNRTI mutations. We showed that this resistance is caused 
by N348I, a mutation in the connection domain of human immunodeficiency 
virus type 1 (HIV-1) reverse transcriptase (RT) which confers dual-class 
resistance to NNRTIs (NVP) and NRTIs (AZT). N348I has been shown to be a 
common mutation with a prevalence of 10% among patients treated with 
antiretroviral therapy and <2% among untreated HIV patients.  
 
To understand the effect of N348I on the biochemical functions of HIV RT we 
carried out detailed characterization of enzymes containing the N348I mutation. 
Using subunit-specific mutagenesis we constructed enzymes with the N348I 
mutation in the p66 (p66N348I/p51WT), the p51 (p66WT/p51N348I), or in 
both subunits (p66N348I/p51N348I, or N348I) of RT. RNase H activity assays 
with these enzymes indicate that the previously reported changes in RNase H 
activity are the result of the mutation in p51. However, changes in both subunits 
affect susceptibility to nevirapine. N348I RT is more processive than the WT 
enzyme and this processivity is affected by mutation in either subunit. Pre-
steady state kinetics analysis demonstrated that N348I moderately enhances 
nucleic acid binding. However, transient kinetics experiments revealed that 
N348I has impaired efficiency of incorporation as compared to WT due to 
reduced nucleotide incorporation rate (kpol). The efficiency ratio (kpol/ Kd,dNTP) 
for WT was ~4 fold higher than that for N348I RT. 
 
The kinetics of NVP binding were determined through the measurement of 
Kd,NVP and observation of kapp,dNTP in the presence of NVP. N348I displayed an 
approximately 3-fold increased Kd,NVP (decreased binding) relative to WT. An 
increase in the dissociation constant koff,NVP for N348I was responsible for the 
difference in Kd,NVP values, while the association rates (kon,NVP) of the WT and 
N348I mutant were similar. 
 
These findings provide the basis for understanding the role of connection 
subdomain mutations in NNRTI resistance. They also expand the previously 
accepted structural support role of p51 to include modulation of diverse 
biological functions including binding affinity for substrates, catalytic turnover, 
polymerase and RNase H activities, and drug resistance. 
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In addition to the PTAP-type L domain, HIV-1 Gag contains a second L 
domain motif, LYPXnL, that promotes virus release from both 293T and T 
cells. LYPXnL interacts with the cellular protein Alix to gain access to the 
host ESCRT-III proteins and facilitate virus separation from the cell. We 
recently described a new interaction between the ESCRT-associated protein 
Alix and the Nedd4-like ubiquitin ligase Nedd4-1, and showed that this 
interaction is important for HIV-1 release mediated via the Alix-binding 
LYPXnL L domain motif. To further characterize this interaction and its 
role in HIV-1 release, we examined the nature of the ubiquitin-modification 
of Alix. We found that Alix is mostly monoubioquitinated in the cell. 
Moreover, mono-ubiquitinated Alix is incorporated in HIV-1 particles 
whose release was triggered with the ectopic expression of Alix, suggesting 
that Alix is ubiquin-modified in late stages of HIV-1 release from the 
plasma membrane. Additionally a short motif in the N-terminal portion of 
Nedd4-1, contained within a region known to mediate the peripheral 
binding of Nedd4-1 to membranes, was also found to be critical for Nedd4-
1’s facilitation of HIV-1 release. Mapping of regions in Alix that interact 
and are ubiquitinated by Nedd4-1 has been conducted, and the significance 
of such modification in Alix’s facilitation of HIV-1 release will be 
presented and discussed. 
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Clinical trials and in vitro cell culture studies have elucidated the beneficial role 
that replication disadvantaged viruses may play in reducing HIV viral loads. 
Ex-vivo studies have demonstrated that wild type HIV-1 induces direct 
apoptosis of infected cells; however, the contribution of less fit viruses in T-cell 
apoptosis is not clear. A fundamental issue is whether less fit viruses can confer 
variable virulence and effect CD4+ T-cell depletion differently than wild type 
viruses. Since CD4+ T-cell apoptosis is a dynamic process and involves a series 
of cytokines/chemokines and –pro and –anti apoptosis inducing proteins, we 
hypothesized that mutated viruses will up-regulate the expression of anti-
apoptosis marker proteins and down regulate the expression of DNA damage 
response proteins in comparison to wild type viruses.  
 
We performed a RT-PCR-based apoptosis-array analysis on total cellular RNA 
isolated from PBM cells infected with wild type (NL4-3) and mutated viruses 
containing RT mutations K65R, and clinical RT containing multiple mutations 
(D67N, S68G, K70R, K103N, T215Y, K219E). Apoptosis-array based RT PCR 
(SA Biosciences, MD) allowed us to compare the expression of 90 apoptosis-
related genes. Analysis of data showed that several anti-apoptosis genes were in 
fact expressed 2 to 10 –fold higher in mutated viruses in comparison to wild 
type virus. We found anti-apoptosis genes BAG1, BIRC6, BRAF, MCL1, TNF 
and CD27 were up-regulated 2 to 4 –fold in the PBM cells infected with viruses 
containing K65R and MDR mutations in comparison to the cells infected with 
WT-NL4-3 viruses. We also found that genes related to p53 and DNA damage 
response, AKT1, APAF1, BAX, BCL2L1, CASP7, TP53 were 2 to 6 –fold 
down regulated in cellular RNA derived from PBM cells infected with K65R 
viruses in comparison to WT viruses.  
 
Based on these observations, it is possible that replication disadvantaged viruses 
could alter apoptosis and reduce CD4+ T-cell depletion associated with HIV 
disease.  
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During the packaging process, HIV-1 genomic RNA (gRNA) is 
preferentially selected amongst a multitude of cellular and viral spliced 
mRNAs. As for all retroviruses, RNA is incorporated into viral particles as 
a dimer of two homologous molecules. Packaging of HIV-1 gRNA involves 
specific interactions between a trans-acting factor, the Gag precursor, and 
cis elements present in the leader region of the gRNA (packaging signals). 
This region located at the 5’-end folds into four stem-loop structures, SL1 to 
SL4, involved in several important steps of the HIV-1 life cycle (RNA 
dimerization and packaging, splicing, initiation of translation).  
The location of the HIV-1 Dimerization Initiation Site (DIS or SL1), 
immediately upstream of the SD site, results in its presence in all spliced 
viral mRNAs. The DIS in the context of HIV-1 spliced mRNAs is fully 
functional in vitro but does not promote their packaging, while it is a major 
element for gRNA encapsidation. Moreover, the fact that RNA dimerization 
takes place during in vitro transcription suggests it could affect the fate of 
HIV-1 RNAs by modulating splicing, transport or/and localization.  
In order to determine if RNA dimerization and splicing could be related, we 
either mutated the DIS or/and moved it away from the SD. We then 
analyzed the yield of viral RNAs in transfected 293T cells and in viral 
particles by quantitative RT/PCR and evaluated the importance of the DIS 
and SD proximity on splicing and RNA packaging. We found that all 
mutations affecting either the DIS or the distance between the DIS and the 
SD site decreased gRNA packaging efficiency, while multi-spliced viral 
RNAs were slightly increased. Interestingly, we observed a 2-3 fold 
increase in splicing efficiency when the DIS was disrupted or displaced 
away from the SD. These results suggest that the DIS and/or RNA 
dimerization could possibly regulate viral RNA splicing and gRNA 
selection. 
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Transcription of HIV-1 cDNA prior to, or in the absence of, integration 
leads to synthesis of all classes of viral RNA transcripts. Yet only a limited 
range of viral proteins, including Nef, are translated in this context. Nef 
expression from unintegrated HIV-1 cDNA has previously been shown to 
reduce cell surface CD4 levels in T-cells. We wished to determine whether 
Nef expressed from unintegrated cDNA is also able to downregulate MHC-
I as well as the chemokine coreceptors CXCR4 and CCR5.  
 
Infected cells bearing unintegrated HIV-1 cDNA were assayed in the GFP 
reporter cell line Rev-CEM for cell surface levels of HLA-A2, HLA-ABC, 
CXCR4, CCR5 and CD4. Viral integration was blocked either through use 
of an inactive integrase, or through the use of the integrase inhibitor 
raltegravir. Reverse transcription, integration and the proliferation of 
unintegrated DNA were confirmed by PCR.  
 
In cells bearing only unintegrated HIV-1 cDNA we found that cell surface 
levels of HLA-A2, HLA-ABC, CXCR4 and CCR5 were significantly 
reduced, and we also confirmed the cell surface down-regulation of CD4. 
Similar patterns of results were obtained with both integrase-deficient virus 
or with wild type virus where integration was blocked by raltegravir.  
 
Our results demonstrate that Nef can be expressed from unintegrated cDNA 
at functionally relevant levels, and suggest that the downregulation of 
MHC-I and entry receptors by Nef in this manner could aid immune 
evasion, restrict superinfection and prevent signal transduction involving 
HIV-1 infected cells.  
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Recent studies have shown that APOBEC3G (A3G), a potent inhibitor of 
HIV-1 replication, is localized to cytoplasmic mRNA-processing (P) 
bodies. However, the functional relevance of A3G colocalization with P 
body marker proteins has not been established. To explore the relationship 
between HIV-1, A3G, and P bodies, we analyzed the effects of 
overexpression of P body marker proteins Mov10, DCP1a, and DCP2, and 
DDX6 on HIV-1 replication. Our results show that overexpression of 
Mov10, a putative RNA helicase belonging to the DExD superfamily, leads 
to potent inhibition of HIV-1 replication at multiple stages. In contrast, 
overexpression of the decapping enzymes DCP1a and DCP2, or the RNA 
helicase enzyme DDX6 did not inhibit HIV-1 replication. Mov10 
overexpression in the virus producer cells resulted in reductions in the 
steady-state levels of HIV-1 Gag protein and virus production. Mov10 was 
efficiently incorporated into virions and reduced virus infectivity, in part by 
inhibiting reverse transcription. In addition, A3G and Mov10 
overexpression modestly reduced proteolytic processing of HIV-1 Gag. 
Quantitation of the amounts of cellular gag and gag released from cells in 
the presence of Mov10 overexpression indicated that there was no apparent 
defect in virion release. The inhibitory effects of A3G and Mov10 were 
additive, implying a lack of functional interaction between the two proteins. 
siRNA-mediated knockdown of endogenous Mov10 by 80% did not 
significantly affect viral replication, suggesting that endogenous Mov10 
was not required for viral infectivity. Intriguingly, Mov10 expression in 
CD4+ T cells was suppressed upon phytohemeagglutinin activation and 
strongly induced in the activated cells by as much as 41-fold upon treatment 
with interferon-γ. There was no induction of Mov10 in macrophages with 
interferon treatment. The levels of Mov10 expressed in transfected 293T 
cells were comparable to those present in interferon treated CD4+ T cells. 
Overall, these results show that Mov10 is an interferon-inducible protein 
that can potently inhibit HIV-1 replication at multiple stages. 
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Xenotropic murine leukemia virus-related virus (XMRV) is a 
gammaretrovirus that was originally discovered in a microarray analysis of 
prostate tumor tissues (Urisman et. al., PLoS Pathog. 2006) and has recently 
been detected in a cohort of patients with chronic fatigue syndrome. 
Previous studies suggest that XMRV is susceptible to AZT in culture but is 
resistant to certain protease inhibitors, integrase inhibitors and the 
nucleoside analogs 3TC, D4T and PMPA (tenofovir). In the present study, 
we used a single-cycle indicator cell assay to directly compare the 
sensitivities of HIV-1 and XMRV to a panel of antiretroviral drugs. Our 
analysis included two independently isolated strains of XMRV: XMRVVP62, 
which was produced from a full-length infectious molecular clone, and 
XMRV22Rv1, an isolate obtained from a prostate carcinoma cell line. With 
regard to nucleoside RT inhibitors (NRTIs), XMRVVP62 and XMRV22Rv1 
were susceptible to AZT, PMEA (adefovir) and PMPA in culture, but were 
13–29-fold resistant to ddI, D4T and ABC (abacavir) and >100-fold 
resistant to 3TC and FTC relative to HIV-1NL4-3. XMRVVP62 and 
XMRV22Rv1 were additionally >20-fold and >200-fold resistant to the 
nonnucleoside RT inhibitors nevirapine and efavirenz, respectively. We 
also measured the sensitivity of XMRVVP62 to each of nine protease 
inhibitors (PIs) that are active against HIV-1 in vitro and in vivo. 
Concentrations of PIs that were 10–40-fold greater than the EC50 for HIV-
1NL4-3 failed to inhibit XMRVVP62 infection in our assay system, indicating 
high-level resistance to this particular drug class. However, the integrase 
inhibitors raltegravir and elvitegravir demonstrated potent activity against 
both XMRVVP62 and XMRV22Rv1, with EC50s in the sub-micromolar range. 
Taken together, our results demonstrate that XMRV exhibits a distinct 
pattern of NRTI sensitivity that correlates with the structure of the 
pseudosugar moiety, and that XMRV is susceptible to a broader range of 
antiretroviral drugs than was previously appreciated. Our findings carry 
important implications for the potential use of antiretroviral drugs for 
treating XMRV infection. 
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Human APOBEC3F (A3F) and APOBEC3G (A3G) cytidine deaminases 
are potent host restriction factors, which suppress retroviral replication by 
hypermutating the viral genome, inhibiting reverse transcription, and 
inhibiting viral DNA integration. To overcome A3F- and A3G-mediated 
inhibition, HIV-1 encodes Vif, which binds and targets these proteins for 
proteasomal degradation. Previously, we reported that the A3F-Vif 
interactions that lead to A3F degradation are distinct from the A3G-Vif 
interactions and are located near the C-terminal end of A3F between amino 
acids 283-300*.  
To further elucidate the A3F-Vif interactions, we performed extensive 
mutational analysis of A3F and analyzed the mutants for their effects on 
antiviral activity, sensitivity to Vif-induced degradation, and co-
immunoprecipitation assays. Our results show that A3F amino acids 
289EFLARH294 are critical for binding to Vif and for sensitivity to Vif-
mediated degradation. Mutation of one or more amino acids in this region 
can decrease A3F protein degradation and significantly increase A3F’s 
ability to inhibit viral infectivity in the presence of Vif. Furthermore, 
coimmunoprecipitation assays showed that Vif binding to mutants with 
changes in these amino acids can be significantly decreased. We also 
identified other A3 proteins which have the EFLARH sequence, including 
human A3C, human A3DE, African green monkey A3F, and rhesus 
macaque A3F, and examined the role of this site in the interactions between 
these proteins and HIV-1 Vif. Consistent with previous findings, we 
observed that human A3C, human A3DE, and African green monkey A3F 
are all susceptible to degradation induced by HIV-1 Vif, while rhesus 
macaque A3F is not. Here, we demonstrate that mutagenesis in the 
EFLARH sites of human A3C, human A3DE, and African green monkey 
A3F decrease their susceptibilities to Vif-induced degradation. Together, 
these results indicate that the EFLARH region in human A3C, A3DE, and 
African green monkey A3F interacts with HIV-1 Vif and that this 
interaction plays a role in Vif-mediated proteasomal degradation. However, 
other determinants in rhesus macaque A3F are important for interaction 
with HIV-1 Vif. These studies provide structural insights into the A3F-Vif 
interactions that could facilitate the development of a novel class of anti-
HIV agents.  
 
*Russell, R.A., Smith, J., Barr, R., Bhattacharyya, D., and Pathak, V.K. (2009) J. 
Virol. 83:1992-2003. 
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The resurrection of inactive endogenous retroviruses allows us to learn about 
interactions between extinct pathogens and their hosts that occurred millions of 
years ago. One such paleovirus, chimpanzee endogenous retrovirus group 2 
(CERV2), is a relative of modern murine leukemia viruses that is found in the 
genomes of a variety of old world primates, but is absent from the human 
genome. The non-existence of a human CERV2 orthologue is peculiar given the 
numerous apparent cross-species transmissions that occurred between ancestors 
of old world monkeys, gorillas, and chimpanzees. In order to determine if the 
absence of CERV2 from the human genome can be explained by species-
specific receptor usage, we constructed a consensus CERV2 envelope protein 
derived using sequences found in the chimpanzee genome. CERV2 enveloped 
MLV particles were capable of infecting cell lines from a wide range of species, 
including humans. The permissivity of human cells for CERV2 argues against 
the notion that human ancestors were protected from CERV2 by the lack of a 
functional receptor. 
Using a Hela cDNA library expressed in CERV2 resistant hamster cells, we 
identified copper transport protein 1 (CTR1) as a novel retrovirus receptor that 
was presumably used by CERV2 during its exogenous replication more than 
one million years ago. Expression of human CTR1 was sufficient to confer 
CERV2 permissively to otherwise resistant hamster cell lines, which was 
accompanied by an increase in virion binding. The observed increase in hamster 
cell infection that came with CTR1 expression was specific to CERV2 
enveloped virus, with no gain in permissivity to pseudotypes bearing envelopes 
from several other gammaretroviruses. Furthermore, siRNA-induced CTR1 
knockdown, or CuCl2 treatment specifically decreased CERV2 infection of 
human cells. We have also identified mutations in highly conserved CTR1 
residues that have rendered hamster CTR1 inactive as a CERV2 cell surface 
receptor, including a deletion in a copper-binding motif that is largely 
conserved from humans to zebrafish. These receptor-inactivating mutations in 
hamster CTR1 are accompanied by an increased number of extracellular 
copper-coordinating residues compared to CTR1 proteins from other species. 
This apparent compensation may represent an evolutionary barrier that primates 
would have had to overcome to avoid CTR1 usage by CERV2.  
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Integration, an essential step for retroviral infection, is executed by a high-
order nucleoprotein complex termed the preintegration complex (PIC) that 
is composed of a copy of viral DNA together with a number of viral and 
cellular proteins. Barrier-to-autointegration factor (BAF) is a cellular 
component of Moloney murine leukemia virus (MoMLV) and human 
immunodeficiency virus type 1 (HIV-1) PICs, which facilitates the 
intermolecular integration and blocks autointegtration of the PIC by its 
DNA-binding activity. Recent report has shown that BAF is phosphorylated 
by a family of cellular serine/threonine kinases called vaccinia-related 
kinases (VRKs) and this phosphorylation disables DNA-binding activity of 
BAF. This data therefore raises a possibility that the VRK-mediated 
phosphorylation of BAF could abolish function of the PIC through removal 
of BAF from viral DNA. In this study, we obtained evidence that murine 
VRK1 indeed induced abolishment of the intermolecular integration activity 
of MoMLV PICs in vitro. Importantly, this was accompanied by an 
enhancement of autointegration activity and dissociation of BAF from the 
PICs. Amongst three VRK family members, VRK1 and VRK2, which 
catalyzed hyperphosphorylation of BAF, inhibited the PIC activity. We also 
found that treatment of PICs with certain nucleotides such as ATP resulted 
in the inhibition of the intermolecular integration activity of PICs and the 
dissociation of BAF. However, the ATP-induced dysfunction of PICs was 
not observed in the PICs derived from VRK1-knockdown cells, indicating 
involvement of endogenous VRK1 in regulation of PIC activity. Our results 
suggest the presence of an intrinsic inhibitory mechanism for the retroviral 
PIC integration.  
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Less than one in three women have vaginal microflora dominated by 
Lactobacilli, and these women are at significantly lower risk of acquiring 
HIV. When Lactobacilli dominate the vaginal flora they acidify the vagina 
to pH~3.8 by maintaining a ~1.0% racemic mixture of D and L isomers of 
LA. LA has a pKa of 3.8, and at pH 3.8 comprises uncharged LA and 
lactate anion. We recently discovered that LA inactivates HSV stereo-
specifically, with L-LA more potent than D-LA. We hypothesized that LA 
inactivates HIV. HIVBa-L was treated with L-LA and incubated with 
continuous monitoring of pH and temperature. HIVBa-L was treated with 
different concentrations of DL-LA, D-LA and L-LA at 37oC for 30 min. 
Virucidal activity of 1% L-LA (pH 3.8) was compared to low pH alone 
(pH 3.8, HCl-adjusted) at different times at 37oC. L-LA was further tested 
against several HIV isolates and in the presence of 75% human seminal 
plasma (SP) to mimic a 1:4 dilution of LA during coitus. Sodium lactate 
was evaluated for virucidal activity. Following incubation, buffered 
medium was added to dilute out LA and virus titre determined in TZM-bl 
cells. 0.3% L-LA was ~102-fold more potent than D-LA in inactivating 
HIVBa-L, and was more potent than DL-LA. Similar results were observed 
with a clade A CCR5 strain. Treatment of HIVBa-L with 1% L-LA (pH 3.8) 
resulted in ~104-fold reduction in titre within 1 min and was 103-fold more 
potent than pH 3.8 alone (HCl-adjusted). 0.4% L-LA inactivated (>103-
fold) HIV-1 clades A, EA, C and three clade B patient isolates. L-LA (at 
1.0% final concentration) retained maximum HIV virucidal activity in the 
presence of 75% SP. 1% sodium lactate (pH 7.0) was not virucidal. LA 
inactivation of HIV, as for HSV, demonstrates stereo-chemical dependence, 
suggesting a viral protein target, and is rapid, irreversible and more potent 
than low pH alone. LA (i.e. protonated, uncharged LA) and not the lactate 
anion is virucidal. LA’s HIV virucidal activity in the presence of SP and the 
ability of LA to inactivate a broad-spectrum of HIV strains (R5, X4 and 
dual-tropic) suggests LA is a vaginal defense factor against HIV. Our 
results also suggest that LA has promise as a microbicide that might block 
female to male, and potentially also reduce male to female transmission of 
HIV. Microbicides that employ LA might be valuable since most women do 
not have Lactobacillus-dominated vaginal flora and are at greater risk of 
acquiring HIV. 
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Background: HIV-1 Vif plays a crucial role in the viral life cycle by 
antagonizing a host restriction factor APOBEC3G. Vif has been reported to 
induce G2 arrest and cell death; however, the mechanisms and biological 
significance of this function remain unclear. Here we demonstrate that p53 
pathway is involved in Vif-mediated G2 arrest and cell death.  
Methods: We examined the effect of Vif and it’s mutants on cell cycle with 
PI staining and apoptosis with TUNEL assays using several cell lines. We 
infected CEM-SS T cells with NL4-3 virus possessing wild-type or mutant 
Vif and measured the concentration of p24 in the supernatant to examine 
the effect of Vif-induced cell cycle arrest on HIV-1 replication.  
Results: NL4-3 Vif overcame the inhibitory activity of MDM2 on p53-
mediated transcription in p21- and bax-promoters. These suggest that Vif 
can enhance p53 stability and transcriptional activity by blocking MDM2-
mediated degradation. Vif could also induce G2 cell cycle arrest and 
apoptosis via the p53 pathway. However, the Vif derived from HXB2 strain 
doesn’t have any these functions. We compared the sequence between NL4-
3 and HXB2 Vif and constructed several mutants and tested their effects on 
cell cycle. We found that several amino acids changes in NL4-3 Vif lost its 
function for inducing G2 arrest, whereas the opposite changes in HXB2 Vif 
render it to induce G2 arrest. Finally, we examined the viral replication in 
CEM-SS T cells infected with NL4-3 wild-type, deltaVif, or mutant viruses 
deficient for the function to induce cell cycle arrest.  
Conclusions: These data imply the functional interaction between Vif and 
the p53 axis.  
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For many retroviruses, direct cell-to-cell transmission appears to be much 
more efficient than spread via free viral particles. The case of Human T cell 
leukemia virus type 1 (HTLV-1) is of particular interest since its 
dissemination in vivo strictly depends on cell contacts. HTLV-1-infected T 
lymphocytes are predisposed to form “virological synapses”, but the 
detailed mechanism of HTLV-1 transmission from cell to cell remains 
poorly understood. Using T cells from naturally infected patients, we show 
that HTLV-1-infected T lymphocytes transiently store viral particles in 
extracellular assemblies that are held together and attached to the cell 
surface by virally-induced extracellular matrix and cellular linker proteins. 
Extracellular viral assemblies rapidly adhere to other cells upon cell 
contacts allowing virus spread. Their removal strongly impairs the capacity 
of HTLV-1-producing cells to infect target cells. Our data unveil a novel 
virus transmission mechanism based on the generation of extracellular viral 
particle assemblies whose structure, composition and functions resemble 
those of bacterial biofilms. HTLV-1 biofilm-like structures promote the 
infectious capacity of the virus enhancing its efficiency of transmission to 
other cells. These results open new perspectives for antiviral strategies. 
 
Part of this work was recently published in Nature Medicine 
Pais-Correia et al. Nature Medicine 2010 Jan;16(1):83-9 
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Recently there have been discovered cytosolic proteins that block retroviral 
infection at an early post-entry stage or are required for steps in the pre-
integration life cycle. The target of these proteins is likely the incoming 
viral core, specifically the capsid protein. Our data, and other work, support 
the possibility that core stability, and the appropriate host environment, are 
required for proper core processing, both temporally and spatially. We 
report here the discovery and initial study of SIV CA mutants whose 
phenotypes suggest a failure to meet these essential requirements. These 
mutants may prove to be useful tools in assessing CA function in early post-
entry events. 
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A fraction of HIV-1 in the blood of infected patients is associated with 
platelets and platelets are often found in an activated state in HIV-1 
infection. We could previously show that the C-type lectin DC-SIGN and 
the lectin-like molecule CLEC-2 are expressed on platelets and facilitate 
HIV-1 capture by these cell fragments. Here, we investigated how the 
activation status of platelets impacts the interaction with HIV-1, and we 
determined the consequences of the HIV-1 association with platelets for 
viral infectivity.  
We show that platelet activation significantly increases the ability of these 
cell fragments to facilitate infection of adjacent C8166 T-cells, and this 
activity was dependent on DC-SIGN and CLEC-2, in agreement with our 
previous results. The HIV-1 transmission assay employed for these studies 
involved removal of unbound virus and was designed to model early steps 
in HIV-1 transmission. In order to assess the impact of platelets on 
infectivity of virions present in the blood of infected patients, we chose a 
closed culture system, in which T-cell-platelet cocultures were infected with 
HIV-1 without removal of unbound virus. Under these conditions, platelets 
reduced HIV-1 replication efficiently and in a concentration-dependent 
manner. Notably, the antiviral function of platelets was dependent on the 
platelet activation status, with resting platelets being significantly more 
adept to suppress HIV-1 spread than activated platelets. Experiments with a 
transwell tissue culture system revealed that the antiviral activity of 
platelets did not require contact with T cells, suggesting that platelets 
reduced viral infectivity by sequestering free virus and/or by secreting 
soluble factors. Indeed, the supernatants of activated but not resting 
platelets profoundly suppressed HIV-1 spread, indicating that resting 
platelets store antiviral factors which are released upon activation and block 
HIV-1 infection.  
In summary, our results demonstrate a so far unappreciated dual role of 
platelets in HIV-1 infection: Upon introduction of HIV-1 in the blood 
stream by e.g. needle stick injury activated platelets might capture and 
transfer the virus to T cells. In contrast, in the context of chronic infection, 
constitutive activation of platelets might result in a constant release of 
antiviral factors. These results help to explain the previously reported 
association of platelet counts, viral load and disease progression, and 
highlight platelets as a component of the antiviral immune response.  
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We have developed a homogeneous time-resolved FRET-based assay that 
detects the formation of HIV -1 integrase (IN) dimers. The assay utilizes IN 
monomers that express two different epitope tags that are recognized by 
their respective antibodies, coupled to either allophycocyanin or europium 
cryptate. Surprisingly, we find that dithiothreitol (DTT), a reducing agent 
essential for in vitro enzymatic activity of IN, weakens the interaction 
between IN monomers. This effect of DTT on IN is dependent on its thiol 
groups since the related chemical threitol which contains hydroxyls in place 
of thiols has no effect on IN dimer formation. However, by studying point 
and deletion mutants of IN, we determined that cysteine residues in IN seem 
to be dispensable for this dimer dissociation effect of DTT. Peptides that 
interact with the IN dimer interface were tested in our novel IN dimerization 
assay. These peptides displayed an intriguing equilibrium binding dose 
response curve characterized by a plateau rising to a peak, and then 
descending to a second plateau. Mathematical modeling of this binding 
system revealed that the shape of this dose response curve was consistent 
with the ability of these peptides to promote IN dimerization and block 
subunit exchange between IN dimers. This dose response behavior was 
further extended to tetraphenylarsonium chloride, a small molecule that 
interacts with the IN dimer interface. By analyzing the kinetics of IN 
heterodimer formation in the presence of the peptides and this small 
molecule, we determined their rate constants (i.e. kon and koff) and 
dissociation constant (Kd). In conclusion, our novel FRET-based IN 
dimerization assay has revealed that peptides and small molecules 
interacting with the HIV-1 IN dimer interface promote dimer formation and 
inhibit dimer subunit exchange. 
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Human immunodeficiency virus type 1 (HIV-1) Gag assembles into viral 
particles at the plasma membrane and, during the viral entry, the mature 
capsid (CA) dissociates from each other. We established an yeast two-
hybrid system to measure the Gag-Gag interaction adopting the SOS 
signaling pathway. Using this system, we conducted a screening of Gag-
Gag interaction inhibitors from a chemical library composed of 20,000 
compounds, and isolated 6 candidates for Gag assembly inhibitors. When 
tested in human MT-4 cell line and primary peripheral blood mononuclear 
cells, one of the candidates (2-(benzothiazol-2-ylmethylthio)-4-
methylpyrimidine, BMMP) displayed an inhibitory effect on HIV-1 
replication in a dose-dependent manner, although a considerably high dose 
of the compound was required (5-20µM). The virus production and Gag 
processing were not significantly inhibited by BMMP. In contrast, single 
round infection assay with envelope-psuedotyped HIV-1 vector revealed 
that BMMP inhibited the postentry phase of HIV-1 life cycle. The 
compound did not block the postentry stage in SIV or MLV infection. 
Interestingly, experiments with HIV x SIV Gag chimeras indicated that CA 
was critical for BMMP-mediated HIV-1 block. The assembly of CA was 
inhibited in the presence of BMMP in vitro. Collectively, BMMP is an 
inhibitor of HIV-1 replication and the primary target of BMMP is the CA 
domain of Gag. As the chemical structure of BMMP is distinct from Gag 
inhibitors previously reported, BMMP may serve as a lead compound for 
the development of novel antiretroviral drugs. 
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The current HIV-1 pandemic is caused by at least nine subtypes (termed A 
through K) and an increasing number of recombinant forms. There has been 
a large skew in research focus on subtype B, which is the most prevalent 
subtype in the Western world. We study the transcriptional promoter in the 
long terminal repeat (LTR). Each subtype has a specific LTR promoter 
configuration and even minor changes in the transcription factor-binding 
sites (TFBS) or their rearrangement can have a significant impact on cell 
tropism and pathogenicity. For the HIV-1 subtypes, it is largely unknown to 
what degree LTR promoter variation contributes to differences in proviral 
latency. Such differences in latency properties may have an impact on the 
establishment of viral reservoirs and the inability to clear the virus by 
therapeutic intervention.  
We have constructed recombinant viral genomes in which the subtype-
specific promoters are cloned in the common backbone of the subtype B 
LAI isolate. The recombinant viruses are isogenic except for the core 
promoter region with all major TFBS (e.g. NF-kB and Sp1 sites). To 
measure proviral latency, we set up a single round infection system in the 
SupT1 T-cell line. The culture is split after 24 hours and either untreated 
(control) or treated with different compounds to activate latent proviruses. 
We measured the number of virus-producing cells (intracellular CA-p24 
production) at 2 days post infection and determined the induction index 
(CA-p24 activated/CA-p24 control) for the different HIV-1 subtypes. 
Considerable proviral latency is apparent in this experimental model. A 3-
fold increase in the percentage of virus-producing cells was triggered by 
TNFα for all subtypes, except AE. In subtype AE, one of the two regular 
NFκB sites is replaced by a GABP site. The GABP-to-NFκB mutation in 
the subtype AE promoter reduces basal transcription and restores the TNFα 
response. The reciprocal experiment, NFκB-to-GABP mutation in subtype 
B, does not increase basal transcription, although the TNFα response is 
reduced. Thus, the GABP site is not the sole determinant of these LTR 
properties and we are currently investigating other sequence variation 
between subtype AE and B to elucidate this difference.  
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Simian immunodeficiency virus from Rhesus macaques (SIVmac) is a 
primate lentivirus that exhibits extensive similarities with human 
immunodeficiency viruses (HIVs) in morphology, genome organization and 
biological properties. Like HIV, SIV is dependent on the host cellular 
machinery for transcription, translation and protein production. Alternative 
RNA splicing generates many mRNAs that allow the expression of all viral 
proteins. Consistent with the idea that translation occurs predominantly via 
a cap-dependent scanning mechanism, one usually does not find AUGs 
upstream of the open reading frames (ORFs) in HIV and SIV.  
 
In SIVmac239, the envelope (Env) glycoprotein is translated from a 4 kb 
mRNA which also contains the upstream ORF (uORF) for Rev. It is 
currently accepted that the level of Env expression is dependent on leaky 
scanning due to suboptimal translation initiation at the upstream Rev AUG. 
Interestingly, another potential start codon is present immediately upstream 
of the Rev-AUG. We also identified an alternative Rev-Env mRNA that has 
in fact four upstream AUGs, raising questions about the regulation of Rev 
and Env translation. We constructed subgenomic Rev-Env reporter mRNAs 
to test the contribution of the different upstream AUGs on protein 
expression. Some mutations were also introduced into the infectious 
SIVmac239 molecular clone. The results indicate that the virus requires a 
delicate balance of protein translation. 
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Human T-cell leukemia/lymphoma virus Type I (HTLV-1) causes a 
persistent infection in T-cells that can culminate with leukemia. HTLV-1 is 
transmitted through cell-to-cell contact upon the formation of the 
virological synapse. However, the nature of the intercellular connections in 
HTLV-1 transmission remains unknown. HTLV-1 encodes a 12kD (p12) 
protein that resides in the ER and is cleaved to remove an ER 
retention/retrieval signal to generate the p8 protein, which traffics to the cell 
surface. The p12 and p8 proteins exert opposite effects on T-cells. The p12 
protein induces T-cell activation by increasing ER calcium influx and 
NFAT activity and T-cell proliferation, by binding the IL-2 receptor  and  
chains and increasing STAT-5 phosphorylation and IL-2 production. In 
contrast, p8 upon T-cell receptor (TCR) ligation is recruited to the 
immunological synapse (IS), the contact site between the antigen presenting 
cell (APC) and the T-lymphocytes, and down-regulates TCR signaling 
causing anergy. Here we reconcile this apparent paradox and found that the 
p8 increases T-cells contact and the number and length of Tunneling Nano-
Tubes (TNT), cellular conduits that establish a physical communication 
network among dendritic cells and T-cells, both targets of HTLV-I 
infection. Strikingly, p8 is rapidly transferred to neighboring cells through 
direct cell-cell contacts and TNT, which may prime surrounding T-cells for 
viral acquisition. The increase of cell-cell contact is explained in part by the 
clustering of LFA-1 adhesion molecule on the cell surface. Quantitative 
analysis revealed HTLV-1 p8 significantly increases transmission of the 
HTLV-1 virus to neighboring cells. The core (Gag) and Envelope proteins 
of HTLV-I and p8 were visualized in the TNTs by confocal microscopy and 
live imaging. Electron microscopy demonstrated virus particles are 
associated with TNT formed following p8 expression. The ability of p8 to 
simultaneously induce T-cell anergy and cluster T-cells by TNT formation 
represents a novel and elegant example of virus adaptation in an immune 
competent host. This model identifies a novel viral target for intervention in 
HTLV-I infection. 
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Betaretrovirus Jaagsiekte Sheep Retrovirus (JSRV) is the etiological agent 
of ovine pulmonary adenocarcinoma (OPA), a contagious lung cancer of 
sheep. It was previously shown that the expression of JSRV envelope 
protein (JSRVEnv) alone can induce transformation of epithelial cells in 
vivo and ex vivo. The transformation led to activation of several signaling 
pathways involved in cellular proliferation and growth but the precise 
interplay between JSRVEnv and these pathways are still unclear. 
Drosophila is a convenient model to investigate to growth, proliferation and 
cell death mechanisms at the genetic level, because most signaling 
pathways are well conserved between vertebrates and invertebrates. We 
have generated Drosophila transgenic lines. Inducible and tissue-specific 
expression of JSRVEnv were observed into eyes and wings tissues. Two 
interesting results were obtained: 1- the whole-wing size was significantly 
reduced when JSRVEnv was expressed in the tissue leading to the adult 
wing due to a reduction of cell size. 2- Apoptosis was induced in larval and 
adult eyes as shown by immunostaining. Interestingly, a recent study has 
shown that apoptosis could induced mechanism of compensatory 
proliferation. Therefore, JSRVEnv could use this mechanism to cause 
cancer. We are currently testing this hypothesis using our experimental 
model. 
 299 
INTEGRATION SITE ANALYSIS IN XMRV-POSITIVE PROSTATE 
CANCERS 
 
Uta von Schwedler1, Troy Brady2, Robert Schlaberg1, Rick Bushman2, Ila 
Singh1  
 
1University of Utah, Pathology, Salt Lake City, UT, 84112, 2University of 
Pennsylvania, Microbiology, Philadelphia, PA, 19104 
 
Xenotropic MLV-related retrovirus (XMRV) is a novel human retrovirus 
discovered in prostate cancers. In our patient population, 27% of all prostate 
cancers tested XMRV-positive by immunohistochemistry (IHC) or 
quantitative PCR (qPCR); the prevalence rates vary in the different studies 
done to date. It is not certain whether the virus causes the prostate cancer. 
Other gammaretroviruses cause cancers by insertional activation of 
oncogenes by viral LTR sequences or by insertional inactivation of tumor 
suppressor genes. If XMRV causes cancers, it is likely to follow a similar 
mechanism. 
 
To establish a causal role for XMRV in human cancers, we are looking to 
identify XMRV integration sites in human prostate cancers, and to 
determine their relationship with oncogenes and tumor suppressors. For this 
analysis, patient genomic DNA is digested with a restriction endonuclease 
and ligated to an adapter linker, which serves as a primer binding site. PCR 
amplification using a primer for this site and a second primer in the XMRV 
3'LTR allows selective amplification of integrated XMRV LTRs with the 
adjoining host cell DNA. Tens of thousands of these PCR products can then 
be sequenced simultaneously by high-throughput 454 sequencing.  
 
The fact that human cancers have very few copies of XMRV proviral DNA 
has posed a significant challenge for all scientists studying XMRV in 
patients. Methods to overcome these challenges will be discussed. Finding a 
set of integration sites that are close to an oncogene and clonal in a tumor 
would strongly suggest a causal role for XMRV in prostate cancer. 
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HIV-1 Gag expression is necessary and sufficient for the production of 
virus-like particles (VLPs) in mammalian cells. Gag is therefore the 
minimal viral determinant required for VLP assembly and release. Studies 
exploring HIV-1 Gag trafficking pathways have used different Gag 
expression vectors in different cell types, in some cases with contrasting 
results. Compared with a panel of commonly used HIV-1 Gag expression 
vectors in different cell lines (e.g., HeLa, and 293T), two X4-tropic proviral 
clones, pNL4-3 and pHXB2R3 (Vpu defective), showed distinct properties 
in virus release (HeLa, 293T, and Jurkat), infectivity (TZM-1b), and 
replication (Jurkat) assays. pNL4-3 shows higher release efficiency, higher 
infectivity, and faster replication kinetics than pHXB2R3. Not only Vpu 
and also additional as-yet-unknown factors contribute to the differences 
observed between these two proviral clones. HXB2R3 or HXB2R3U 
viruses collected at the peak of virus replication in Jurkat cells demonstrated 
accelerated replication capacity in the second round of infection. Mutations 
were identified in pHXB2R3/pHXB2R3U Vpu and/or Env: pHXB2R3 
Env531AT and pHXB2R3U Vpu52SI/Env403AT or Env33YH. Replication 
defects were corrected in all clones by the Env mutations and improved to a 
lesser degree with the Vpu52SI mutation. Further molecular/cellular 
analyses will be presented to explore the basis for these effects. 
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Members of the host restriction factors, apolipoprotein B mRNA-editing 
catalytic polypeptide (APOBEC) super family, mainly A3G and A3F are 
potent inhibitors of retroviruses and retroelements. In the absence of Vif, 
these APOBEC molecules are incorporated into budding virions to induce 
cytidine deamination on the minus stand viral DNA, inhibit cDNA 
synthesis, and inhibit integration of newly infected cells. HIV-1 Vif 
overcomes this host restriction by binding to the N-terminal region of 
APOBEC, and recruiting the E3-ubiquitin ligase machinery consisting of 
Cullin 5- EloginB/C to the C-terminal domain of Vif, thus 
polyubiquitylating and targeting APOBEC for proteasomal degradation. To 
identify dominant-negative (dn) effects of Vif mutants on APOBEC, we 
constructed non-functional Vif variants containing either mutations and/or 
deletions of key substrate binding domains to APOBEC, Cullin 5/Elogin B-
C, and potential sites of Vif homodimerization. These Vif mutants with the 
potential to interfere with the function of wild type Vif were co-expressed 
with wild type HIV-1 NL4-3. Their ability to promote the packaging of 
A3G and A3F into budding virions and reduce the infectivity of HIV-1 in 
target cells was determined. Our earlier studies show that the expression of 
mutations of Vif at the C-terminus counteracted the Vif-induced reduction 
of intracellular A3G levels presumably by preventing Vif-induced A3G 
degradation. Consequently, dn Vif interfered with wild type Vif’s ability to 
exclude A3G from viral particles, and reduced viral infectivity despite the 
presence of wild type Vif. Currently, we have expanded our studies to test 
the dn properties of these Vif mutants in the presence of A3F. Despite the 
fact that the domains in A3G/A3F and Vif required for interaction are 
distinct, we found that the dn properties of our Vif mutants applied to both 
A3G and A3F. We are currently testing our mutants in conjunction with 
other Vif-sensitive deaminases to see if dn interference by Vif is a general 
non-selective characteristic or restricted to certain deaminases. The ability 
of our dn Vif mutants to induce packaging of APOBEC in the presence of 
wt Vif offers a promising target for drug therapeutics in the treatment of 
HIV/AIDS. 
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Review of the Stanford drug resistance database for clinical occurrence of 
combinations of NNRTI resistant mutants shows that 37% of isolates with 
the mutation G190S in RT also had K101E. To determine whether the 
double mutant K101E+G190S has an advantage over G190S alone, we 
introduced K101E+G190S into an NL4-3 backbone and measured in PM1 T 
cells and the viral fitness using growth competition assays in the absence of 
efavirenz (EFV) and viral resistance in the presence EFV. Surprisingly, we 
found that the replication of NL4-3 (K101E+G190S) was stimulated in the 
presence of drug compared to the absence (2-fold maximum stimulation at 
400nM EFV). NL4-3 (K101E+G190S) reduced the fitness (41%) and 
increased the resistance 47-fold compared to G190S alone. NRTI resistance 
mutation L74V improved the fitness of K101E+G190S 32% in the absence 
of drug, and abolished stimulation without affecting. M41L+T215Y 
improved the fitness of K101E+G190S 12% and abolished stimulation, but 
reduced the IC50 52-fold. To confirm the stimulation of K101E+G190S by 
drug, we cloned an RT with these mutations from a patient that failed EFV. 
This clone, D10, which has the resistance mutations M41L, K101E, G190S, 
and T215Y, showed 20-fold maximum stimulation at 800 nM EFV. 
Stimulation was eliminated when K101E was back-mutated, and resistance 
decreased as well (87-fold). In contrast, stimulation increased 6-fold and 
resistance increased 3-fold when M41L+T215Y were back-mutated. These 
results indicate that polymorphisms in the D10 clone can influence the level 
of stimulation compared to an NL4-3 backbone. These studies were 
confirmed in PBMCs. Stimulation was also observed with the NNRTI 
nevirapine (NVP), but not with etravirine. Studies of the mechanism of 
stimulation showed that EFV did not increase the specific polymerase 
activity or heterodimer formation of recombinant RT, nor did the drug 
increase gag-pol processing in the virion. These results show that some 
NNRTI mutations are stimulated by drug and that stimulation is eliminated 
by the addition of nRTI resistance mutations. When anti-retroviral treatment 
includes nRTIs and NNRTIs, stimulation may influence which mutations 
are selected in vivo. Newly developed NNRTIs, which do not stimulate 
NNRTI mutants, such as etravirine, would be preferred over others, such as 
EFV and NVP. 
 303 
STUDY ON THE CELLULAR MECHANISM REGULATING HIV 
INFECTION OF MEMORY AND NAÏVE CD4 T CELLS. 
 
Weifeng Wang, Dongyang Yu, Paul Vorster, Yuntao Wu  
 
George Mason University, Molecular and Microbiology, Manassas, VA, 
20110 
 
HIV-1 preferentially establishes latent infection in memory CD4 T cells, but 
the underlying virological and cellular mechanisms remained largely 
undefined. Here we studied the differential susceptibility of memory and 
naïve CD4 T cells to HIV infection, and found that memory CD4 T cells 
supported much higher levels of HIV-1 latent infection when compared 
with naïve CD4 T cells. However, when HIV was pseudotyped with the 
VSV-G glycoprotein, the virus is equally capable of infecting both memory 
and naïve T cells, either pre-activated or immediately activated after 
infection. These results suggested that the differential ability of HIV to 
infection memory and naïve T cells is at the early steps such as entry and/or 
early post entry events. We detected no differences on the surface levels of 
CD4 and CXCR4 between memory and naïve T cells, and, as a 
consequence, the fusion efficiencies are comparable in both cell subsets. 
However, we found that viral DNA synthesis and nuclear localization were 
much more efficient in memory T cells. The cellular mechanisms regulating 
these early viral processes are further investigated, and indeed we found 
distinctive cellular environment between these two cell subsets. 
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Central to the development of much needed new treatments for HIV-1 is a 
more thorough understanding of the viral lifecycle and the cellular co-
factors required by the virus. This will allow the identification of novel drug 
targets. Targeting cellular proteins and their interaction with the virus is 
likely to reduce the problem of emerging viral resistance to drugs. We are 
particularly interested in cellular proteins which are required for the 
assembly phase of the viral lifecycle. During assembly, full length viral 
RNA fulfils dual roles. It serves as an mRNA to produce viral structural 
proteins and is packaged into assembling virions as genomic RNA. We 
hypothesise that the conformation of the viral RNA may be important in the 
spatiotemporal control of these two functions. Chaperone proteins, such as 
cellular RNA helicases, may be required for regulating the conformation of 
the viral RNA, and so the outcome of viral infection. To date, seven cellular 
RNA helicases have been proposed to play roles at various stages of the 
HIV-1 lifecycle.  
 
With the aim of identifying further RNA helicases required for viral 
assembly we carried out a targeted siRNA library screen in HeLa cells. 
siRNAs targeting 59 cellular RNA helicases were tested for their effect on 
viral replication. Both viral protein production and infectious virion 
formation were assessed. Five RNA helicases were identified which 
reproducibly decreased viral replication when knocked down. The helicases 
identified are DDX5, DDX10, DDX17, DDX28 and DDX52. Whilst DDX5 
and DDX17 have a variety of well established functions in RNA 
metabolism, the cellular functions of the other helicases are not known. We 
are currently carrying out overexpression and siRNA rescue experiments 
and will go on to characterise the interaction between HIV-1 and the RNA 
helicases identified in this siRNA screen. 
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HIV persistence is the major barrier to AIDS treatment using highly active 
antiretroviral therapy. Understanding the mechanisms of HIV persistence is 
essential for developing effective strategies to eradicate AIDS. The HIV-1 
protein Vpr is a small viral accessory protein that contributes to HIV-1 
replication and pathogenesis through dysregulation of a number of cellular 
events, including cell cycle, apoptosis, and host and viral gene expression. 
Vpr can also impair the immune functions and may play an essential role in 
HIV-1 immune evasion. Monocyte-lineage cells, including monocytes, 
dendritic cells (DCs) and macrophages, are critical for HIV-1 infection and 
transmission. Previous studies indicate that HIV-1 Vpr enhances HIV-1 
replication in monocytes and macrophages in vitro, which likely contributes 
to persistent HIV-1 infection in vivo. Vpr specifically recruits the nuclear 
form of uracil DNA glycosylase (UNG2), a cellular DNA-repair enzyme, 
into HIV-1 virions. A Vpr mutant (W54R) HIV-1 that fails to recruit UNG2 
into virions demonstrates a significant replication defect in macrophages. 
However, the role of Vpr in HIV-1 infection of DCs and in viral persistence 
remains unknown. We hypothesize that Vpr contributes to viral persistence 
by promoting HIV-1 infection of monocyte-lineage cells and impairing the 
immune functions of DCs. Our preliminary studies demonstrate that: (1) 
Vpr is required for efficient HIV-1 infection of monocyte-derived DCs; (2) 
Vpr complementation modestly enhances Vpr-defective HIV-1 replication 
in DCs; (3) Vpr enhances HIV-1 reverse transcription and nuclear import of 
viral cDNA in DCs; (4) A single mutation in Vpr (W54R) significantly 
impairs HIV-1 replication in DCs, but not in peripheral blood mononuclear 
cells. These results indicate that Vpr promotes HIV-1 replication in 
monocyte-lineage cells, suggesting a potential mechanism of HIV-1 
persistence. We are investigating the mechanisms by which Vpr enhances 
HIV-1 infection in DCs. Our studies will provide important new 
information to understand the function of Vpr in HIV-1 pathogenesis. 
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The nucleic acid chaperone activity of HIV-1 NCp7 is crucial for efficient 
and specific reverse transcription. NCp7 precursors, NCp9 (NCp7-SP2), 
NCp15 (NCp9-p6), and Gag, are also nucleic acid chaperones. Yet, NCp9 
and NCp15 do not have any known role in viral DNA synthesis, while Gag 
facilitates primer placement. To determine the molecular basis for these 
findings, we monitored chaperone function, using a sensitive (-) strand 
transfer assay that measures annealing of (-) strong-stop DNA to acceptor 
RNA and strand transfer (annealing plus DNA elongation). Assay of these 
activities revealed that NCp9 was only slightly less active than NCp7. 
However, NCp15’s strand transfer activity was lower than that of the other 
two NCs and 4-fold more protein than NCp9 was required to reach a 
comparable rate and extent of annealing. This is not due to lower nucleic 
acid binding affinity, since the three NCs have similar Kd values. Possibly, 
interaction of the acidic p6 domain with basic residues in the protein 
inhibits chaperone activity, as shown for HTLV-1 NC1. Gag had the 
greatest annealing activity and nucleic acid binding affinity, consistent with 
its role in primer placement, but its strand transfer activity was abolished at 
0.46 μM, a concentration at which the NCs are active. This result reflects 
Gag’s slow dissociation from bound nucleic acid (in contrast to NCp7’s 
high on-off rate)2 and suggests that Gag acts as a “roadblock” to DNA 
elongation by blocking RT movement along the template. Preliminary data 
show that NCp9 and NCp15 dissociate more rapidly than Gag, but slower 
than NCp7. Taken together, our results indicate why NCp7 has evolved as a 
critical cofactor in reverse transcription. This work was funded in part with 
federal funds from NCI, NIH, under contract HHSN261200800001E.  
 
1. Qualley et al. J. Biol. Chem. 285:295-307, 2010. 
2. Cruceanu et al. Nucleic Acids Res. 34:593-605, 2006. 
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The development of broadly neutralizing antibody (NAb) is important for 
immunological control and clinical quiescence in EIAV-infected horses. 
Over time, however, viral genotypes evolve that resist NAb, resulting in 
recrudescence of clinical disease. We previously reported that variation in a 
400 nt region of EIAV env, which contains the principle neutralizing 
domain (PND), conferred resistance to broadly neutralizing antibody. 
Chimeric viruses containing the PND1 genotype were readily neutralized by 
both the heterologous and autologous sera whereas chimeric viruses 
containing the PND5 genotype were neutralization resistant. Genetic 
changes in PND5 included size variation of V3 loop as well as increased 
numbers of potential N-link glycoslyation sites. These changes may 
facilitate immune evasion by potentially masking or shielding neutralizing 
epitopes, but are also thought to incur a cost in virus replication fitness. To 
address this question, we used direct growth competition experiments to 
compare the relative fitness of PND1 and PND5 virus. Equine dermal cells 
were infected with 100 FFU of PND1 and/or PND5 at an MOI of 0.002. At 
sequential times, supernatant and cells were collected, and the viral RNA 
and proviral DNA were quantified using a highly sensitive, PND type-
specific quantitative real-time PCR assay. The results showed that both 
viruses spread through the cultures with similar kinetics; the number of 
PND1- and PND5-infected cells increased at a similar rate from day 1 to 
day 6 and reached maximal levels at day 9. Virion production, as measured 
by supernatant copy number, was also similar between PND1 and PND5, 
and the two viruses did not different in overall estimates of relative fitness. 
To further investigate the infectivity of PND1 and PND5 virus, we used 
pseudotype reporter viruses containing different reporter genes in single 
round infectivity assays. Preliminary results indicate no differences in 
infectivity of PND1 and PND5 pseudovirus. Together these results suggest 
that NAb–driven changes in EIAV PND region that confer resistance to 
broadly neutralizing antibody are not accompanied by a loss of replication 
fitness. 
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Primary lentiviruses contain accessory genes that are essential for infection and 
spread. Simian immunodeficiency viruses (SIV) and HIV-2 but not HIV-1 
contain Vpx which was the result of gene duplication of an ancestral Vpr. We 
and others have shown that Vpx is indispensable for SIV and HIV-2 infection of 
primary macrophage and dendritic cells. In addition, we found that the 
restriction was active against HIV-1 and Vpx enhanced HIV-1 infection of 
macrophage. We demonstrated that Vpx supports virus infection by 
counteracting a cellular restriction that is expressed in myeloid cells. This 
function of Vpx is largely depending on either a functional proteasome, or on its 
binding partners VprBP and DDB1 in target cells. Several Vpx mutants, which 
lose either the ability to form a complex with VprBP and DDB1, or the ability 
to be ubiquitinated, have been described as having a functional defect. Previous 
studies have been performed on either packaging Vpx variants in trans into SIV 
viral particles, or producing SIV viruses harboring wild type of mutant Vpx 
alleles. However, the efficiency of packaging of Vpx and its mutants varied 
significantly, which impaired the functional analysis of Vpx in target 
macrophages. Furthermore, the ability of SIV and HIV-2 to infect human 
macrophages can impact infection efficiency. It is therefore difficult to compare 
the requirement of Vpxs in target cells from different species. 
In this study, we used a HIV-1 based lentiviral vector (HIVec2GFP), in which 
we cloned SIVpBj Vpx, its derived VprBP and DDB1 mutants, ubiquitination 
defective lysine mutants, as well as HIV-2 ROD Vpx and AgmVer Vpx in the 
place of GFP. HIVec2GFP efficiently infected primary macrophages from a 
variety of donors. We evaluated the ability of this vector to deliver Vpx to 
macrophages and to rescue the infectivity defect of a Vpx-defective virus in 
macrophages. We examined the stability of different Vpxs proteins in 
macrophages and correlated that with their ability to rescue a Vpx virus or to 
enhance HIV-1 infectivity. We found that ROD Vpx enhanced HIV-1 
infectivity better than SIV pBj, while pBj Vpx more effectively rescued SIV. 
Agm Vpx failed to rescue HIV-1, HIV-2 or SIV Both ubiquitination mutants 
and VprBp-DDB1 binding mutants were functionally defective. However, we 
did not find a correlation between the amount of Vpx protein that was expressed 
and its ability to rescue in macrophages. ROD Vpx is the most stable protein in 
macrophage, while pBjVpx was the least. Furthermore, the turnover of Vpx 
protein was accelerated in macrophage as compared to cell lines. 
 
NIH grant to MS5R37AI037475-16 
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Lactic acid bacteria (LAB) are an important part of our body microbiota, 
which naturally inhabit the human genital tract (e.g. vaginal) and 
gastrointestinal (GI) tract (e.g. rectum) in a large quantity. We are trying to 
employ these bacteria for the prevention of sexual transmission of human 
immunodeficiency virus (HIV-1). 
 
A specific shuttle construct has been used to express anti-HIV inhibitors on 
the surface of LAB. The inhibitors include soluble CD4, monoclonal 
antibodies (e.g. b12) and the T20 peptide. The expression of these inhibitors 
has been detected and verified by several approaches such as Western 
blotting, immunofluorescent microscopy and flow cytometry. The 
engineered LAB have demonstrated the ability to absorb and neutralize 
several different HIV-1 viruses, including difficult-to-neutralize HIV-1 
primary viruses. The results indicate the potential for using bacteria that 
capture and inactivate the incoming HIV particles for the prevention of 
HIV-1 infection. As these bacteria naturally colonize the human body, this 
approach might become a potential long-term prevention strategy for 
HIV/AIDS sexual transmission.  
 
 
*This work was supported by Bill and Melinda Gates Foundation in Grand 
Challenge Explorations (GCE) grant (#51783).  
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Tetherin/BST2 is a type II membrane glycoprotein, which has been shown 
as a potent restriction factor for multiple enveloped viruses. It has a unique 
topology with a short cytoplasmic tail, followed by a transmembrane helix, 
an extracellular domain (ED), and a glycosyl-phosphatidylinositol (GPI) 
anchor. Three cysteine residues in tetherin ED have been reported to be 
functionally important and contribute to dimerization of the molecule. We 
have purified wild type and cysteine mutants of recombinant tetherin ED 
and used size exclusion chromatography, light scattering, and cross-linking 
to study its native oligomerization state and the contribution of the cysteine 
residues. Our study demonstrates that tetherin ED exists as a stable dimer 
even without the formation of any disulfide bond, suggesting the cysteine 
residues might be involved in the formation of a higher oligomer state 
functionally important. We further used static light scattering and 
diffraction methods to study the conformation of tetherin ED. Out results 
confirm that tetherin ED exists as a coiled-coil and provide inside into its 
geometry. 
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Xenotropic viruses are gammaretroviruses that can infect a wide variety of cells 
from heterologous species. Gibbon ape leukemia virus (GALV) and the recently 
identified human xenotropic murine leukemia virus-related virus (XMRV) 
represent examples of xenotropic viruses isolated from primates. Most cells 
resistant to infection by GALV or XMRV can be rendered susceptible after 
expressing its human receptor, PiT1 or Xpr1, respectively. We have now 
discovered that BHK hamster kidney cells retain their resistance to these viruses 
even when their respective receptors are expressed.  
 
We determined that BHKPiT1 and BHKXpr1 resistance to infection mapped to 
the viral envelope protein implying that viral envelope-receptor interactions 
compromised viral entry. Resistance of BHKPiT1 to GALV infection is not due 
to reduced receptor level, since we demonstrated that PiT1 receptor levels on 
BHKPiT1 cells were comparable to susceptible cells. Furthermore, we provide 
evidence that, unlike resistance of BHK to certain murine retroviruses caused 
by cell specific N-linked glycosylation of respective receptors, failure of the 
human PiT1 to function as a receptor for GALV in BHK cells is not the 
consequence of cell specific glycosylation of human PiT1.  
 
To further explore the mechanism of resistance of BHKPiT1 to GALV 
infection, we determined the effect of fusing BHKPiT1 and murine Mus dunni 
tail fibroblast MDTF cells. MDTF cells are resistant to GALV but can be 
rendered susceptible to infection after expression of human PiT1. We found that 
BHKPiT1 fused to MDTF cells are susceptible to infection by GALV raising 
the possibility that MDTF cells contain an ancillary factor absent in BHK cells 
that is required for efficient entry. These results indicate that both the ancillary 
factor and human PiT1 are required to facilitate efficient viral entry into BHK 
cells.  
 
We are currently investigating whether the mechanism for BHKXpr1 cells 
resistant to XMRV infection is comparable to the resistance of BHKPiT1 to 
GALV. Using similar analyses, we will fuse BHKXpr1 with NIH3T3 cells and 
determine the susceptibility of the hybrid cells to XMRV. Our finding will 
provide important information as to whether an auxiliary factor is required for 
XMRV infection in cells expressing xpr1.  
 312 
MODULATION OF HIV-1 INFECTION AT LATE PHASE BY AN 
INTEGRASE-INTERACTOR, HUWE1 
 
Seiji P Yamamoto1,3, Katsuya Okawa4, Takao Masuda5, Yuko Morikawa6, 
Yoshio Koyanagi1, Youichi Suzuki2  
 
1Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto 
University, Kyoto, 606-8507, Japan, 2Laboratory for Host Factors, Institute 
for Virus Research, Kyoto University, Kyoto, 606-8507, Japan, 
3Department of Molecular and Cellular Biology, Graduate School of 
Biostudies, Kyoto University, Kyoto, 606-8507, Japan, 4 Drug Discovery 
Research Laboratories, Kyowa Hakko Kirin Co., Ltd., Mishima, 411-8731, 
Japan, 5Department of Immunotherapeutics, Graduate School of Medicine 
and Density, Tokyo Medical and Dental University, Tokyo, 113-8519, 
Japan, 6Kitasato Institute of Life Sciences, Kitasato University, Tokyo, 108-
8641, Japan 
 
 
Integration, an indispensable step for retrovirus replication, is catalyzed by 
integrase protein (IN). Although a number of studies have identified cellular 
interactors to IN as co-factors for the integration function, some interactors 
appear to have distinct roles in several steps of virus replication other than 
integration. These pleiotropic effects of IN have been found from a series of 
extensive investigation on IN-mutant viruses. In this study, we show that 
Huwe1, a HECT-domain containing E3 ubiquitin ligase, is new cellular 
interactor for both Moloney murine leukemia virus (MoMLV) and human 
immunodeficiency virus type 1 (HIV-1) IN. The interaction was mediated 
through catalytic core domain and insensitive to nuclease treatment. In 
addition, Huwe1 was co-immunoprecipitated with MoMLV PICs in virus-
infected cells, indicating that Huwe1 is incorporated into integration 
complex after viral entry. Huwe1 is known to catalyze poly-ubiquitination 
of Mcl-1 and p53 and induce consequent degradation of these proteins. 
Nevertheless, we did not observe Huwe1-dependent ubiquitination of HIV-
1 IN in ectopic HIV-1 IN expressing cells. Also, we detected equivalent 
level of luciferase activity in Huwe1-knockdown and control cells after 
single-round luciferase-expressing HIV-1 infection. These data suggest that 
Huwe1 is an inert adaptor protein at early phase of the infection. On the 
other hand, depletion of Huwe1 in a human T cell line (MT-4 cells) resulted 
in increasing infectivity of HIV-1 virion released from virus-infected cells. 
Further IP-western blotting analysis revealed that Huwe1 interacts with 
HIV-1 Gag-Pol precursor protein through an IN region. These results 
suggest that Huwe1 somehow modulates efficient production of infectious 
virions in late events of the retroviral replication cycle. 
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HTLV-I is the causative agent of adult T-cell leukemia/lymphoma (ATL), a 
malignancy of CD4+ T cells whose etiology is thought to be associated with 
the viral trans-activator, Tax. We have shown recently that Tax can 
drastically up-regulate the expression of p27Kip1 and p21CIP1/WAF1 through 
protein stabilization and mRNA trans-activation and stabilization 
respectively. The Tax-induced surge in p21CIP1/WAF1 and p27Kip1 begins in S 
phase and leads to aberrant cell cycle progression that ends in cellular 
senescence. Importantly, HeLa and SupT1 T cells infected by HTLV-1 also 
arrest in senescence, raising questions about the notion that HTLV-1 
induces proliferation of infected cells. Here we show that Tax causes the 
DNA replication licensing factor, Cdt1, to accumulate in S phase. The 
increased Cdt1 level in Tax-expressing cells correlated with DNA hyper-
replication. Most Tax-expressing HeLa cells had dramatically elevated 
levels of p27Kip1 and p21CIP1/WAF1 as well as reduced levels of cyclin B1 and 
Skp2. They developed elongated S/G2, and were slow to progress into 
mitosis. The use of HeLa cell lines that express EGFP under the control of 
18 copies of the Tax-responsive 21-bp repeat element (HeLa/18x21-EGFP) 
and fluorescent ubiquitin cell cycle indicators (HeLa-FUCCI) respectively 
in time-lapse microscopy further revealed that many Tax-expressing cells 
eventually progressed through S/G2, and entered into irreversible G1 
arrest/senescence, with some bypassing mitosis altogether. Indeed, cells that 
failed mitosis were enlarged with exaggerated nuclei and expressed 
senescence-associated β-galactosidase, consistent with the development of 
mitotic defects and senescence. Interestingly, a small population of 
HeLa/18x21-EGFP cells was found to be capable of progressing into 
mitosis with high levels of Tax expression, suggesting that genetic or 
epigenetic changes can occur in cell culture to prevent Tax-induced 
senescence.  
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Phylogenetic studies indicate that HIV-1 was transmitted to humans from 
primates through four independent events, giving rise to groups M and N 
that are most closely related to SIVcpz, and groups O and P that are more 
like SIVgor. Only group M viruses have resulted in widespread human 
infections and are responsible for the worldwide AIDS pandemic. Group O 
infections are restricted to West and Central Africa and account for only a 
small percent of HIV-1 infections, Group N infections are even more rare 
and geographically restricted, and HIV-1 group P virus was recently 
identified in a single Cameroonian woman. Transmission of viruses from 
primate hosts would require the evolution of strategies to counteract human 
versions of anti-viral restriction factors such as TRIM5α, APOBEC and 
tetherin. It is possible that the lower penetration of the non-pandemic 
viruses into the human population reflects less than optimal adaptation to 
one or more of these factors.  
 
Tetherin (BST-2/CD317/HM1.24) is an interferon-inducible restriction 
factor that inhibits the release of enveloped viruses from the plasma 
membrane. Different primate lentiviruses have evolved host-specific anti-
tetherin activities as functions of Vpu (HIV-1, SIVmus/mon/gsn/den), Env 
(HIV-2, SIVtan) and Nef (SIVmac/sm/agm). Last year we reported that 
although the Vpu proteins from both group M and N strains are active 
against human tetherin, the group O Vpu has no such activity. Further 
investigations have now shown that group O Nef, Vpr and Env proteins do 
not counteract human tetherin, although the HIV-1 O Nef protein retains 
activity against primate tetherins (chimpanzee and macaque). In addition, a 
proviral clone (pCMO2.5) of HIV-1 O is sensitive to human tetherin 
restriction despite intact open-reading frames for all 9 HIV-1 genes. 
Together, this suggests that the lower rate of infection by HIV-1 group O 
isolates could arise, in part, from their inability to counteract human 
tetherin.  
 
We have also investigated the basis for the lack of adaptation of HIV-1 O 
Vpu to human tetherin. Using chimeras of HIV-1 M and O Vpu, we mapped 
this difference to a region in the TM domain of Vpu that could represent a 
protein interacting domain. Confocal studies also suggest that the lack of 
activity of HIV-1 O Vpu could result from the different cellular localization 
of this protein compared to the functional group M and N Vpu proteins.  
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The host helicases XPB and XPD restrict transposition of the LTR 
retrotransposon Ty1 and retroviral infection. Mutations of these essential 
proteins allow greater accumulation of retroelement cDNA. Retroviral 
infection was compared between cell lines derived from patients expressing 
XPB(F99S) or XPD(R683W) mutations and these cell lines complemented 
with the wild type genes. As part of the TFIIH complex, XPB and XPD are 
required for transcription. Inhibition of transcription by α-amanitin or 
translation by cycloheximide did not affect HIV cDNA accumulation in any 
of the XP cell lines, suggesting that XPB/XPD effects on cDNA are not via 
the transcription of secondary proteins. Previous results indicate that 
XPB/XPD participate in degradation of the retroviral cDNA. The host 
protein APOBEC3G may also degrade retroviral cDNA. Infection of the XP 
cell lines with HIV produced in cells expressing African green monkey 
APOBEC3G or human APOBEC3G suggest that the XPB/XPD pathway is 
distinct from the APOBEC3G degradation pathway. By arresting cells with 
aphidicolin, XPB/XPD proteins are exclusively nuclear. Retroviral cDNA 
accumulation was greater in arrested cells than in cycling cells. HIV cDNA 
accumulation in arrested wild type and XPB(F99S) cells is equal when the 
cDNA is in the cytoplasm, but is less in wild type cells when the cDNA has 
migrated to the nucleus. Similarly, MMLV cDNA accumulation is equal in 
arrested wild type and XPB(F99S) cells during aphidicolin mediated arrest. 
Since MMLV cannot enter the nucleus while the cells are arrested, the 
MMLV cDNA accumulates and remains stable until aphidicolin is 
removed. Following removal of aphidicolin, the MMLV cDNA is reduced. 
The rate of disappearance of MMLV cDNA is greater in wild type cells 
compared to XPB(F99S) cells. XPB/XPD mediated restriction of 
retroviruses appears to act through retroviral cDNA degradation in the 
nuclear compartment. 
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HIV requires Vif to replicate efficiently in primary cells and certain T-cell 
lines (e.g., H9, CEMx174, and MT-2), which are designated as 
“nonpermissive cells”. In contrast, Vif is dispensable for replication in other 
cells (e.g., SupT1, Jurkat, and Molt4), known as “permissive cells”. 
APOBEC3G (A3G) was identified as the cellular factor. However, the 
details regarding cell-line dependent expression of A3G remain unknown. 
To address this issue, we analyzed regulated A3G expression in primary 
cells and compared the factors involved in the signal cascade of the cell 
lines.  
 
Initially, we investigated A3G induction in primary macrophages (MDMs). 
Analysis of APOBEC3 mRNAs by quantitative real-time PCR revealed that 
A3G mRNA is significantly induced by interferon (IFN)α (18-fold), IFNβ 
(10-fold), or Toll-like receptor (TLR) 3 ligand (>20-fold), as previously 
reported. In contrast, IFNγ, or other TLR ligands marginally increase the 
A3G mRNA level in MDM. There are two types of signal transducers that 
commonly play key roles in the downstream cascade of IFNα, β, and TLR3 
ligand stimulation: IFN-responsive transcription factors (IRFs), IRF-3, -7, -
9 and STAT1 and 2. Therefore, we tested to see whether different 
expression patterns of these factors occur in permissive and nonpermissive 
cell lines. When the relative mRNA of IRF-3, -7, -9 and STAT1 among cell 
lines (H9, CEMx174, MT-2, A3.01, Molt4, Molt3, SupT1, Jurkat, U937, 
and THP-1) were measured by real-time PCR, A3G mRNA expression level 
in each cell was correlated with the STAT1 mRNA level. In addition, 
analysis by Western blot showed that the nonpermissive cell lines 
constitutively express STAT1 as well as phosphorylated STAT1 (activated 
forms phosphorylated at Tyr701 and Ser727), whereas the permissive cells 
commonly express significantly less. Moreover, treatment of H9 cells with 
an inhibitor that blocks the Janus kinase 1 (JAK1) for STAT1 activation 
decreased A3G expression, suggesting that JAK1 inhibitor enables the 
nonpermissive cell, H9 to exhibit a permissive cell phenotype. These results 
suggest that spontaneous A3G expression in T-cells, which is dependent on 
constitutive expression and activation of STAT1, determines whether vif-
deficient HIV is capable of replication.  
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XMRV is a human gammaretrovirus originally identified in a subset of prostate 
cancer patients with a subtle deficiency in the interferon (IFN) regulated 
antiviral protein, RNase L. IFN induces OAS proteins that produce 2’-5’-
oligo(rA) activators of RNase L in response to viral dsRNA. Virus-host 
interaction studies could provide insight on the pathogenic consequences of 
XMRV infections as well as a means for controlling infections. Here we studied 
effects of candidate IFN regulated proteins on XMRV infections in prostate 
cancer cells and other cell types. Viral RNA levels were determined in Northern 
blots, protein levels in Western blots and viral release by RT activity in 
conditioned media. XMRV expression and replication was sensitive to IFN-beta 
treatment in both acutely- and chronically-infected DU145 cells. IFN-beta 
treatment decreased levels of XMRV genomic RNA while also preventing 
accumulation of viral proteins. Effects of RNase L were determined by 
decreasing its expression with RNA silencing. Cells with reduced levels of 
RNase L were partially resistant to the antiviral effect of IFN-beta. Moreover, 
after transfection with XMRV cDNA, RNase L null mouse embryonic 
fibroblasts (MEF) were less sensitive than wild type MEF to IFN inhibition of 
Gag expression. Apobec3G is a host restriction factor that suppresses retroviral 
infections and whose expression can be enhanced by type I IFN in a cell-type 
dependent manner. A comparison between prostate tumor cell lines and primary 
prostate cells (stromal and epithelium) suggested loss of apobec3G expression 
occurred during tumorigenesis. Expression of Gag protein as well as 
intracellular viral RT activity was lower in XMRV infected HEK/A3G cells 
than the parental HEK cells which lack apobec3G expression. No expression of 
apobec3G was observed in two prostate cancer cell lines, DU145 and LNCaP, 
while low levels of apobec3G were found in PC3 cells. In addition, IFN-beta 
did not induce apobec3G in these three cell lines. In contrast, tetherin/BST-2, 
was IFN inducible in DU145 cells. Interestingly, apobec3G was observed in 
primary prostate epithelial (PrEC) and stromal (PrSC) cells. These findings 
suggest that apobec3G is not responsible for the IFN anti-XMRV effect in 
DU145 cells, but tetherin and RNase L may still play a role. IFN induces many 
other antiviral genes, some of which are likely to be involved in the antiviral 
effect of IFN against XMRV. Studies in progress are aimed at identifying and 
studying which of these IFN induced proteins are inhibitory for XMRV 
infections. 
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Four major A3H variants were reported to circulate the human population 
(HapI:18R/105G/121K/178E; HapII: 18R/105R/121D/178D, HapIII: 
d15N18R/105R/121D/E178D, HapIV:d15N18L105R/121D/178D). HapII, 
differing only in three amino acids from A3H-HapI, has the strongest 
inhibitory effect on both HIV-1 and Line-1. When introduced in vitro into 
cells, HapII has stronger protein stability in comparison to HapI and thus 
expressed at higher level. When expressed at similar expression level, both 
HapI and HapII can be packaged into the ∆Vif HIV-1 virion in comparable 
level and have similar anti-HIV-1 activity. 
 
7SL RNA is a host RNA that is selectively packaged into the HIV-1 virion 
and many other retroviruses. It plays important roles in mediating 
APOBEC3G (A3G) and APOBEC3F (A3F) packaging into HIV-1 virion. A 
unique motif RLLYF/YW is conserved on amino-terminal of A3G and A3F 
and is required for their binding of 7SL RNA and virion incorporation. 
However A3G and A3F still differ greatly in their ability to bind to 7SL 
RNA, indicating that other motifs maybe also invovled in 7SL RNA 
binding. 
 
Interestingly, we found that the RLLYF/YW motif is conserved on all A3H 
variants. Furthermore, introduction of a single point mutation from 140E to 
K on A3H_HapI abolished its anti-HIV-1 activity even when expressed at 
high expression level. A3H_HapI_140K also lost its ability to associate 
with 7SL RNA and cannot be packaged into the ∆Vif HIV-1 virion. 
Similarly, introduction of 140K to A3H_HapI_105R, 
A3H_HapI_105R/121E or A3H_HapII also greatly impaired their anti-HIV-
1 activity. Therefore, we have newly identified amino acid 140E as a new 
motif important for A3H variants packaging into the HIV-1 virion. 
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REGULATE APOBEC3G AND APOBEC3F NEUTRALIZING 
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Vif binding to APOBEC3G (A3G) and APOBEC3F (A3F) is a key step for 
A3G/A3F neutralization, and this mechanism has been extensively studied. 
So far, six discontinuous surfaces on Vif have been found to regulate A3G 
and/or A3F degradation. The 40YRHHY44 domain specifically binds to 
A3G and determines Vif specificity to A3G; the 11WxxDRMR17 and 
74TGERxW79 domains specifically bind to A3F and determine Vif 
specificity to A3F; and the 21WxSLVK26, 55VxIPLx4L64, and 69YxxL72 
domains determine Vif specificity to both A3G and A3F. Based on thse 
findings, it has been thought that Vif interacts with A3G and A3F mainly 
via its N-terminal region, and with Cul5 E3 ubiquitin ligase machinery via 
its C-terminal region.  
 
Here, we identified two additional Vif regulatory motifs: one from the 
central region, and the other from the C-terminal region. Via sequence 
analysis of more than 2,000 different HIV-1 Vif proteins, we identified two 
highly conserved amino acid sequences 81LGxGxSIEW89 and 
171EDRWN175. Within the 81LGxGxSIEW89 sequence, residues L81, 
G82, G84, and to a lesser extend I87 and W89, play very critical roles in 
A3G/A3F neutralization. Interestingly, residues L81 and G82 only regulate 
Vif activity to A3F, whereas residues G84, I87, and W89 regulate Vif 
activity to both A3G and A3F. Accordingly, this 81LGxGxSIEW89 
sequence is designated as 81LGxGxxIxW89 domain. Within the 
171EDRWN175 sequence, all residues except N175 are almost equally 
important for regulation of A3F neutralization. Accordingly, this domain is 
designated as 171EDRW174. Our binding assays indicated that the 
81LGxGxxIEW89 domain determines Vif binding to both A3G and A3F, 
where the 171EDRW174 domain only determines Vif binding to A3F. The 
LGxGxxIxW domain is also partially conserved in SIVmac239, and has a 
similar activity. Our results indicate that A3G and A3F interaction surfaces 
on HIV-1 Vif are structurally complex, and more efforts are required for a 
complete understanding of this host-pathogen interactive mechanism. 
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Human T lymphotropic virus type 1 (HTLV-1) trans-activator, Tax, alters a 
multitude of basic cellular processes, including gene transcription, I-κB 
kinases (IKKs) signaling, cell cycle entry, DNA replication, and mitosis. 
These activities of Tax have been implicated in leukemogenesis. Expression 
of Tax in most cells, however, leads to drastic up-regulation of cyclin-
dependent kinase inhibitors, p21CIP1/WAF1 and p27KIP1, and irreversible cell 
cycle arrest/senescence. Here we show that Tax causes senescence by 
disrupting the NF-κB/I-κBα auto-regulatory loop. Tax-induced senescence 
can be attenuated by amino acid substitutions in Tax that reduce IKK/NF-
κB activation, and prevented by blocking NF-κB using a degradation-
resistant mutant of I-κBα despite constitutive IKK activation by Tax. Small 
hairpin RNA-mediated knockdown of RelA, but not RelB, c-Rel or p100, 
prevents senescence induction by Tax. These results link unchecked NF-κB 
activation to Tax-induced cell cycle abnormalities and cellular senescence. 
We suggest that during viral infection, moderation of NF-κB activation by 
HBZ ― a newly discovered HTLV-1 protein that negatively regulates RelA 
― may prevent Tax-induced senescence to allow proliferation of infected T 
cells, a pre-requisite for leukemia development. 
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HIV can spread by either of two modes, via the cell-free aqueous 
environment or by direct cell-cell contact. The contributions of both 
pathways to HIV spreading are poorly understood and evidence for either 
pathway has been presented. Here we identify parameters that influence the 
relative contributions of both modes in a simple co-culture model system of 
HIV producing HEK293 cells and various T cells. Using this system, we 
demonstrate that experimental conditions that hinder cell-free virus 
spreading promote cell-to-cell spread. For instance, T lymphocytes that are 
poorly susceptible to cell-free HIV are readily infected when co-cultured 
with producer cells. These effects are possibly due to the high concentration 
of receptors at sites of cell-cell contact that facilitates virus entry and induce 
signaling cascades that activate target cells to promote subsequent HIV 
replication. Moreover, if viruses are retained at the surface of producer 
cells, release of cell-free virus is blocked, but HIV can still spread by cell-
cell contact. Last, spreading from cells with low viral gene expression can 
be stimulated by co-culture with target cells, probably due to the enrichment 
of viral proteins at sites of cell-cell contact. Thus, we demonstrate that HIV 
favors cell-to-cell transmission under condition of low HIV gene expression 
and surface retention in the producer cell as well as poor susceptibility of 
target lymphocytes. Our data are consistent with the emerging model that 
several steps of the viral replication cycle can be efficiently coordinated at 
sites of cell-cell contact. 
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Retroviruses are susceptible to a variety of host-derived restriction factors, 
but they have developed antagonistic mechanisms for productive infection 
of their hosts. Previously, we demonstrated that the CEM-derived cell line 
CEM.NKR expresses a factor that potently restricts the wild-type HIV-1 
replication at a post-entry step. This factor is distinguishable from TRIM5α 
or any APOBEC3 cytidine deaminases. Here, we further characterized this 
unknown factor by testing whether it also targets several other retroviruses 
including amphotropic murine leukemia virus (MLV) and SIVs isolated 
from African green monkeys (SIVagm9063, SIVagmTan, SIVagmSab) and 
rhesus monkeys (SIVmac239). Although MLV replication was not, the 
replication of all tested SIV strains was effectively inhibited by this factor-
mediated restriction in CEM.NKR cells. In addition, although this factor is 
constitutively expressed in CEM.NKR cells, it does not seem to be an 
interferon-inducible factor. Thus, CEM.NKR cells express a general 
antiviral factor that specifically targets primate lentiviruses. Since viruses 
have not yet developed a counteractive mechanism, further studies on this 
host factor may provide a new system to study viral evolution and open new 
avenues for antiretroviral therapies. Currently, we are mapping the major 
target for this factor on HIV-1, and we are also trying to rescue HIV-1 
replication in CEM.NKR by small chemical compounds to understand this 
novel antiretroviral mechanism. These new progresses will be presented in 
this meeting. 
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The IFN-inducible antiviral protein tetherin (or BST-2/CD317/HM1.24) 
impairs release of mature HIV-1 particles from infected cells. HIV-1 Vpu 
antagonizes the effect of tetherin. The fate of virions trapped at the cell 
surface remains poorly understood. Here, we asked whether tetherin impairs 
HIV cell-to-cell transmission, a major means of viral spread. Tetherin-
positive or -negative cells, infected with wild-type or delta-Vpu HIV, were 
used as donor cells and cocultivated with target lymphocytes. We show that 
tetherin inhibits productive cell-to-cell transmission of delta-Vpu to targets 
and impairs that of WT HIV. Tetherin accumulates with Gag at the contact 
zone between infected and target cells, but does not prevent the formation 
of virological synapses. In the presence of Tetherin, viruses are then mostly 
transferred to targets as abnormally large patches. These viral aggregates do 
not efficiently promote infection after transfer, because they accumulate at 
the surface of target cells and are impaired in their fusion capacities. 
Tetherin, by imprinting virions in donor cells, is the first example of a 
surface restriction factor limiting viral cell-to-cell spread. 
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Direct cell-to-cell spread of human immunodeficiency virus type-1 (HIV-1) 
between CD4+ T cells at the virological synapse (VS) is an efficient 
mechanism of viral dissemination. Tetherin (BST-2 /CD317) is an 
interferon-induced, anti-retroviral restriction factor that inhibits nascent 
cell-free particle release and is antagonized by the HIV-1 accessory protein 
Vpu, but whether tetherin can restrict cell-cell spread of HIV-1 is unknown. 
Here we show that Vpu-defective virus disseminates more efficiently than 
wild-type virus by direct T cell-T cell transmission because of increased VS 
formation. Tetherin, but not Vpu, was enriched at the T cell VS and 
colocalized with Env on infected T cells. Upregulating tetherin expression 
with interferon did not impair HIV-1 spread at the VS; instead interferon 
treatment increased VS formation. Moreover, siRNA knockdown of 
endogenous tetherin in Jurkat T cells and primary CD4+ T cells decreased, 
not enhanced, cell-cell transmission of Vpu-defective virus. We conclude 
that cell-cell spread of HIV-1 at the T cell VS can overcome tetherin-
mediated restriction. In addition, tetherin may contribute to more efficient T 
cell-T cell transmission of Vpu-defective HIV-1. Since tetherin antagonism 
is conserved in primate immunodeficiency viruses, this suggest that one role 
of Vpu is to maintain a balance between cell free and cell-cell spread in the 
face to an innate immune response. 
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Tetherin directly blocks the release of nascent retrovirus particles from 
infected cells and is antagonized by Vpu. Vpu phosphorylation of its two 
cytoplasmic serines is required to recruit the ß-TrCP ubiquitin ligase and to 
induce cell surface downregulation and degradation of Tetherin. However, a 
Vpu mutant (Vpu2/6) that lacks these phosphorylation sites remains 
partially active as a tetherin antagonist. How this 
degradation/downregulation-independent activity of Vpu is manifested is 
unknown. 
 
Here, we used light microscopy to demonstrate that Vpu2/6 was incapable 
of downregulating tetherin from the cell surface but was capable of 
displacing tetherin from nascent virions at the cell surface. A tetherin TM 
domain mutant that is resistant to antagonism by Vpu was resistant to this 
displacement activity. By constructing artificially membrane anchored Vpu 
proteins lacking the TM domain and phosphorylation sites that were 
directed to ‘interact’ with tetherin by direct fusion of the C-terminus of Vpu 
to the N-terminus of tetherin, we could demonstrate that the cytoplamic 
domain of Vpu, particularly the second predicted helical domain, was 
sufficient to delocalize tetherin from sites of viral assembly. Moreover, the 
artificially anchored, tetherin-fused Vpu antagonized the ability of tetherin 
to block particle release. 
 
Previously, we showed that removal of the tetherin 
glycophosphatidylinisotol (GPI) anchor rendered it inactive as a viral tether. 
However, this tetherin(∆GPI) mutant is efficiently incorporated into 
extracellular virions, in a manner that is blocked by Vpu. We used 
tetherin(∆GPI)-based proteins to show that the artificially anchored, 
tetherin-fused Vpu could block the incorporation of tetherin(∆GPI) into 
virions. Together these data indicate that in addition to surface 
downregulation/degradation, Vpu appears to have a further activity. 
Specifically, Vpu can reduce tetherin’s antiviral function by inhibiting its 
localization to sites of viral assembly at the plasma membrane and its 
incorporation into virions. 
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BST-2 restricts HIV-1 production by directly retaining nascent virions on 
the surface of infected cells. HIV-1 Vpu counteracts this restriction by 
decreasing the effective concentration of BST-2 at the cell surface. The 
optimal down-regulation of BST-2 depends on the interaction of Vpu with 
β-TrCP, the substrate adapter of a multi-subunit E3 ubiquitin ligase 
complex. This leads to the hypothesis that Vpu induces ubiquitination of 
BST-2 to induce trafficking events that remove BST-2 from the plasma 
membrane. Here, we observed that Vpu stimulates the ubiquitination of 
BST-2 in a manner dependent on its β-TrCP-binding sequence. Mutation of 
all potential ubiquitin acceptor sites in the cytoplasmic domain of BST-2 
abrogated stimulation of ubiquitination by Vpu and was associated with a 
relative resistance to Vpu-mediated surface down-regulation. These data 
support a model in which Vpu induces the ubiquitination of BST-2, leading 
to the removal of BST-2 from its site of action as a virion-tethering factor 
and the relief of restriction. 
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HIV-1 Vpu enhances virus release from the cell surface. This phenomenon 
is cell type dependent. Recent work identified BST-2/CD317/tetherin as a 
host factor whose inhibitory activity on viral release is counteracted by 
Vpu. A current model suggests that BST-2 inhibits virus release by 
physically tethering viral particles to the cell surface using its N-terminal 
TM domain and C-terminal gpi modification as anchors in the cell and viral 
membranes, respectively. Vpu is believed to counteract this inhibitory 
activity by down regulating BST-2 from cell surface. However, our own 
data suggest that in the context of an acute infection of T lymphocytes, 
BST-2 surface downregulation is not mandatory for efficient virus release.  
We have recently developed a high-titered antibody recognizing 
endogenous as well as exogenously expressed BST-2. The antibody was 
raised against the ectodomain of BST-2 and reacts well with cell-surface 
BST-2 in a variety of human cell types. We and others have found that 
structural features in the BST-2 ectodomain, incl. a coil-coil domain and 
three cysteines involved in protein-dimerization, are critical for BST-2 
function. We hypothesized that antibody binding to BST-2 could affect the 
formation of cysteine-linked dimers and/or affect coil-coil-mediated 
protein-protein interactions and thus interfere with BST-2 function. Here, 
we analyzed the antagonistic potential of our BST-2antibody. Indeed, we 
found that treatment of transfected HeLa cells with BST-2 antibody 
effectively blocked the inhibitory effect of BST-2 on virus release. 
Interestingly, antibody-treatment not only increased the release of Vpu-
deficient virus but enhanced the release of wt HIV-1 virions as well. This 
suggests that Vpu expressed from wt NL4-3 is not sufficient to fully negate 
the inhibitory effect of endogenous BST-2 in HeLa cells. BST-2 antibody-
induced enhancement of virus release required pretreatment of the cells. 
Furthermore, kinetic data suggest that virus particles already tethered to the 
cell surface prior to antibody addition are not released. Therefore, we 
conclude that antibody neutralization of BST-2’s tethering activity requires 
antibody binding prior to BST-2’s engagement with budding viruses. 
Experiments will be presented to address the subcellular location where 
antibody interference occurs and to elucidate the precise mechanism of 
interference. 
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It has been shown that switches between Vpu-, and Nef-mediated tetherin 
antagonism preceded the emergence of HIV-1 (Sauter et al., 2009). The 
precursors of HIV-1, SIVcpz from chimpanzees and SIVgor from gorillas, 
use Nef to counteract tetherin. Human tetherin, however, is resistant to Nef 
because of a deletion in its cytoplasmic region. This deletion most likely 
forced HIV-1 to switch from Nef to Vpu to counteract tetherin in the new 
human host. Notably, only pandemic HIV-1 M strains mastered this hurdle 
perfectly by switching from Nef- to Vpu-mediated tetherin antagonism. 
Currently, it is unknown how rapidly Nef or Vpu can acquire anti-tetherin 
activity in vivo and which domains in Nef are involved in tetherin 
antagonism. To address this, we analyzed nef alleles from a chimpanzee 
who had been experimentally infected with HIV-1 ten years earlier. In 
contrast to the nef genes of the original HIV-1 strains (SF2 and LAV) used 
for infection, the nef gene of the virus (JC16) obtained after ape passage 
antagonized chimpanzee (but not human) tetherin. Notably, the 
chimpanzee-adapted JC16 strain maintained the capability to counteract 
human and chimpanzee tetherin by Vpu. In the context of the infectious 
JC16 provirus, however, mainly Nef is used to antagonize chimpanzee 
tetherin. This is most likely because the proviral construct expresses Nef at 
higher levels than Vpu. The nef alleles derived from the chimpanzee differ 
in at least 25 amino acid residues from those of the input HIV-1 strains. 
Currently, we are mapping the changes underlying the gain of anti-tetherin 
function by HIV-1 Nef. Our data show that primate lentiviruses can regain 
lost anti-tetherin activities of their accessory genes within a single in vivo 
passage in a new host species. The analysis of these chimp-adapted HIV-1 
nef alleles will give novel insights into the mechanism of Nef-mediated 
tetherin antagonism. 
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XMRV is a human retrovirus first identified in prostate cancer tissues from 
men with a deficiency in the innate immunity gene, 
RNASEL/HPC1(Urisman et al., 2006). To gain insight into the 
consequences of XMRV infections, we performed studies that compared 
viral nucleic acid levels and cell tropism in men and in male and female 
adult rhesus macaques. FISH methods used SpectrumGreen labeled nucleic 
acid segments spanning the entire viral genome. IHC used a monoclonal 
antibody against SFFV Gag protein. In prostate cancer patients, XMRV 
nucleic acid and protein was present in the prostate only in stromal cells, 
mostly fibroblasts, but also in hematopoetic cells. Only about 1% of the 
stromal cells were positive for XMRV. Animal studies were performed with 
five healthy rhesus macaques (four males and one female) infected with 
XMRV intravenously. XMRV genomic RNA levels peaked at 7,500 copies 
per ml on day 7 pi in one animal. XMRV showed a wide dissemination of 
replicating virus even when the plasma viral load was undetectable. Isolated 
lymphoid cells and primarily CD4+ T cells were found positive in most 
lymphoid organs including spleen, lymph nodes and GI tract. The virus 
infection was, however, not restricted to bone marrow derived cells, but 
showed distinct target specificities in various organs. Foci of infected 
epithelial cells were detected in organs such as prostate, seminal vesicles 
and epididymis. In the lone female animal, XMRV positive epithelial and 
fibroblast like cells were detected in the vagina and cervix suggesting that 
the virus may be transmitted via sexual contact. Although XMRV 
dissemination was complete at day 6 pi, the prostate was positive by IHC 
only during the acute infection but contained during chronic infection in 
these healthy animals. Results show that XMRV has tropism for the 
prostate in both men and rhesus macaques. The animal studies show that in 
acute infection, XMRV localizes to the prostate epithelium while in 
chronically-infected humans the virus was present in the stroma suggesting 
the possibility of epithelial to mesenchymal transition. Our findings have 
implications for the possible role of XMRV in prostate cancer and other 
diseases. 
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The xenotropic murine leukemia virus-related virus (XMRV) was first 
detected in human prostate cancer patients, and while it has been found to 
be associated with prostate cancer, no causality has been shown. We have 
investigated the ability of the XMRV envelope protein to transform 208F 
rat fibroblast cells, and found that although functional XMRV envelope 
could be produced in transfected 208F cells, no transforming activity was 
observed. We also investigated the ability of replicating XMRV to induce 
foci of transformation in cell culture. Virus was collected from HT-1080 
cells infected with conditioned medium from 22Rv1 cells. The HT-1080 
cells also contained an integrated copy of the LAPSN retroviral vector used 
as a marker of functional virus production. Only rare transformed foci were 
observed in XMRV-infected 208F rat fibroblasts, showing that the virus 
does not have acute transforming activity. Three foci of transformation were 
isolated, and all contained integrated copies of XMRV and produced virus. 
One of the three transformed 208F foci produced an acutely transforming 
virus generated by recombination between the LAPSN vector used in 
titration of virus and the mutant human NRAS genes from the HT-1080 
cells used to produce XMRV. No transfer of human NRAS was observed in 
the other foci isolated, or from a fourth transformed 208F focus generated 
from virus made from HT-1080 cells without the LAPSN vector. This 
suggests that the transformed 208F cells that did not produce a transforming 
virus were transformed by insertional mutagenesis. Our results show that, as 
with other retroviruses, XMRV may have the ability to transform cells by 
activation of host cell oncogenes, but no direct transforming activity of the 
virus was observed. 
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Xenotropic murine leukemia-related retrovirus (XMRV) is a recently 
discovered infectious agent [1] that has been linked to human prostate 
cancer [2] and chronic fatigue syndrome (CFS) [3]. Both diseases affect a 
large fraction of the world population, with prostate cancer affecting one in 
six men, and CFS affecting an estimated 0.4 to 1% of the population. 
 
Forty-five compounds including twenty-eight drugs approved for use in 
humans were evaluated against XMRV replication in vitro. We will present 
data showing four of these compounds to be active against XMRV at sub-
micromolar concentrations, in MCF-7 and LNCaP cells, a breast cancer and 
prostate cancer cell line, respectively. When combined these drugs 
displayed mostly synergistic effects against this virus, suggesting possible 
combination therapies to treat XMRV infections, thus delaying or 
preventing the selection of resistant viruses.  
 
If XMRV proves to be a causal factor in prostate cancer or CFS, these 
discoveries may allow for rational design of clinical trials. 
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XMRV represents the first reported case of a gammaretrovirus infection in 
humans. It bears very close resemblance to some of the endogenous 
xenotropic MLVs (Xmvs) found extensively in the genomes of inbred mice. 
XMRV was initially isolated from a subset of prostate cancer patients; it 
was then detected in a number of chronic fatigue syndrome patients as well 
as in some healthy subjects. Although its association with human disease is 
currently the subject of ongoing debate, the implication of cross-species 
transmission prompted us to study its possible origins. 
 
Despite the high degree of sequence identity, the XMRV genome is clearly 
distinct from all Xmvs described so far. Different XMRV isolates from 
human tissues in several independent studies show very little variation in 
sequence and seem to tightly cluster together in phylogenetic analyses. Over 
the course of evolution Xmvs have successfully invaded the genomes of 
wild and inbred mice and a fraction of these elements have the ability to 
produce infectious virus. Given the high degree of similarity between 
XMRV and endogenous Xmvs, we hypothesized that there could be a 
reservoir of XMRV, or an ancestral virus that gave rise to XMRV, in mice. 
Although the provirus is not present in the sequenced mouse genome, there 
exists the possibility that other strains of mice might harbor XMRV-like 
sequences. We sought to determine whether we could find such elements in 
various mouse genomic DNA samples. We developed a highly sensitive 
PCR-based assay, using primers specific for regions of XMRV that show 
marked differences from some of the closest Xmvs described so far. We 
assessed the specificity of our assay by detecting XMRV-specific sequences 
in the genomic DNA from as few as 8 cells of a cell line chronically 
infected with XMRV, while not detecting any of the endogenous Xmvs that 
inhabit the C57BL/6 genome. Using this assay, we have screened genomic 
DNA samples from 70 different wild and inbred mouse strains that 
represent a total of 18 Mus species. None of the tested samples yielded an 
XMRV-specific sequence, strengthening the argument against the 
possibility of a laboratory contaminant giving rise to XMRV.  
 
We are also interested in characterizing an endogenous Xmv that is a close 
relative of XMRV, namely Xmv-43 (Bxv-1). Currently, studies are 
underway to compare infectivity and replication properties of Bxv-1 with 
those of XMRV. 
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Recent studies of the role of XMRV in prostate cancer or chronic fatigue 
syndrome (CFS) have provided conflicting evidence for the association of 
the virus with these conditions. There are also limited and variable reports 
of the prevalence of the virus in healthy donor populations. As an initial 
step in characterizing the sero-prevalence of XMRV in both disease states 
and in healthy populations, we initiated the development and validation of a 
multiplex, ELISA-based test. 
 
Each XMRV viral gene was individually expressed in different systems and 
purified under different conditions to simultaneously evaluate the optimal 
antigen(s) for this platform. Using pooled human normal plasma (negative 
for HIV-1/2, HCV, HTLV-I/II and HBV), normal un-screened donor 
plasma and sera, and clinical specimens from patients XMRV-positive (by a 
qPCR, nested PCR or antibody test), assay conditions were rigorously 
defined and antigens with antibody reactivity were down-selected for 
further validation and inclusion in the Meso Scale Discovery multiplex 
format. The test includes a negative control antigen to reduce the possibility 
of false positives. Using this platform, initial studies have detected XMRV 
antibodies in a majority of samples from individuals previously shown to be 
positive by PCR. Final test validation is on-going and results from a screen 
of >1,000 samples will be discussed.  
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Xenotropic murine leukaemia virus-related virus (XMRV) is a newly 
discovered gammaretrovirus that was first identified from prostate cancer 
samples and has recently been reported to be present in 67 % of patients 
with chronic fatigue syndrome (CFS). We are interested in defining the host 
cell tropism of this virus as well as studying the link to human disease. 
 
As XMRV was recovered from PBMCs, which express several known anti-
viral restriction factors, this raised the possibility that like HIV, XMRV may 
have acquired resistance to restriction. We therefore investigated the 
susceptibility of XMRV to a panel of different restriction factors. We found 
that both human APOBEC3 and tetherin proteins, but not human TRIM5α, 
were able to block XMRV replication. In addition, the virus was inhibited 
by factors from non-human species including mouse Apobec3, tetherin and 
Fv1 proteins. These results have important implications for predicting the 
natural target cells for XMRV replication, for relating infection to viral 
pathogenicity and pathology, as well as for the design of model systems 
with which to study XMRV-related diseases. 
 
In addition to this work we have examined 170 UK CFS patient samples 
and 385 controls for evidence of XMRV infection. We have not identified 
XMRV DNA in any samples by quantitative PCR (0/321) and although 
some serum samples showed XMRV neutralising activity (26/565) only one 
of these positive sera came from a CFS patient. Therefore, we have not 
observed any association between XMRV infection and CFS. Most of the 
neutralising sera showed significant cross-reactivity in serological 
responses. However, four positive samples were specific for XMRV in our 
assays, indicating that XMRV infection may occur at low levels in the 
general population, although with currently uncertain outcomes. 
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CD4 binding triggers conformational changes in the human 
immunodeficiency virus (HIV-1) gp120 envelope glycoprotein that promote 
its interaction with one of its chemokine receptors, CCR5 or CXCR4. CD4 
binding ultimately leads to viral-cell membrane fusion mediated by the 
gp41 transmembrane envelope glycoprotein. We have recently reported that 
a key network of interactions that modulate the interaction of layers in the 
inner domain is important for gp120-gp41 association and regulates CD4 as 
well as CCR5 and 17b binding (1). Importantly, based on sequence 
alignment, this network is conserved among the envelope glycoproteins of 
primate lentiviruses. We have now extended our analysis to the simian 
immunodeficiency virus (SIV) gp120. In SIV this network also regulates 
gp41 interaction but in a slightly different manner than in HIV-1 gp120. 
These differences may compensate for the presence of a tryptophan residue 
in the Phe 43 cavity of SIV envelope glycoproteins; this modification has 
been shown to be sufficient to induce the adoption of a CD4-bound 
conformation. Consistent with the necessity to balance the spontaneous 
adoption of such conformation by SIV gp120, we observed that the inner 
domain layers of SIV modulated CD4 binding in a manner different than 
that in HIV-1. Thus, a key network of interactions in the inner domain of 
primate lentivirus envelope glycoproteins modulates gp41 interaction and 
negotiates conformational transitions from and towards the CD4-bound 
state.  
 
(1) Finzi et al., Molecular Cell (2010), doi:10.1016/j.molcel.2010.02.012  
 336 
STRUCTURAL BASES OF RETROVIRAL INTASOME ASSEMBLY, 
ACTIVITY AND INHIBITION 
 
Stephen Hare1, Saumya Shree Gupta1, Alan Engelman2, Peter Cherepanov1  
 
1Imperial College London, Division of Medicine, London, W2 1PG, United 
Kingdom, 2Dana Farber Cancer Institute, Department of Cancer 
Immunology & AIDS, Boston, MA, 02115 
 
A retrovirus must integrate a DNA replica of its genome into a host cell 
chromosome as an obligatory step of its lifecycle. This process is 
orchestrated by integrase (IN), an enzyme that binds both termini of a viral 
DNA molecule and catalyzes two distinct reactions. Firstly, in 3´ 
processing, a di- or tri-nucleotide is removed from the 3´ ends of viral DNA 
and secondly, in strand transfer, the two newly processed ends are inserted 
in a concerted fashion into the genomic DNA of the host.  
 
We recently reported a 2.9 Å crystal structure of full-length IN from the 
prototype foamy virus (PFV) in complex with pre-processed viral DNA 
mimics. The structure reveals the organization of the retroviral intasome 
comprising an IN tetramer tightly associated with a pair of viral DNA ends. 
All three canonical IN structural domains are involved in extensive protein-
DNA and protein-protein interactions. The viral DNA termini are partly 
melted, and the 3´-OH group of the invariant CA dinucleotide is involved in 
coordination of a metal cofactor.  
 
Herein we further report the structure of this enzyme bound to unprocessed 
viral DNA and two metal cofactors, thereby revealing the structural basis 
for the first step of retroviral integration. 
 
Soaking clinical strand transfer inhibitors Raltegravir and Elvitegravir into 
the original crystals revealed their mechanism of action. The conserved 
metal chelating and halobenzyl groups of these compounds cooperate to 
displace the reactive 3´ viral DNA end from the active site, disarming the 
viral nucleoprotein complex. We will present additional structures and 
discuss the mechanism of drug resistance via the N155H escape pathway. 
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We report a successful use of lentiviral vector gene therapy in the treament of beta-
thalassemia, which was accompanied by a clonal expansion involving integration of 
the lentiviral vector in the HMGA2 gene. The hemoglobinopathies are the most 
prevalent genetic diseases worldwide. An 18 year old male with severe ßE/ß0-
thalassemia dependent on monthly transfusions was treated ex vivo with a lentiviral 
vector expressing a marked ßA-T87Q-globin gene. Twenty two months post-
transplantation, hemoglobin (Hb) levels are 9.5 g/dL, of which ~ 3 g/dL contains ßA-
T87Q-globin, the remainder being HbE and HbF. No transfusion has been provided 
for more than one year, and there are near physiological levels of ßA-T87Q-globin 
expression on a per gene basis. Much of the therapeutic effect derives from a 
dominant cell clone with vector insertion within the HMGA2 gene. The vector is 
integrated in the third intron of the gene resulting in formation of a chimeric 
message containing 5’ HMGA2 sequences and a new 3’ end derived from the 
lentiviral vector. As a consequence, negative acting microRNA binding sites in the 
3’ end of the normal message were not present in the chimeric form. Analysis of 
message levels indicated that the chimeric message is overexpressed, probably due 
to a combination of release from microRNA control and also an increased rate of 
transcription initiation. Expression of HMGA2 is associated with increased stem cell 
persistance and HMGA2 rearrangments that remove microRNA binding sites are 
associated with benign tumors. The subject to date remains transfusion independent 
and thus continues to benefit from gene therapy. This study provides an example of 
clonal expansion in a lentiviral gene therapy trial, where the vector may have 
contributed to cell growth or persistence. 
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Integration of viral genes into germline cells can lead to vertical inheritance 
of viral genetic material. Integration is primarily a characteristic of 
retroviruses, but has also been described in other virus groups. We carried 
out systematic screening of mammalian and avian genomes to identify 
sequences derived from non-retroviral viruses. Screening led to the 
detection of endogenous sequences derived from five viral families, 
including single stranded DNA viruses, negative sense RNA viruses and 
DNA reverse transcribing viruses. Endogenous virus-like elements 
(EVLEs) occurred as complete genomes, single genes, and isolated gene 
fragments. Comparative sequence analysis indicated that EVLEs derived 
from RNA-viruses were generated through interactions with cellular 
retroelements, whereas virally mediated integration was implicated for 
those derived from DNA viruses. Characterization of EVLE distribution 
and diversity allowed the minimum ages of the represented virus groups to 
be estimated, and indicated likely reservoir host species for their 
contemporary exogenous members. Phylogenetic analysis revealed that 
some EVLEs represent novel virus groups that may have contemporary 
counterparts. This study provides the first evidence that viral genetic 
material derived from both DNA and RNA viruses can stably enter the host 
germline, a discovery that greatly broadens the scope of paleovirological 
investigations. 
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Immediately following retroviral invasion of the target cell cytoplasm, the 
capsid of retroviruses is engaged by TRIM5, a germ-line encoded host 
restriction factor. Recognition of the hexagonal capsid lattice requires either of 
two domains – PRYSPRY or cyclophilin - depending upon the TRIM5 
orthologue. Antiviral potency correlates with avidity for the capsid but the 
mechanism of restriction is unknown. Conditional requirement for its RING 
finger E3 ubiquitin ligase domain and B-Box-type zinc finger protein-protein 
interaction domain, host cell-dependent activity, suppression by drugs that 
block signal transduction, and induction by interferon suggest that TRIM5 
activity requires cellular cofactors and signal transduction, properties 
reminiscent of innate immune receptors for pathogen associated molecular 
patterns (PAMPs). We found that TRIM5 disruption in THP1 macrophages or 
monocyte-derived dendritic cells rescued HIV-1, SIV, Vesicular Stomatitis 
Virus, or New Castle Disease Virus from the antiviral state established by TLR 
agonists. TRIM5 stimulated NF-kB and AP1/Jun transcription, and cooperated 
with IRF3 to activate IFNbeta. These activities required the RING finger and B-
Box and were observed with all TRIM5 orthologues, but not close paralogues. 
TRIM5 associated with TAK1 and TRAF2, stimulated the phosphorylation of 
TAK1, IKKs, and JNK, and contributed to transcriptional induction of 
inflammatory chemokines, cytokines and interferon-stimulated genes. In 
addition to its ability to function as an E3 ubiquitin ligase forming ubiquitin-
K48 linkages, TRIM5 catalyzed the assembly of free ubiquitin chains linked via 
K63, and the free ubiquitin chains contributed to TAK1 activation. The effects 
of TRIM5 overexpression or knockdown were mimicked by similar 
perturbations of TAK1 or the K63-specific E2 ubiquitin ligase Ubc13. 
Challenge of THP1 cells, monocyte-derived macrophages, or dendritic cells 
with retroviruses induced transcription of inflammatory genes, the magnitude of 
which correlated with the avidity of the particular TRIM5-capsid combination. 
These findings demonstrate that TRIM5 stimulates innate immune signaling by 
catalyzing the assembly of free K63-ubiquitin chains that activate TAK1, and 
that TRIM5 has the properties of a pathogen associated molecular pattern 
receptor specific for the hexagonal retroviral capsid lattice. 
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Dendritic cells (DC) serve a key function in host defense, linking innate 
detection of microbes to the activation of pathogen-specific adaptive immune 
responses. Whether there is recognition of a HIV-1 Pathogen-Associated 
Molecular Pattern (PAMP) by host innate Pattern-Recognition Receptors (PRR) 
and subsequent coupling to antiviral T cell responses is not yet known. DC are 
largely resistant to infection with HIV-1, but this host restriction can be 
overcome by co-infection with SIVmac pseudovirions containing the Vpx 
protein. 
We found that, in such circumstances, HIV-1 induces a type-I interferon 
response. By using anti-retroviral drugs and viral mapping, we found that this 
innate response occurs after integration and requires Gag synthesis. We further 
found that Capsid (CA) mutants T54A/N57A and Q63A/Q67A had an increased 
ability to induce an innate response, while the cylcophilin A (CypA)-binding 
mutant G89V was defective in this process. Cyclosporin A (CsA) treatment, 
delayed after viral exposure to maintain infectivity, inhibited the induction of 
the innate response. Inhibition of CypA expression using shRNA also prevented 
the induction of the response. This indicates that the innate response is 
dependent on the interaction of newly-synthesized HIV-1 CA with cellular 
cyclophilin A (CypA). Because the peptidyl-prolyl isomerase CypA also 
interacts with CA to promote HIV-1 infectivity, our results suggest that CA 
conformation has evolved under opposing selective pressures for infectivity 
versus furtiveness. 
The transcription factor IRF3 induces type-I interferon expression following 
activation of PRRs such as TLR3 and RIG-I. By using shRNA, we 
demonstrated that the innate response to HIV-1 also requires IRF-3. By using T 
cell clones and HLA-matched DC, we further found that infection of dendritic 
cells with HIV-1 in the presence of Vpx, and induction of an innate immune 
response, leads to potent activation of HIV-specific T cells. 
HIV-2 is less pathogenic than HIV-1 and this is associated with control of the 
infection by the host immune system. Unlike HIV-1, HIV-2 expresses Vpx. We 
found that HIV-2 is able to infect DC and also to induce an innate immune 
response. Thus, an innate response to HIV-1 exists, but is cryptic in the absence 
of DC infection. The lack of induction of this response in HIV-1-infected 
individuals may contribute to the failure the immune system at controlling HIV-
1 infection. Manipulating this response may be essential to generate a HIV-1 
vaccine. 
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The HIV-1 accessory protein Vpu, an 81-amino-acid integral membrane 
protein, enhances virus particle release by counteracting host restriction 
factor(s) that retain budded virions on the surface of infected cells. 
Recently, BST-2/CD317 (also named tetherin), was identified as the host 
restriction factor whose depletion enhances Vpu-defective virus release. 
Human tetherin blocks the release of not only HIV-1 but also that of a 
variety of other enveloped viruses. Vpu enhances virus release by 
counteracting tetherin. Recent studies have demonstrated that tetherin 
variants from mice, rhesus macaques (rh), and African green monkeys 
(agm) were able to inhibit HIV-1 particle release, but were resistant to 
antagonism by Vpu. In the present study, we investigated the mechanism of 
Vpu-mediated antagonism and its specificity for tetherins from human, 
mouse, rh, and agm. We observed that the antagonism of tetherin by Vpu is 
associated with proteasome-mediated degradation, as MG132 and ALLN 
inhibit Vpu-mediated tetherin degradation. Lysine-mediated ubiquitylation 
of tetherin is not required for tetherin degradation, as multiple-lysine 
mutants also undergo degradation by Vpu. The resistance of non-human 
tetherin proteins to antagonism by Vpu correlates with the absence of Vpu-
mediated degradation. Recent studies show that in agm kidney cells (COS) 
human tetherin is poorly expressed compared to 293T cells. Surprisingly, 
we observed that Vpu markedly increases levels of human tetherin 
expression in COS cells, suggesting a Vpu-mediated stabilization of human 
tetherin in this cell type. This stabilization of tetherin by Vpu is specific for 
human tetherin, and maps to the transmembrane sequence, as chimeric 
tetherins containing rh and agm transmembrane sequences are not stabilized 
by Vpu. Despite the Vpu-mediated stabilization of human tetherin levels in 
COS cells, Vpu is still able to enhance HIV-1 release from this cell type. 
These observations demonstrate that Vpu-mediated enhancement of HIV-1 
release and Vpu-mediated tetherin degradation are two separable 
phenomena. COS cells thus provide a system for the molecular dissection of 
Vpu and tetherin function. 
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HIV-1 counteracts the virion release restriction imposed by CD317 by 
expressing Vpu, yet the mechanism of this antagonism is not understood. 
Vpu targets the CD4 receptor for proteasomal degradation by bridging it to 
β-TrCP, a component of an E3 ubiquitin ligase complex. Recently, it has 
been suggested that β-TrCP is also critically involved in Vpu’s ability to 
overcome the CD317-mediated virion release block.  
To test this model we analyzed the consequences of several experimental 
strategies to interfere with the Vpu-β-TrCP protein-protein interaction. 
Under these conditions, we, in parallel, studied effects of Vpu on expression 
and localization of CD317 and CD4, as well on its ability to promote HIV-1 
release. Our results demonstrate a strict requirement for Vpu’s di-serine 
motif S52/S56 for degradation of CD4 and CD317, reduction of cell surface 
exposure of CD317, and HIV-1 release enhancement. They further show a 
critical role of β-TrCP2, but not of the structurally related β-TrCP1, for 
Vpu-mediated degradation of both receptors. In β-TrCP2-depleted cells, 
however, Vpu remained fully active to downregulate CD317 from the cell 
surface and to overcome the HIV-1 release restriction. Furthermore, Vpu 
remained capable to efficiently antagonize degradation-insensitive CD317 
variants and this correlated with a preserved ability to downregulate the 
restriction factor from the cell surface.  
We conclude that Vpu can overcome the release restriction in the absence of 
a β-TrCP-dependent depletion of intracellular pools of CD317, indicating 
cell surface downmodulation of the restriction factor as the key mechanism 
of Vpu antagonism. Thus, β-TrCP is dispensable for the Vpu antagonism to 
CD317-mediated restriction of HIV-1 particle release. Together, these 
findings predict that the critical di-serine motif of Vpu in its 
phosphoryplated state, besides interacting with β-TrCP, also binds to yet 
unidentified host cell factor(s) with essential roles in HIV-1 release 
enhancement.  
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The HIV-1 Vpu protein enhances the release of viral particles from the cell 
surface in a cell-type specific manner. In the absence of Vpu, nascent 
virions remain tethered to the cell surface in restricted cell types. Recently, 
a human host factor, BST-2/CD317/tetherin was found to be responsible for 
the inhibition of virus release. It was also reported that HIV-1 Vpu can 
target human BST-2 but is unable to interfere with the function of murine or 
monkey BST-2. Previous work demonstrated that the TM domains of both 
Vpu and BST-2 are critical for antagonism of BST-2. The TM domain of 
the Vpu-sensitive human BST-2 carries a two amino acid insertion and 7 
substitutions relative to the Vpu-insensitive rhesus BST-2. We performed a 
gain-of-function study to determine, which of these differences in the BST-
2 TM domain account for the differential sensitivity to Vpu. We transferred 
human BST-2 TM sequences into the rhesus BST-2 TM domain and 
assessed the resulting chimeras for inhibition of HIV-1 virus release and 
sensitivity to Vpu. We found that a single-amino-acid change in the rhesus 
BST-2 TM domain was sufficient to confer Vpu sensitivity. In an extension 
of that study we analyzed Vpu sequences from serially passaged SHIV 
isolates. SHIV viruses are chimeric viruses carrying Vpu and Env 
sequences from HIV-1 in the backbone of SIVmac239. Virus from an 
animal exhibiting increased pathogenicity contained mutations in Vpu 
relative to the input SHIV. Replication studies in rhesus PBMC of this virus 
and a vpu-defective variant revealed profiles similar to those of Vpu+/- 
HIV-1 in human cells suggesting the SHIV Vpu protein had acquired the 
ability to target rhesus BST-2. Experiments in 293T cells expressing human 
and rhesus BST-2, respectively, confirmed that the SHIV Vpu isolate had 
gained the ability to target rhesus BST-2. This gain of function was 
accompanied by a partial loss of activity towards human BST-2 and mapped 
to the Vpu TM domain. In conclusion, we identified two novel gain-of-
function mutants. One is a BST-2 mutant which can be antagonized by 
NL4-3 Vpu and the other is a Vpu mutant that can enhance the release of 
NL4-3 particles in the presence of rhesus BST-2. These results highlight the 
critical importance of the TM domains for Vpu-BST-2 functional 
interaction and demonstrate that Vpu’s ability to enhance virus release is 
under positive selection pressure in vivo. 
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The human immunodeficiency virus type 1 (HIV-1) Vpu protein promotes 
CD4 downregulation and enhances particle release from restrictive cell 
types. The effect of Vpu on particle release is mediated through its effects 
on tetherin, an interferon-inducible host restriction factor that potently 
retains particles on the plasma membrane. The mechanism by which Vpu 
elicits relief of tetherin-mediated restriction to particle release is not yet 
clear. The cytoplasmic tail of Vpu contains signals responsible for 
intracellular targeting and colocalization of Vpu with tetherin in the trans-
Golgi network (TGN). We undertook a scanning mutagenesis approach to 
identify residues in the Vpu cytoplasmic tail that are critical to relief of 
tetherin-mediated restriction of particle release. Substitution of residues 42-
46 within helix two of Vpu (the membrane-proximal helix of the 
cytoplasmic tail) abrogated particle release. Three site-specific substitutions 
within this region were identified (D43R, R44E, and L45S) that resulted in 
substantial impairment in the ability of Vpu to overcome tetherin’s effects. 
Surprisingly, all three of these mutants retained their ability to downregulate 
cell surface tetherin. In contrast, the S52A/S56A double mutant was 
impaired in downregulation of cell surface tetherin, but retained the ability 
to enhance particle output of Vpu-deficient virus. This study identifies a key 
region in the Vpu cytoplasmic tail involved in overcoming tetherin’s 
effects, and points out a discordance between the ability of Vpu to 
overcome tetherin-mediated restriction and its effects on downregulation of 
cell surface levels of tetherin. 
 345 
ANALYSIS OF INDIVIDUAL AMINO ACIDS WITHIN THE BST-2 
AND HIV-1 VPU TRANSMEMBRANE DOMAINS IN THE CONTEXT 
OF SIMIAN-HUMAN IMMUNODEFICIENCY VIRUSES (SHIV). 
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Pathogenic simian-human immunodeficiency viruses (SHIV) contain HIV-1 
Vpu and SIV Nef, both shown to counteract BST-2 inhibition of virus 
release in a species-specific manner. Analysis of BST-2 sequences isolated 
from multiple rhesus and pig-tailed macaques displayed an increase in 
sequence variability among rhesus versus pig-tailed macaques. We show 
that human and pig-tailed BST-2 proteins restrict SHIV release and are 
susceptible to the Vpu and Nef proteins. We found that sequential 
“humanization” of the pig-tailed BST-2 (ptBST-2) protein resulted in a 
fluctuation in the sensitivity to Vpu. Mutations with the most significant 
impacts during sequential “humanization” were: i) substitution of the valine 
at position 38 with an isoleucine; and ii) mutation of the leucine at position 
41 to an isoleucine. We also tested the hypothesis that the length of the 
transmembrane domain was a determinant of susceptibility using a human 
BST-2 with the leucine and glycine residues at positions 24 and 25 either 
deleted or substituted with alanines or isoleucines and a ptBST-2 with an 
insertion of a leucine and glycine at positions 29 and 30. Our results show 
that the length of the transmembrane (TM) domain in human and ptBST-2 
proteins is important for BST-2-mediated restriction and susceptibility to 
viral proteins rather than the hydrophobicity of the amino acids present. We 
show that substitution of the invariant tryptophan in the HIV-1 Vpu TM 
domain with an alanine abrogated the enhanced virion release function, but 
only slightly diminished Vpu-mediated CD4 down-regulation. Mutation of 
residues surrounding the tryptophan residue also decreased the ability to 
enhance virion release, but had no impact on the CD4 down-regulation. 
Finally, we show that exchange of the HIV-1 Vpu TM domain with that of 
the M2 protein of influenza A virus resulted in a diminished capacity to 
enhance virion release in Hela cells. Taken together, our results show that 
SHIV can be used as a model to study both human and non-human primate 
BST-2 mechanisms of restriction and emphasize the importance of the 
tertiary structure in this restriction. We provide evidence for possible 
alternate mechanisms of HIV-1 Vpu in enhancing virion release in vivo 
separate from BST-2 antagonism.  
 
This study supported by NIHAI51981. 
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COMPENSATORY CHANGES IN GP41 CONFER RESISTANCE TO 
TETHERIN IN A PATHOGENIC DERIVATIVE OF A NEF-DELETED 
SIV VACCINE STRAIN  
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Nef is the viral gene product in SIV that counteracts restriction by tetherin 
(BST2, CD317 or HM1.24), an interferon-inducible host-cell factor that 
inhibits the detachment of virus particles from infected cells. A role for Nef 
in opposing restriction by tetherin may help to explain the attenuated 
phenotype of nef-deleted SIV. However, since Nef is a polyfunctional 
protein, the loss of other functional activities may also contribute to 
attenuation. Macaques infected with nef-deleted strains of SIV typically 
control virus replication and do not develop AIDS. However, under certain 
circumstances, nef-deleted SIV may regain the ability to replicate to 
moderate levels and cause disease.  
We found that a pathogenic derivative of a nef-deleted SIV vaccine strain 
regained resistance to rhesus tetherin. Similar to wild-type SIV, the ability 
of this virus to antagonize tetherin was species-specific, since it remained 
susceptible to human tetherin. Resistance to rhesus tetherin mapped to 
amino acid changes in the cytoplasmic tail of gp41 and, similar to HIV-2 
Env, depended on the presence of a conserved tyrosine-based endocytosis 
motif in the cytoplasmic tail of gp41. The compensatory changes also 
resulted in the co-localization of SIV Env with tetherin in infected primary 
rhesus macaque CD4+ T cells.  
These observations suggest that the ability to antagonize tetherin is 
important for lentiviral pathogenesis, since this activity was restored in a 
nef-deleted strain of SIV that regained a pathogenic phenotype in vivo. 
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HIV-1 efficiently forms pseudotyped particles with Murine leukemia virus 
(MLV) Env but not by the related Gibbon ape leukemia virus Env (GaLV) 
or a chimeric MLV Env with the GaLV cytoplasmic tail. We have 
determined that this is incompatibility is modulated by the HIV-1 accessory 
protein Vpu. In this study, we sought to determine the modular sequence in 
the GaLV Env cytoplasmic tail required for this restriction in the presence 
of Vpu. With a series of truncation and point mutants in the chimeric Env, 
we have identified that the sequence conferring sensitivity to Vpu is 16 
amino acids in length extending from the -25 to the -9 positions of the C 
terminal cytoplasmic tail. This region is predicted to form an alpha helix. 
Disruption of this proposed helix by the addition of Proline at any of 
multiple positions results in a protein that remains infectious but is no 
longer sensitive to Vpu. The restriction by Vpu is phosphorylation 
independent as the conserved tyrosine can be mutated without losing Vpu 
sensitivity. Using an Alanine scan we have determined the motif that makes 
GaLV Env Vpu sensitive is INxxIxxVKxxVxRxK. While many of these 
positions can be replaced with amino acids with similar biophysical 
properties without disrupting the Vpu sensitivity, the final lysine residue is 
absolutely required. This Vpu sensitivity sequence appears to be modular as 
the unrelated Rous Sarcoma Virus (RSV) Env with a GaLV cytoplasmic tail 
is also Vpu sensitive. In addition, MLV Env can be made Vpu sensitive by 
mutating 2 amino acids in its cytoplasmic tail to make it more closely 
resemble the Vpu sensitivity motif. This Vpu target sequence is contained 
in other host cellular transmembrane proteins and may be targeted by Vpu. 
These data will help elucidate mechanisms of host protein modulation by 
Vpu and possibly identify novel cellular Vpu targets. 
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REQUIREMENT OF THE HUMAN T-CELL LEUKEMIA VIRUS P12 
AND P30 GENES FOR INFECTIVITY OF HUMAN DENDRITIC 
CELLS AND MACAQUES BUT NOT RABBITS  
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The identification of the viral genes necessary for HTLV-1 persistence in 
humans may provide targets for novel therapeutic approaches. We ablated 
the p12, p30, or HBZ genes in HTLV-1 and tested the infectivity of the 
mutant viruses in human dendritic cells, rabbits, and macaques. All these 
viral mutants retained their ability to infect rabbits, the absence of HBZ 
reduces virus levels and no reversion of the point mutations introduced in 
the genome of the viral mutants was observed. In contrast, none of the four 
macaques inoculated with p12 knock out virus were infected; some of the 
macaques inoculated with the HBZ knock out or the p30 knock viruses 
selected within weeks from infection wild type virus and had serum 
antibodies to HTLV-1 proteins. The impairment of infectivity in macaques 
paralleled the infectivity of these mutant viruses in human dendritic cells in 
vitro, as neither the p30 nor the p12 knock out viruses were able to 
productively infect human dendritic cells. Collectively, these data 
demonstrate that the p30 and p12 genes are essential for infectivity of 
dendritic cells and suggest that infection of this cell type is important for the 
initiation and maintenance of HTLV-1 infection in primate species. 
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CCR5 KNOCKOUT IN HUMAN HSC AS AN ANTI-HIV THERAPY 
AND STRAIN-SPECIFIC EFFECTS OF R5-TROPIC HIV-1 INFECTION. 
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CCR5 is the major cellular co-receptor used by HIV-1 and an important 
target for both drug and gene based anti-HIV therapies. Using CCR5 
targeted zinc finger nucleases (ZFN) we can permanently disrupt the CCR5 
gene in human hematopoietic stem cells (HSC) at high efficiency. 
Transplantation of ZFN-treated HSC into NSG mice leads to the generation 
of CCR5-negative HIV-resistant human hematopoietic progeny that 
completely suppress CCR5-tropic HIV-1 replication in vivo. Such findings 
suggest that ZFN treatment of autologous HSC could be used to control 
virus replication in HIV patients, and our progress towards this clinical 
application will be presented.  
 
Using ZFNs, we are also able to achieve site-specific gene addition at a 
disrupted CCR5 locus through homologous recombination (HR) repair. This 
allows the possibility of inserting additional anti-HIV genes at the CCR5 
locus, thereby protecting cells that are only modified at a single CCR5 
allele, as well as providing protection against CXCR4-using viruses. Such 
site-specific gene addition should also result in more predictable expression 
of therapeutic genes and reduce the potential for insertional mutagenesis.  
 
Humanized NSG mice are a powerful new model system in which to 
evaluate anti-HIV therapies and study HIV-1 pathogenesis. As part of our 
studies of this anti-CCR5 gene/cell therapy, we noted differential effects of 
a panel of R5-tropic viruses on the rate and extent of human T cell depletion 
in various tissues, including the thymus and GALT, and on overall levels of 
immune activation in the human cells. Interestingly, we observed a 
correlation between the pathogenicity of an R5-tropic virus and its ability to 
up-regulate CCR5 expression in the thymus, peripheral blood, spleen and 
GALT. We propose that such CCR5 up-regulation results in the depletion 
of cells from tissues that do not normally have a large population of CCR5-
expressing lymphocytes, and increases the pathogenic consequences of R5-
tropic infections.  
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POTENT DOWN-REGULATION OF CCR5 BY RNA INTERFERENCE 
PROTECTS CD4+ T CELLS FROM HIV INFECTION IN THE HU-BLT 
MOUSE MODEL. 
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Inhibiting the expression of the HIV-1 co-receptor CCR5 holds great 
promise for controlling HIV-1 infection in patients. Here we report stable 
knockdown of human-CCR5 by a short hairpin RNA (shRNA) in a 
humanized bone marrow/liver/thymus (BLT) mouse model. We delivered a 
potent shRNA against CCR5 into human fetal liver-derived CD34+ 
hematopoietic progenitor/stem cells (HPSCs) by lentiviral vector 
transduction. We transplanted vector-transduced HPSCs solidified with 
matrigel and a thymus segment under the mouse kidney capsule. Vector-
transduced autologous CD34+ cells were subsequently injected in the 
irradiated mouse intended to create systemic reconstitution. CCR5 
expression was down-regulated in human T cells and 
monocytes/macrophages in systemic lymphoid tissues, including gut 
associated lymphoid tissue (GALT), the major site of HIV-1 replication. 
The shRNA-mediated CCR5 knockdown had no apparent adverse effects on 
T cell development as assessed by polyclonal T cell receptor Vβfamily 
development and naive/memory T cell differentiation. CCR5 knockdown in 
the secondary transplanted mice suggested the potential of long-term 
hematopoietic reconstitution by the shRNA transduced HPSCs. We next 
examined HIV inhibition ex vivo and in vivo. CCR5 tropic HIV-1 infection 
was effectively inhibited in isolated human splenocytes ex vivo. When mice 
were challenged with CCR5 tropic HIV-1, we observed selective 
maintenance of CCR5-shRNA expressing CD4+ T cells in various tissues 
including GALT in vivo. These results demonstrate that lentiviral vector 
delivery of shRNA into human HPSCs could stably down-regulate CCR5 
and prevent CD4+ T cell depletion in vivo. Our current results provide 
further evidence that it may be possible to create a single administration 
reagents, using a lentiviral vector expressing CCR5 shRNA through 
hematopoietic stem cell transduction and transplantation, to stably control 
HIV-1 infection. 
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It is currently under debate whether Nef-mediated down-modulation of 
TCR-CD3 protects SIV- and/or HIV-2-infected hosts against damaging 
high levels of immune activation and the loss of CD4+ T cells. To further 
address this question, we cloned nef alleles from 20 viremic (plasma viral 
load >500 copies/ml) and 16 non-viremic (<500 copies/ml) HIV-2-infected 
individuals into proviral HIV-1 IRES/eGFP constructs and analyzed their 
effect on CD4, CD3, CD28 and class I MHC cell surface expression, 
activation and apoptosis of primary CD4+ T cells. We found that the 
potency of nef alleles derived from viremic individuals in down-modulating 
TCR-CD3 correlated significantly with high numbers of CD4+ T cells in 
vivo and with low levels of activation and apoptosis of virally infected 
primary CD4+ T cells in vitro. No such correlations were observed in non-
viremic HIV-2-infected individuals and for other Nef functions. None of 
these nef alleles antagonized human tetherin, although several showed 
significant activity against the tetherin variant found in the original host of 
HIV-2, the sooty mangabey. Altogether, our data suggest that many HIV-2-
infected individuals do not progress to AIDS irrespectively of Nef function 
because they efficiently control the virus. However, the ability of Nef to 
remove TCR-CD3 from the cell surface may help HIV-2-infected 
individuals with relatively high viral loads to maintain normal CD4+ T cell 
counts by preventing activation-induced cell death, just as previously 
observed in SIVsmm-infected sooty mangabeys. 
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Murine leukemia viruses (MuLVs) and other gammaretroviruses encode a 
unique form of Gag polyprotein, gPr80gag or glyco-gag, by initiation of 
translation from an upstream initiation site in the same reading frame as the 
Pr65gag Gag precursor. gPr80gag is evolutionarily conserved among 
gammaretroviruses, and there is strong selection for recovery of gPr80gag if 
mutant virus is infected into animals. We previously reported that gPr80gag 
facilitates release of virions from cells along an IFN-sensitive pathway 
(Nitta et al., PNAS 2010). In particular, gPr80gag-facilitated release occurs 
through lipid rafts, because gPr80gag-negative M-MuLV has lower 
cholesterol content (higher buoyant density), it is less sensitive to inhibition 
of release by the cholesterol-depleting agent MßCD, and there is less 
Pr65gag associated with detergent-resistant membranes (DRMs) in mutant-
infected cells. In recent studies, we found that a plasmid expressing only the 
N-terminal 88 amino acids of gPr80gag (pMuLV-gg88) shows full activity in 
facilitating release of an MuLV vector (AKAQ188) from transiently 
transfected 293T cells. To further understand the mechanism of gPr80gag 
action we sought to identify cellular proteins that might be involved. We 
performed a yeast two-hybrid screen with a bait plasmid consisting of the 
N-terminal unique region of gPr80gag fused to bacterial LexA protein on a 
human cDNA library. Only one cDNA was identified corresponding to the 
cellular protein La/SSB – a protein associated with several aspects of RNA 
metabolism such binding of Pol III transcripts. In vivo interaction between 
gPr80gag and La was evident from relocalization of human or mouse La into 
the cytoplasm of cells transfected with pMuLV-gg88. Overexpression of 
mouse or human La could substitute for pMuLV-gg88 in enhancing release 
of MuLV virions from 293T cells transiently transfected with AKAQ188. 
The resulting virus showed a buoyant density characteristic of higher 
cholesterol content, and DRMs from La-overexpressing cells showed higher 
Pr65gag content. These results are consistent with gPr80gag functioning by 
recruiting La to the cytoplasm. 
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, west wing, lower level 
 PIN#:  Press 64360 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
